PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA)
SPECIAL 301 SUBMISSION 2020
# Table of Contents

**PhRMA 2020 SPECIAL 301 OVERVIEW** ........................................................................................................... 1  

**PRIORITY FOREIGN COUNTRY** .................................................................................................................. 40  
- CANADA.................................................................................................................................................. 41  
- JAPAN....................................................................................................................................................... 55  
- KOREA.................................................................................................................................................... 66  
- MALAYSIA............................................................................................................................................. 72  

**SECTION 306 MONITORING** .................................................................................................................. 79  
- THE PEOPLE’S REPUBLIC OF CHINA...................................................................................................... 80  

**PRIORITY WATCH LIST** ................................................................................................................................ 101  
- ASIA – PACIFIC........................................................................................................................................ 102  
- INDIA...................................................................................................................................................... 103  
- INDONESIA........................................................................................................................................... 117  
- THAILAND.......................................................................................................................................... 124  
- EUROPE............................................................................................................................................... 128  
- RUSSIA............................................................................................................................................... 129  
- TURKEY............................................................................................................................................. 141  
- UKRAINE............................................................................................................................................ 150  
- LATIN AMERICA................................................................................................................................. 153  
- ARGENTINA....................................................................................................................................... 154  
- BRAZIL............................................................................................................................................... 159  
- CHILE.................................................................................................................................................. 164  
- COLOMBIA..................................................................................................................................... 169  
- MIDDLE EAST / AFRICA......................................................................................................................... 176  
- ALGERIA............................................................................................................................................. 177  
- SAUDI ARABIA................................................................................................................................. 183  

**WATCH LIST** ........................................................................................................................................... 186  
- ASIA – PACIFIC........................................................................................................................................ 187  
- AUSTRALIA......................................................................................................................................... 188  
- SINGAPORE....................................................................................................................................... 199  
- EUROPE.............................................................................................................................................. 202  
- EUROPEAN UNION............................................................................................................................. 203  
- UNITED KINGDOM............................................................................................................................. 216
PhRMA 2020 SPECIAL
301 OVERVIEW
PhRMA 2020 SPECIAL 301 OVERVIEW

The Pharmaceutical Research and Manufacturers of America (PhRMA) appreciates the opportunity to provide this submission for the 2020 Special 301 Report. America leads the world in the research and development of valuable new medicines and vaccines. Established by the Trade Act of 1974, the Special 301 review gives the Administration a critical opportunity to confirm its strong commitment to defend these and other American inventions in overseas markets and a critical tool to address damaging market access and intellectual property barriers abroad that harm America’s innovative and creative industries and the more than 45 million jobs they support across the country.¹

Urgent action is required to address serious market access and intellectual property barriers in the 24 overseas markets named in this submission. As explained further below, biopharmaceutical innovators in the United States face a wide array of damaging pricing policies abroad that free ride on American innovation, threaten billions of dollars in lost sales and put American jobs and exports at risk. Medicines discovered and manufactured by PhRMA member companies are the constant target of compulsory licensing and other harmful practices that deny the most basic intellectual property protections necessary to drive discovery and bring new treatments and cures to patients around the world.

The Office of the U.S. Trade Representative and other federal agencies should prioritize action to reverse compulsory licensing in Malaysia and to end discriminatory pricing policies in several markets, including Canada, Japan and South Korea. Government price controls imposed in many markets are non-tariff barriers to trade that substantially eliminate incentives to invest in the development of new medicines for patients. They deny American inventors and workers the ability to compete on fair and equitable terms in foreign markets, undermine the expected benefit of intellectual property protections and exacerbate the U.S. trade imbalance by inappropriately raising barriers in their own markets, while their own inventors enjoy access to the U.S. market. Ending damaging pricing policies in these markets and others could add billions of dollars to research and development for new medicines and lower overall health care costs in the U.S. and around the world.²

I. The Innovative Biopharmaceutical Sector

The U.S. biopharmaceutical industry is the world leader in medical research – producing more than half the world’s new molecules in the last decade. Innovators in this critical sector depend on strong intellectual property protection and enforcement, and on fair and equitable access to overseas markets. With the right policies and incentives in place at home and abroad, they can continue to bring valuable new medicines to patients and contribute powerfully to the American economy and jobs.

A. Biopharmaceutical innovation delivers value for patients and economies

PhRMA member companies and the more than 800,000 women and men they employ across the United States are devoted to inventing, manufacturing and distributing valuable medicines that enable people to live longer, healthier, and more productive lives. They work in partnership with universities, clinical researchers, patient organizations, health care providers and others to bring new treatments and cures to patients who need them at home and abroad – introducing nearly 650 new therapies since 2000 and investing in many of the over 8,000 new drugs currently in development worldwide, with about three quarters having the potential to be first-in-class treatments.

Pioneering work by biopharmaceutical innovators in the United States contributes significantly to economic growth and supports good-paying jobs in all 50 states. In 2015, biopharmaceutical research and development activity added more than $1.3 trillion to the U.S. economy and supported over 4 million American jobs, including indirect and induced jobs. For all occupations involved in the biopharmaceutical industry, the average total compensation per direct employee is twice the average compensation in any other U.S.

---


private sector industry. In 2018, the industry exported over $60 billion in biopharmaceuticals, making the sector one of the top U.S. exporters among intellectual property-intensive industries.

Even more important than the biopharmaceutical sector’s role in the U.S. economy is its contribution to global patient health. Biopharmaceutical innovation extends lives, improves worker productivity and cuts health care costs. Between 1950 and 2016, life expectancy for women and men in the United States increased by more than a decade – adding trillions of dollars to the U.S. economy. New medicines are responsible for much of this increase. According to a National Bureau of Economic Research working paper, new treatments accounted for three-quarters of life expectancy gains in the United States and other high-income countries between 2000 and 2009.

For example, the AIDS death rate has dropped nearly 87% since the approval of antiretroviral treatments in 1995. Today, a 20-year old diagnosed with HIV can expect to live another 50 years. New medicines have cut heart disease deaths by 38%, according to the Centers for Disease Control and Prevention. More than 80% of the increase in life expectancy of cancer patients since 1980 is attributable to new

9 Id.
16 Id.
treatments. New hepatitis C therapies approved since 2013 cure over 90% of patients – a more than two-fold increase from previously available treatment options.

PhRMA member companies are building on these achievements and pioneering new treatments and cures for some of the world’s most devastating diseases. Researchers are developing more than 1,200 new medicines for infectious diseases, including viral, bacterial, fungal, and parasitic infections such as the most common and difficult-to-treat form of hepatitis C, a form of drug-resistant malaria, a form of drug-resistant MRSA, and a novel treatment for smallpox. Advances in biotechnology and genomics are propelling the discovery of new medicines to treat a range of chronic and infectious diseases. Made using living organisms, biologic medicines are revolutionizing the treatment of cancer and autoimmune disorders. Biologics are critical to the future of the industry and promise progress in the fight against conditions like Alzheimer’s, which today lack effective treatments.

New medicines can lower the overall cost of treating these and other devastating diseases by reducing medical complications, hospitalizations and emergency room visits. For example, the use of cholesterol-lowering statin drugs has cut hospitalizations and saved the U.S. health care system at least $5 billion. Every $24 spent on new medicines for cardiovascular diseases in OECD countries saves $89 in hospitalization costs. Treating high blood pressure according to clinical guidelines would result in annual health system savings of about $15.6 billion. In addition to lowering overall health care costs, appropriate use of medicines can increase worker productivity by reducing rates of absenteeism and short-term disability. A recent study demonstrated that appropriate

---


21 Id.


use of diabetes medicines saved 15% and 20% per month in medical spending after one year of initiating treatment\textsuperscript{26} and an estimated reduction of more than one million emergency department visits and hospitalizations annually, for an annual savings of up to $8.3 billion.\textsuperscript{27}

PhRMA members are working to overcome significant systemic challenges that can prevent the poorest patients from accessing medicines. Together with governments, academia and others, they are leading more than 300 initiatives with more than 1,000 partners to help shape sustainable solutions that improve the health of all people.\textsuperscript{28} In 2017, more than 20 biopharmaceutical companies joined the World Bank and the Union for International Cancer Control to launch Access Accelerated – a first-of-its-kind global initiative to address cancer and other non-communicable diseases that cause more than 28 million deaths per year in low and lower-middle income countries.\textsuperscript{29}

Between 2000 and 2011, biopharmaceutical innovators contributed an estimated $98.4 billion dollars toward achieving health-related Millennium Development Goals.\textsuperscript{30} Despite a three percent drop in public funding for neglected disease (excluding Ebola) research and development in 2014, biopharmaceutical industry funding increased by 28% during the same period.\textsuperscript{31}

\textbf{B. Policies that power prevention, treatments and cures}

Strong protection and enforcement of patents, regulatory test data and other intellectual property, and fair and transparent market access to overseas markets provide powerful incentives that drive and sustain substantial investments in valuable treatments and cures. Where markets are open and intellectual property is protected and enforced, available at http://journals.lww.com/joem/Abstract/2012/07000/Impact_of_Medication_Adherence_on_Absenteeism_a nd.7.aspx (last visited Feb. 6, 2020).


biopharmaceutical innovators have the predictability and certainty they need to collaborate with partners, compete successfully and accelerate the launch of new medicines.

**Figure 1: Collaboration and the biopharmaceutical R&D process**

As highlighted in Figure 1 above, research, development and distribution of innovative medicines increasingly involves collaboration and the exchange of commercially sensitive information between multiple partners across borders and around the world. Strong intellectual property protection and enforcement enable innovators to license their patented inventions to others with the certainty that valuable information disclosed is secure. Thanks to the technology transfer framework established by the Bayh-Dole Act, licensing of intellectual property is also enabling collaboration among industry, university and public sector researchers in the development of new medicines and other products – adding close to $591 billion to the U.S. economy and supporting about 4.2 million American jobs between 1996 and 2015.\(^\text{32}\) Such collaboration is

\(^{32}\) See Association of University Technology Managers, Statistics Access for Technology Transfer (STATT) database, available at https://autm.net/surveys-and-tools/databases/stat (last visited Feb. 6,
delivering similar benefits in other countries. Recent research in the United Kingdom found that public expenditure on biomedical and health research leveraged even greater private sector investment, delivering a total rate of return to public biomedical and health research of up to 28%.33

Patents and market-based pricing policies promote competition and greater treatment options. In exchange for the limited period of protection patents provide, innovators must fully disclose their inventions to the world. That disclosure accelerates innovation and empowers potential competitors to build on those inventions. Competition means more medicines in the same therapeutic class, more options for patients and even lower prices.34 For example, less than a year after market entry of the first in a new class of hepatitis C treatments, there were multiple suppliers that competed both on price and clinical benefits. Indeed, competition was so fierce that the largest U.S. pharmacy benefit manager claimed hepatitis C treatment is less expensive in America than in other western countries.35 European countries have seen similar gains from competition.36

Today, biopharmaceutical innovators face competition faster – both from other innovators and from generic drug companies. In the 1970s, a new medicine might remain the only innovative treatment available in its therapeutic class for ten years or more. By the 2000s, that period had declined to about two years.37 Generic competitors now challenge patents earlier and more frequently – even as early as four years after the launch of an innovative medicine.38 Today, over 94% of innovative medicines experience at least one patent challenge prior to generic entry – compared to 25% in 1995.39
Increasing competition from biosimilars is driving down the cost of cutting-edge treatments.⁴⁰

Patents promote faster access to new medicines. A major 2014 study found firms launch innovative medicines sooner in countries where there is effective patent protection and enforcement. The study looked at data from the launch of more than 600 drugs in almost 80 countries between 1983 and 2002. It showed that strong patent protection accelerates new product launches in higher and lower income countries alike.⁴¹ Launching a medicine in a particular country also has important effects on the whole health care system. For instance, when a new medicine is introduced, biopharmaceutical companies invest in educating health care providers on the science and appropriate use of that medicine.⁴² This investment later enables accelerated acceptance of generic versions once relevant patents expire.

Strong intellectual property protection and enforcement supports American innovation and jobs and has long been a critical goal of America’s trade policy agenda. Strong intellectual property protection and enforcement at home and abroad, and the efficient market conditions necessary to enjoy those rights, provide essential incentives for investment in the biopharmaceutical sector and in all of the innovative industries that today account for nearly 40% of U.S. gross domestic product.⁴³ For each of these industries, developing and bringing new products and processes to market is a risky endeavor; it requires time and substantial resources. In most cases, new products will fail to deliver returns that meet or exceed investment. Some three-quarters of all venture capital-backed internet startups fail.⁴⁴ And even those that succeed often fail to make a profit. Biopharmaceutical firms face similar challenges. Just two of every ten marketed medicines achieve returns that match or exceed average research and development costs.⁴⁵ Of the approximately 1,200 biopharmaceutical companies in the United States, more than 90% do not earn a profit.⁴⁶

---


The lengthy approval process for new products makes the research-based biopharmaceutical sector particularly reliant on the temporary protection intellectual property rights provide. Unlike products made by other innovative industries, new medicines are not market-ready at the time they are developed. As highlighted in Figure 2 above, biopharmaceutical firms rigorously test and evaluate potential therapies through a series of clinical trials to demonstrate they are safe and effective for treatment of a particular disease or condition. In 2017, the innovative biopharmaceutical industry sponsored more than 4,500 clinical trials across all 50 states. Test data generated

---


through those trials is then submitted to national regulatory agencies for marketing approval.

For these reasons and others, research and development is more capital intensive in the innovative biopharmaceutical sector than in other industries. Firms in this sector invest twelve times more in research and development per employee than the average of all other manufacturing industries. In 2017 alone, American biopharmaceutical companies invested approximately $97 billion in research and development in the United States. Clinical trials can account for more than 60% of the total cost of bringing a new medicine to market, and there is no guarantee promising molecules and proteins that enter clinical trials will result in a new treatment or cure. The process of evaluating potential new therapies is so exacting that less than 12% of all potential new drugs entering clinical trials result in an approved medicine.

Advances in the treatment of diseases typically are not driven by large, dramatic developments, but more commonly build on a series of continuous improvements over time. The best clinical role and full value of a particular therapy typically emerges years after initial approval as further research is conducted and physicians and other health care providers gain real-world experience. These improvements and the further development of therapeutic classes of medicines often lead researchers to explore new treatments in related areas – restarting the research and development cycle. Indeed, nearly a quarter of existing therapeutic indications are treated by medicines initially developed to address a different concern. And more than 60% of therapies on the World Health Organization’s (WHO’s) Essential Medicines List relate to improvements on older


treatments.55 This step by step transformation in knowledge has led to increased survival, improved patient outcomes and enhanced quality of life for many patients.56

II. Practices that Undermine Innovation and Access to New Treatments

To research, develop and deliver new treatments and cures for patients who need them around the world, biopharmaceutical innovators must be able to secure and effectively enforce patents and protect regulatory test data. They must be able to obtain timely marketing approval for new medicines and make those therapies available to patients according to reimbursement rules and procedures that are fair, transparent, reasonable, non-coercive, and non-discriminatory, and that appropriately value and reward patented pharmaceuticals.

For well over a century, governments have recognized the need for global minimum standards that enable inventors to effectively and efficiently protect and share their inventions in a territorial system of intellectual property rights. Signed in 1883, the Paris Convention for the Protection of Industrial Property allowed inventors, regardless of nationality, to claim priority for their inventions and to take advantage of the intellectual property laws in each member country. To facilitate the process of filing patent applications around the world, many members of the Paris Convention established the Patent Cooperation Treaty (PCT) in 1970. Today, more than 90% of all countries are members of the Paris Convention and the PCT.

The World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which entered into force in 1994, was a major achievement in strengthening the worldwide protection and enforcement of intellectual property rights by creating an international minimum standard of protection for intellectual property rights. TRIPS was premised on the view that its obligations, if faithfully implemented by the diverse WTO Membership,57 would create the policy and legal framework necessary for innovation-based economic development of WTO Members by rewarding innovation with reliable rights-based systems and permitting the flow of its attendant commercial benefits. Because it concerns both the definition and enforcement of rights, TRIPS is one of the single most important steps toward effective protection of intellectual property globally. WTO Members, including the United States, have an important role to play not only in fully and effectively implementing, but also in reiterating and enforcing, TRIPS minimum standards.

57 164 members since July 29, 2016.
Critically, the United States and other countries have promoted, given effect to and built on the global minimum standards of protection provided by these international rules through eligibility criteria for trade preference programs, WTO accessions and regional and bilateral trade agreements that establish strong intellectual property protections and require fair and equitable market access. However, certain U.S. trading partners maintain or are considering acts, policies or practices that are harming or would harm the ability of biopharmaceutical innovators to research, develop and deliver new treatments and cures for patients around the world. These acts, policies or practices deny or would deny adequate and effective intellectual property protection and/or fair and equitable market access for innovative medicines. In many cases, they appear to be inconsistent with global, regional and bilateral rules.

Multilateral organizations that once served as custodians of the international rules-based system increasingly are seeking to undermine and even eliminate intellectual property protections that drive and sustain biopharmaceutical innovation in the United States and around the world. By reinterpreting international agreements and through meetings, reports, guidelines and training programs, the WHO, the United Nations Development Program (UNDP), the United Nations Conference on Trade and Development (UNCTAD), Unitaid and other organizations are promoting acts, policies and practices globally and in specific countries that prevent biopharmaceutical innovators from securing and maintaining patents, protecting regulatory test data and from enjoying fair and equitable market access.58

The following sections highlight the most serious challenges facing PhRMA members around the world. The acts, policies and practices of specific countries are described further below. PhRMA members urge USTR and other federal agencies to highlight these challenges, acts, policies and practices in the 2020 Special 301 Report and to use all available tools to address and resolve them.

A. Practices that deny fair and equitable market access

PhRMA members increasingly encounter acts, policies and practices abroad that deny fair and equitable market access. Through arbitrary, coercive, and often discriminatory government price controls, unnecessary regulatory delays and high tariffs and taxes, countries across Europe, Asia, North America and beyond are limiting market competition, increasing costs and undermining the ability of biopharmaceutical innovators in the United States to bring new medicines to patients who need them.

In recent years, America’s biopharmaceutical sector has witnessed a surge in the number and severity of arbitrary, coercive and discriminatory government price controls abroad that threaten U.S. exports and jobs. Such measures cause serious damage in the countries that maintain them by rationing patient access to health care. They also can

have significant ripple effects across other markets. For example, government price controls implemented in one country can spill over to many other countries through international reference pricing. These policies can restrict competition and artificially depress prices below market value, depriving American inventors of the ability to enjoy their intellectual property protections and ultimately delaying and denying patient access to new medicines.59

A 2004 Commerce Department study60 found that international reference pricing and other such measures that “rely heavily on government fiat to set prices rather than competition in the marketplace” put short-term government objectives ahead of long-term strategies that would ensure continued R&D into medicines that patients need most. The report showed that moving to market-based systems would add billions to research and development for new medicines and lower overall health care costs around the world by promoting greater efficiencies in off-patent markets. Urgent action is needed to address and resolve the following government price control regulations, policies and practices that are limiting market access for medicines researched and developed in the United States:

- **Government price controls.** In many countries, governments are the primary payer of medicines and in effect dictate prices. This dominant position often results in U.S. trading partners failing to appropriately recognize the value of innovation in their pricing and reimbursement policies, instead engaging in actions that distort markets and artificially depress prices below what a competitive market would provide. Foreign governments are increasingly employing a range of regulatory measures, including international reference pricing, therapeutic reference pricing, mandatory price cuts, clawback taxes, and flawed health technology assessments. These measures are often layered to exert maximum pressure. **Korea** employs several price control measures – including health technology assessments that require unreasonable thresholds for cost-effectiveness, international reference pricing of inappropriate off-patent and generic comparators, and *ad hoc* measures – to systematically cut prices. In the past couple years, **Japan** approved sweeping changes to pricing policies that significantly undermine efforts to carry a fair share of the costs of global research and development. In particular, the new eligibility criteria for the Price Maintenance Premium (PMP) program as well as other price-cutting measures such as flawed health technology assessments and expanded re-pricing rules will mean that some of America’s most innovative medicines will be significantly undervalued. In **Canada**, the Patented Medicine Prices Review Board regulates the maximum allowable price that a manufacturer can charge for a patented medicine to public or private payers. Last year, the Board announced

---


draconian changes intended to set prices at levels paid by less wealthy countries and based on inappropriate economic factors. Examples of other highly-developed countries that undervalue innovative medicines include Australia, France, Germany, Italy, the Netherlands, New Zealand, Spain, Switzerland and the United Kingdom.

- *Discriminatory pricing policies.* In many countries, governments have policies that further benefit domestic drug companies and wholesalers at the expense of innovators in the United States. For example, in 2018, Japan revised its PMP program based on company criteria that appear to be inherently biased towards domestic companies (e.g., number of local clinical trials and whether the product was launched first in Japan), and in 2019 implemented new health technology assessments that will subject imported products to greater scrutiny and price cuts than domestic products. These new company and country-of-origin criteria call into question Japan’s commitment to fair and non-discriminatory policies, including that of national treatment.

Other acts, policies and practices delay or limit market access for America’s biopharmaceutical innovators and the benefits patients overseas could realize from faster access to medicines and greater competition between treatments in the same therapeutic class. These barriers include:

- *Import barriers.* High tariffs and taxes can limit U.S. biopharmaceutical exports and prevent access to new treatments in overseas markets.\(^{61}\) Under the WTO Pharmaceutical Agreement, the United States and the 33 other countries do not impose any import duties on a wide range of medicines and other health products.\(^{62}\) However, biopharmaceutical innovators in the United States do not benefit from the same access to China, India and other emerging economies that are leading producers and net exporters of drugs\(^ {63}\) and active pharmaceutical ingredients\(^ {64}\) but are not parties to the WTO Pharmaceutical Agreement. Between 2006 and 2013, the value of worldwide biopharmaceutical trade in countries that are not parties to that Agreement increased at a compound annual growth rate of

---


more than 20 percent. This means that a larger proportion of medicines distributed around the world are potentially subject to tariffs.\textsuperscript{65} For example, the United States is by far the largest market for Indian generic drug exports,\textsuperscript{66} but India’s basic import duties on biopharmaceutical products and active ingredients average about ten percent.\textsuperscript{67} Additional duties and assessments can raise the effective import duty to as high as 20 percent or more.\textsuperscript{68} Federal and state taxes on medicines in Brazil\textsuperscript{69} can add nearly 34 percent to the retail price of medicines – among the highest tax burdens on medicines in the world.\textsuperscript{69} Examples of other countries that maintain high tariffs and taxes on imported medicines include Argentina and Russia. Thailand recently eliminated tariffs on orphan drugs – a positive step other countries should emulate.

- **Regulatory approval delays.** China is making significant strides in reforming and strengthening its regulatory framework but remains an outlier in the drug approval process compared to other regulatory authorities, with new medicines typically taking three to five years longer to reach China than other major markets. In other words, a “drug lag” remains in China. Examples of other markets with complex and lengthy regulatory approval processes include Mexico, Russia and Turkey. Accelerating regulatory approval in these countries and others will improve the efficiency of global drug development, facilitate U.S. exports and reduce the time it takes for new medicines to reach patients.

- **Government pricing and reimbursement delays.** Restrictive government pricing and reimbursement policies delay market access for biopharmaceutical innovators in the United States and prevent timely patient access to new treatments and cures that have received regulatory approval. These processes vary by country with the result that government reimbursement decisions can be almost immediate in some countries to several years in others. For example, prior to 2017, China had only undertaken two substantive updates (2004 and 2009) to the National Reimbursement Drug List which delayed reimbursement by up to seven years. In Mexico, delays can stretch as long as 1,500 days or more, on average, compared


to 230 days in other countries. PhRMA is encouraged by efforts China and Mexico have made to accelerate updates to their reimbursement lists. However, patients would be better served by a model that allows all new drugs to be reviewed for reimbursement on a regular, or rolling, basis.

- **Lack of transparency and due process.** Lack of transparency, due process, and delayed reimbursement decisions are widespread across the world. In **Japan**, the government continues to make significant changes to pricing policies without adequate consultation with the industry. In **Mexico**, excessive regulatory approval delays are compounded by consolidated procurement processes that lack transparency and are applied inconsistently. In **Turkey**, reimbursement decision criteria are not clearly defined, the process is non-transparent, and unpredictable delays in decision-making significantly postpone patient access to innovative medicines.

PhRMA members recognize the efforts undertaken by the U.S. Government to address these barriers, including eliminating tariffs and promoting fair, reasonable and non-discriminatory pricing and reimbursement policies in trade agreements and addressing regulatory approval delays and other market access challenges in bilateral forums. PhRMA also welcomes the Administration’s continued focus on the problem of advanced economies undervaluing U.S. innovative medicines. As the Council for Economic Advisors highlighted in 2018, “foreign, developed nations, that can afford to pay for novel drugs, free-ride by setting drug prices at unfairly low levels, leaving American patients to pay for the innovation that foreign patients enjoy.” It remains critical for the U.S. Government to engage on these issues with its trading partners, and to require immediate and meaningful steps to resolve existing barriers and to ensure patients have faster access to new treatments and cures as well as parity between

---


relevant market conditions, including through effective enforcement of U.S. trade agreements.

**B. Practices that undermine biopharmaceutical innovation**

In addition to many developed economies not appropriately rewarding U.S. innovation, biopharmaceutical innovators in the United States face myriad other intellectual property challenges around the world. The six intellectual property challenges described below and highlighted in Figure 3 have the most serious and immediate impact on the ability of PhRMA members to invest in discovering and transforming promising molecules and proteins into useful new medicines for patients around the world. These challenges hinder or prevent biopharmaceutical innovators from securing patents (restrictive patentability criteria and patent backlogs), maintaining and effectively enforcing patents (market-size damages, weak patent enforcement and compulsory licensing), and protecting regulatory test data (regulatory data protection failures).

**Figure 3: Biopharmaceutical intellectual property challenges**
Restrictive Patentability Criteria

To bring valuable new medicines to patients, biopharmaceutical innovators must be able to secure patents on all inventions that are new, involve an inventive step and are capable of industrial application. National laws, regulations or judicial decisions that prohibit patents on certain types of biopharmaceutical inventions or impose additional or heightened patentability criteria restrict patient access to valuable new medicines and undermine investment in future treatments and cures. These restrictions prevent innovators from building on prior knowledge to develop valuable new and improved treatments that can improve health outcomes and reduce costs by making it easier for patients to take medicines and by improving patient adherence to prescribed therapies. Some of the most serious examples of restrictive patentability criteria challenges facing PhRMA members in countries around the world include:

- **Patentability restrictions and additional patentability criteria.** A number of countries maintain laws and regulations that, per se, prevent the patenting of a wide range of specific improvements to existing medicines – improvements that are valuable.

73 See, generally, TRIPS Article 27.1.

74 New improvements to existing treatments, such as new dosage forms and combinations, are of tremendous value to patients. They can make it easier for patients to take medicines and increase patient adherence. Specifically, they make it more likely patients will take their medicines consistently and as prescribed. Such improvements might allow patients to take an oral medication instead of an injection or reduce the number of doses required. Adherence is inversely proportional to the number of times a patient must take their medicine each day. The average adherence rate for treatments taken once daily is nearly 80%, compared to about 50% for medicines that must be taken four times a day. Patient adherence to prescribed courses of treatment leads to better health outcomes and is particularly important for the management of chronic, non-communicable diseases like diabetes, heart disease and cancer. According to the WHO, “[a]dherence to therapies is a primary determinant of treatment success.” See Shrank, William H. et al., “A Blueprint for Pharmacy Benefit Managers to Increase Value,” American Journal of Managed Care, Feb. 2009, available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737824/ (last visited Feb. 6, 2020).


to patients and payers and that require significant investment and research to develop. For example, **Argentina** issued regulations in 2012 that prevent biopharmaceutical innovators from securing patents on certain types of inventions, including new dosage forms and combinations. In the **Philippines**, national law limits patentability of new forms and new uses of existing medicines. **Indonesia** adopted a new patent law in 2016 that similarly prohibits patents for new forms and new uses of existing medicines. **India**’s Patent Law harms its own domestic drug companies by prohibiting patents on new forms and new uses of known substances, unless applicants can demonstrate they meet an additional “enhanced therapeutic efficacy” test. **Ukraine** is currently considering legislation that would restrict the patentability of new forms and uses.

In addition, multilateral organizations such as **UNDP** and **Unitaid** advocate actively for patentability restrictions and additional patentability requirements that are inconsistent with international practice. For example, although UNDP does not appear to have specialized expertise on intellectual property matters, it issued patent examination guidelines in 2016 that, if followed, would prevent innovators from securing patents on many kinds of biopharmaceutical inventions. Similarly, Unitaid partnered with various non-governmental organizations in 2018 to launch a campaign to erode intellectual property policies and laws globally.

- **Restrictions on post-filing submissions.** Unlike patent offices in the United States, Europe, Japan, Korea and other major markets, **China**’s National Intellectual Property Administration (CNIPA) does not consistently accept data generated after a patent is filed during patent prosecution to describe inventions or satisfy inventive step requirements. This practice, contrary to China’s December 2013 U.S.-China Joint Commission on Commerce and Trade (JCCT) commitment to allow patent applicants to submit additional data after filing patent applications, has caused significant uncertainty about the ability to obtain and maintain biopharmaceutical patents in China and caused denials of patents on new medicines in that country that received patents in other jurisdictions. PhRMA and its members look forward to addressing these concerns through implementation of Article 1.10 of the recently concluded Phase One of the Economic and Trade Agreement (Phase One Trade Agreement) between the United States and China.

Restrictive patentability criteria in many of these countries and others appear to be contrary to WTO rules and U.S. trade agreements, which require parties to make patents available for inventions that are new, involve an inventive step and are capable of

---


industrial application. These laws also appear to apply solely to pharmaceutical products, either expressly by law or in a de facto manner as applied. This is not consistent with the obligations of WTO Members and U.S. trade agreement partners to make patents available without discrimination as to the field of technology.

PhRMA members appreciate steps USTR and other federal agencies have taken to address restrictive patentability criteria and look forward to continuing to work closely with these agencies to secure concrete progress and real results. Effective enforcement of U.S. trade agreements is needed to resolve these challenges in particular countries and to prevent others from adopting similar practices.

Patent Backlogs

Long patent examination and approval backlogs harm domestic and overseas inventors in every economic sector. Backlogs undermine incentives to innovate, prevent timely patient access to valuable new treatments and cures, and impose huge societal costs. Because the term of a patent begins on the date an application is filed, unreasonable delays can directly reduce the value of granted patents and undermine investment in future research. For biopharmaceutical companies, patent backlogs can postpone the introduction of new medicines. They create legal uncertainty for research-based and generic companies alike, and can increase the time and cost associated with bringing a new treatment to market.

Patent backlogs are a challenge around the world, but a few countries stand out for persistently long delays. In Brazil and Thailand, for example, it can take ten years or more to secure a patent on a new medicine. In Brazil, the patent backlog challenge is compounded by an unnecessary dual examination process for biopharmaceutical patent applications. The Brazilian Health Surveillance Agency (ANVISA) may review all patent applications for new medicines, in addition to the formal patent examination process conducted by the Brazilian Patent Office. Thailand approved a patent application filed by a domestic inventor on March 1, 2011, but the granting decision was only published on October 17, 2017.

by one PhRMA member six weeks before the patent expired. The situation is only somewhat better in markets like India, where it takes an average of six years to secure a patent, and yet in 2015, India granted one patent based on an application filed 19 years earlier.

Long patent examination delays cause significant damage. A London Economics study estimated the value of lost innovation due to increased patent pendency at £7.6 billion per year. Patents are a particular challenge for small start-up firms that are playing an increasingly important role in biopharmaceutical innovation. According to a U.S. Patent and Trademark Office (PTO) Economic Working Paper, for every year an ultimately-approved patent application is delayed, a start-up firm’s employment growth decreases by 21% and its sales growth decreases by 28% on average over the following five years. Each year a patent application is delayed, the average number of subsequent patents granted decreases by 14%, and the probability that a startup will go public is cut in half.

PhRMA members support patent term restoration provisions in trade agreements and national laws to address unreasonable patent examination delays. They support initiatives to increase the efficiency of patent prosecution and reduce patent backlogs, including the PCT and work sharing arrangements through the IP5 and Patent Prosecution Highway (PPH) programs. Through these and other initiatives, national and regional patent offices in the European Union, Japan, Korea, Mexico and elsewhere are succeeding in reducing patent examination delays. However, damaging legislation in the European Union threatens to weaken patent term restoration mechanisms in Europe by reducing safeguards provided by Supplementary Protection Certificates. Further work is needed to consolidate gains in patent protections and to extend effective models to other countries.

Compulsory Licensing

Biopharmaceutical innovators support strong national health systems and timely access to safe, effective, and high-quality medicines for patients who need them. Patents drive and enable research and development that delivers new treatments and cures. These limited and temporary intellectual property rights are not a barrier to access to

84 Id.
88 Id.
medicines particularly when governments and the private sector partner to improve health outcomes.

Compulsory licenses (CLs) have been issued in several countries, including India, Indonesia, Russia and Malaysia, that allow local companies to make, use, sell or import particular patented medicines without the consent of the patent holder. Other governments, including Argentina, Australia, Chile, Colombia, El Salvador, Peru, the Philippines, Saudi Arabia, Turkey, Ukraine and Vietnam, have adopted or considered resolutions, laws or regulations that promote or provide broad discretion to issue such licenses. PhRMA believes governments should grant CLs in accordance with international rules and only in exceptional circumstances and as a last resort. Decisions should be made on public health grounds through fair and transparent processes that involve participation by all stakeholders and consider all relevant facts and options.

Experience and research demonstrates that compulsory licensing is not an effective way to improve access or achieve other public health objectives. It does not necessarily lower prices or speed access in the short-term, or provide sustainable or comprehensive solutions to longer-term challenges. It does not address systemic barriers to access from weak health care delivery systems to low national health care funding and high taxes and tariffs on medicines. Compulsory licensing is particularly ineffective relative to the many alternatives available. Biopharmaceutical innovators support different tools and programs that make medicines available to patients who could not otherwise afford them, including drug donation and differential pricing programs, voluntary licensing and non-assert declarations. In sub-Saharan Africa, for example, the majority of

---


antiretrovirals are manufactured under voluntary licenses to local generic drug companies.\textsuperscript{94}

Unfortunately, some countries appear to be using CLs to promote the local production of medicines at the expense of manufacturers and jobs in the United States and elsewhere.\textsuperscript{95} For example, Malaysia issued a CL in 2017 in a move that appears designed to facilitate the local development and marketing of a competing combination product. Indonesia’s patent law enables the government to grant CLs on the grounds that an inventor is not manufacturing a patented product in Indonesia within three years after the patent was granted. In 2013, India’s Intellectual Property Appellate Board affirmed a CL for a patented oncology medicine, based in part on a finding that the patented medicine was not being manufactured in India.\textsuperscript{96}

In its 2019 Special 301 Report, USTR rightly highlighted concerning actions by “trading partners to unfairly issue, threaten to issue, or encourage others to issue, compulsory licenses” and committed to “engage, as appropriate, with trading partners”.\textsuperscript{97} PhRMA members welcomed these statements and urge USTR and other federal agencies to engage to address serious and growing compulsory licensing threats across Latin America, Southeast Asia and elsewhere.

\textit{Weak Patent Enforcement}

To continue to invest in the research and development of new medicines, biopharmaceutical innovators must be able to effectively enforce patents. Mechanisms such as patent linkage that provide for the early resolution of patent disputes before potentially infringing follow-on products enter a market are essential for effective enforcement. The premature launch of a product that is later found to infringe a patent may disrupt patient treatment and require governments to adjust and re-adjust national formularies and reimbursement policies. For biopharmaceutical innovators, it may cause commercial damage that is impossible to repair later.

At a minimum, effective early resolution mechanisms (1) require governments to notify the holder of a patent on a biopharmaceutical product if another party applies for marketing approval for a generic or biosimilar versions of that product, (2) enable the

\begin{itemize}
\end{itemize}
holder of a patent on a biopharmaceutical product to seek provisional enforcement measures, such as a stay, preliminary injunction or interlocutory injunction, to prevent the marketing of a potentially infringing generic or biosimilar version of that product, and (3) provide for the timely resolution of patent disputes before marketing approval is granted for a generic or biosimilar.

PhRMA members welcomed bold proposed intellectual property reforms China announced in 2017, including planned implementation of a patent linkage system. Unfortunately, further action to implement these proposals has not been advanced. On the contrary, the new DAL (August 2019) as well as the proposed amendments to the Patent Law (January 2019) and Drug Registration Regulation (DRR) (October and December 2019) did not include provisions to advance these reforms. Even worse, since 2019, NMPA has approved at least 12 follow-on products while the reference products in each case are still subject to patent protection. As such, PhRMA and its member companies strongly welcome the intellectual property commitments in the Phase One Trade Agreement and look forward to securing expeditious implementation of Article 1.11 of these commitments in a manner fully grounded in international best practices.

Biopharmaceutical innovators strongly supported passage of patent linkage legislation in Taiwan in late 2017. We welcomed regulations issued on January 30, 2019, to implement patent linkage for both biologic and chemically synthesized medicines. In July 2019, Taiwan published the final patent linkage regulation and shortly thereafter the Executive Yuan approved implementation of the patent linkage system effective August 20, 2019. We commend the Taiwan government for taking this important step to improve that economy’s climate for biopharmaceutical research and development. We stand ready to work with the Taiwan Government to support implementation of the regulation and to ensure that patents on all innovative medicines are effectively enforced.

U.S. trade agreements generally require parties to notify patent holders, to act expeditiously on requests for provisional enforcement measures and to prevent the marketing of generic or biosimilar products during the patent term without the consent of the patent holder. However, some U.S. trade agreement partners do not comply with these obligations. For example, U.S. biopharmaceutical innovators do not ordinarily receive notice of a third party’s intention to obtain marketing approval in Australia, so as to enable final resolution of patent claims before marketing approval, and are unable to quickly secure effective preliminary injunctions in Mexico.

Saudi Arabia has knowingly facilitated the infringement of the patent on a medicine formulated and exported from the United States by giving a local company approval to produce a competing product during the patent term. Similarly, in 2017 the United Arab Emirates approved the sale of patent infringing generics despite the government’s pharmaceutical patent commitments in Ministerial Decree No. 404 and reciprocal patent recognition obligations under the Gulf Cooperation Council. In Bangladesh, local companies are taking advantage of the country’s least developed country (LDC) status to undermine intellectual property protections in other countries. Specifically, they are reverse engineering and making copies of biopharmaceutical
products in Bangladesh that are under patent in other parts of the world. These unlicensed biopharmaceutical products are entering markets abroad, e.g. India, where patent protection exists. The quality and safety of these products have not been reviewed and could pose significant risks. Furthermore, local companies are adopting product names for biopharmaceutical products that are nearly identical to well-known product names of U.S. biopharmaceutical companies creating confusion in the market as to their source and/or association. Under the terms of a waiver adopted in 2001 (and extended in 2015), LDCs are not obligated to comply with WTO intellectual property rules.98

Effective early resolution mechanisms are also needed in India, Russia and other countries, where innovators are not notified of marketing approval applications filed for potentially infringing products and generally are unable to secure provisional enforcement measures.

PhRMA urges USTR and other federal agencies to enforce intellectual property commitments in existing U.S. trade agreements and to continue to promote effective patent enforcement abroad, including through the JCCT, the U.S.-India Trade Policy Forum and other bilateral dialogues.

Excessive and Punitive Damages

Biopharmaceutical innovators must be able to rely on and enforce patents issued by competent government authorities. Laws or policies that allow governments or other non-parties to a patent dispute to collect excessive and punitive damage awards after the fact from innovators that pursue unsuccessful patent claims unfairly penalize and discourage the use of provisional enforcement measures as part of well-functioning early resolution mechanisms. These policies undermine legal certainty, predictability and the incentive provided by patents to invest in new treatments and cures.

The ability to enforce patents in Canada continues to weaken. Canada’s current policies inappropriately discourage and penalize innovators from seeking patent enforcement actions by enabling generic litigants to recover excessive and punitive damage awards simply because innovators unsuccessfully sought to protect patents granted by the Canadian Government. Pending court decisions could make that situation far worse – increasing the potential that innovators forfeit patents prematurely in Canada rather than defend them. Section 8 of the Patented Medicines (Notice of Compliance) Regulations (PM(NOC) Regulations) is intended to compensate generic drug companies that successfully defended patent disputes initiated by innovators for actual losses suffered during the stay period. But, Canada’s courts are granting generic litigants damages in excess of 100 percent of the total generic market.

Canada’s implementing regulations of the Comprehensive Economic and Trade Agreement further expose innovators to excessive liability under Section 8. These

regulations enable competitors to claim indefinite future losses and to seek compensation for production “ramp-up” costs they may have incurred before the stay was granted and after it was lifted. In addition, Canada’s courts are now contemplating even more excessive damage awards for generic litigants using obscure legal theories under the “Statute of Monopolies” to seek treble damages from innovators that unsuccessfully enforced their patent(s) against a generic litigant. An Ontario trial court decision awarding a generic litigant damage under this statute is currently under appeal.

Australia’s Therapeutic Goods Act passed as part of legislation implementing the U.S.-Australia Free Trade Agreement,\(^99\) provided for “market-size damages” in certain instances. Since 2012, the Australian government has stated its intent to seek – and has sought – market-size damages from biopharmaceutical innovators that have pursued unsuccessful patent claims. Those damages are designed to compensate Australia’s pharmaceutical reimbursement scheme (PBS) for any higher price paid for a patented medicine during the period of a provisional enforcement measure. The PBS imposes automatic price cuts on medicines as soon as competing versions enter the market, but the policy entails no corresponding mechanism to compensate innovators for losses if an infringing product is launched prematurely.

By pursuing market-size damages, Australia is unfairly tipping the scales in commercial patent disputes – encouraging competitors to launch at risk and discouraging innovators from enforcing their patents. This action creates an inappropriate conflict of interest by permitting the same government that examined and granted a patent to seek damages if that patent is later ruled invalid or not infringed. It exposes innovators to significant additional compensation claims that are difficult to quantify and were not agreed to at the time provisional enforcement measures were granted. The size of these additional claims equates legitimate patent enforcement with patent abuse. Allowing governments or other non-parties to a patent dispute to collect market-size damages undermine legal certainty, predictability and the incentives patents provide for investment in new treatments and cures. Australia’s practice appears to be inconsistent with the U.S.-Australia Free Trade Agreement and with WTO intellectual property rules, including with respect to provisional measures.

In a 2004 letter\(^100\) to Australia’s trade minister, USTR raised concerns about the significant and negative impact that the Therapeutic Goods Act amendments permitting market-size damages could have on patent rights and the consistency of those amendments with Australia’s international obligations. The letter stated that the “United States reserves its right to challenge the consistency of these amendments with such obligations.” PhRMA members urge USTR and other federal agencies to prioritize actions to address Australia’s pursuit of market-size damages.


Regulatory Data Protection Failures

Regulatory data protection (RDP) complements patents on innovative medicines. By providing temporary protection for the comprehensive package of information biopharmaceutical innovators must submit to regulatory authorities to demonstrate the safety and efficacy of a medicine for marketing approval, RDP provides critical incentives for investment in new treatments and cures and increases the likelihood of successful commercialization of new medicines.101

RDP is a carefully balanced mechanism that improves access to medicines of all kinds. Prior to 1984, generic drug companies in the United States were required to generate their own test data for marketing approval. The Hatch-Waxman Act introduced abbreviated pathways that enabled generic drug companies to rely on test data developed by innovators.102 In exchange, innovators received a period of protection for test data gained through substantial investments in clinical trials over many years. As a result of this and other provisions of Hatch-Waxman, the percentage of prescription drugs filled by generics soared from 19% in 1984 to 74% in 2009. Today, generics account for approximately 90% of all prescriptions filled in the United States.103

RDP is particularly critical for biologic medicines, which may not be adequately protected by patents alone. Made using living organisms, biologics are so complex that it is possible for others to produce a version – or “biosimilar” – of a medicine that may not be covered within the scope of the innovator’s patent. For this reason and others, U.S. law provides twelve years of RDP for biologics. This was not an arbitrary number, but rather the result of careful consideration and considerable research on the incentives necessary to ensure biopharmaceutical innovators and the associated global scientific ecosystem are able to sustainably pursue groundbreaking biomedical research.104

Unfortunately, many U.S. trading partners do not provide RDP. Examples, some of which are described further in the country profiles below, include Algeria, Argentina, Brazil, China, Egypt, India and Turkey. Others, like Saudi Arabia, provide RDP but have allowed local companies to rely on data submitted by American innovators during the period of protection. This is contrary to WTO rules, which require parties to protect regulatory test data submitted as a condition of obtaining marketing approval against both disclosure and unfair commercial use. U.S. trade agreements generally require parties to

103 PhRMA analysis based on IQVIA National Sales Perspective and Quintiles, IMS Institute MIDAS™ audited data, 2017.
provide RDP for a specified period of time, but some partner countries have not fully honored their commitments. For example, Mexico and Peru provide RDP for small-molecule treatments, but not for biologics. Israel enacted legislation affording limited RDP to new chemical entities, but it fails to provide such protection for biologics. Israel established an inter-governmental committee in 2018 to consider providing RDP for biologics, although the process has not yet yielded a policy recommendation for providing adequate protection. We urge Israel to complete the regulatory impact assessment process and provide a period of RDP for biologic drugs that reflects the highest international standards. Meanwhile Canada passed legislation in 2014 that gives the Health Minister broad discretion to share undisclosed test data without safeguards to protect against unfair commercial use. Other countries provide RDP in a manner that discriminates against foreign innovators.

PhRMA urges USTR and other federal agencies to enforce intellectual property commitments in existing U.S. trade agreements, to address RDP failures in bilateral forums and to seek and secure RDP commitments in trade agreement negotiations that reflect the high standards found in U.S. law.

C. Localization barriers – A cross-cutting challenge

Like businesses in many other sectors of the U.S. economy, PhRMA members are witnessing a proliferation of acts, policies and practices abroad that are designed to benefit local producers at the expense of manufacturers and their employees in the United States and elsewhere around the world. In countries like Argentina, China, India, Indonesia, Russia, and Turkey these localization barriers have become so pervasive that they are now a routine part of many transactions between businesses and governments – from securing patents, regulatory approval and market entry to the most minor administrative formalities.

These discriminatory measures put American jobs at risk and appear to violate the most basic principles of the global trading system found in the General Agreement on Tariffs and Trade, TRIPS and the WTO Agreements on Technical Barriers to Trade and Trade-Related Investment Measures. They deny adequate and effective intellectual property protection for biopharmaceutical innovators in the United States and fair and equitable market access for new medicines, vaccines and other health technologies. Some examples of the most serious localization barriers that are undermining the ability of PhRMA members to develop and deliver new treatments and cures include:

- Market entry or other benefits conditioned on local manufacturing. While many economies provide positive incentives for businesses to conduct research and development and to manufacture in their markets, an alarming number are

---

seeking to grow their economies by discriminating against innovators in the United States and other countries. For example, Turkey has removed products from the reimbursement list that are not produced in Turkey. Algeria prohibits imports of virtually all biopharmaceutical products that compete with similar products manufactured domestically. Russia’s Law on the Federal Contract System allows government medicines procurement agencies to ban foreign goods in public procurement tenders. Moreover, Russia is implementing legislation that limits national medicine procurement to manufacturers in the Eurasian Economic Union if there are two or more manufacturers for a particular class of medicine. Indonesia’s new Patent Law permits the government to compulsory license patented medicines if the patent holder does not begin manufacturing that medicine in Indonesia within three years after the patent is granted.\footnote{Cory, N., “The Worst Innovation Mercantilist Policies of 2016,” Information Technology and Innovation Foundation, Jan. 2017, available at http://www2.itif.org/2017-worst-innovation-mercantilist-policies.pdf?_ga=1.176855585.581989633.1484510758 (last visited Feb. 6, 2020).}

- \textit{Mandatory technology transfer}. In Indonesia and other countries, local manufacturing requirements are coupled with other policies that directly expropriate sensitive intellectual property and know-how. For example, a foreign biopharmaceutical company may import medicines into Indonesia only if it partners with an Indonesian firm and transfers relevant technology so that those medicines can be domestically produced within five years. Requiring technology transfer to import medicines into Indonesia creates a windfall for domestic firms and artificially distorts the market.

- \textit{De facto bans on imports}. Manufacturing licensing requirements generally are intended to ensure that companies meet globally recognized standards – such as good manufacturing practices (GMP). Some countries exploit these licensing requirements by adopting policies that virtually prevent market entry. For example, Turkey does not recognize internationally accepted GMP certifications from other countries unless they have mutual recognition agreements (MRAs) on inspections with Turkey. Given, however, the many steps that would need to be satisfied before an MRA could be pursued between the United States and Turkey, this policy serves as a \textit{de facto} ban on imports from biopharmaceutical innovators in the United States. Turkey has stated publicly that the purpose of this policy is to promote Turkish drug companies.

barriers in place. They cost businesses and their employees in the United States and other leading nations by cutting tens of billions of dollars in global trade and by reducing global income and innovation. They do not increase biopharmaceutical investment or knowledge-intensive employment in countries that adopt localization barriers. In fact, they can even reduce employment – particularly for the less skilled – by raising input costs and severing connections to global value chains.  

PhRMA members appreciate the attention USTR and other federal agencies have given to localization barriers in recent reports and publications. However, action is urgently needed to remove these barriers and to discourage other countries from adopting similar acts, policies and practices. Biopharmaceutical innovators in the United States look forward to concrete progress and real results in 2020.

III. Addressing Challenges and Securing the Benefits of Biopharmaceutical Innovation

To address these pressing challenges and ensure biopharmaceutical innovators in the United States can continue to research, develop and deliver new treatments and cures for patients who need them around the world, PhRMA members urge USTR and other federal agencies to take the following five actions. These actions can help ensure access to quality, safe and effective medicines at home and abroad by promoting high standards of protection for patents and regulatory test data, effective enforcement of these and other intellectual property rights and transparent and predictable legal and regulatory regimes.

A. Enforce and defend global, regional and bilateral rules

USTR and other federal agencies should use all available tools and leverage to ensure America’s trading partners live up to their obligations in global, regional and bilateral trade and investment agreements. Modernizing existing trade agreements and stepping up enforcement activity in the months ahead will be critical to end discriminatory pricing policies and to address longstanding intellectual property challenges around the world – particularly in countries that are U.S. trade and investment agreement partners, that have made important unfulfilled WTO accession commitments and that benefit from U.S. trade preference programs.

U.S. regional and bilateral trade agreements affirm globally accepted standards for the patentability of biopharmaceutical and other inventions and require countries to protect regulatory test data, provide mechanisms that enable innovators to resolve patent

---


disputes prior to the marketing of potentially infringing products, and establish a stronger intellectual property framework. Some also include government pricing and reimbursement and transparency commitments. However, Australia, Canada, Chile, Colombia, Korea and other U.S. trading partners fail to adequately comply with some or all of these obligations. USTR and other federal agencies should consider a process to systematically review compliance with trade and investment agreements and take steps necessary to ensure agreed rules are followed.

On joining the WTO in 2001, China committed to provide six years of protection for clinical test and other data submitted for regulatory approval of biopharmaceutical products containing a new chemical ingredient. China has never implemented this obligation, despite agreement to do so during the 2012 U.S.-China Joint Commission on Commerce and Trade meeting. In light of these deficiencies, we strongly welcomed the CFDA draft Circular 55 (Relevant Policies on Protecting Innovators’ Rights to Encourage New Drug and Medical Device Innovation) and draft “Implementing Provisions on Protection of Drug Trial Data” (April 2018), which propose up to twelve years of RDP for therapeutic biologics, orphan and pediatric medicines and six years of RDP for new small molecule drugs. These proposals represent a strong first step toward reform in this area, but it is now imperative that these proposed policy revisions are transparently and expeditiously implemented in a manner that provides for effective protection for U.S. biopharmaceutical companies and is consistent with international best practices and China’s renewed commitment to provide RDP as affirmed in the chapeau to Section C of Chapter One of the Phase One Trade Agreement.

The Generalized System of Preferences (GSP) program provides unilateral duty-free access to the U.S. market for more than 3,500 products. Before granting GSP benefits to an eligible country, the President must take into account a number of factors, including the extent to which the country is willing to “provide equitable and reasonable access to its markets” and is “providing adequate and effective protection of intellectual property rights.” However, GSP beneficiaries like Argentina, Brazil, and Indonesia do not provide adequate and effective protection of intellectual property rights or fair and equitable market access.

The Special 301 Report is an important tool to identify and prioritize acts, policies and practices in these and other overseas markets that are harming America’s creative

---

and innovative industries by denying adequate and effective intellectual property protection and fair and equitable market access. PhRMA members urge USTR and other federal agencies to ensure this tool is used effectively. Action plans required by the Trade Facilitation and Trade Enforcement Act of 2015 should be developed for countries listed on the Priority Watch List with input from relevant stakeholders.\(^\text{113}\) Out-of-cycle reviews announced in the Special 301 Report should be conducted and should involve the participation of relevant stakeholders.

USTR should prioritize actions to fill key enforcement positions, including the position of Chief Innovation and Intellectual Property Negotiator. Where necessary, USTR should consider bringing dispute settlement cases to secure compliance with trade and investment agreement commitments.

**B. Secure strong commitments in global, regional and bilateral negotiations**

Global, plurilateral, and bilateral trade and investment negotiations provide critical opportunities to build on the existing foundation of international rules and to secure commitments necessary to drive and sustain 21\(^{\text{st}}\) century biopharmaceutical innovation. Ending discriminatory pricing policies, eliminating restrictive patentability criteria, addressing unreasonable patent examination and approval delays, providing for the early and effective resolution of patent disputes, ensuring robust protection of regulatory test data, and reducing unnecessary regulatory barriers can promote biopharmaceutical innovation and improve market access.

PhRMA supports trade agreements that include strong protections for intellectual property, ensure fair and equitable market access and enable biopharmaceutical innovators in the United States to export lifesaving medicines to patients around the world. Free and fair trade agreements open new markets. They help grow our economy and create better, higher-paying jobs. PhRMA members look forward to continuing to work with USTR and other federal agencies to modernize existing trade agreements and to consider opportunities to further improve public health and grow American manufacturing exports and jobs through additional trade agreements, including with leading U.S. biopharmaceutical export markets.\(^\text{114}\)

**C. End discrimination in pricing and reimbursement**

PhRMA members are, and seek to be, partners in solutions to health care challenges facing patients and their communities around the world. However, some governments have proposed or implemented pricing and reimbursement policies that discriminate against medicines made in America, do not appropriately value innovation

---


and lack predictable, transparent, and consultative processes. Such measures can undermine the ability of biopharmaceutical innovators to bring new medicines to patients who need them and to invest in future treatments and cures. Free-riding by developed nations that can afford to pay for novel drugs leaves American patients to pay for the innovation that foreign patients enjoy.

The biopharmaceutical industry is unique in that most foreign governments, as sole or primary health care providers, impose burdensome and often discriminatory price controls and regulations on the sector. Others have resorted to improperly using national compulsory licensing provisions to threaten or coerce manufacturers to accept pricing agreements on unreasonable commercial terms and conditions. As a result, market access for pharmaceuticals is not only dependent on innovators meeting strict regulatory approval standards and obtaining necessary intellectual property protections, but also on obtaining positive government pricing and reimbursement determinations. It is imperative, therefore, that regulatory procedures and decisions regarding the approval and reimbursement of medicines are governed by fair, transparent and verifiable rules guided by science-based decision making. There should be meaningful opportunities for input from manufacturers and other stakeholders to health authorities and other regulatory agencies and a right to appeal government pricing and reimbursement decisions to an independent, objective court or administrative body.

The U.S. government can play a critical role in ensuring transparency and due process of pricing and reimbursement policies, as well as in highlighting the global benefits to patients that result from a reduction in trade barriers. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 called for the Administration to develop a strategy to address foreign price controls on pharmaceuticals and related practices through bilateral and multilateral trade negotiations. PhRMA believes that the cornerstone of any such strategy must be a proactive U.S. trade policy focused on: (i) addressing discriminatory government price controls and related practices; and (ii) highlighting the global benefits for patients from the potential groundbreaking research that could result from a reduction in key trade barriers. Unfortunately, governmental policies around the globe over the last year have continued to harm patient access to innovative medicines.

PhRMA members appreciate steps USTR and other federal agencies have taken to ensure fair and equitable market access for innovative medicines in overseas markets, including seeking and securing commitments in trade agreements that ensure pricing and reimbursement policies abroad are fair, reasonable, and non-discriminatory, and appropriately value patented pharmaceuticals. PhRMA urges USTR and other federal agencies to continue to promote the full implementation of these commitments and to build on them in future trade negotiations by ensuring future trade agreements meet the Trade Promotion Authority objective to “ensure that government regulatory
reimbursement regimes are transparent, provide procedural fairness, are non-discriminatory, and provide full market access for United States products.”

In particular, proposed laws, regulations and procedures concerning how medicines are approved, priced, and reimbursed should be:

- Promptly published or otherwise made available to enable interested parties to become acquainted with them.
- Published prior to adoption in a single official journal of national circulation, with an explanation of the underlying purpose of the regulation. In addition, interested parties (including trading partners) should be provided a reasonable opportunity to comment on the proposed measures. Those comments and any revisions to the proposed regulation should be addressed in writing at the time that the agency adopts its final regulations. Finally, there should be reasonable time between publication of the final measures and their effective date so that the affected parties can adjust their systems to reflect the new regulatory environment.

In turn, specific regulatory determinations or pricing and reimbursement decisions should be:

- Based on fair, reasonable, consistent and non-discriminatory procedures, rules and criteria that are fully disclosed to applicants.
- Completed within a reasonable, specified timeframe. In some countries, there are no deadlines for making decisions on whether to approve new medicines. In others, deadlines exist, but are regularly not met. These delays impede market access, deplete the patent term, and are detrimental to patients waiting for life-saving medicines.
- Conducted so that they afford applicants timely and meaningful opportunities to provide comments at relevant points in the decision-making process.
- Supported by written reports which explain the rationale for the decision and include citations to any expert opinions or academic studies relied upon in making the determination.
- Subject to an independent review process.

D. Combat the worldwide proliferation of counterfeit medicines

PhRMA members view counterfeit medicines as a critical public health and safety concern threatening patients around the world, and as such commend the U.S. and Chinese Governments for the commitments in Section G of Chapter One of the Phase One Trade Agreement to combat counterfeiting. Counterfeit medicines may deprive patients of the medicines they need and contribute to drug-resistant forms of tuberculosis.

---

115 Section 102(b)(7)(G) of the Bipartisan Congressional Trade Priorities and Accountability Act of 2016 (P.L. 114-26).
and other serious diseases and contain impurities or toxins that can cause harm or even death.\textsuperscript{116} This challenge is exacerbated by the ease with which counterfeiters can offer fake medicines over the Internet\textsuperscript{117} and ship them by mail\textsuperscript{118} to patients and consumers worldwide.\textsuperscript{119}

Counterfeit medicines are a potential danger to patients everywhere, including in the United States. During fiscal year 2018, U.S. Customs and Border Protection seized more than 2,200 shipments of counterfeit pharmaceuticals at America’s borders.\textsuperscript{120} Using a broader measure that includes counterfeiting, illegal diversion and theft, the Pharmaceutical Security Institute documented more than 4,400 incidents of pharmaceutical crime in the United States in calendar year 2018 – an all-time high.\textsuperscript{121} Across all sectors, the Organization for Economic Cooperation and Development (OECD) found that global counterfeiting and piracy accounts for 2.5 percent of world trade and disproportionately harms innovators in the United States.\textsuperscript{122}


\textsuperscript{118} An OECD study found that more than 60% of counterfeit goods seized around the world between 2011 and 2013 were shipped by mail or express carrier. OECD, “Trade in Counterfeit and Pirated Goods: Mapping the Economic Impact,” 2016, available at http://www.keepeek.com/Digital-Asset-Management/oecd/governance/trade-in-counterfeit-and-pirated-goods_9789264252653-en#WHv5mpcraBc#page1 (last visited Feb. 6, 2020).

\textsuperscript{119} Institute of Medicine (IOM), \textit{Countering the Problem of Falsified and Substandard Drugs}, Feb. 2013, available at https://iom.nationalacademies.org/~/media/Files/Report%20Files/2013/Substandard-and-Falsified-Drugs/CounteringtheProblemofFalsifiedandSubstandardDrugs_RB.pdf (last visited Feb. 6, 2020). The IOM notes that “because the internet facilitates easy international sales, online drug stores have spread the problem of falsified and substandard drugs…. Id.


China and India are leading sources of fake medicines seized at ports of entry in the United States\textsuperscript{123} and elsewhere,\textsuperscript{124} though many other jurisdictions are involved – particularly in online sales.\textsuperscript{125} According to the WHO, regions where protection and enforcement systems are weakest also see the highest incidence of counterfeit medicines. In these jurisdictions and others, customs and other law enforcement officials often are not able to seize counterfeit medicines, particularly goods in transit, goods in free trade zones and goods offered for sale on the Internet. Violations of limited laws on the books often are not effectively enforced or do not come with sufficient penalties to deter counterfeiting.\textsuperscript{126}

PhRMA member companies work to maintain the safety of their manufacturing facilities and the security of their global supply chains. They currently employ and routinely enhance a variety of anti-counterfeiting technologies, including covert and overt features on the packaging of high-risk prescription medicines. They have adopted a range of business processes to better secure prescription drug supply chains and facilitate the early detection of criminal counterfeiting activity. They partner with law enforcement officials around the world.

To combat the global proliferation of counterfeit medicines and active pharmaceutical ingredients, PhRMA supports strengthening training and collaboration with U.S. trading partners to adopt and implement a comprehensive regulatory and enforcement framework that: (i) subjects drug counterfeiting activity to effective administrative and criminal remedies and deterrent penalties; (ii) adequately regulates and controls each link in the legitimate supply chain; (iii) trains, empowers and directs drug regulators, law enforcement authorities and customs to take effective and coordinated action, including against exports and online activity; and (iv) educates all stakeholders about the inherent dangers of counterfeit medicines.

\textbf{E. Build and strengthen global cooperation}

Finally, PhRMA members urge USTR and other federal agencies to further build and strengthen partnerships with countries around the world that also have a critical stake in combating counterfeit medicines.


in a strong and effective intellectual property system that values and protects innovation. Federal agencies should promote full implementation and ensure effective enforcement of global, regional and bilateral commitments and support training of regulators, law enforcement officials, judges and other court personnel overseas to enforce those commitments.

PhRMA members appreciate the steps USTR and other federal agencies are already taking to strengthen cooperation with other governments. Bilateral forums like the Transatlantic IPR Working Group have helped to build understanding and to identify and advance common priorities. They can be a model for similar engagement with other countries. The network of PTO intellectual property attachés around the world is a vital resource for American inventors and should be expanded. Cooperation between PTO and other leading patent offices through the PCT, the IP5 and PPH programs is cutting costs, improving the efficiency of patent examination in overseas markets and helping to reduce stubbornly high patent examination backlogs.

All this provides a valuable foundation on which to build in the coming year and beyond. PhRMA members believe that strengthening such coalitions will be particularly critical in multilateral organizations that advise countries and provide assistance on policies related to global trade, intellectual property, and pharmaceutical markets. Organizations such as the WHO, the World Intellectual Property Organization (WIPO), the WTO, UNDP, and UNCTAD often focus their work inappropriately on limitations and exceptions to intellectual property rights, as well as promote a range of harmful policies that would undermine vital incentives for innovation. For example, WHO’s new Roadmap on Access to Medicines envisions providing “technical support” to countries that intend to engage in compulsory licensing, with one regional WHO office openly asserting that compulsory licensing is “important and to be encouraged.” Unitaid has directed millions of dollars to programs that seek to weaken intellectual property laws and lobby governments to reject provisions in international trade agreements that would strengthen innovation incentives. U.S. leadership will be essential to preventing such organizations from weakening or even eliminating the intellectual property protections that drive America’s innovation economy.

As the leading funder of the United Nations, WHO, and many other multilateral organizations, the United States must remain vigilant in these forums and work with other like-minded countries to advocate for robust intellectual property protection and fair and equitable market access. Federal agencies should ensure intellectual property matters are addressed in organizations with the appropriate mandate and expertise, and with full

---

visibility of the organization’s Member States. The U.S. government should strengthen interagency coordination and ensure officials with intellectual property expertise are part of U.S. delegations to relevant global meetings. U.S. leadership can also help ensure all stakeholders, including the private sector, are able to contribute to discussions in multilateral organizations on relevant topics.

IV. Country Designation Index

A. Priority Foreign Country

PhRMA urges USTR to designate Canada, Japan, Korea and Malaysia as Priority Foreign Countries. Market access and/or intellectual property acts, policies and practices in these four countries are the most onerous and egregious. They are having or could have the greatest adverse impact on medicines developed and manufactured in the United States. USTR and other federal agencies should use all available tools to remedy serious concerns in these countries.

B. Priority Watch List

PhRMA recommends that 13 countries be included on the Priority Watch List. We further recommend that China continue under Section 306 Monitoring. The detailed information presented in the country-specific sections below demonstrates that the acts, policies and practices of these countries are denying adequate and effective intellectual property protection or fair and equitable market access. They are harming biopharmaceutical innovators and their employees in the United States and limiting their ability to bring new treatments to patients around the world. In many cases, they appear to be inconsistent with relevant global, regional and bilateral trade and investment agreement rules. To evaluate progress and secure action and real results, PhRMA recommends that USTR conduct meaningful Out-of-Cycle Reviews for Chile and Colombia.

C. Watch List

PhRMA recommends that seven markets be included on the Watch List. We urge USTR and other federal agencies to include all these countries in the 2020 Special 301 Report – particularly Australia and other countries that are current or potential U.S. bilateral trade agreement partners. To evaluate progress and secure action and real results, PhRMA recommends that USTR conduct a meaningful Out-of-Cycle Review for Mexico. USTR and other federal agencies should monitor developments in these countries and address specific intellectual property and market access concerns through bilateral and multilateral engagement.
CANADA

PhRMA and its member companies operating in Canada are extremely concerned about Canada’s pricing environment and intellectual property (IP) protections for patented products. Of particular concern are Canada’s new pricing policies for patented products that would significantly undermine the practical benefits to U.S. companies of Canada’s trade-related intellectual property commitments, and which create uncertainty for patients. In addition, Canada’s IP regime continues to lag behind that of other developed nations in several respects.

Key Issues of Concern:

- **The Patented Medicine Prices Review Board (PMPRB):** On December 2, 2017, Canada proposed regulatory changes to the current mandate of the PMPRB from ensuring “non-excessive” prices to ensuring “affordable” prices, and to change its pricing regulations accordingly. An initial analysis of the potential impacts of these proposed changes to the PMPRB regulations estimated that industry revenues could be reduced by a minimum of $2.2 billion annually, or 25 percent of the Canadian market for innovative medicines.\(^{130}\) An updated analysis conducted in July 2018 found that the proposals would lead to dramatic ceiling price reductions ranging from 40 to 90 percent, depending upon the medicine and, so, an even sharper decline in revenues than originally estimated.\(^{131}\) Key changes amend the basket of reference countries (removing the U.S. and Switzerland from the basket and including other lower priced jurisdictions) with the intent of setting prices of patented medicines at the OECD median, introduce various new factors to determine whether a price is “excessive,” and require manufacturers to report all indirect price reductions. These changes could have a serious negative impact on U.S. biopharmaceutical companies operating in Canada, the availability of new medicines for Canadian patients, and the competitiveness of Canada for research-based pharmaceutical investment.

On August 21, 2019, Canada published the final regulations governing the PMPRB in Canada Gazette, Part II\(^{132}\) (the “Amended PMR”). The Amended PMR do not contain significant changes from what was proposed in December 2017. Canada is estimating that the Amended PMR will cost industry $8.8 billion CAD in lost revenue (over 10 years at net present value); however, depending on how they are implemented, the cost to industry could be as high as $24.9 billion CAD over


\(^{131}\) Ernst & Young, Analysis of impacts of PMPRB Pharmacoeconomic factors analysis, July 2018.

the same period. It is expected that the Amended PMR will significantly undermine the marketplace for innovative pharmaceutical products, delay or prevent the introduction of new medicines in Canada and reduce investments in Canada’s life sciences sector.

The changes require manufacturers to report to the PMPRB health technology assessments (HTAs) produced by the Canadian Agency for Drugs and Technologies in Health (CADTH) and any other publicly funded agency. HTA analyses involve analytical decisions which can be subjective and are not an appropriate tool to set binding regulatory price ceilings. Further, manufacturers have concerns with current CADTH proposals to no longer protect confidential business information as part of its review processes. We urge the U.S. government to elevate concerns with Canada regarding the PMPRB reforms and the evolving role of CADTH within this process.

- **Following market approval, regulatory barriers to patient access to new medicines:** Bureaucratic barriers exist in Canada that extend the time between submission to the federal government of newly discovered medicines and vaccines for safety approval, and their ultimate availability through public reimbursement plans to benefit Canadian patients. This results in significant delays in access to innovative medicines, while also decreasing the time that innovative companies have to recoup their investments.

- **Weak patent enforcement:** The Canadian Patented Medicines (Notice of Compliance) Regulations (the “PM(NOC) Regulations”)\(^{133}\) include several key deficiencies that weaken Canada’s enforcement of patents, including excessive and windfall damage awards to generic litigants, and limitations and inequitable eligibility requirements on the listing of patents in the Patent Register. Recent jurisprudence under the PM(NOC) Regulations has also resulted in a heightened level of liability for patent owners akin to punitive damages. PhRMA and its member companies are also troubled to see that Canada has used implementation of the Canada-EU Comprehensive Economic and Trade Agreement (CETA)\(^{134}\) to implement reforms not required by that Agreement, which expose innovators to even greater potential liability under Section 8 of the PM(NOC) Regulations.\(^{135}\) PhRMA members are also concerned about potential damage awards which could stem from various common law theories within the Canadian provincial courts.

- **Inadequate patent term restoration (PTR):** Under CETA, Canada is required to provide innovators with some compensation for delays in obtaining marketing

\(^{133}\) Patented Medicines (Notice of Compliance) Regulations, SOR/93-133.


\(^{135}\) Supra note 133, at s.8.
approval for pharmaceuticals. The USMCA also requires Canada to provide PTR for unreasonable delays during the prosecution and issuance of any patent. However, in its CETA implementing regulations, Canada has chosen to implement an “export” exception that is inconsistent with the fundamental purpose of restoring a portion of the patent term lost due to the marketing approval process and has only adopted the minimum term of PTR negotiated under CETA further deviating from global standards. Furthermore, Canada’s adoption of restrictive time limits and eligibility criteria will unduly and unreasonably limit patent term restoration eligibility in Canada in a manner that is contrary to the intent of the negotiation and the CETA text itself. PhRMA’s member companies believe Canada should support innovation by ensuring that its PTR system effectively ameliorates the effects of lengthy regulatory processes, which can significantly erode the duration of the IP rights of innovators.

- **Standard for the disclosure of confidential business information (CBI):** In November 2014, Canada enacted legislation to update its Food and Drugs Act (Bill C-17). Provisions in that law granted the Health Minister discretion to disclose a company’s CBI without notice to the owner of the CBI and in accordance with a standard that is both inconsistent with other similar Canadian legislation and Canada’s treaty obligations. On March 20, 2019, regulations were put in place respecting these authorities to release information about therapeutic products. Further, on July 9, 2018, the Federal Court of Canada issued a decision ordering Health Canada to release vast amounts of pharmaceutical clinical trial data on five medications to a researcher, undercutting the federal government’s attempts to keep the information confidential. The decision, which was not appealed by Health Canada, has the potential to exacerbate the negative impacts of the draft regulations and guidelines on biopharmaceutical innovators.

For these reasons, PhRMA requests that Canada be designated a **Priority Foreign Country** in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

**Intellectual Property Protection and Pricing of Patented Products**

**The Patented Medicine Prices Review Board (PMPRB)**

The PMPRB is a quasi-judicial body, created under the Canadian *Patent Act*. The legislative mandate of the Board is to ensure that patented prices are not “excessive.”

---

138 Doshi v. Canada (Attorney General), 2018 FC 710.
Due to its power in shaping the real-world benefits of IP property protections, the PMPRB is an important institution within Canada’s broader IP regime for pharmaceuticals. The PMPRB regulates the maximum allowable price that a manufacturer can charge for all patented medicines in Canada. The Board does not make decisions about the amount of reimbursement for a product, which is appropriately the responsibility of separate federal and provincial/territorial government agencies, or private insurers.

On December 2, 2017, Health Canada proposed Regulations amending the Patented Medicines Regulations (PMR) in Canada Gazette, Part I. On August 21, 2019, Health Canada published the Amended PMR in Canada Gazette, Part II. The Amended PMR was largely unchanged from the proposals put forward in Canada Gazette, Part I, on December 2, 2017. The PMPRB changes were initiated as part of the Board’s professed role as a “counterweight to the patent rights of pharmaceutical manufacturers.” The Amended PMR constitutes an impermissibly broad exception to IP rights in contrast to Canada’s obligation under the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which requires that a member state not impose measures that “unreasonably conflict with a normal exploitation of the patent” and not “unreasonably prejudice the legitimate interests of the patent owner”. The changes could negatively impact the innovative biopharmaceutical industry, the availability of new medicines to Canadian patients, and the competitiveness of Canada for research-based pharmaceutical investment. The Amended PMR will come into force on July 1, 2020.

Recent analysis found that patented drugs accounted for only 6.7 percent of the $232.9 billion reported by the Canadian Institute for Health Innovation for total health spending in Canada in 2016. Moreover, patented drugs have experienced near zero

---


143 TRIPS Article 28 provides that a patent “shall confer” on its owner the exclusive rights to prevent third parties without the owner’s consent from “the acts of: making, using, offering for sale, selling, or importing for these purposes that product.” In turn, TRIPS Article 30 permits WTO members to grant only “limited” exceptions to these exclusive rights, provided that such exceptions do not conflict with the “normal exploitation” of the patent and do not prejudice the legitimate interests of the patent owner. The Canada—Pharmaceuticals panel appropriately recognized that the “normal exploitation” of a patent includes the realization of anticipated “economic returns” during a defined period of exclusivity “as an inducement to innovation.” See WTO, Panel Report, Canada – Patent Protection of Pharmaceutical Products, WT/DS/114/R, ¶¶ 7.54-55 (Mar. 2000), available at https://www.wto.org/english/tratop_e/dispu_e/7428d.pdf (last visited Feb. 6, 2020).

real cost growth over the last decade. These data suggest that patented medicines are not the primary cost driver of Canadian health expenditure, so we question whether the reforms will generate benefits to outweigh the potential risks to access and innovation that will be created. Low prices should not be the only goal of pharmaceutical policy and we urge the government to take a more holistic view. It is crucial to carefully consider the impact of pricing policy on access to new medicines, clinical studies, launch of new treatments, investment, jobs, and the research ecosystem as a whole.

One conservative analysis of the initially proposed changes to the PMPRB estimated that industry revenues could be reduced by a minimum of $2.2 billion annually, or 25 percent of the Canadian market for innovative medicines. An updated analysis completed in July 2018 indicates that the Amended PMR could result in dramatic ceiling price reductions ranging from 40 to 90 percent, depending upon the medicine and, so, an even sharper decline in revenues. These analyses do not account for the full scope of the potential impacts to the innovative industry and the Canadian economy. Depending on how the reforms are implemented, the financial and non-financial impacts could be more severe.

Through the Amended PMR, Canada amended the PMPRB’s basket of reference countries with the goal of setting ceiling prices of patented medicines in Canada at the Organization for Economic Cooperation and Development (OECD) median. Specifically, the PMPRB removed the U.S. and Switzerland, the two jurisdictions in the OECD with higher prices than Canada. The amendments also added six jurisdictions with lower drug prices than Canada to the basket: Japan, Australia, Belgium, the Netherlands, Norway and Spain. The new basket will now consist of: Australia, Belgium, France, Germany, Italy, Japan, the Netherlands, Norway, Spain, Sweden and the United Kingdom. Despite being at the forefront of OECD economies, Canada has amended its list of reference countries to replace the U.S. and Switzerland with countries which are poorer and/or have onerous price control policies. The U.S. is Canada’s largest trading partner and the pharmaceutical markets in both countries share many common features. Any pricing determinations in Canada based on reference to other countries should include the U.S. and other countries with pro-innovation pharmaceutical policies.

Canada also introduced new economic factors to determine whether a price is “excessive.” The new economic factors to regulate prices include pharmacoeconomic evaluation based on an arbitrary monetary threshold of the value of an additional year of life; price ceilings based on projected market size; and the proportion of gross domestic

145 Id.
147 Ernst & Young, Analysis of impacts of PMPRB Pharmacoeconomic factors analysis, July 2018.
product spent on patented medicines. Such thresholds will impact the future viability of many drugs for rare diseases, oncology treatments, gene therapy, precision medicine and other similar innovations in Canada. While cost-effectiveness thresholds are used downstream in other nations in making reimbursement decisions, their utilization as part of a binding regulatory price ceiling is unique to Canada.

In the thirty years since the PMPRB was established, a variety of mechanisms have emerged in Canada for the government and industry to work together to ensure the affordability of medicines. These mechanisms include the Canadian Agency for Drugs and Technologies in Health (CADTH), the Common Drug Review (CDR) and pan-Canadian Oncology Drug Review, the pCPA, and confidential product listing agreements, among others. Indeed, the specific change to include a cost-effectiveness factor as part of PMPRB’s price evaluation overlaps with and duplicates the work of existing publicly funded agencies (e.g., CADTH), and its major beneficiary would be for-profit private insurers as opposed to patients. Any expansion of the PMPRB’s mandate to include “affordability” is therefore unnecessary and would harm U.S. innovative biopharmaceutical companies through additional downward pricing pressures.

In addition, the Amended PMR will require manufacturers to report all indirect price reductions given as a promotion or in the form of rebates, discounts, refunds, free goods, free services, gifts, or any other benefit in Canada (including confidential rebates agreed to with public/private insurers). Given the lack of information on the purpose and use of this information, potential legal concerns and the risk of significant and negative consequences for public payers and other market participants, PhRMA is concerned with the mandatory submission of indirect price reduction information to the PMPRB.

The Amended PMR will come into effect on July 1, 2020, and will apply to new and existing medicines for sales that occur after July 1, 2020 with the exception of the new economic factors which will apply to medicines that receive a drug identification number after August 21, 2019, the date the Amended PMR were published in Canada Gazette Part II. The Canadian innovative pharmaceutical industry, led by its industry association Innovative Medicines Canada, is challenging the Amended PMR through a judicial review proceeding that will seek to invalidate the amendments on several grounds. The judicial review hearing is scheduled to take place before the regulations come into force. In addition, six innovative pharmaceutical companies are challenging the constitutional jurisdiction of the PMPRB’s legislative and regulatory framework in the Superior Court of Quebec on the basis that price regulation is a provincial responsibility.

Additionally, the process of implementing the Amended PMR through changes to the PMPRB’s Guidelines raise many additional points of uncertainty and risk for U.S. biopharmaceutical innovators. The PMPRB released its draft Guidelines on November

---


While the Guidelines are non-binding, they are indicative of the PMPRB’s regulatory approach, and often assist stakeholders in understanding how the regulations will be interpreted and applied. In this case, the draft Guidelines are extremely complex and create further uncertainty. The Guidelines exacerbate the initial concerns arising from the Amended PMR and if implemented, will have significant negative impacts on patentees and patients. Comments on the Guidelines are due by February 14, 2020.151

PhRMA recommends that the U.S. Government urge the Government of Canada to reconsider any changes to the PMPRB’s mandate that would harm U.S. innovative biopharmaceutical companies and undermine the competitiveness of Canada’s innovative medicines sector. The PMPRB’s role must be placed in its proper context with the many other agencies already active in the Canadian pharmaceutical marketplace and should not be a means to contradict Canada’s international obligations on patent rights.

The PMPRB is also required to report to the Federal Minister of Health on pharmaceutical trends and on R&D spending by pharmaceutical patentees. Due to the antiquated 1987 tax law formula used to measure R&D spending, which is referenced in its governing regulations, PMPRB has consistently and systematically under-reported the R&D levels of innovative pharmaceutical companies operating in Canada for many years, underestimating the industry’s contribution to private sector R&D spending and lessening the government’s willingness to address the myriad issues described above. To the extent that the PMPRB should have a mandate to report on R&D spending in Canada, PhRMA members urge the U.S. Government to encourage Canada’s Innovation, Science and Innovation Ministry (ISI) to engage with industry as it assesses how to update the regulatory R&D definition so that the PMPRB can more accurately calculate the significant R&D contributions made by pharmaceutical patentees to the Canadian knowledge-based economy.

**Weak Patent Enforcement**

In 1993, the PM(NOC) Regulations were promulgated for the stated purpose of preventing the infringement of patents by the premature market entry of generic drugs as a result of the “early working” exception. In 2015, the Canadian government helped resolve significant difficulties related to inappropriate court decisions that prevented the listing of patents relevant to combination inventions, which seriously undermined patent enforcement actions relevant to those inventions. However, serious and systemic deficiencies remain with the PM(NOC) Regulations. The regulations do not reliably provide “expeditious remedies to prevent infringements and remedies which constitute a deterrent to further infringements,” as required under the TRIPS Agreement. For example:

---

1. Proceedings under the PM(NOC) Regulations and appeal rights

The negotiated CETA text stipulates that “patent linkage” systems must provide all litigants with “equivalent and effective rights of appeal.” The intention behind this negotiated outcome was to address the asymmetry in legal rights that flowed from Canada’s previous restrictive PM(NOC) Regulations regime under which a patent owner did not have an equal ROA as that afforded to a generic drug producer. CETA simply required Canada to correct this imbalance. The changes to the PM(NOC) Regulations,\textsuperscript{152} however, have proven to be far more extensive than necessary to comply with Canada’s CETA obligations in a manner that prejudices existing innovator rights.

For example, despite adopting significantly more procedural complexity under the new regime, including full pleadings, discovery and trials in order to make final patent determinations in a single proceeding, Canada has maintained the same 24-month statutory stay that governed the old summary system. Given that 90 percent of patent infringement/invalidity actions in Canada in recent years have taken over two years to be determined, the innovative industry is concerned that patentees will now be forced to choose between the surrender of procedural rights and obtaining any kind of meaningful injunction under the new regime, contrary to Canada’s many other related international obligations to protect intellectual property rights.

2. Limitation on Listing of Valid Patents and Inequitable Listing Requirements

Patent owners continue to be prevented from listing their patents on the Patent Register established under the PM(NOC) Regulations if the patents do not meet certain arbitrary timing requirements that are not present in the United States under the Hatch-Waxman Act. The effect of these rules is to deny innovative pharmaceutical companies access to enforcement procedures in the context of early working for any patent not meeting these arbitrary listing requirements.

3. Excessive Level of Liability for Lost Generic Profits

The PM(NOC) Regulations allow an innovator to seek an order preventing a generic manufacturer from obtaining Notice of Compliance, on the basis that the innovator’s patent covers the product and is valid. When the innovator seeks such an order, but is ultimately unsuccessful, Section 8 provides the generic manufacturer the right to claim damages in the form of lost profits for the period of time they could have been selling the product, but for the innovator’s action. As such, Section 8 unreasonably prejudices the legitimate interests of the patent owner. One legitimate right of a patent owner is to petition the government to enforce a patent which that government granted in the first place. Unless the patent owner has obtained its patent by fraud or otherwise knows that the patent is invalid or uninfringed, any grievance or damages claim by a

generic manufacturer in connection with a patent that is later found invalid or uninfringed should not result in punishment of a patent owner for relying in good faith on a patent duly issued by the Canadian Intellectual Property Office (CIPO).

PhRMA members are also concerned that Canadian courts have taken an approach to Section 8 damages that allows for excessive damages. Subsection 8(1) compensates for all losses actually suffered in the period during which the second person/company was held off the market – a provision that, as currently interpreted by the courts, has led to instances of overcompensation. The Courts have granted damages in excess of 100 percent of the total generic market, despite holdings that the provision is meant to be compensatory and not punitive in nature. Such overcompensation is contrary to the law of damages and reflects a punitive as opposed to a compensatory theory of damages.153, 154

Recent CETA implementing regulations established new rules that further expose innovators to excessive liability under Section 8. The amended PM(NOC) regulations eliminate previous language specifying that the period during which the innovator is liable to the competitor for any losses suffered ends on the date the stay is withdrawn or discontinued by the innovator or is dismissed or reversed by the court. This unwarranted change is likely to result in excessive damages awards by enabling competitors to claim indefinite future losses and to seek compensation for production "ramp-up" costs they may have incurred before the stay was granted and after it was lifted. In addition, innovators are now "jointly and severally" liable for any damages. Expanding the scope of liability in this manner will enable competitors to claim damages from local subsidiaries or licensees, as well as their licensors or corporate partners in the United States.

Also in the area of excessive damage liability, PhRMA members are concerned about ongoing litigation under various common law theories within the provincial courts. In spite of Canadian PM(NOC) Regulations governing compensatory damages for generic companies held off the market due to patent litigation, other proceedings have been allowed to proceed under various common law theories (Statute of Monopolies, 153 The Supreme Court of Canada granted leave with respect to a Section 8 damages case, but in April 2015 dismissed this case from the bench, stating that it did so substantially for the reasons of the majority in the Federal Court of Appeal. Sanofi-Aventis, et al. v. Apotex Inc., et al., SCC 35886, available at http://www.scc-csc.gc.ca/case-dossier/info/dock-regi-eng.aspx?cas=35886 (last visited Feb. 6, 2020). The dismissal of the appeal provided parties to Section 8 damages litigation with no meaningful higher court guidance with respect to how these damages are to be calculated in future lower court decisions, which means any clarity must come from regulatory amendments by the Government of Canada.
154 On April 23, 2018, Eli Lilly Canada (Lilly) applied to the Supreme Court of Canada for leave to appeal in respect of a March 2018 decision of the Federal Court of Appeal. The Federal Court of Appeal had dismissed Lilly’s appeal of a trial decision awarding more than $70 million to Teva Canada (Teva) under Section 8. The Federal Court of Appeal granted Teva’s cross-appeal seeking to add to its recovery lost pipecell sales and an adjustment to account for an under-reporting of sales in the data relied on by both parties’ experts/ Eli Lilly Canada Inc v Teva Canada Limited, 2018 FCA 53, available at https://decisions.fct-cf.gc.ca/fca-caf/decisions/en/307557/1/document.do (last visited Feb. 6, 2020). Lilly was denied leave by the Supreme Court of Canada on November 8, 2018.
Trademarks Act, unjust enrichment and others). These cases could result in damages liability for PhRMA members which exceed the compensatory threshold.

Therefore, PhRMA members request that the U.S. Government urge Canada to implement amendments to the PM(NOC) Regulations to address this issue.

**Inadequate Patent Term Restoration**

PTR seeks to compensate for a portion of the crucial effective patent life lost due to clinical trials and the regulatory approval process. Most of Canada’s major trading partners, including the United States, the European Union and Japan, offer forms of PTR which generally allow patent holders to recoup a valuable portion of a patent term where time spent in clinical development and the regulatory approval process has kept the patentee off the market. In these countries, up to five years of lost time can be recouped.

By way of implementing CETA, Canada has made a potentially significant step to provide innovators with some compensation for delays in obtaining marketing approval for pharmaceuticals. Under CETA, Canada agreed to implement a “sui generis protection” period of between 2 to 5 years for pharmaceuticals to compensate for delays in drug marketing approval, subject to certain specified conditions.

However, PhRMA has concerns with Canada’s implementation of this commitment under the new Certificate of Supplemental Protection Regulations (CSP) Regulations. At a fundamental level, the sui generis protection provided by the CSP does not appear to grant the full patent protections that PTR is intended to provide, and instead appears to be implemented subject an exception for “manufacture for export.” While this is permitted by the CETA text, this is not consistent with Article 20.46 of the U.S.-Mexico-Canada Agreement (USMCA) or PTR in other jurisdictions. Such an implementation of PTR that does not confer full patent rights, e.g., that would provide an exception for “manufacturing for export” or other infringing activities, is not consistent with the fundamental purpose of restoring patent term lost due to the lengthy marketing approval process.

Moreover, having only adopted the minimum term of PTR negotiated under CETA (i.e., Canada’s term is capped at two years of a possible five), Canada’s further adoption of restrictive time limits and eligibility criteria will unduly and unreasonably limit CSP eligibility in Canada in a manner that is contrary to the intent of the negotiation and the CETA text itself.

In particular, the CSP Regulations introduce a new and complex CSP application requirement whereby only those Canadian new drug submissions (NDSs) filed within 1

---


year of any first international drug submission filed for the same drug (in any of EU, US, Australia, Switzerland or Japan) will be CSP eligible (the “Timely Submission Requirement”). The Timely Submission Requirement is a novel requirement in Canada that is unprecedented amongst the PTR regimes of Canada’s major trading partners, including the United States. PhRMA is concerned that the 1-year time limit being enforced under the Timely Submission Requirement will inappropriately bar otherwise deserving and eligible innovative medicines from benefiting from the period of sui generis protection.

Moreover, Canada’s new PTR regime requires that CSP-eligible medicinal ingredients be “first” approvals. Unlike other jurisdictions, Canada has further implemented a list of “variations” of medicinal ingredients and other prior drug approvals that will automatically exclude new drug submissions from possible CSP eligibility. Neither the U.S. nor EU patent term extension regimes provide enumerated lists of excluded variations ineligible for CSP.

PhRMA members urge the U.S. Government to engage with the Government of Canada on this issue in all available fora, and encourage Canada to join the ranks of other industrialized countries who are champions of IP protection internationally and to provide for effective and competitive PTR measures in Canada. CSP eligibility should not be circumscribed by overly restrictive enumerated exclusions on medicinal ingredients and patents.

**Standard for the Disclosure of Confidential Business Information**

PhRMA members are concerned with amendments to the Food and Drugs Act,157 which could allow for an unprecedented disclosure of CBI contained in clinical trial and other data submitted by pharmaceutical companies in the course of seeking regulatory approval for medicines. The amendments could significantly impact incentives for drug innovation and are inconsistent with Canada’s international treaty obligations.

There is particular concern surrounding issues of confidentiality, the broad definition of CBI (broad enough to also cover trade secrets), and the threshold for the disclosure of CBI by Health Canada to governments and officials, as well as to the public. These amendments are inconsistent with the standards set out in other Canadian federal health and safety legislation, including similar provisions in more recent federal legislation,158 are inconsistent with Canada’s treaty obligations under USMCA and TRIPS, and are also inconsistent with the standards and practices of other national health regulators, including the U.S. Food and Drug Administration.


Both USMCA and the TRIPS Agreement require that CBI be protected against disclosure except where necessary to protect the public. For disclosure to the public, the amendments require a “serious risk,” but it does not reach the standard set out in the treaty language since subjective and discretionary language has been included: the Minister may disclose CBI “if the Minister believes that the product may present a serious risk of injury to human health.” (Emphasis added.) In other words, it is not necessary that there be a serious risk of injury to justify the disclosure; rather the amendments merely require that the Minister believes the disclosure to be necessary.

The amendments also state that the Minister may disclose CBI to a person who “carries out functions relating to the protection or promotion of human health or safety of the public” and this can be done “if the purpose of the disclosure is related to the protection or promotion of health or safety of the public.” There is no necessity requirement for the disclosure to occur, only that it be related to protecting or promoting health. USMCA and TRIPS do not refer to disclosure for the promotion of health, but rather to disclosure needed to protect the health of the public.

Finally, the amendments provide inadequate protections to ensure that there is no unfair commercial use of the disclosed CBI as required by TRIPS Article 39.3. The potential recipients of the disclosed CBI are very broad, and there is no mechanism, such as a confidentiality agreement, to ensure that those recipients (or anyone else to whom they disclose that data) are not able to use the divulged CBI to secure an unfair commercial advantage.

In July 2015, a final guidance document was issued by Health Canada with respect to the administration of its powers to require and disclose CBI. PhRMA and its member companies are pleased that the document provides some reassurances with respect to the administration of Health Canada’s new powers under the amended Food and Drugs Act. However, the document is a non-binding guidance as opposed to binding law or regulations.

In September 2015, a pharmaceutical company was subjected to a disclosure by Health Canada of CBI related to its pharmaceutical product, representing the first known usage of the new legislative disclosure powers. Following a request made under the new mechanisms in the Food and Drugs Act, approximately 35,000 pages of raw trial data were released, demonstrating the potential prejudice to U.S. innovative biopharmaceutical companies that could result from future CBI disclosures.

---

159 See Amendments to the Food and Drugs Act: Guide to New Authorities (power to require and disclose information, power to order a label change and power to order a recall), available at http://www.hc-sc.gc.ca/dhp-mps/legislation/unsafedrugs-droguesdangereuses-amendments-modifications-eng.php (last visited Feb. 6, 2020).

More recently, in December 2017, Health Canada released a draft regulatory package that would amend the Food and Drug Regulations (Regulations) and facilitate automatic public access to manufacturer submitted clinical information following the issuance of a final Health Canada regulatory decision.\(^{161}\) As previously noted, those Regulations were published March 20, 2019.

The Regulations specify the scope of clinical information in drug submissions that cease to be CBI following the issuance of a final regulatory decision (Notice of Compliance, Notices of Non-Compliance – Withdrawal, or Notice of Deficiency – Withdrawal). The amendments authorize the Minister to release information that has ceased to be CBI to the public without notifying or receiving consent from the originator. Clinical information provided in drug submissions would continue to be treated as confidential during the regulatory review process. In addition, the Regulations apply to drugs for human use and medical devices, and apply to clinical information in drug submissions filed with Health Canada both before and after the coming into force of the Regulations. The Regulations establish a mechanism to release previously submitted information, even from years or decades prior, within the scope of public disclosure.

Further complicating matters, on July 9, 2018, the Federal Court of Canada issued a decision ordering Health Canada to release vast amounts of pharmaceutical clinical trial data on five medications, undercutting the federal government’s attempts to keep the information confidential. The effect of this decision, which Health Canada chose not to appeal, on the Regulations and/or the guidelines document is unknown at present, but it presents the risk that the scope of clinical information susceptible to public release will be made even broader than under the current regulatory and guidance document proposals.

PhRMA members therefore urge the U.S. Government to press the Government of Canada to ensure that regulations to implement these amendments to the Food and Drugs Act are consistent with Canada’s international treaty obligations.

**Market Access Barriers**

**Regulatory Barriers to Patient Access to New Medicines**

Beyond the safety approval process, there are additional time-consuming market access hurdles that significantly delay Canadian patients’ ability to access new medicines and vaccines. These include the PMPRB review, health technology assessments, price negotiations through the pan-Canadian Pharmaceutical Alliance (pCPA), and, finally, the execution of product listing agreements with individual public drug plans.


Listing data between 2012 and 2016 revealed that it takes an average of 602 days after Health Canada approval before a patient can access a new medicine through at least one Canadian public drug plan.\textsuperscript{162} This delays access to the benefits of new medicines and vaccines for Canadian citizens, and also erodes the already limited time that innovative companies have to recoup their significant investments in R&D, clinical trials and regulatory approval processes. PhRMA and its members urge the U.S. Government to engage with the Government of Canada on these growing delays that are hindering patient access to new medicines.

Over the past decade, Japan has made important reforms in the areas of drug pricing, drug evaluation and approval, and vaccine policy that have made the system more transparent, more supportive of innovation, and more conducive to innovative biomedical research and development. These changes have increased patient access to life-saving medicines and reduced regulatory delays in the introduction of new drugs, making Japan the second largest market in the world for innovative medicines.\textsuperscript{163}

However, PhRMA notes that the environment related to pricing and reimbursement in Japan has significantly deteriorated over the last few years, and particularly between 2018 and 2019. Over the past year, the Japanese government has pursued, and the Central Social Insurance Medical Council (Chuikyo) has approved a number of new pricing cutting mechanisms and efforts that significantly undermine Japan’s pro-innovation environment and its efforts to carry its fair share of the costs of global R&D efforts. Japan imposed its first out-of-cycle price cuts on pharmaceuticals in 2019 claiming these were necessary in conjunction with the increase of the consumption tax from eight to ten percent. Japan failed to make necessary improvements to its Price Maintenance Premium system to ensure it was science-based, non-discriminatory and fairly evaluated innovative products and innovative companies. On top of this, the Japanese government made a sudden announcement that another price cutting mechanism will be imposed in April 2020, despite clear evidence that the costs of medicines within the Japanese healthcare system are under control and that there are significant areas within the system for further efficiency and cost savings that remain unexplored. Further, these reforms to the system are being developed with limited meaningful opportunities for stakeholders to provide timely input. Similarly, a number of the new policies are being implemented in a non-transparent manner and in a growing number of cases in a way that is contrary to their stated intent. All of this has raised serious questions about the fairness, transparency and predictability of the reform process and its outcome to date.

**Key Issues of Concern:**

- **Patent term restoration (PTR):** PhRMA members appreciate Japan’s PTR laws, as they provide term extensions for subsequent marketing approvals for additional indications or medical uses, or modifications of previously approved products. The Japanese law acknowledges the value that additional approvals can provide to patients. However, the laws as currently interpreted by the Japanese Patent Office (JPO) often result in extensions for subsequent marketing approvals which are shorter in term than the extensions for the original approval, and can thus act as a disincentive to conduct research on additional medical uses and indications, including new formulations for an approved product.

\textsuperscript{163} IQVIA MIDAS\textsuperscript{TM}, 2017.
• **Inappropriate and discriminatory revisions to the Price Maintenance Premium (PMP) system:** The new drug pricing package announced in December 2017, included several new pricing policies that run counter to the government’s pledge to fuel innovation in Japan and efforts to appropriately value innovation. PhRMA member companies are concerned that the number of innovative products that qualify for the PMP have been reduced dramatically and fewer PhRMA member companies qualify for the full benefit of the PMP under the new company requirements for the PMP. According to the Ministry of Health, Labor and Welfare (MHLW), approximately 30 percent of patented medicines no longer qualify. 164 Unfortunately, when the Japanese government undertook a review of the outcome of the new PMP rules in 2019, they made only minimal changes. The PMP system continues to severely and inappropriately undervalue U.S. intellectual property. Further, the PMP eligibility criteria that are biased in favor of domestic companies were not adequately revised, seriously calling into question Japan’s commitment to fair and non-discriminatory policies.

• **Health technology assessment (HTA):** The Japanese government implemented a new HTA system in April 2019. In 2018, the Japanese government cut the prices of several leading innovative products that were subject to an ongoing cost-effectiveness assessment pilot program. For these products, the price premium granted at launch for innovativeness and clinical benefit was reduced based on a poorly justified cost-effectiveness threshold of JPY 5 million yen per quality-adjusted life year. Given the challenges experienced during the pilot program, the Japanese government decided to re-review the outcome of the pilot program for several products. In January 2019, the Japanese government announced that it would implement the new HTA system, which is broader in scope than originally proposed (although still limited to revising the price premium granted at launch), and inconsistent with international norms. In particular, the HTA criteria ignore many aspects of a product’s value. Further, the system has been developed without meaningful opportunities for interested stakeholders, including the innovative pharmaceutical industry, to provide input. PhRMA remains very concerned about the current direction of the new HTA system in Japan and its potential to significantly undervalue U.S. innovation and ultimately harm patient access to new medicines.

• **Other concerning government pricing reforms:** Other changes to the pricing rules such as “huge seller repricing” and “optimal use guidelines” have been imposed suddenly and without meaningful stakeholder involvement. These actions by the Japanese government reduce the predictability and transparency of the drug pricing system in Japan and threaten to undervalue innovative U.S. products.

• **Lack of predictability in the Japanese marketplace:** Another issue of serious concern is the stated intention by the Japanese government to move from the current biennial price revision system to an annual revision system. Further, the

---

Japanese government has signaled its intention to expand the scope of the new HTA system within the next few years, despite acknowledged limitations in capacity and expertise. This, combined with the other recent changes to the government pricing and reimbursement system, has made the Japanese market highly unpredictable.

- **Reform initiatives continue to lack transparency:** As the Japanese government developed its detailed plans to carry out the drug pricing reform initiative over the last three years, there were few formal attempts by the decision-making bodies to seek input from stakeholders, including the innovative pharmaceutical industry. For example, despite the key policy issues being debated by the government throughout 2018 and 2019, the Japanese government has not once put proposed new rules out for public comment. In addition, the industry was only invited to testify before the Chuikyo on two occasions in 2019, and the time allotted for that testimony was rigidly limited. Details on the topics for discussion at important meetings of the Chuikyo are not always shared with stakeholders in advance. Further, except for the formal hearings at which industry was invited to testify, industry representatives were only able to attend Chuikyo meetings as observers. Moving forward, PhRMA’s member companies request more regular and meaningful opportunities to provide input regarding the development of further reforms to Japan’s government pricing and reimbursement system.

- **Regulatory policies:** The Japanese Government continues to seek to accelerate and expand drug development in Japan, ensure that patients have prompt access to the newest drugs and support the pharmaceutical industry as a key driver of economic growth in Japan. To achieve these goals, more flexible approaches are needed in the approval and regulatory process to promote simultaneous global development, including Japanese sample size for multi-regional clinical trials and long-term clinical studies, and to increase the number of drugs designated and approved early under the Sakigake designation and conditional early approval systems so they are equivalent to similar systems in the U.S. and EU.

- **Vaccines:** In order to ensure that Japanese citizens have access to the world’s newest and most innovative vaccines, Japan needs to execute the National Vaccine Plan and to develop a system that provides for permanent and full funding of all recommended vaccines, transparency in the evaluation and adoption of new vaccines into the recommended (i.e., funded) vaccination schedule, and a science-based process to determine the benefits of vaccines and to manage adverse events. In addition, in order to ensure a stable supply of recommended vaccines, the Japanese government should establish a national stockpiling system.

For these reasons, PhRMA requests that Japan be designated a **Priority Foreign Country** in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.
Intellectual Property

Patent Term Restoration

Japan’s PTR system permits term extensions for subsequent approvals for a product, such as for a new use of a previously approved product. PhRMA members appreciate Japan’s PTR laws, as they acknowledge the value that additional approvals can provide to patients. However, PhRMA urges the JPO to review its practices in granting PTR for subsequent approvals, to take into account the full regulatory review period in determining the length of any extensions. In particular, the current JPO practice, which provides an extension period based only on what is considered “necessary testing” for the subsequent approval, often results in extension periods for subsequent approvals that are shorter than the extension period of the first approval. As a result, the current practice can act as a disincentive to conduct research on additional medical uses and indications, including new formulations for an approved product.

Market Access Barriers

Pharmaceutical Pricing and Reimbursement

1. Price Maintenance Premium

The introduction of the PMP in 2010 as a two-year pilot project (followed by its renewal in 2012, 2014 and 2016), has been a critical factor in promoting innovation in Japan, eliminating the drug lag, ensuring that Japanese patients have timely access to innovative medicines, and ensuring that U.S. and other innovative products were appropriately valued. This system has demonstrably led to increased R&D and applications and approvals for new drugs and indications, even though the net benefit of the price maintenance premium has been somewhat reduced by the 80 percent ceiling on the premium under certain circumstances and the continued use of the market expansion and other re-pricing rules.

Investment in drug innovation is a long-term endeavor, such that any unpredictability in the PMP could lead to slower development or launch of new drugs. Therefore, the top public policy priority of PhRMA’s member companies over the years has been to advocate for the PMP to be made a permanent part of the government’s pricing and reimbursement system without reducing the scope of products eligible for the premium.

However, under the government pricing reforms implemented in April 2018, products eligible to receive the PMP are those that either: (1) received a price premium at launch or post-launch; (2) meet certain criteria for new mechanisms of action; (3) are second- or third-in-class and launched within three years of a comparator product in the above groups; (4) received an orphan designation or; (5) were developed in response to an open request from MHLW. Particularly for the third set of products, in essence, this new system equates “innovativeness” with the speed and the order in which products
launch. PhRMA is opposed to such a non-science-based evaluation of innovation, and notes that several U.S. global best-selling products have been deemed “non-innovative” under the new criteria and stripped of their PMP eligibility. This clearly demonstrates that the new system fails to appropriately value U.S. innovation.

Companies with products eligible to receive the PMP were ranked and sorted into three tiers based on: (1) the number of phase 2+ clinical trials conducted in Japan; (2) the number of new products launched in Japan within the past five years; (3) the number of new products developed in response to open requests from MHLW; and (4) the number of products with a Sakigake designation. The number of companies eligible for Tier 1 status was limited to 25 percent but not exceeding 30 percent, even if there are many companies with the same score. All of the eligible products from these companies were awarded the full premium. Eligible products marketed by the middle tier or bottom tier of companies were awarded 90 percent or 80 percent of the premium, respectively.

While the Japanese government undertook a review of the new PMP rules in 2019, only very minor changes were made to the system. PhRMA believes that limiting the number of companies eligible for the full PMP cannot be a true test of innovativeness. Further, these criteria continue to inappropriately favor larger companies, and specific elements of the PMP company eligibility criteria appear to be inherently biased towards domestic companies, seriously calling into question Japan’s commitment to fair and non-discriminatory policies pursuant to its WTO obligations.

In addition to the failure to provide adequate meaningful opportunities for interested stakeholders, including the U.S. industry to provide input into the development of these policies, the Japanese government has also failed to publish clear rules on how some of the new policies are being interpreted and implemented.

2. Health Technology Assessment

PhRMA agrees that appropriate HTA systems have the potential to assist governments in making informed decisions about allocating resources. However, deficient HTA processes can run counter to their key objectives and risk denying or delaying patients’ appropriate access to medical technologies, inefficiently allocating resources, constraining clinical freedom, and harming innovation through pure cost containment methods.

In 2018, the Japanese government cut the prices of several leading innovative products that were subject to an ongoing cost-effectiveness assessment pilot program. For these products, the price premium granted at launch for innovativeness and clinical benefit was reduced based on an poorly-justified cost-effectiveness threshold of JPY 5 million per quality-adjusted life year, ignoring many other elements of a product’s value. Given the challenges experienced during the pilot program, the Japanese government decided to review the outcome of the pilot program for several products.
In April 2019, the Japanese government implemented a new HTA system which is broader in scope than originally proposed and is out of line with international norms. The system remains focused on cost-effectiveness thresholds and excludes many aspects of a product’s value, including those incorporated into the initial pricing premium, as well as broader clinical, societal and economic benefits not captured by an incremental cost-effectiveness ratio. By primarily serving to reduce the price premiums granted at launch for superior products, the adopted approach perversely acts to remove the incentives for medicines that deliver better patient outcomes. Further, the system has been developed without meaningful opportunities for interested stakeholders, including the innovative industry, to provide input. Unfortunately, presentations to the Chuikyo did not fully include proposals put forward by the industry and other materials presented were inconsistent with international norms. PhRMA remains very concerned about the current direction of the new HTA system in Japan and its potential to significantly undervalue U.S. innovation and ultimately harm patient access to new medicines.

Other Government Pricing Policies of Concern

Other changes to the pricing rules such as the expansion of market expansion repricing” and “indication change repricing” rules and the launch of “huge seller repricing” and “optimal use guidelines” have been imposed suddenly and without meaningful stakeholder involvement. These actions by the Japanese government reduce the predictability and transparency of the drug pricing system in Japan and threaten to undervalue innovative U.S. products. Reform of the pricing system should be done via a fully fair and transparent system and should avoid reactive short-term, ad hoc re-pricing mechanisms that fail to appropriately value innovation. The huge seller repricing program should be revisited and the effect of optimal use guidelines on the health insurance system should be strictly limited so that patients’ early access to innovative medicines is ensured.

The industry also recommends that other unfair or unreasonable rules in Japan's drug pricing and reimbursement system be corrected as follows:

1. **Limit Scope of the Repricing for Market Expansion Rule (including huge seller repricing):** The repricing for market expansion rule was introduced decades ago to address significant market changes since the initial drug price was established. As such, it should be limited to products of which the preconditions on initial pricing have clearly changed and that have considerable fiscal impact. To the extent that it has deviated from this intent, the modality of repricing for market expansion, including huge seller repricing, should be revisited.

2. **Reward for innovative additional indications:** The MHLW should consider not only the strengthening of the repricing rules, but also the mechanism by which the reward for innovative additional indications can be reflected in the drug price. According to the current rules, when pediatric or orphan indications are added, a corrective premium can be granted at the time of repricing. In the same manner,
when adding highly innovative indications, corrective premiums should be added at the time of repricing.

3. **Apply Innovation and Usefulness Premiums**: Under the comparator pricing method of new drugs, certain premiums may be granted where the drug shows greater innovation or usefulness than its comparator. PhRMA welcomes recent increases in the range of allowable premiums. However, as it is being applied, most new drugs eligible for the price premium still receive no, or relatively low, premiums. PhRMA’s members continue to support full use of the sliding scale in the application of premiums.

4. **Relax the 14-day Limit Rule for New Drug Prescriptions**: Prescriptions for newly approved drugs can only be written for a 14-day supply during the first year after reimbursement price listing. This restriction imposes a physical and financial burden on patients who are forced to visit their doctors twice a month for the first year simply to receive a prescription. It also imposes a burden on overworked doctors who have to see a patient as many as 26 times during this first year simply to renew a prescription.

**Lack of Predictability in the Japanese Marketplace**

Another issue of serious concern is the stated intention by the Japanese government to move from the current biennial price revision system to an annual revision system. In December 2017, the government postponed a decision on the criteria to be used to determine those products subject to annual price revisions. This will be discussed in 2020, and is of serious concern to the innovative pharmaceutical industry. PhRMA and its members believe that the current system should be maintained, and that if annual price revisions need to be conducted, products subject to revisions in off-years should be limited to those with a significant price discrepancy rate between the NHI price and the current market price.

**Pharmaceutical Regulatory Reform and Related Issues**

1. **Simultaneous Global Development of Drugs**

PhRMA welcomes the government’s continued support of simultaneous global development and efforts to promote multiregional clinical trials (MRCT) in order to eliminate the drug lag and expedite the availability of life-saving and life-enhancing drugs to patients. Therefore:

- PhRMA encourages the government to increase its global and regional regulatory harmonization efforts, especially to include the reduction of market-specific requirements that can delay simultaneous global development. In particular, PhRMA hopes the MHLW and Pharmaceuticals and Medical Devices Agency (PMDA) will be increasingly flexible in the approval and regulatory process for
promoting simultaneous global development, including Japanese sample size for multi-regional clinical trials and long-term clinical studies.

- PhRMA encourages harmonization of the following CMC data points:
  - Requirement to provide detailed description in the application form about manufacturing and manufacturing control;
  - Bio-equivalency (BE) data requirements for drug products under development, including adherence to ICH M9 guidelines; and
  - CMC data requirements for biological products.

- The industry appreciates the continuing efforts of the PMDA to report metrics on the number of simultaneous global development protocols and consultations. The commitment of PMDA to transition to using the 80 percent level rather than the median in reporting progress is a welcome development.

- PhRMA encourages PMDA to continue to ensure consistency across its review offices as they consider drug development strategies based upon the scientific aspects of each drug.

- The threat of drug-resistant pathogens to antibacterial drugs is becoming a worldwide issue. In the U.S., the Generating Antibiotic Incentives Now (GAIN) Act is being implemented to provide incentives such as an exclusivity period and fast track approval for new drugs against drug-resistant pathogens. The gap in drug development in this area between the U.S. and Japan may lead to a future drug lag in this area. PhRMA encourages the Japanese government to consider measures to promote drug development for Antimicrobial Resistance (AMR), and stands ready to cooperate to accelerate drug development in this area in support of the G7 Health Ministers’ declaration on AMR.

2. Improved Efficiencies at PMDA

PhRMA appreciates and applauds the significant efforts made by PMDA to meet its review performance goals for standard and priority files, as well as its efforts to meet the demands for consultations in an expeditious manner. PhRMA values its participation in PMDA’s Expert Working Groups on consultations and review practices. PhRMA looks forward to continuing its active participation in these groups and hopes that its participation will lead to the development and implementation of concrete process improvements that will aid PMDA in continuing to meet its performance goals.
3. Revision of Post-Approval Change Process and Reduction in Review Times

PhRMA appreciates the opportunity to discuss Japan’s post-approval changes to manufacturing and control processes and will continue to provide constructive recommendations based on global best practices for revising the system so that it is more aligned with those systems used by other major regulatory agencies. PhRMA further appreciates the efforts to reduce the review times of partial change applications and encourages PMDA to include biologic products, especially those arising from recombinant technology, in those review targets.

4. Risk Management Plan (RMP)

Reform of the safety system and risk management is an important undertaking by the government, and PhRMA has supported the government’s preparation and implementation of its Risk Management Plan. The RMP went into effect on April 1, 2013. Global standardization of risk minimization measures is critical. PhRMA looks forward to continuing to engage collaboratively with academia and regulatory authorities on the implementation of this process.

5. AMED – the Japan Agency for Medical Research and Development

PhRMA welcomes the creation of AMED in April 2015 as a new agency designed to enhance translational research, to support drug development from the laboratory through the clinical development process and into the marketplace, and to coordinate the national government’s health care research and development budgets now assigned to different ministries without strategic coordination. PhRMA emphasizes the need to ensure that AMED’s programs will be open to all pharmaceutical companies, whether Japanese or foreign-based.

6. Sakigake Program and Conditional Early Approval System

PhRMA welcomes the creation of the “Sakigake” program and the conditional early approval system which will encourage the early evaluation and approval of important new drugs. To avoid a drug lag for innovative products in Japan, PhRMA encourages the government to adopt a flexible approach to the acceptance requirements for applications in order to increase the number of drugs designated and approved early under the Sakigake designation and conditional early approval systems. This will ensure Japan’s expedited approval pathways are equivalent to similar systems in the U.S. and EU. Further, the industry recommends that the Sakigake program be formally implemented from the current pilot phase as soon as possible and applauds the government’s recent efforts to expand the program by increasing the number of reviewers.

Preventive Health Care and Vaccines

Prevention plays a critical role in protecting a population’s health and well-being. However, more effective and efficient awareness initiatives aimed at the public should be
undertaken. Vaccines are particularly important in reducing disease burden and medical expenses, as well as improving the quality of life. The past several years have seen some important changes, including a revision in 2013 of the Preventive Vaccination Law, implementation of National Vaccine Plan and adoption of six vaccines into the national immunization program (NIP). PhRMA applauds the government for these efforts, as well as for co-hosting six annual, high-level, important, and very successful Vaccine Policy Exchanges with the U.S. Department of Commerce, the U.S. Department of Health and Human Services, and the U.S. Centers for Disease Control and Prevention (CDC). However, outstanding issues continue to require attention:

- Although the revision of the Preventive Vaccination Law provided for full national funding for most recommended vaccines, including several foreign-origin vaccines, the changes did not apply to several other vaccines that are already approved. The value of vaccines should be recognized by a funding system and an NIP process that incentivize manufacturers to develop and bring new vaccines to Japan as quickly as possible, together with a nationwide program to educate citizens, and especially parents, about the importance of vaccinations.

- It is critical that decisions related to vaccines be based on science. This is especially important in any evaluation of adverse events and attendant actions.

- The current recommendation (and reimbursement) process is not transparent as it relates to the evaluation and adoption of new vaccines. As a result, vaccine manufacturers lack crucial information as to what data are necessary to receive a national recommendation and when the data should be presented.

- Furthermore, the vaccination decision-making process is unclear. While a Vaccination Policy Committee under MHLW exists, the timeline of a new vaccine’s evaluation, the criteria by which it is evaluated, and the committee’s ability to change vaccination policy, are not transparent.

In October 2019, MHLW’s Vaccination Policy Committee made the decision to include rotavirus vaccines into the NIP. This decision came eight years after the vaccine’s approval in Japan, exemplifying the above issues.

With these issues in mind, PhRMA recognizes the importance of the beginning of a National Vaccine Plan in Japan and the creation of a Japan version of the U.S. Advisory Committee on Immunization Practices (ACIP). PhRMA supports their fair operation and urges that the Committee on Immunizations be given the maximum possible responsibility and autonomy to make recommendations based on scientific evidence and fair assessment of innovation. A priority should be full execution of the National Vaccine Plan.

Japan faces sporadic outbreaks due in part to shortage of available vaccines. The most recent example is measles that started in the spring of 2018 and continued into 2019. In addition, rubella that started in the summer of 2018 and prompted the issuing of
a warning for pregnant women traveling to Japan by foreign governments, including the CDC. Introduction of vaccines from outside Japan is one effective option in such circumstances, and in order to facilitate and accelerate this, there should be a more harmonized regulatory system, including modernization of various requirements such as Minimum Requirements for Biological Products (MRBP).

Quality standards for vaccines and pre- and post-approval vaccine supply processes, including the current national testing requirement, should be streamlined and harmonized with global standards in order to supply innovative vaccines in a timely manner.

While stable supply of vaccines is critical for immunization programs, disruptions can occur given that vaccines are biological products and the production processes are complex and take a long time. As such, it is critical to establish stockpile programs based on foreign best practices and, as mentioned above, to diversify supply sources within and outside of Japan to ensure reliable vaccine supplies during any disruptions.
KOREA

PhRMA and its member companies remain highly concerned with intellectual property (IP) issues and several market access in Korea. Korea’s drug pricing policies severely devalue U.S. IP and favor Korea’s own pharmaceutical industry at the expense of U.S. companies. As a result, America’s cutting-edge R&D and manufacturing sectors are losing out. The upshot is fewer U.S. jobs, fewer U.S. exports, and fewer new medicines for patients worldwide. Korea’s pricing practices are inconsistent with its commitments under the U.S.-Korea Free Trade Agreement (KORUS).

Recognizing these deficiencies, PhRMA and its member companies commended the U.S. Government for securing a commitment from Korea to amend its premium pricing policy for global innovative drugs to ensure non-discriminatory and fair treatment for U.S. pharmaceutical exports. While it was hoped that Korea would use this opportunity to demonstrate its broader pledge to appropriately value innovative medicines, Korea has implemented this commitment in a manner that eviscerates the ability of any company to qualify for premium pricing and is in contradiction with the spirit of their 2018 commitment. PhRMA stands ready to work with the U.S. and Korean Governments to secure amendments to Korea’s pricing and reimbursement policies consistent with Korea’s broader KORUS obligations.

Key Issues of Concern:

- **Unduly strict patentability criteria for selection inventions**: The patentability requirements for a selection invention in Korea are overly strict as compared to the standards in other countries, and fall short of substantially protecting useful chemical, biological, and pharmaceutical inventions. Many valuable inventions in the chemical, biological, and pharmaceutical fields that are filed worldwide have difficulties to meet these strict requirements in Korea. The current practice in Korea does not reflect the nature of these types of inventions, and should be harmonized with the standards in other countries, so that these valuable inventions are protected.

- **Patent enforcement concerns**: While Korea has implemented a patent linkage mechanism pursuant to its KORUS commitment, certain key issues of concern remain. These issues include the discretion afforded to the Ministry of Food and Drug Safety (MFDS) as to whether to list a patent in the Green List or to permit a change to the patent listing and the limited period of only nine months for a sales stay. In addition, an automatic stay is only granted against the first generic/biosimilar application; no stays are granted against subsequent generic/biosimilar applications certifying against the same patent(s).

- **Issues with patent term restoration (PTR)**: While Korea has implemented PTR, there are two significant issues. First, the PTR calculation should include all relevant essential clinical trials used for the approval of the Korean product,
including international clinical trials that are submitted as a part of the Korean dossier for approval of the product. Failure to do so has a discriminatory effect on companies outside Korea that conduct necessary trials, on which the Korean Ministry of Health relies in approving the drug, outside of Korea. Second, there is a lack of due process in the PTR procedures. If the Patent Office determines a certain duration of PTR that is less than the full amount originally requested by the patentee, and the patentee challenges that determination and subsequently loses the challenge, no PTR is granted; even the duration previously determined by the Patent Office is lost. This all-or-nothing approach significantly undermines a patentee’s right to appeal, effectively deterring appeals of erroneous calculations, and undermines the patentee’s rights.

- **Impermissible government pricing and reimbursement policies**: On multiple levels, Korea’s pricing practices contravene its KORUS commitments and negatively impact the rights of U.S. innovators. First, Korea restricts the prices of innovative medicines by valuing them according to the prices of off-patent medicines. Given the vast amount of medical research that occurs in the United States, Korea seeks to benefit from this research without paying its fair share. This incredibly short-sighted approach, however, harms not just the U.S. industry but patients overall. It is also inconsistent with Korea’s commitments under KORUS to value U.S. innovation appropriately, to ensure that patent owners can recognize economic return for its investments, and to guarantee market access free from price distortions. In addition, Korea’s pricing policies are formulated without the degree of stakeholder input required by KORUS.

For these reasons, PhRMA requests that Korea be designated a **Priority Foreign Country** in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

**Intellectual Property Protection and Pricing of Patented Pharmaceuticals**

**Discriminatory Pricing and Reimbursement Policies**

Since the implementation of the Positive Listing System (PLS) in 2007, new drug prices are determined in a two-step process based primarily on cost reduction rather than a holistic assessment of a drug’s value. **First**, the Drug Reimbursement Evaluation Committee (DREC) under the Health Insurance Review & Assessment Service (HIRA) recommends drugs for listing on the basis of a health technology assessment, which takes into account clinical usefulness and cost-effectiveness. **Second**, the National Health Insurance Service (NHIS) makes pricing recommendations following negotiations with pharmaceutical companies, using international reference pricing. The Ministry of Health and Welfare (MOHW) has the ultimate authority for approving all P&R decisions.

This two-step process inappropriately depresses the price of innovative medicines in several significant ways. First, HIRA’s cost-effectiveness analysis recommends reimbursement prices for patented drugs by referencing comparator groups based on
therapeutic class, which include off-patent and generic drugs. Off-patent and generic drugs are already subject to drastic price reduction measures in Korea. Linking prices of new patented drugs to prices of already heavily-discounted prices of off-patent and generic drugs results in unsustainably low prices for innovative drugs. Second, regardless of the cost-effectiveness demonstrated in the HIRA process, the NHIS exploits its superior bargaining power as a single payer to secure an even lower negotiated price and volume cap from the companies of the innovative medicine. Third, the NHIS has enforced annexed obligations included in the Drug Price Agreement (DPA) since 2018, which impose unduly burdensome responsibilities on pharmaceutical companies. These problems are exacerbated by Korea’s failure to provide an independent mechanism to review these pricing determinations (as discussed above).

Over the last decade, the Korean Government has used other ad hoc measures to further reduce prices of patented medicines including PVAs and mandated price cuts for medicines. For example, for products costing the National Health Insurance system more than WON 1.5 billion, prices are cut by 10 percent if sales increase by more than 10 percent in the first year, and the increase in sales exceeds WON 5 billion. Other aspects of Korea’s pricing system have created incentives for larger hospitals to force pharmaceutical companies to supply drugs at lower prices. The direct result is that patented pharmaceuticals are subject to repetitive and excessive price cut mechanisms.

The impact of price cuts is compounded because existing drug prices are then referenced in setting new drug prices. It is difficult for a new drug to be listed under the Korea’s cost-effectiveness analysis given the current comparator selection criteria, which inappropriately reference generics. In sum, while these policies have been driven by goals of cost-savings and cost-containment, the end result has been reduced access to innovative medicines for Korean patients and doctors.

Korea’s numerous price controls constitute a failure to “appropriately recognize the value of the patented pharmaceutical product,” in violation of KORUS Article 5.2(b). Korea’s pricing system inappropriately links patented drug prices to off-patent and generic drug prices. This unavoidably and automatically devalues patents and undermines incentives for innovation. These effects are amplified by a second round of price reductions following unpredictable negotiations with NHIS – which, as a single payer, is necessarily driven by budget concerns – as well as ad hoc price cuts that further lower reference prices for new drugs. As a result of this two-step price reduction process, and other ad hoc price cuts, Korea is failing to recognize the value of patented drugs. In so doing, Korea’s P&R system has severely restricted Korean patients’ access to patented medicines – as demonstrated, for example, by the exceptionally low rate of rare disease drugs listed for reimbursement. This outcome is precisely what KORUS Article 5.2(b) seeks to prevent.

Moreover, Korea’s P&R regime goes far beyond a “limited exception” to the patent holder’s exclusive rights, and thus is inconsistent with KORUS Article 18.8(3) and Korea’s broader TRIPS obligations. TRIPS Article 28 provides that a patent “shall confer” on its owner the exclusive rights to prevent third parties without the owner’s consent from “the
acts of: making, using, offering for sale, selling, or importing for these purposes that product.”\textsuperscript{165} In turn, TRIPS Article 30 permits WTO members to grant only “limited” exceptions to these exclusive rights, provided that such exceptions do not conflict with the “normal exploitation” of the patent and do not prejudice the legitimate interests of the patent owner.\textsuperscript{166} The \textit{Canada – Pharmaceutical Patents} panel appropriately recognized that the “normal exploitation” of a patent includes the realization of anticipated “economic returns” during a defined period of exclusivity “as an inducement to innovation.”\textsuperscript{167} This TRIPS jurisprudence supports a parallel reading of KORUS Article 18.8(3).

These factors demonstrate the extent to which Korea’s P&R measures exceed their purported goal of reasonably controlling health care costs. As the U.S. Department of Commerce has noted, when countries rely on “government fiat rather than competition to set prices” for new drugs, their price controls “reduce company compensation to levels closer to direct production costs,” and leave less revenue for research and development “that would provide substantial health benefits to all.”\textsuperscript{168} Korea’s onerous and multiple layers of price cuts are depriving U.S. pharmaceutical manufacturers of the right to sell pharmaceutical products at prices that would permit recoupment of investments and are undermining the incentive to develop innovative products.

According to the KORUS FTA commitments agreed in 2018, HIRA has revised the premium pricing policy for global innovative drugs effective from January 2019. However,

\begin{footnotes}
\item[165] TRIPS Article 28.
\item[166] \textit{Id.} Article 30.
\item[167] WTO, Panel Report, \textit{Canada – Patent Protection of Pharmaceutical Products}, WT/DS/114/R, ¶¶ 7.54-55 (adopted Mar. 17, 2000), available at https://www.wto.org/english/tratop_e/dispu_e/7428d.pdf. (last visited Feb. 6, 2020). Similarly, the TRIPS Agreement negotiating history indicates that the “rights conferred” by a patent within the meaning of TRIPS Article 28 include the right to sell pharmaceutical products at prices that would permit recoupment of investments and provide an incentive to develop innovative products. In a 1987 statement, the United States set forth this view, stating that “price control” was not a legitimate reason to deny intellectual property protection or to “impose conditions that preclude reasonable compensation for use of an invention or creation.” See Statement by the United States at Meeting of 25 March 1987, MTN.GNG/NG11/W/2 (Apr. 3, 1987), at 3. As the United States expressed at that time, “[s]uch policies interfere with obtaining and maintaining intellectual property rights and thus reinforce the direct distortion of trade that results from such policies.” \textit{Id.} Others involved in the TRIPS negotiations made similar statements. At a September 1989 meeting, a participant discussed providing patentees “the right to exclude others from making, using or selling the patent or invention for a specified time” and asserted that “[t]hese rights were necessary to provide patentees with the necessary economic incentive to justify investment in innovation.” Negotiating Group on Trade-Related Aspects of Intellectual Property Rights, Meeting of the Negotiating Group of 12-14 July 1989: Note by the Secretariat, MTN.GNG/NG11/14 (Sept. 12, 1989), ¶ 75. In a previous meeting, another TRIPS negotiator noted that “the recovery of an investment [of a patented product] depended not only on the duration of patent[] rights[s] but also on a number of other factors, for example whether there was price control.” Negotiating Group on Trade-Related Aspects of Intellectual Property Rights, Meeting of Negotiating Group of 16-19 May 1988: Note by the Secretariat, MTN/GNG/NG11/7 (June 21, 1988), ¶ 11.
\end{footnotes}
the new criteria are so strict and unrealistic that it is highly unlikely that any innovative
drug would be eligible for premium prices. While it was hoped that Korea would use this
opportunity to demonstrate its broader pledge to appropriately value innovative
medicines, Korea has implemented this commitment in a manner that eviscerates the
ability of any company to qualify for premium pricing and is contrary to the spirit of the
commitment it made to the U.S. Government.

**Unduly Strict Patentability Criteria for Selection Inventions**

The patentability requirements for a selection invention in Korea are overly strict
as compared to the standards in other countries, and fall short of substantially protecting
useful chemical, biological, and pharmaceutical inventions. Specifically, if an invention is
in a genus-species relationship with a prior art reference, the invention is classified into a
selection invention, and, in order to be patentable, is required by Korea to have a
qualitatively different or qualitatively the same but quantitatively remarkable effect which
is clearly described in the specification. Many valuable inventions in the chemical,
biological, and pharmaceutical fields that are filed worldwide have difficulties to meet
these strict requirements in Korea. The current practice in Korea does not reflect the
nature of these types of inventions, and should be harmonized with the standards in other
countries, so that these valuable inventions are protected.

**Patent Term Restoration**

While Korea has implemented PTR, there are two significant issues. First, the PTR
calculation should include all relevant essential clinical trials used for the approval of the
Korean product, including essential clinical international trial that are submitted as a part
of the Korean dossier for approval of the product. Failure to do so has a discriminatory
effect on companies outside Korea that conduct necessary trials, on which the Korean
Ministry of Health relies in approving the drug, outside of Korea.

Second, there is a lack of due process in the PTR procedures. If the Patent Office
determines a certain duration of PTR that is less than the full amount originally requested
by the patentee, and the patentee challenges that determination and subsequently loses
the challenge, no PTR is granted; even the duration previously determined by the Patent
Office is lost. This all-or-nothing approach significantly undermines a patentee’s right to
appeal, effectively deterring appeals of erroneous calculations, and undermines the
patentee’s rights.

**Patent Enforcement**

Consistent with its IP obligations under KORUS,169 effective March 15, 2015, Korea implemented the framework of an effective patent enforcement system. Key issues that PhRMA continues to monitor include:

---

169 See U.S.-Korea Free Trade Agreement, Art. 18.9, para. 5.
• The discretion afforded to MFDS to determine whether to list a patent in the Green List or to permit a change to the patent listing.

• Korean law only provides for a nine-month sales stay. In the ordinary course, this is not an adequate period of time to resolve a patent dispute (consistent with Article 18.9(5)(b) of KORUS) before an infringing product is allowed to enter a market.

• The sales stay system under Korean law is problematic in that the patentee cannot request a sales stay against an infringing generic/biosimilar product unless a sales stay is also sought against non-infringing generic/biosimilar products. Further, an automatic stay is only granted against the first generic/biosimilar application; no automatic stays are granted against subsequent generic/biosimilar applications certifying against the same patent(s).

Market Access Barriers

Lack of Transparency and Predictability in Government Policy-making

Since 2010, MOHW has repeatedly changed its pharmaceutical pricing and reimbursement policies without considering the long-term implications for innovation and market predictability, resulting in an uncertain business environment for innovative pharmaceutical companies in a manner that is inconsistent with Korea’s transparency and due process obligations under KORUS.

Also, there are still repetitive and excessive price cut mechanisms working in the market after reimbursement listing, such as biannual Actual Transaction Pricing investigations, Price-Volume Agreements (PVAs), listing of first generic and expanding reimbursement scope with new indications or change of treatment guidelines.

Separately, the Risk Sharing Agreement (RSA) system should be expanded to provide an alternative pathway for reimbursement listing to enhance patient access to innovative medicines regardless of disease area and alternatives. Other issues with the system include an unpredictable contract renewal process and overly strict pharmacoeconomic requirements.

Independent Review Mechanism (IRM)

Under Article 5.3(5)(e) of KORUS and the side letter thereto, Korea agreed to “make available an independent review process that may be invoked at the request of an applicant directly affected by a [pricing/reimbursement] recommendation or determination.” Korea has taken the position, however, that reimbursed prices negotiated with pharmaceutical companies should not be subject to the IRM because the NHIS does not make “determinations” and merely negotiates the final price at which a company will be reimbursed. However, this interpretation completely negates the original purpose of the IRM, which should apply to the negotiation process for prices of all reimbursed drugs, particularly patented medicines.
MALAYSIA

PhRMA and its member companies operating in Malaysia are alarmed by recent Government of Malaysia actions which undermine intellectual property (IP) protection and, if unaddressed, could inspire other countries to take similarly damaging actions. Addressing serious market access and IP concerns in Malaysia will help narrow America’s $22B trade deficit with Malaysia.

Key Issues of Concern:

- **Compulsory licensing**: Through a flawed and non-transparent process, the Malaysian government issued an unjustified compulsory license (CL) for a breakthrough innovative medicine developed in America that provides a cure for patients suffering from hepatitis C. This action was taken despite the fact that the U.S. manufacturer had agreed to include Malaysia in its voluntary license program. If not met with a forceful U.S. Government response, this action carries significant risks of contagion to other markets, which would significantly undermine the current R&D model for innovative medicines on which the U.S. pharmaceutical industry and patients around the world rely. Currently, the Malaysian government is considering legislative amendments that could further promote vague and ambiguous grounds for compulsory licensing and introduce unnecessary procedures that would undermine granted patents.

- **Inadequate IP protection and enforcement**: Malaysia does not have an effective patent enforcement system that provides for the early resolution of patent disputes before marketing approval is granted to infringing follow-on products during the patent term. In addition, its regulatory data protection (RDP) system fails to provide (1) any protection for biologics; and (2) effective protection for a sufficient period of time for chemically synthesized drugs from the date of marketing approval in Malaysia.

- **Listing pharmaceuticals on the national formulary**: Effective 2016, Malaysia adopted a new process for listing products on the Ministry of Health (MOH) Medicines Formulary. While this is a welcome development, PhRMA and its members are concerned that the final guidelines require 12 months of post-marketing surveillance data prior to listing and that there is no mechanism to ensure that patients who benefited from the medicines during local clinical trials maintain access during this period. In addition, if a product is not approved for listing on the Formulary, the applicant should be provided a detailed explanation for that decision so that it can better understand the criteria for listing and to determine if it may negotiate an alternative access scheme with the government. MOH listing decisions, both by the body responsible for conducting health technology assessment (HTA) analysis and making listing recommendations, and by the panel responsible for the ultimate listing decision currently lack transparency and appear to be based on ambiguous criteria.
• **Halal pharmaceuticals:** In December 2017, the MOH published a guideline on prescribing and administration of non-halal pharmaceuticals. PhRMA’s member companies are strongly supportive of religious and cultural sensitivities, but do not believe that the government should provide preferential treatment to such products in government procurement. Furthermore, it is important to ensure that patients, in partnership with their health care providers, are prescribed the appropriate medicine for their conditions.

• **Preferential treatment of local manufacturers:** The Government of Malaysia indirectly discourages an open and competitive marketplace for international pharmaceutical compounds through procurement preferences for locally manufactured products. For example, the Government of Malaysia has recently announced that it will grant three-year procurement contracts to companies who move production of imported products to Malaysia (with the potential for a two-year extension if those locally produced products are exported).

For these reasons, PhRMA requests that Malaysia be designated a Priority Foreign Country in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

**Intellectual Property Protection**

**Compulsory Licensing**

In September 2017, the Malaysian government utilized a non-transparent process to issue a CL on a patent-protected innovative U.S. medicine. This unnecessary and unjustified measure was taken in a unilateral and non-transparent fashion, despite the fact that the U.S. manufacturer had decided to include Malaysia in its voluntary licensing program. The CL has sent a devastating signal to America’s biopharmaceutical innovators that their patents are not safe in Malaysia. If this action is not met by a strong response, the Government of Malaysia may use CLs on other innovative medicines or inspire other countries to unilaterally determine that it is exempt from its obligations with respect to IP protections under well-established and binding international agreements.

While imposing a license is rarely, if ever, an appropriate mechanism to improve patient access, that is particularly true in this instance where the innovative company has already announced plans to voluntarily license the patent. The manufacturer in this instance had decided to include Malaysia in a mutually beneficial voluntary licensing scheme for hepatitis C when the government moved forward with a CL for use in state-owned hospitals. However, industry experience clearly demonstrates that collaborative access policies enable significantly better treatment access outcomes. Malaysia’s compulsory license reportedly only treated 1,501 patients over a 12-month period in
However, cooperative discussions and collaborative access policies like voluntary licensing treated over 15,000 patients over the same period in neighboring Vietnam.171

The non-transparent manner in which this decision was made raises serious questions around whether appropriate consideration was given as to how it may impact Malaysia’s access to innovative medicines in the future. The sudden and unexpected announcement of a CL was made immediately following a meeting between President Trump and then-Prime Minister Razak, without any indication during the visit that such a provocative step would be taken. Furthermore, at no point prior to the announcement did the MOH or any other government ministry or agency offer to meet with relevant industry stakeholders, consider their concerns, or evaluate their input. This is surprising given the Government of Malaysia’s historical support for open, transparent, and fair market practices. The sudden nature of this decision denies U.S. manufacturers any sense of predictability around Malaysia’s regulatory decision-making in the future. The lack of industry stakeholder input is also troubling given the immediate significance of such a decision to the global market for medicines, and to the potential long-term ramifications for U.S. producers of innovative medicines and other cutting-edge inventions.

In August 2019, Malaysia’s intellectual property office, MyIPO, released for public comment a “consultation paper” on proposed amendments to the Patents Act 1983.172 The consultation paper and commenting period were not widely publicized. While the consultation paper lacked specific textual proposals, PhRMA members are very concerned that the proposed amendments could promote vague and ambiguous grounds for compulsory licensing, restrictions on what can be patented, and unnecessary procedures that would undermine granted patents. Considering the preliminary nature of that consultation paper and limited information, PhRMA provided MyIPO an initial response calling for the Malaysian government to engage in a meaningful and transparent consultation process.

Regulatory Data Protection (RDP)

Biopharmaceutical innovators work with hospitals, universities and other partners to rigorously test potential new medicines and demonstrate they are safe and effective for patients who need them. Less than 12 percent of medicines that enter clinical trials ever result in approved treatments.173

To support the significant investment of time and resources needed to develop test data showing a potential new medicine is safe and effective, governments around the world protect that data submitted for regulatory approval from unfair commercial use for a period of time. TRIPS Article 39.3 requires WTO members, including Malaysia, to protect proprietary test data submitted to market authorizing bodies, including the MOH, “against unfair commercial use” and against “disclosure.”

The stated objective of Malaysia’s Directive (11) dlm. BPFK/PPP/01/03 Jilid 1 is “to protect the undisclosed, unpublished and non-public domain pharmaceutical test data … for the purpose of scientific assessment in consideration of the quality, safety, and efficacy of any new drug product.” 174

Further, paragraph 4.2 of that Directive provides:

An application for Data Exclusivity shall only be considered if the application in Malaysia for:
(i) New drug product containing a New Chemical Entity is made within eighteen (18) months from the date the product is first registered or granted marketing authorization; AND granted Data Exclusivity / Test Data Protection in the country of origin or in any country, recognized and deemed appropriate by the Director of Pharmaceutical Services. 175

As such, Malaysia requires the marketing authorization application of the new medicine to be filed within 18 months from the first worldwide regulatory approval in order to be considered as a “new chemical entity” and, thus, eligible for RDP in Malaysia. If the 18-month deadline is not met, the product loses data protection, allowing a follow-on molecule to be approved based on the originator’s regulatory data during what should have been the RDP period. It is challenging – if not impossible – to meet the 18-month application requirement if the first worldwide registration was not in the EU or the United States (both are relied upon for the Certificate of Pharmaceutical Product application).

In addition to this inappropriate restriction on products eligible for RDP in Malaysia, the actual term of the protection in Malaysia is measured from the date of first approval in the world. Thus, if a new chemical entity is registered in Malaysia one year after first approval in the world, Malaysia only provides four years of RDP. Indeed, the only instance in which an innovator can receive the full five years of RDP in Malaysia is if they seek marketing approval in Malaysia first.

available at https://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5ac66afc6d2a732e83aae6bf/1522952963800/Tufts_CSDD_briefing_on_RD_cost_study_-_Nov_18%2C_2014..pdf (last visited Feb. 6, 2020).

174 See paragraph 1.2 of Directive BPFK/PPP/01/037.
175 Id.
Malaysia’s flawed Directive improperly penalizes innovators for first seeking marketing approval in other countries. As in other markets that seek to promote research and development into innovative medicines, Malaysia should measure the term of the RDP protection from the time that the new molecule is approved in Malaysia.

Finally, Malaysia fails to provide any RDP for biologics. Made from living organisms, biologics are complex and challenging to manufacture and may not be protected adequately by patents alone. Without the certainty of a substantial period of exclusivity, innovators may not have the incentives needed to conduct the expensive, risky and time-consuming work to discover and bring new biologics to market.

Effective Patent Enforcement

PhRMA members encourage Malaysia to efficiently and effectively enforce its Patent Act. A competent and practical enforcement mechanism provides redress and solutions to infringements of IP rights and deters future infringement. Timely and efficient patent enforcement gives owners an appropriate period over which to recoup the value of their significant efforts and investment. For example, patent protection and enforcement would be enhanced by structured enforcement guidelines and a mechanism to curb unfair promotion and sale of generic drugs either prior to patent expiry of innovator drugs, or, in the event of a patent dispute, prior to a court decision on patent disputes.

PhRMA’s member companies strongly encourage the improvement and adoption of mechanisms that strengthen patent enforcement and the ability to resolve outstanding patent concerns prior to marketing approval and launch of follow-on products, such as generics. These mechanisms could greatly enhance Malaysia’s business environment by: (1) providing transparency and predictability to the process for both innovative and the generic pharmaceutical companies; (2) creating a more predictable environment for investment decisions; and (3) ensuring timely redress of genuine disputes.

Patent and Trademark Laws

Proposed amendments to Malaysia’s patent and trademark laws that include provisions for disclosure of traditional knowledge and genetic resources, as well as compulsory licensing, raise concerns for the research-based pharmaceutical industry, and PhRMA encourages a continued consultative process with stakeholders before such amendments are implemented in order to avoid policies that deter or discourage innovation across fields of technology. These proposed amendments also include provisions for effective patent enforcement and patent term restoration. PhRMA member companies are eager to engage in meaningful dialogue with Malaysian Regulatory Authorities to build a system that reflects international best practices.
Market Access Barriers

Medicines Price Control

Industry is aligned with the Malaysian Government to improve patient access to medicines. However, the proposal on Medicines Price Control to set ceiling wholesale and retail price for medicines will not address the long-term health care cost challenges, and could delay patient access to new medicines. Further, the proposed phased implementation of Medicines Price Control to apply first on single-source products which are generally patent protected appears to discriminate against foreign companies.

Listing Pharmaceuticals on the National Formulary

Industry welcomes advances from the Malaysian Government for companies to directly request inclusion on the national formulary through guidelines introduced in January 2016. However, industry is disappointed that the process lacks transparency and appear to be based on ambiguous criteria. In addition, the final guidelines require six months of post-marketing surveillance data prior to listing. If local clinical trials have been completed for a product, it should be automatically listed on the national formulary to enable patients who were on the treatment to continue receiving the product after the clinical trial is complete. A policy is needed to bridge the gap for patients from the end of a clinical trial to the listing in the formulary.

Further, as the government pursues reforms aimed at improving access of medicines to its population, member companies hope that sufficient financing is provided to ensure that more patients can receive innovative medicines in as timely a manner as possible to achieve better health outcomes. We hope that short term measures, such as cost containment policies, do not become a barrier to access and the government considers fair mechanisms to value innovations that are proven to raise the standards of care in Malaysia.

Halal Pharmaceuticals

In December 2017, the MOH published a guideline on prescribing and administration of non-halal pharmaceuticals. PhRMA’s member companies are strongly supportive of religious and cultural sensitivities, but strongly believe that it is important to ensure that patients, in partnership with their health care providers, are prescribed the appropriate medicine for their conditions.

---

Preferential Treatment of Local Manufacturers

Malaysia’s National Medicines Policy (MNMP/DUNas), which prioritizes the medium and long-term goals set by the Government for the pharmaceutical sector, endorses price controls, generic drugs substitution, and preferences for generics and local manufacturers by promoting national self-reliance for drugs listed on the National Essential Medicines List (NEML). PhRMA member companies submit that the Government of Malaysia should eliminate discriminatory preferences for locally manufactured pharmaceuticals. This preferential treatment discourages an open and competitive marketplace in Malaysia.
SECTION 306
MONITORING
THE PEOPLE’S REPUBLIC OF CHINA

PhRMA and its member companies operating in the People’s Republic of China are committed to supporting the government’s efforts to build a patient-centered and pro-innovation health care system. China is taking positive steps to strengthen government reimbursement for innovative medicines and align its regulatory framework with international standards. However, we remain concerned about the lack of progress on intellectual property (IP) protections, including ineffective regulatory data protection (RDP) and patent enforcement, and inconsistent patent examination guidelines. In addition, we are concerned about the non-transparent and unpredictable government pricing and reimbursement policies, the downstream regulatory approval barriers, burdensome biological sample exportation policies, areas of divergence from international registration standards, rampant counterfeiting of medicines, and under-regulated active pharmaceutical ingredients (APIs).

We applaud the governments of China and the United States for securing Phase One of the Economic and Trade Agreement (Phase One Trade Agreement) between the two countries in January 2020. We look forward to the robust and effective implementation of the Phase One provisions on supplemental data, early resolution of patent disputes, and patent term extension in a manner that results in meaningful improvement in IP protection for innovative medicines in China. We also welcome the countries’ affirmation of their commitment to provide “effective protection and enforcement of pharmaceutical-related intellectual property rights, including patents and undisclosed test or other data submitted as a condition of marketing approval”, and stand ready to work with both Governments to ensure provision of these critical IP protections in China. Finally, industry commends the countries for their strong commitments to “ensure fair and equitable market access” (Article 1.2), “take effective and expeditious enforcement actions against counterfeit pharmaceutical and related products” (Article 1.18), and ensure “that the transfer of technology occurs on voluntary, market-based terms” (Chapter 2).

PhRMA is encouraged by China’s ongoing work to strengthen its drug regulatory framework, including through the new revision to the Drug Administration Law (DAL) (August 2019), which includes provisions on nationwide-adoption of the marketing authorization holder (MAH) system and facilitate drug review and approval; draft revisions to the Drug Registration Regulation (DRR) (October and December 2019); the Central Committee of the Communist Party / State Council Opinions (CCP/State Council Opinions) on Strengthening Intellectual Property Rights Protection (IPR) (November 2019) and on Deepening the Reform of the Review and Approval System and Encouraging the Innovation of Drugs and Medical Devices (October 2017); and the draft NMPA Circulars (Nos. 52-55) issued in May 2017. NMPA’s May 2017 accession to the International Council on Harmonization (ICH), June 2018 elevation to the ICH Management Committee and its subsequent efforts to implement ICH guidance documents further exemplifies China’s regulatory reform efforts.
Many of the above-mentioned draft proposals include provisions to bolster IP protection, and PhRMA is eager to continue supporting China in its reform effort to strengthen RDP, patent enforcement and patent examination guidelines. We were encouraged to see the proposed Patent Law amendments (January 2019) included language to provide patent term restoration (PTR) to compensate for a portion of the lengthy regulatory review process. However, we are concerned that the draft Patent Law amendment, the new DAL, and the 2019 draft DRR do not include provisions to advance RDP and patent enforcement. Furthermore, we are very concerned that NMPA thus far in 2019 has granted marketing approvals of at least 12 generic products while the reference products in each case are still subject to patent protection. PhRMA strongly encourages China to move swiftly to implement the proposed reforms in a manner that enables biopharmaceutical innovators both in China and abroad to meet the growing needs of China’s patient population and in a manner consistent with its commitments in the Phase One Trade Agreement.

Further, in order to meet the needs of China’s patient population, particularly those with rare diseases and for whom there is unmet need, PhRMA recommends that China consider further strengthening of the regulatory framework to promote and incentivize the development of treatments for people with rare diseases in China. PhRMA notes the documented success of regulatory incentives, namely orphan drug designation and companion regulatory exclusivity, in achieving significant increases in drug development and marketing authorization of these important treatment options in other regions.

We also remain concerned that the newly revised DAL does not define the term “new drug,” potentially leaving in place the concept of a globally new drug or biologic, which appears in earlier policy documents. An analogous concept is also implied in the draft 2019 DRR amendment, which maintains a separate category for drugs and biologics approved outside of China. These developments undercut the laudable goals of the CCP/State Council Opinion and China’s long-term innovation plans. This globally new standard is very likely to be counterproductive for China, making it more difficult for both foreign and domestic innovative manufacturers to benefit from the proposed policy reforms and engage in the type of meaningful development and collaboration with partners in China and around the world that promotes innovation. As such we urge NMPA to clarify the definition of new as it applies to drug and biologic registration applications and define “new” to mean never marketed in China, as opposed to new to the world.

PhRMA is encouraged by the 2017 and 2019 updates to the National Reimbursement Drug List (NRDL) as well as the addition of 17 oncology medicines to the NRDL in 2018. We are eager to continue supporting China in its reform effort to develop a regular mechanism for government reimbursement and a value assessment system. PhRMA urges China to establish a comprehensive and sustainable policy framework for government pricing and reimbursement that would include predictable and timely reimbursement decisions for new drugs, systematic and transparent mechanisms for price negotiation linked to reimbursement, adoption of evidence-based methodologies for drug value assessment and an enhanced role for commercial health insurance.
A fair and transparent regulatory and legal process is another priority element for a sound and sustainable drug regulatory regime in China. PhRMA is concerned about China’s inconsistency in meeting its domestic legal requirements and bilateral U.S.-China commitments in this regard. In particular, China frequently does not provide reasonable periods for public comment on draft laws, rules, regulations and other binding measures, despite these obligations. As such, PhRMA welcomes the commitment in Article 8.5 of the Phase One Trade Agreement to afford stakeholders at least 45 days to comment on all proposed measures to implement this Agreement.

**Key Issues of Concern:**

- **Weak patent enforcement:** Transparent mechanisms and legal standing to sue are needed in China to ensure parties are afforded the opportunity to resolve patent disputes before potentially infringing pharmaceutical products are launched in the market. Neither China’s DAL or DRR nor the Patent Law provide an effective mechanism for enforcing an innovator’s patent rights vis-à-vis regulatory approval of follow-on products before those products are launched. As evidence, since 2019, NMPA has granted marketing approvals of at least 12 generic products while the reference products in each case were still subject to patent protection. PhRMA and its member companies stand ready to work with both governments on the implementation of an effective patent enforcement system in China, consistent with its commitments in Article 1.11 of the Phase One Trade Agreement.

- **Lack of regulatory data protection:** China committed as part of its accession to the World Trade Organization (WTO) to provide a six-year period of RDP against unfair commercial use for clinical test and other data submitted to secure approval of products containing a new chemical ingredient. In practice, however, China does not have a mechanism to grant RDP and the criteria are inconsistent with China’s commitments. As such, we strongly welcomed the draft NMPA measures on the Implementation of Drug Clinical Trial Data Protection (April 2018), which proposed up to six and 12 years of RDP for chemically synthesized drugs and therapeutic biologics, respectively. This draft measure represented a strong first step toward reform in this area, and we look forward to implementation of final measures that are consistent with international best practices and China’s renewed commitment to provide RDP as affirmed in the chapeau to Section C of Chapter One of the Phase One Trade Agreement.

- **Loss of patent term due to regulatory processes:** Patent Office delays, and lengthy regulatory approval processes for pharmaceutical products result in a significant loss of effective patent term for such products. As such, we commend

---

177 See, e.g., Fact Sheet: 25th U.S.-China Joint Commission on Commerce and Trade (Dec. 2014), available at https://ustr.gov/about-us/policy-offices/press-office/fact-sheets/2014/december/us-fact-sheet-25th-us-china-joint (last visited Feb. 6, 2020) (stating that “China and the United States agree that for all draft pharmaceutical and medical device rules and regulations where notifications are required under the relevant WTO rules, a comment period will be provided that will be no less than 60 days.”).
the inclusion of effective patent term extension provisions in Article 1.12 of the Phase One Trade Agreement and would refer the Chinese Government to the proposed revised language that we submitted in response to draft Patent Law Amendments in 2019 (regarding the provision of patent term restoration) that would ensure that the resulting mechanism achieves its objectives of encouraging the development of innovative medicines.

- **Restrictive patentability criteria:** In late 2016, the China National Intellectual Property Administration (CNIPA) issued an amendment to its Patent Examination Guidelines that would require examiners to take into account post-filing experimental data submitted by an applicant. PhRMA welcomed this positive step, but concerns remain regarding CNIPA implementation and interpretation of the proposed amendment, especially at the PRB (Patent Reexamination Board) level. As such, PhRMA and its members look forward to addressing these concerns through implementation of Article 1.10 of the Phase One Trade Agreement. In addition, certain therapeutic methods, referred to as “specific therapeutic methods,” essentially cannot be protected by patents in China. Inventions in such methods very often bring important patient benefits, and the inability to obtain patents on these inventions undermines the incentives to invest in them, particularly to the extent they are targeted at particular medical and health problems in China.

- **Lack of transparency in government pricing and reimbursement:** PhRMA welcomes the 2017 and 2019 updates to the NRDL as well as the addition of 17 oncology medicines to the NRDL in 2018. We encourage the Chinese government to shift towards a more timely, transparent and predictable reimbursement system, in which manufacturers may apply for reimbursement at any time, drug clinical assessment is completed within a pre-defined period following the application (e.g., within 90 days), and negotiations between manufacturers and the responsible government agency take place periodically (e.g., semi-annually). While the manner in which the national reimbursement negotiations were conducted in 2017 and 2019 diverge from a sound pricing and reimbursement system, PhRMA is pleased to see the newly established National Healthcare Security Administration (NHSA) moving forward with a negotiation process and the establishment of a regular reimbursement mechanism.

- **Regulatory approval process:** Historically, the overall drug development and approval process in China could take longer than international best practice and was particularly long for biologics and vaccines. Lengthy regulatory approval processes result in a significant loss of effective patent term for biopharmaceutical products and delayed access for patients. However, NMPA has undertaken

---

178 In August 2018, the State Intellectual Property Office (SIPO) changed its name to the China National Intellectual Property Administration (CNIPA). Although many of the policies and draft proposals referenced in this submission were issued under the name of SIPO, we have used CNIPA consistently throughout this document.
significant reform efforts to accelerate the drug review and approval process and align its regulatory framework with international standards (e.g., in 2018 NMPA adopted a 60-business day notification procedure for new drug clinical trials, which has now been adopted for all clinical trials (except bioequivalence studies) in the newly revised DAL). The draft DRR also outlines a communication system to address major issues prior to the submission of the CTA and MA. PhRMA recommends policies that promote transparency and communication throughout the CTA and MA process to shorten the review and approval timelines. The Center for Drug Evaluation has also increased its staff significantly from 200 to 800. NMPA has also adopted a number of reforms since 2015 to speed up the review and approval process for certain drugs, including expedited approval programs for innovative drugs, drugs treating orphan diseases, oncology drugs, and drugs with pediatric indications, among other priority categories. PhRMA is equally encouraged by NMPA approving a number of drugs in 2018 under timelines consistent with or even faster than U.S. and European standards.

These efforts continue to grow. PhRMA is encouraged with the development of expedited review pathways (breakthrough, conditional approval, priority review and special review) that will facilitate accelerated development and approval of new drugs. It is important that the process and timelines for these pathways are clearly defined. The newly revised DAL codifies existing expedited programs for conditional approval for urgently needed drugs used to treat life-threatening illnesses and other priority categories described above. The draft 2019 DRR has proposed to establish separate programs for breakthrough therapies, conditional approval, priority review, and special review to house these and other various categories. PhRMA recommends that NMPA develop regulatory guidance regarding the conversion of conditionally approved medicines to regular approval and to implement policies that leverage the best science and innovation to improve the efficiency and predictability of this conversion process.

At the same time, there remain significant impediments to development that delay the clinical trial timeline in China. One concerning impediment is the additional approval or notification now applicable to all trials conducted in China by foreign companies or their affiliates that collect any samples that contain Chinese human genetic resources, regardless of whether those samples are for genetic testing. Pursuant to Human Genetic Resource (“HGR”) Regulations that have been in effect since 1998, but were largely unenforced until 2015, foreign applicants must apply to the Human Genetic Resources Administration Office of China (HGRAC), under the Ministry of Science and Technology (MOST) before they can collect and transfer these samples and associated data. The trial may not commence until this process is complete. While an amendment to the HGR Regulations in 2019 now permits manufacturers to submit a notification (rather than an approval application)

---

for trials that are intended to support a marketing application in China, provided that no samples from the trial will be exported from China, the filing criteria is very stringent and the vast majority of cases do not qualify.

- **Counterfeit medicines**: We commend the two governments on the commitments in Section G of Chapter One of the Phase One Trade Agreement to combat counterfeiting. Over the last several years, China has implemented national plans to improve drug safety and severely crack down on the production and sale of counterfeit medicines, resulting in several positive and tangible actions on the enforcement front. However, the production, distribution and sale of counterfeit medicines and unregulated APIs continue to pose a problem in China and continue to pose a threat to China and its trading partners. The revised DAL expressly subjects APIs to applicable good manufacturing practice regulations, but also removes APIs from the scope of the definition of drug, which leaves the application of other drug regulations to APIs unclear. Also, the DAL removes the prohibited act of manufacturing or importing unapproved drugs from the definition of counterfeit drug. The DAL now further states that individuals who import small quantities of unapproved drugs that are approved abroad may receive lesser or no penalties. That provision is not limited to drugs that are not for resale. It is not yet clear how these provisions will affect enforcement against counterfeit drugs.

For these reasons, PhRMA requests that China remain on the **Priority Watch List** and be subject to **Section 306 Monitoring** for the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

**Intellectual Property Protection**

In 2017 and 2018, China released a series of proposed policies that had the potential to strengthen its regulatory framework for innovative medicines. Specifically, these policies could address long-standing industry concerns about the lack of RDP, loss of patent term due to lengthy regulatory approval processes, ineffective patent enforcement, and inconsistent patent examination guidelines. For example, the April 2018 draft NMPA measures on the Implementation of Drug Clinical Trial Data Protection, propose up to six and 12 years of RDP for chemically synthesized drugs and therapeutic biologics, respectively. The CCP/State Council Innovation Opinion, which was issued in October 2017, is the first time that this level of the Chinese government has openly endorsed RDP and patent linkage in a meaningful way. In addition, the NMPA draft Circulars, which were issued in May 2017, propose the establishment of a patent linkage system and specific RDP terms. Unfortunately, further action to implement these proposals has not been advanced. On the contrary, the new DAL (August 2019) as well as the proposed amendments to the Patent Law (January 2019) and Drug Registration Regulation (DRR) (October and December 2019) did not include any provisions to advance these critical IP protections. Even worse, since 2019, NMPA has approved at least 12 follow-on products while the reference products in each case are still subject to patent protection.
In light of this standstill, PhRMA and its member companies strongly welcome the IP commitments in the Phase One Trade Agreement and look forward to securing expeditious implementation of these commitments in a manner fully grounded in international best practices. The input U.S. stakeholders have already submitted on China’s proposed reforms related to several of these IP protections will offer important guidance in this regard. It is equally critical to ensure that these reforms are implemented fully in a manner that advances innovation and patient access, is consistent with China’s international commitments, and ensures that U.S. biopharmaceutical companies can compete on a level playing field with China’s domestic industry.

Weak Patent Enforcement

Consistent with Article 1.11 of the Phase One Trade Agreement, transparent mechanisms and a legal standing to sue are needed in China to ensure parties are afforded the opportunity to resolve patent disputes before potentially infringing pharmaceutical products are launched on the market. If a follow-on company actually begins to market a drug that infringes the innovator’s patents, the damage to the innovator may be irreparable even if the innovator later wins its patent litigation. This could undermine the goal of encouraging innovation in China. In fact, NMPA has approved at least 12 infringing follow-on products since 2019, and research-based pharmaceutical companies have no effective legal means to resolve patent disputes prior to the marketing of those infringing drugs. Further, although China’s laws and regulations provide for injunctive relief, in practice injunctions are rarely, if ever, granted in the context of preventing premature follow-on product market entry, due to high procedural barriers.

China’s law allows NMPA to begin reviewing generic drug applications for marketing approval within two years prior to the patent expiration date for the innovative drug, but it does not allow market approval while a patent is still in force. The right of a patent holder to maintain exclusive control over production and sale of its product while the patent is in effect is fundamental to the patent system worldwide. China’s laws reflect this rule, as does the WTO TRIPS Agreement.

While there have been sporadic reports of generic products being approved while patents remained valid on the innovative reference medicine, since January 2019 there has been a significant uptick in NMPA granting market approvals to local drug makers for a variety of medicines used to treat common conditions – even though these drugs are all still under patent (including their basic compound patent). To date, we are aware of 12 such generic products that have been approved. In taking these actions, NMPA has facilitated the infringement of patents owned by inventors based in the United States and elsewhere outside China.

Objections by innovative drug makers have not changed any outcome. In some cases, the Chinese companies have challenged the patents while applying for marketing approval, but no patent has been invalidated. The slowness of the Chinese patent court system and the near impossibility of securing preliminary injunctions to keep infringing
products off the market already make it very difficult for innovative drug makers to stop patent violations. These NMPA actions seriously exacerbate the problem in China.

In addition, parallel patent enforcement proceedings through China’s judiciary and CNIPA’s Patent Reexamination Board (PRB) further frustrate biopharmaceutical innovator’s ability to effectively and efficiently resolve patent disputes. Patent owners are often faced with unnecessary and burdensome procedural hurdles to seek the timely resolution of patent disputes because invalidity decisions issued by CNIPA’s PRB during an ongoing judicial proceeding are grounds for automatic dismissal of relevant infringement litigations. In that situation, patent owners are required to appeal the PRB decision through the judiciary, and if successful, seek a court to compel PRB to confirm the judgment. Due to PRB’s extremely strict inventive step and supplemental data requirements, and fast docket times, patent infringement defendants can use the PRB proceedings as a tactic to circumvent the judicial process.

In this light, we were encouraged by NMPA’s draft Circular 55, which proposes a patent enforcement system with the critical components of: a) notice to innovators of potentially infringing subsequent applications referencing the original application prior to approval of such subsequent applications; and b) a stay of marketing approval pending the resolution of disputes concerning those patents. (Industry understood that separate amendments would be required to the Patent Law to create the cause of action to allow for the resolution of the patent dispute during the stay of marketing approval.) However, these promising proposals have not been advanced. On the contrary, neither the revised DAL, nor the October and December 2019 DRR amendments included provisions to establish an effective patent enforcement system. We strongly suggest that NMPA make it clear in the final DRR amendment, or DAL implementing regulations, that it will not approve potentially infringing follow-on application during the pendency of timely filed patent litigation or for a designated period of time, whichever is shorter. NMPA should also apply linkage to “relevant” patents, i.e., formulation, composition, and method of use patents, as well as process patents for biologics.

Further, PhRMA and its member companies are encouraged by the preliminary steps taken (in 2017) by the Center for Drug Evaluation to establish an Approved Drug List, akin to the Orange Book maintained by the U.S. Food and Drug Administration, that would provide greater certainty to innovators and generic manufacturers alike regarding the patent status of approved medicines and facilitate effective patent enforcement and implementation of regulatory data protection. We are hopeful that NMPA and CNIPA will provide more guidance on the listing process and mechanics of the stay described in Circular 55, and we look forward to working with the Chinese and U.S. governments to ensure that China implements an effective patent enforcement system consistent with its commitments in Article 1.11 of the Phase One Trade Agreement.

Lack of Regulatory Data Protection

As part of its accession to the WTO in 2001, China committed to provide a six-year period of RDP for undisclosed test or other data submitted to obtain marketing approval
for pharmaceuticals in accordance with Article 39.3 of the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). While China’s DAL and DRR anticipate a six-year period of protection for test data of products containing a new chemical ingredient, in practice there is no mechanism in China to prevent the unfair commercial use of safety and efficacy data generated by innovative pharmaceutical companies.

Moreover, even if there were a mechanism for granting RDP in China, key aspects of the RDP provisions are inconsistent with TRIPS Article 39.3. First, certain key concepts such as “new chemical ingredient” (sometimes referred to as “new chemical entity”) and “unfair commercial use” are undefined or are not in line with international standards. The term “new chemical ingredient” should be clearly defined in the DAL, DRR, and other relevant laws and regulations in line with international standards and include biologic and chemically synthesized drugs, recognizing the considerable investment by innovative pharmaceutical companies in developing and proving safety and efficacy of all new pharmaceutical products.

Second, RDP should be granted to any product that is “new” to China, i.e., has not been approved by NMPA. Proposals to date, however, suggest that China would only grant RDP to pharmaceutical products that are “new” to the world – in other words, products that make their international debut in China. That is at odds with the approach of other regulatory systems and even at odds with the approach taken in China for RDP for agricultural chemicals. PhRMA is concerned that this definition of “new drug” or similar concepts may continue to create risk that a drug approved or marketed first outside of China may receive weaker or no priority or protection in China. This approach would also

---


182 During the December 2012 JCCT, China “agreed to define new chemical entity in a manner consistent with international research and development practices in order to ensure regulatory data of pharmaceutical products are protected against unfair commercial use and unauthorized disclosure.” See Fact Sheet: 23rd U.S.-China Joint Commission on Commerce and Trade (Dec. 19, 2012), available at https://ustr.gov/about-us/policy-offices/press-office/fact-sheets/2012/december/23rd-JCCT (last visited Feb. 6, 2020). Following many years of discussion in the JCCT and other venues, this commitment was a positive development. Unfortunately, this commitment remains unfulfilled.

183 NMPA continues to draw distinctions between drug applications in China relative to approvals in other countries. The February 2016 NMPA “Chemical Drug Registration Category Work Plan,” defined a “new drug” as a chemical entity that is “new to the world.” Although this definition is contrary to international practice and the definition in the earlier DAL Implementing Regulation itself, NMPA continues to utilize this concept to grant priority to certain applications. NMPA and CNIPA are also proposing that only products “new to the world” would qualify for patent term restoration (in the January 2019 Patent Law draft) and the full regulatory data protection terms (in an April 2018 draft of NMPA measures on the Implementation of Drug Clinical Trial Data Protection). Applicants that submit marketing applications in China before or at the same time as other countries receive benefits; those who submit later in China receive less. The draft 2019 DRR contains a separate application category for drugs approved abroad but not in China, which could be used to perpetuate this disparate treatment of drugs approved abroad.
be discriminatory in that it would favor domestic industry and innovation, contrary to China’s international obligations.

As it stands, China provides no period of protection during which a non-originator (or follow-on) applicant is prevented from relying on the data submitted to NMPA or a foreign regulatory agency to secure approval of the originator product. This practice gives an unfair commercial advantage to the follow-on manufacturer by permitting it to rely on the full clinical data submitted by an innovator – which the follow-on manufacturer did not incur the costs to produce – while having to submit only a small amount of China-specific supplemental data to NMPA. NMPA should not approve follow-on drugs during the RDP period unless the follow-on applicant submits full clinical trial data that it has independently developed or received a license to cross-reference from the innovative drug manufacturer.184

In light of these deficiencies, we strongly welcomed the draft NMPA measures on the Implementation of Drug Clinical Trial Data Protection, which proposed up to six and 12 years of RDP for chemically synthesized drugs and therapeutic biologics, respectively. However, the proposed location- and time-based conditions and limitations placed on the terms for innovative drugs are not consistent with China’s international commitments, are not practical, and could well undermine the very goals that are driving these proposed reforms. In this respect, the Draft Measures would make it difficult – if not impossible – to obtain the benefits of RDP by forcing innovators into arbitrary choices concerning the location of development and timing of submissions. In some cases, the costs of these choices for the overall development program could exceed the benefits of RDP. Moreover, there remains significant uncertainty regarding the scope of the data protected and the criteria for protected categories, and we are very troubled by the broad post-approval data disclosure requirements. Consistent with its commitment in the chapeau to Section C of Chapter One of the Phase One Trade Agreement, now is the time for China to advance reforms to provide “effective protection and enforcement of pharmaceutical-related intellectual property rights, including … undisclosed test or other data submitted as a condition of marketing approval.”

Lack of Patent Term Extension Mechanisms

PhRMA and its member companies applaud the U.S. and Chinese Governments for their commitment in Article 1.12 to provide effective patent term extension mechanisms to compensate for unreasonable delays that occur in granting patents and unreasonable curtailment of the effective patent term as a result of the lengthy marketing approval process for innovative medicines. Pharmaceutical companies must adhere to a drug registration process before marketing drugs in China, as they must in other

184 Notably, this approach would be consistent with the goals of encouraging innovation in China by protecting innovators’ investment in clinical trials. To meet these goals, China will need to ensure that it has regulatory and legal systems that are compatible with other major markets. While the systems need not be identical, implementation of a meaningful RDP mechanism can promote harmonization and enable companies to function more easily in multiple markets.
countries, which causes delays in marketing that reduce the effective term of patent protection for products once they reach the market. Many countries respond to this problem by restoring the term of patents (PTR) to compensate for a portion of the effective patent life lost in securing marketing approval. PhRMA members are encouraged by the proposed amendments to the Patent Law (January 2019), which include the provision of PTR in Article 43. As China looks to implement its Phase One Trade Agreement commitments, we would refer the Chinese Government to the proposed revised language that we submitted in response to these proposed amendments to the Patent Law to ensure that the resulting mechanism achieves its objectives of encouraging the development of innovative medicines.

Restrictive Patentability Criteria

Reforms need to continue in China to provide clear and coherent standards, consistent with other major drug markets, for obtaining biopharmaceutical patents. It is critical that such standards reflect the realities of the drug development lifecycle. For example, unlike patent offices in the United States, Europe, Japan, Korea and other major markets, CNIPA does not consistently accept data generated after a patent is filed to satisfy sufficiency and inventive step requirements, pursuant to Articles 26.3 and 22.3 of China’s Patent Law, respectively. This practice has caused uncertainty about the ability to obtain and maintain biopharmaceutical patents in China, and has caused denials of patents on new medicines in China that received patents in other jurisdictions.

In late 2016, CNIPA issued an amendment to its Patent Examination Guidelines that requires examiners to consider post-filing experimental data submitted by the applicant. This amendment sought to implement China’s commitment, made during the 2013 JCCT, to permit patent applicants to file additional data after the application filing date.

PhRMA recognized and welcomed this positive step, but has repeatedly expressed concerns regarding the extent and implementation of the data supplementation amendment. First, the amendment to Section 3.5 makes the data supplementation approach applicable only to “Sufficiency of Disclosure of Chemical Inventions.” We believe the same approach should be taken to the examination of other patentability issues, such as inventive step, and therefore should be incorporated into Section 6, Chapter 10 of Part II as well. Second, we are concerned that certain language in the proposed amendment may be interpreted too narrowly by CNIPA examiners, resulting in less patent incentives for new medicines in China and thereby harming Chinese patients. Specifically, the amendment permits data supplementation only where “the technical effect to be proved by the supplemented experimental data shall be one which can be derived by a person skilled in the art from the disclosure of the patent application.” If this is interpreted so as to require the application to already disclose or demonstrate the precise technical effect to be proven by the offered supplemental data, which seemingly continues to be the case even after the amendment to the Patent Examination Guidelines came into effect, the result would be that supplemental data is rarely accepted. This result can be avoided by incorporating more detailed guidance in the Guidelines to make it
explicit that the requirements are in line with those commonly used in other countries. For example, the European Patentability Examination Guidelines (Section 11) provide that supplemental data will be accepted if it proves effects that “are implied by or at least related to the technical problem initially suggested in the originally filed application.”\textsuperscript{185} We urge CNIPA to keep these considerations, goals and benefits in mind and provide additional guidance consistent with them as it moves to implement Article 1.10 of the Phase One Trade Agreement.

In addition, specific therapeutic methods essentially cannot be protected by patents in China. New “specific therapeutic methods” are new methods of treatment of a known indication with a known product (such as new dosage regimens, treatment of new subgroups of patients or new routes of administration). They are distinguished from new product forms (such as dosage forms and formulations), manufacturing processes and treatment of new indications, which can be protected by patents in China either directly or through use of the Swiss-type claim format. Most countries with strong IP laws provide patent protection for specific therapeutic methods either directly (by permitting methods of treatment to be patented) or indirectly (by permitting alternative claim formats that, in effect, can provide patent protection for such inventions). Incentives to develop such new specific therapeutic methods should be provided by the patent system because such new uses of existing medicines can bring important patient benefits, including methods of treatment specific to the Chinese population that may not be developed in the absence of a local incentive to do so. However, Article 25(3) of China’s Patent Law does not allow for direct patenting of methods of treatment. The courts, including the Supreme Court (see, e.g., in the decision on Genentech v. PRB against the validity of patent No. ZL 00814590.3) and CNIPA (as stipulated in the Guidelines for Patent Examination), do not permit alternative claim formats that could protect specific therapeutic methods, including either Swiss-type claims where the point of novelty is a specific therapeutic method or other alternative formats that are accepted by patent offices in other countries, including the European Patent Office. We urge CNIPA to revisit this gap in China’s patent system and conform China’s practice to that of many other countries.

Loss of Patent Rights

Overly rigid requirements to prove patent ownership for subsidiary patents, a lack of clarity about what constitutes adequate proof of patent ownership, and short response timeframes have resulted in the loss of patent rights in Chinese Patent Office invalidation proceedings, without the possibility of appeal.

Lack of Transparency in Patent Prosecution

According to Rule 48 of the Implementing Regulations of the Patent Law, any person may, from the date of publication of a patent application till the date of allowance,

submit his observations why the application does not satisfy the patentability criteria. In turn, section 4.9 of Part II Chapter 8 of the Patent Examination Guidelines provides:

The observations submitted by anyone to the Patent Office on an invention application not in conformity with the provisions of the Patent Law shall be included in the application file. The examiner shall take them into consideration during substantive examination…. The handling of the observation submitted by the public does not need to be notified to the public concerned. (Emphasis added.)

The Examination Guidance does not indicate whether the observations/opinions submitted by “anyone” must be shared with the applicant.

Contrary to international best practice, patent applicants in China are not typically notified of the submission of third party observations nor offered the opportunity to rebut any allegations that they contain even though these observations may influence the substantive examination of their patent applications. We strongly encourage China to amend the Examination Guidelines and/or Implementing Regulations of the Patent Law to provide this basic transparency and due process as part of its patent prosecution process.

Mandatory intellectual property sharing related to certain biological material

As discussed further below, any research conducted by foreign companies using Chinese human biological samples must be undertaken in collaboration with Chinese partners (i.e., Chinese state hospitals) under the HGR regime. In both the original HGR Regulation and the 2019 amended version, there are provisions that require (1) that the foreign and Chinese party jointly submit any patent applications arising from the results of the collaboration (e.g., results of exploratory research) and (2) that the two parties agree on an arrangement for sharing or, in the event that there is no arrangement, jointly share the rights and benefits to other intellectual property, including obtaining the consent of the other party to transfer those rights. While not necessarily impacting rights over the investigational product, applicants are required to submit their clinical trial agreements (including the IP-related provisions) and make declarations on forms186 as to how they will share these IP rights with Chinese parties, sometimes requiring a negotiation with the HGRAO that creates uncertainty as to the rights over exploratory research.

In 2017, MOST further released the Guidelines on Optimizing the Approval Process of Human Genetic Resources to streamline the approval process and allow for parallel reviews of CTAs and genetic testing (HGRAC). However, under the new process, foreign sponsors and vendors are required to sign an “undertaking letter,” which certifies that they will comply with Chinese regulations that govern clinical studies and the

186 The forms that are part of the notification process introduced by the 2019 amendment to the HGR Regulations do not require IP-related declarations, although applicants must still submit the clinical trial agreements.
Chinese Administrative Permit Law. They are also accountable for the validity and accuracy of the application in its entirety, based on the official instructions on the application form. The intellectual property sharing requirement and the undertaking letter together form a significant hurdle and create uncertainty for foreign companies conducting clinical research in China.

Sample collection during a clinical trial should be left out of the approval process. More clarity with respect to the intellectual property sharing requirement is also needed to ensure, consistent with Chapter 2 of the Phase One Trade Agreement, that any transfer of technology as part of securing marketing approval for innovative medicines occurs on voluntary, market-based terms.

Market Access Barriers

Government Pricing and Reimbursement

To appropriately address the Chinese patient access and affordability challenges, PhRMA urges China to establish a comprehensive and sustainable policy framework for government pricing and reimbursement that would include predictable and timely reimbursement decisions for new drugs, systematic and transparent mechanisms for price negotiation linked to reimbursement, adoption of evidence-based methodologies for drug value assessment, and an enhanced role for commercial health insurance. PhRMA and its members are committed to working with the appropriate government authorities in China to assist in the timely and transparent development of this policy framework.

Government Reimbursement List

PhRMA welcomes the 2017 and 2019 updates to the NRDL as well as the recent addition of 17 oncology medicines to the NRDL in 2018. These important steps as well as the government’s commitment to conduct annual negotiations will significantly improve the access and affordability of innovative medicines for patients in China. While any additions to the NRDL are a positive development, it appears that the negotiation process for these new medicines lacked transparency and diverges from a sound government pricing and reimbursement system. By early 2018, all 31 provinces had included the negotiated drugs into their PRDLs. Still, there remain major implementation challenges, such as low reimbursement percentages and hospital listing restrictions, and cost control regulations, which will continue to restrict patient access to innovative and life-saving medicines. Patented medicines accounted for just 6.6 percent of 2018 pharmaceutical sales in China.187

PhRMA recommends that the Chinese government shift towards a more timely, transparent and predictable reimbursement system, in which manufacturers may apply for reimbursement at any time, drug clinical assessment is completed within a pre-defined

187 IQVIA Institute International Innovation Segmentation Analysis of Q2 2019 IQVIA Market Prognosis and MIDAS data.
period following the application (e.g., within 90 days), and negotiations between manufacturers and the responsible government agency take place on a more regular basis. The drug clinical assessment should be transparent, evidence-based, focused on clinical benefits and independent of economic considerations. Following the clinical assessment, a fair negotiation based on clear conditions and open communication should be conducted between the national reimbursement authority and the manufacturer. These reimbursement system reforms would provide U.S. companies increased market access and improve patient access to innovative medicines.

**Government Pricing and Procurement Policies**

China, as part of its WTO accession, committed to apply price controls in a WTO-consistent fashion, taking into account the interests of exporting WTO members, and without having the effect of limiting or impairing China’s market access commitments on goods and services. Notwithstanding that commitment, PhRMA is concerned that reforms to China’s government pricing and procurement mechanisms could exacerbate the already uncertain business environment and further reduce reward for innovation, restrict patient access to high-quality medicines and undermine China’s health care reform and innovation policy objectives.

In late 2018, China’s new Joint Procurement Office of National Volume-Based Procurement initiated a pilot program to centrally procure off-patent medicines for all public hospitals in 11 cities (the four directly managed municipalities of Beijing, Shanghai, Chongqing and Tianjin, and seven key cities in other provinces), which collectively represent around a third of the pharmaceutical market. Twenty-five of the 31 molecules proposed for procurement were selected based on the lowest winning bidder, with an average price cut of 52 percent. Generic products that passed a generic quality consistency evaluation (GQCE) accounted for 88 percent of winners and off-patent originator brands accounts accounted for 12 percent.

In September 2019, the Chinese government expanded the program to most of China but modifying the procurement methodology to allow for the three suppliers with the lowest bids. While allowing for multiple winning bidders is a positive development, PhRMA urges the Chinese government to ensure that the Volume-Based Procurement program does not reduce the number of quality suppliers in the market and increase the risk of drug shortages, or otherwise hinder patient and physician choice in selecting the clinically most appropriate medicines. PhRMA encourages the Chinese government to provide additional sales channels to ensure that patients have the full range of treatment options available.

PhRMA is committed to working collaboratively and expeditiously with the appropriate government authorities to implement a transparent and appropriate government pricing policy that recognizes quality-systems, innovation, and the value that our member companies’ products bring to patients and China.
Regulatory Approval Process

China is making significant strides in reforming and strengthening its regulatory framework, including shorter review times for CTAs and the expedited programs described above. Although there were a number of examples where NMPA granted expedited regulatory approval consistent with timelines in the U.S. and EU or even faster, China remains an outlier in the biologic and vaccine drug development and approval process compared to other regulatory authorities. We encourage China to rapidly address these issues, particularly with a significant number of promising gene therapies on the horizon and the importance of predictable and timely review processes to encourage innovators to bring these new therapies to China for regulatory approval.

China continues to catch-up to other countries in terms of the number of innovative medicines available. Statistics show that NMPA’s Center for Drug Evaluation approved a record number of 132 small molecule drug NDAs in 2018, compared with 113 in 2017 and 23 in 2016. It approved 11 preventive biologic NDAs and 30 therapeutic biologic NDAs. Still, just eight percent of the new medicines launched between 2011 and 2017 are available in China. Due to China’s stringent regulatory requirements and lengthy review and testing procedures, a “drug lag” remains in China.

PhRMA is encouraged by China’s recent legislative and regulatory developments including the newly revised DAL and certain aspects of the draft 2019 DRR revision released for comment on September 30, 2019 (and the revised drafts issued on October 15, and December 10, 2019), which implement reforms to speed up the approval process for some drugs. This new legislation continues to support greater flexibility in the drug development process, including a shortened timeline for the approval of clinical trials, streamlined amendment and reporting processes for clinical trial applications, and strengthened channels for stakeholder-NMPA communications. Furthermore, we support NMPA’s implementation of various conditional approval programs, including for two lists of drugs approved in the U.S., Europe, and Japan that China considers to be urgently needed for clinical use. We also support the issuance of guidance in July 2018 on the acceptance of overseas clinical trial data.

Additionally, NMPA’s May 2017 accession to the ICH and successful election to the ICH Management Committee further exemplifies China’s reform efforts. Being an ICH Member will further encourage NMPA’s harmonization with international regulatory standards, including but not limited to the China Pharmacopeia 2020, enforcement of GXP, and further implementation of standardized electronic submission for new drug applications (eCTD) and safety reporting, which will enable companies to pursue global simultaneous drug development and accelerate Chinese patient access to innovative medicines. Industry and other ICH stakeholders have high expectations for NMPA to implement all of ICH’s technical guidelines in the coming years. CDE is working on

---

189 PhRMA analysis of IQVIA Analytics Link.
implementing various ICH guidance documents and established related training programs.

Clinical Trial Applications

To help China further integrate into the global innovation network and reduce the time it takes for innovative medicines to reach patients, it is critical for China to shorten the CTA review and approval time. As discussed above, China now permits a new drug clinical trial to move forward if NMPA has not raised objections within 60 business days. Under the newly revised DAL and draft 2019 DRR this 60-day implicit approval should apply to all trials. Also, the newly revised DAL now permits filing administration of clinical trial sites to proceed via a faster notification process to increase the availability of resources. This will significantly reduce the drug lag as China’s CTA review time has represented the largest regulatory barrier for multinational companies in China. Therefore, PhRMA recognizes and applauds the important steps NMPA is taking to make the development process more efficient.

Based on PhRMA member company experience in other major markets, it is critically important for NMPA to maintain consistent and specific timelines for reviewing and approving applications. In addition, applications should be evaluated based on a clear set of standardized criteria coupled with science-based and risk-based decision making (principles embedded in ICH guidelines) that applies equally to both local and foreign manufacturers.

Specifically, we are encouraged that the newly revised DAL and draft 2019 DRR create a more uniform system that does not draw distinctions between local trials and international multicenter trials, building on prior reports in this area. For example, in 2017 NMPA began to permit International Multi-Center Trials (IMCTs) to commence in China in parallel with the rest of the world, with the exception of vaccine trials. IMCTs may now also support registration in China without going through a lengthy waiver process that NMPA imposed between 2013 and late 2017. These reforms coupled with the increasing acceptance of foreign data have the potential to further facilitate the drug development process. With respect to foreign data acceptance, further clarity on whether ethnic differences require additional clinical studies in China and whether this data can be accepted without filing a time-consuming clinical trial waiver application, will help to avoid any uncertainty in China’s drug registration process.

Still, obstacles remain. One of the more significant recent impediments to development has been an additional approval or notification now applicable to all trials conducted in China by foreign companies or their affiliates that collect any samples that contain Chinese human genetic resources, regardless of whether those samples are for genetic testing. Pursuant to HGR Regulations that have been in effect since 1998, but were largely unenforced until 2015, foreign applicants must apply to the HGRAC, under the MOST before they can collect and transfer these samples and associated data. The trial may not commence until this process is complete. While an amendment to the HGR Regulations in 2019 now permits manufacturers to submit a notification (rather than an
approval application) for trials that are intended to support a marketing application in China, provided that no samples from the trial will be exported from China, the filing criteria is very stringent and the vast majority of cases do not qualify. In addition, other trials still require approval.

The HGR application process potentially adds months to the development timeline and restricts both the movement of samples and data inside of China and abroad. Under the 2019 amendment, applicants must file any data that they intend to transport to third parties with the HGRAO. This situation presents a hurdle for China to participate in global development and contradicts various reform policies to encourage innovation. To improve the HGR process, clear and detailed guidelines on document requirements, standardized assessment and approval criteria and a systematic communication channel between HGRAO and sponsor are needed, consistent with China’s due process and transparency commitments in Article 2.4 of the Phase One Trade Agreement.

PhRMA’s view on intellectual property sharing related to certain biological material in connection with the HGRAO process is noted above.

**Drug Approvals Process**

PhRMA welcomes a number of other key regulatory reforms described above because they represent positive movement in China’s regulatory reform toward supporting a simultaneous global development/registration framework in China. These reforms are consistent with industry’s primary recommendations, including streamlined processes for IMCT registrations, strengthened expedited programs, acceptance of foreign clinical data to satisfy registration in China, structured agency consultation, and the establishment of an orphan disease list. PhRMA encourages China to pair the establishment of an orphan disease list with an orphan drug regulatory framework that provides for the expedited development and review of orphan drugs, as well as regulatory incentives.

The newly revised DAL adopts a MAH system nationwide and applies it to ex-China applicants. This system unifies the previously separate imported and domestically made drug pathways in certain ways. Applicants can now receive a marketing authorization tied to a product and have the freedom to contract out manufacturing, whether in China or abroad, and distribution to multiple partners. Also, the newly adopted DAL unifies what were previously separate applications for the drug product, the active ingredient, excipients and packaging materials. Materials related to the latter three will be registered to certain applicants as part of a drug masterfile system that began in 2017. These reforms will increase flexibility to structure and submit marketing applications.

To ensure Chinese patients receive timely access to new therapies, PhRMA recommends that NMPA continue to bring its regulatory framework into compliance with accepted international standards and adopt science-based, transparent, consistent and predictable policies for evaluating and approving drugs and biologics. PhRMA commends NMPA on its emerging leadership at ICH and reminds NMPA of the importance of timely
and robust implementation of all ICH guidelines. PhRMA recommends finalizing the revisions to the DRR and other implementation regulations in accordance with the principles stated in the NMPA draft Circulars from and the Opinions on Deepening Reform of the Review and Approval System to Encourage Innovations of Drugs and Medical Devices 2017 in order to accelerate and simplify the drug regulatory approval process, continue to unify requirements and practices for locally manufactured and imported products and clearly outline and streamline the criteria and timeline for reviewing and approving clinical trial and marketing application processes. PhRMA and its members stand ready and look forward to working closely with the U.S. and Chinese governments to support China’s regulatory reform efforts.

Counterfeit Medicines

Pharmaceutical counterfeiting poses global public health risks, exacerbated by rapid growth of online sales of counterfeit medicines and the production and sale of unregulated APIs used to manufacture counterfeit products. China has been stepping up enforcement efforts against counterfeited drugs in recent years, both through legislative reforms and increased police activity, and we commend the two governments on the commitments in Section G of Chapter One of the Phase One Trade Agreement to combat counterfeiting. In implementing these commitments it will be particularly important to address online distribution of counterfeit medicines and unregulated API. A number of stories involving counterfeit medicines continue to make national headlines, including a scandal in 2016 which uncovered nearly $88 million USD in substandard vaccines being circulated throughout 20 provinces.190

Under current pharmaceutical regulations, there is no effective regulatory control over the manufacture and distribution of API, which creates a major regulatory loop-hole that impacts negatively on the security of China’s upstream drug supply chain. The new DAL states that APIs used in drug production must comply with good manufacturing practice regulations and that drug producers must verify the compliance of APIs they purchase. But the DAL is not clear on the applicability of other regulations to APIs as it has removed API from the definition of “drug.”

The new DAL also introduces provisions on a system for drug traceability. This includes building upon existing efforts to establish an online platform for collecting and publishing traceability records and a requirement for a unique identifier according to uniform coding rules on each drug package. In addition, the DAL also contains increased fines and longer debarment penalties for counterfeiting.191

191 See DAL Chapter 11. The potential fines for manufacturing or distributing counterfeit drugs increased from 2 to 5 times the value of the goods to 15 to 30 times the value of the goods with a minimum fine of RMB 1,500,000 (about USD 208,000). These entities can be debarred for 10 years. The maximum penalty for a responsible person increased from ten years’ debarment to lifetime debarment from the
The amended DAL is a start, but further measures are still required, including:

- amending the Criminal Code to ease the burden of proof to prosecute brokers or API suppliers who knowingly deal with illegal APIs;
- empowering NMPA or another authority to regulate any party that manufactures API even if that party has not declared an intent to do so;
- empowering NMPA (through implementation of the revised DAL) to penalize API manufacturers based on *prima facie* evidence of a product having medicinal use or being an “API” or a “chemical drug substance” without cGMP certification; and
- deepening cooperation with major Internet Service Providers, portal sites, and search engines for earlier identification and tracking of illegitimate API suppliers through B2B websites.

While the State Administration for Market Regulation plays a critical role in developing future solutions, any significant reform plan will require coordination and consultation among all relevant ministries within the central government. These efforts to crack down on unregulated API must go hand-in-hand with China’s current campaign against counterfeit drugs in order to enhance the effectiveness of China’s national drug safety plan objectives.

China has continued to coordinate joint special enforcement campaigns targeting counterfeit drug crimes, including in 2018. It also appears that China is beginning to spend more efforts tackling the sale of counterfeit on the Internet. In 2016, NMPA pursued 14 cases of online drug counterfeiting in collaboration with the Guangdong and Shenzhen MPAs. In 2013, NMPA and the State Information Office jointly led a five-month crackdown campaign with collaboration of several ministries and offices against illegal online sales of drugs.

Reportedly, the government also demands major search engines to filter out fake drug posts, which is a significant partnership with the private sector aimed at protecting Chinese patients. Under the new E-Commerce Law and the new DAL, platforms that

---


194 Reportedly, search engines have been required to ensure that qualified websites are listed earlier in the search results, to conduct active searches for illegal online drug sales, to delete false and illegal medical advertising, and to report unqualified websites to the National Internet Information Office and
sell drugs must be registered with the government, verify the credentials of those who sell via their sites, and cease content and submit a report to the government related to any illegal activities it discovers.

PhRMA hopes that the U.S. Government will work with China to increase transparency of such campaigns, including enhancing information sharing with drug manufacturers to help evaluate the effectiveness of online actions, and supporting enforcement efforts, given the importance of protecting patients. China’s actions in this area could serve as a model for other countries facing similar challenges online.

PhRMA encourages China and the U.S. Government to continue and increase further their cooperation related to counterfeit medicines sold on the Internet, given the role of the Internet in the global counterfeit drug trade. This notably requires a holistic approach since not only finished counterfeit medicines are sold on the major online platforms in China but also separate materials (i.e., API, secondary packaging, primary packaging, labels) especially on business to business platforms for these to be assembled in and outside China.

Finally, while we commend China for improvements in customs regulations, which include monitoring and seizure of imports and exports, Chinese Customs authorities rarely exercise their authority to monitor pharmaceutical exports. PhRMA believes that more and better trained resources and support should be targeted to monitoring pharmaceutical and chemical exports to ramp up efforts against counterfeiting and unregulated API producers. This could include, for example, encouraging greater cooperation between Chinese Customs and the Public Security Bureau to ensure the identification and prosecution of those manufacturing and exporting counterfeit medicines. In addition, Chinese Customs could consider working with the World Customs Organization to exchange information and potentially align activities. Close cooperation and intense risk analysis with key intermediaries such as online e-commerce platforms and postal courier companies is critical to effectively monitor and detect small parcels with counterfeit medicines.

NMPA. In response, several Internet companies have stepped in to support the fight against counterfeit drugs. One of the most prominent companies, 360, introduced several products to provide users with accurate information on medicines and block false medical information websites, claiming that such sites accounted for 7.9% of all blocked websites or approximately 40,606 websites.
PRIORITY WATCH LIST
ASIA – PACIFIC
INDIA

We support the Indian Government’s efforts to create a stronger business, innovation, and health care environment through the “Make in India” initiative, the National Intellectual Property Rights (IPR) Policy 2016, the National Health Policy 2017, and the National Health Protection Scheme (NHPS) announced in February 2018 to provide health insurance coverage up to INR 500,000 (~$7,150 USD) to 500 million Indians and opening of health and wellness centers under the Ayushman Bharat Mission. These efforts can advance improved access to health care for Indian patients, while driving economic growth by enhancing India’s global competitiveness and improving ease of doing business. However, despite some positive signs, PhRMA’s members remain concerned about the challenging policy and regulatory environment in India.

Market access challenges persist and despite important announcements to expand health care programs, the Indian Government has not increased investment in this critical area, leaving public health care spending at a very low level of approximately 1.5 percent of GDP during the year 2018-19, and with only 34 percent of the population covered under any health insurance in 2016-17. Moreover, there are cumbersome procedures related to compensation which prevent India from becoming a part of global clinical trial programs and thereby limit patient access to innovative medicines in India.

Pharmaceutical innovators again saw positive signs from the Indian Government in 2019, including the release of the Manual of Patents Practice and Procedure (MPPP) that was notified by the Office of the Controller General of Patents Designs & Trademarks (CGPDTM) on November 26, 2019. However, these signals have not yet been translated into real policy and practical change. To research, develop, and deliver new treatments and cures to patients, biopharmaceutical innovators must be able to secure and effectively enforce intellectual property (IP) rights. With the right policies put in place, India could become a globally-competitive leader in life sciences and biomedical development. The National IPR Policy, 2016, puts forward an important framework for strengthening India’s innovation ecosystem; still, greater predictability and reliability is needed and implementation of the policy offers an opportunity to advance concrete policy improvements.

The innovative biopharmaceutical industry greatly appreciates the efforts to address these concerns at the highest levels of the U.S. and Indian Governments. We welcome the opportunity to continue working with both Governments to improve access to medicines for patients and advancing a “Healthy India” by removing market access barriers and fostering legal and regulatory certainty for the protection of IP in India.

Key Issues of Concern:

• **Unpredictable patent environment**: India’s legal and regulatory systems pose procedural and substantive barriers at every step of the patent process, ranging from impermissible hurdles to patentability posed by narrow patentability standards as set out in Section 3(d) of India’s Patents Act, 1970, patent grant delays due to cyclic filings of pre-grant oppositions followed by rampant post-grant opposition proceedings, to onerous patent application disclosure requirements and conditioning patent grant on unclear and subjective access and benefit sharing requirements that disproportionately affect foreign patent applicants. Not only is this a concern in the Indian market, but also in other emerging markets that may see India as a model to be emulated. Patent applicants continue to face rejections under Section 3(d), infringement due to state-level marketing authorization for generic versions of on-patented drugs, and the threat of compulsory licenses (CLs), all of which demonstrate that much work needs to be done to improve the patent environment in India.

• **Lack of patent enforcement**: One of the most significant challenges facing biopharmaceutical applicants seeking marketing approval in India is that marketing and manufacturing approvals are not transparent or coordinated between federal and state agencies. Indian law allows Central Drugs Standard Control Organization (CDSCO) to approve third-party manufacturers to commercialize copies of innovator chemically-synthesized products, regardless of whether those products infringe on an innovator’s patent(s). After four years of the medicine’s first approval in India, a mere license from any of the state drug regulators to manufacture and market the product in India suffices – resulting in irreparable harm to patients, innovators, and other follow-on producers. Coincident with changes to Indian customs procedures that eliminated patent enforcement at the border, biopharmaceutical innovators are seeing an increased incidence of infringing products manufactured outside India in neighboring territories being illegally imported into India. Not only do such products violate patents granted in India, they may also potentially threaten patient safety.

• **Regulatory data protection failures**: The Indian Regulatory Authority misinterprets Article 39.3 of the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and relies on test data submitted by originators to seek approval in India and/or another country when granting marketing approval to follow-on pharmaceutical products. This reliance results in unfair commercial use prohibited by the TRIPS Agreement and discourages the development and introduction into India of new medicines for unmet medical needs.

• **High tariffs and taxes on medicines**: Medicines in India face high effective import duties for active ingredients and finished products with the basic import duties averaging around 10 percent. When combined with the Integrated Goods and Service Tax, the effective import duty can exceed 20 percent. Additionally, the
Goods and Service Tax (Central GST & State GST) on medicines ranges from 5-12 percent.\(^{197}\)

- **Discriminatory and non-transparent market access policies:** While we commend the Department of Pharmaceuticals (DoP) for amending Paragraph 32 of the Drug Price Control Order (DPCO) to provide exemptions from price controls for five years from the commencement of marketing in India for patented products and for life for orphan drugs, there remains significant concerns of an evolving pricing regime that is discriminatory, unpredictable and opaque. There exists a potential and immediate threat of inclusion of patented medicines in the National List of Essential Medicines (NLEM) and thereby a threat of direct price setting under the DPCO, significantly reducing the benefits of patent protection and creating an unviable business environment for the innovative industry. The broad authority granted to the National Pharmaceutical Pricing Authority (NPPA) and continued lack of transparency, predictability, and trust in the decision-making process hinders further investment in India.

- **Unpredictable environment for clinical research:** While the Government is keen to reinvigorate clinical research in India, ambiguities and discriminatory practices in the Indian regulatory space continue to hinder that effort. In particular, the granting of waivers of India’s local clinical trials requirements is highly subjective and unpredictable. Further, deemed approval of clinical trials applications is discriminatory in nature, as it does not apply to drugs whose research and development was conducted outside of India. These issues perpetuate a burdensome environment for clinical research that undermines the availability of new treatments and vaccines for Indian patients.

For these reasons, PhRMA requests that India remain on the **Priority Watch List** in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

**Intellectual Property Protection**

India announced the new National IPR Policy in May 2016.\(^{198}\) The Policy recognizes the tremendous economic and socio-cultural benefits that a strong IP regime could bring to India through economic growth, employment, and a vibrant R&D environment. While the Government has established the Cell for IPR Promotion and Management under the National IPR Policy to conduct an IPR awareness campaign


across the country in educational institutions, no concrete measures have been taken to improve the IP regime, i.e., to promote innovation.

The Policy also puts forward important administrative and procedural improvements. However, it should be strengthened to accelerate the reforms needed to foster medical innovation and enhance India’s global competitiveness. For example, while the policy focuses on government, open source R&D, Corporate Social Responsibility credits, tax breaks, loan guarantees for start-ups, support systems for Micro-, Small- and Medium-sized Enterprises and other mechanisms to encourage innovation in India, it is also important to incentivize the private sector and scientific institutions by providing effective and meaningful IP protection and enforcement mechanisms. Implementation of the National IPR Policy, 2016 should include a consultative process with relevant stakeholders and meaningful reforms to India’s IP policies that lead to improvements in IP protection and enforcement for medicines.

Restrictive Patentability Criteria

PhRMA members continue to face considerable barriers at every step of the patent application process, including restrictive patentability criteria posed by Section 3(d) of India’s Patents Act, 1970, narrow patentability standards applied during pre- and post-grant opposition proceedings, conditioning patent grant on unclear and subjective access and benefit sharing requirements, and outdated patent application disclosure requirements.

TRIPS Article 27 requires that patents shall be available for any inventions, whether products or processes, in all fields of technology, provided that an invention is new, involves an inventive step, and is capable of industrial application. Section 3(d) of the Indian Patents Act, 1970, as amended by the Patents (Amendment) Act 2005 adds an impermissible hurdle to patentability by adding a fourth substantive criterion of “enhanced efficacy” to the TRIPS requirements. Moreover, this additional hurdle appears to be applied only to pharmaceuticals. Under this provision, salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of known substances are presumed to be the same substance as the original chemical entity and thus not patentable, unless it can be shown that they differ significantly in properties with regard to efficacy. Further, indiscriminate and routine use of Section 3(d) by the Indian Patent Office during prosecution of patent applications even for a novel compound or a derivative, with the onus of proof on the applicant to prove otherwise, poses an unreasonable and unnecessary burden on innovators.

Additional substantive requirements for patentability beyond those enumerated in the TRIPS Agreement are inconsistent with India’s international obligations. For example, Article 27 of the TRIPS Agreement provides an exclusive list of the types of subject matter that can be precluded from patent coverage, and this list does not include “new forms of known substances lacking enhanced efficacy,” as excluded by Section 3(d) of the Indian law. Therefore, Section 3(d) is inconsistent with the framework provided by the TRIPS
Agreement. Moreover, Section 3(d) represents an additional hurdle for patents on inventions specifically relating to chemical compounds and, therefore, the Indian law is in conflict with the non-discrimination principles provided by TRIPS Article 27 and WTO rules.199

From a policy perspective, Section 3(d) undermines incentives for biopharmaceutical innovation by preventing patentability for improvements that do not relate to efficacy, for example an invention relating to the improved safety of a product. Further, Section 3(i) of the Indian Patents Act, 1970, excludes method of treatment claims, effectively preventing U.S. biotechnology companies with needed treatment methods from entering the Indian market and providing life-saving products.

India’s pre- and post-grant patent opposition system is another source of unreasonable restrictive standards for patentability. Patent revocations using “hindsight” analyses made during pre- and post-grant oppositions have cited a lack of inventiveness concluding that inventions were based on “old science” or failed to demonstrate an inventive step. In addition, the lack of clear rules guiding pleading and evidentiary standards during pre-grant opposition proceedings create further uncertainty relating to the patentability of inventions. Further, pre-grant opposition procedures under Section 25 of India’s Patents Act, 1970, have created significant uncertainty and delayed the introduction of new inventions by undermining patent office efficiency and delaying patent prosecution.

Weak Patent Enforcement

Indian law permits CDSCO to approve third-party manufacturers to commercialize copies of innovator chemically-synthesized products, regardless of whether those products infringe on an innovator’s patent(s). After four years of the medicine’s first approval in India, a medicine is deemed to no longer be a new drug.200 As such, approval from CDSCO is not required and a mere license from any of the state drug regulators to

---

199 The additional patentability hurdle imposed by section 3(d) was recently reinforced by the Pharmaceutical Patent Examination Guidelines issued in October 2014.

200 As per Rule 2(1)(w) of the New Drugs Clinical Trials Rules, 2019 a drug (apart from a modified or sustained release form of a drug or novel drug delivery system of any drug or a vaccine, r-DNA derived product, living modified organism, monoclonal anti-body, stem cell derived product, gene therapeutic product or xenografts, intended to be used as drug) “shall continue to be new drugs for a period of four years from the date of their permission granted by the Central Licensing Authority ....” Further, after obtaining permission under Rule 81 of the New Drugs Clinical Trials Rules, 2019 the person intending to manufacture a new drug in India for sale shall also make an application for grant of license to manufacture for sale or for distribution in accordance with the provisions of the Act and the Drugs and Cosmetics Rules, 1945.

Thus, to obtain a manufacturing license for a new drug, the Central Drug Regulatory must provide written approval. In the case of drugs which do not meet the definition of a new drug, an “Application for grant and renewal of license to manufacture for sale or distribution of drugs shall be made to the licensing authority appointed by the State Government.” See MOHFW, “The Drugs and Cosmetics Rules, 1945 (As amended up to the 30th June 2005),” available at http://apps.who.int/medicinedocs/documents/s20107en/s20107en.pdf (last visited Feb. 6, 2020).
manufacture and market the product in India suffices. State regulatory authorities are not required to verify or consider the remaining term of the patent protection on the original product. Therefore, an infringer can obtain marketing/ manufacturing authorization from the state government for a generic version of an on-patent drug, forcing the patent holder to seek redress in India’s court system, which often results in irreparable harm to the patent holder. India’s National IPR Policy, 2016 calls for identification of important areas of potential policy development related to ambiguities between IP laws and other laws or authorities whose jurisdictions impact administration or enforcement of patents. At a minimum, India should amend its rules for “new drugs” in the New Drugs and Clinical Trials Rules, 2019, by increasing the period a drug is considered “new” from four years to ten years (thereby extending the period before which a manufacturer can seek approval for a follow-on product).

India also does not provide mechanisms for notification or resolution of patent disputes prior to marketing approval of generic products. Such mechanisms are needed to prevent the marketing of patent infringing products and resolve disputes in a timely manner. The SUGAM initiative launched in November 2015 to implement e-Governance with respect to the licensing system within India’s CDSCO lacks transparency and does not facilitate timely notification to a patentee of a possible infringement. In April 2017, India amended Form 44 of the Drugs and Cosmetics Rules to omit Item 8 which previously required new drug applicants to disclose the “patent status of the drug.” This action further eroded the ability of patent owners to effectively and timely notify generic manufacturers and state drug regulatory authorities of existing patents related to medicines approved by CDSCO or get timely and adequately notified of filing of applications for marketing or manufacturing approval by any subsequent applicant. CDSCO’s Notification GSR 19(E), dated January 10, 2019, falls short in providing an opportunity to facilitate notification of manufacturing applications between government agencies and patent holders under the SUGAM initiative. The industry has submitted many formal representations urging the Ministry of Health and Family Welfare (MOHFW) to take immediate steps to increase transparency and cooperation between central and state medicines regulatory authorities. At a minimum, MOHFW should ensure all biopharmaceutical manufacturers, the relevant Indian authorities and the broader public have timely notice of marketing and manufacturing applications filed with central and state regulators.

With regard to patent enforcement, in at least one specific case, the patent holder was forced to wait seven years before receiving a court decision upholding its patent. In that case, the court ultimately did not grant an injunction because by the time the decision was issued the patent was close to expiration. In another case, a company waited two years for a Court to grant an injunction. During that time the infringing product was

201 See Secs. 3.8 and 3.8.3 of the National IPR Policy.
202 Form 44, Schedule A, Drugs and Cosmetics Rules, 1945.
203 Id.

108
marketed and sold. Recent cases also reveal that defendants have started to obtain market authorizations and manufacturing licenses without the knowledge to the innovator and preemptively filed declaratory suits as to the non-infringement of the patents in a civil court so as to delay grant of any injunction orders.

The Commercial Courts, Commercial Division and Commercial Appellate Division of High Courts Act, 2015 (as amended in 2018) provides for the creation of commercial and commercial appellate divisions in high courts, and commercial courts at the district level to assist in addressing disputes in a timely manner. While this is a promising development, these courts are now overburdened with cases and will require a significant amount of technical expertise and commitment of resources to be properly implemented. Patents involve technical issues and therefore, designation of a specialized patent bench with the appropriate knowledge is critical for accurately examining and interpreting the issues involving complex technologies.

While the draft National IPR Policy proposed to establish specialized patent benches at the High Court level and designate an IP court at the district level, the final National IPR Policy did not include this provision. Further, the continued lack of a technical member on India’s Intellectual Property Appellate Board coupled with the Chairman rendering the Board non-functional are denying patent holders access to the appeal rights provided under the Patents Act.

Compulsory Licensing

The grounds for issuing a CL in India under the Patents Act, 1970 are broad, vague and appear to include criteria that are not clearly related to legitimate health emergencies. While the Indian Government continues to take a more measured and cautious approach in responding to recent CL cases, the MOHFW continues to entertain potential recommendations to impose CLs on certain anti-cancer and rare disease medicines under the special provisions of Section 92 of India’s Patents Act, 1970, which would cause further difficulty for patent owners to defend their patents. Moreover, some Indian pharmaceutical companies routinely initiate requests for voluntary licenses under Section 84(6)(iv) of the Patents Act as a precursor to seeking a CL, reducing CLs to a commercial tool rather than a measure of last resort. Internationally, in various multilateral forums, India has advocated for the broad adoption and implementation of legislation that facilitates the use of CLs, contrary to the spirit of the TRIPS Agreement. A market with ongoing threats of CLs perpetuates an unreliable environment for patent protection and investment.

---

205 Merck Sharp & Dohme Corp. v. Glenmark Pharms, Delhi High Ct., 2015 (64) PTC417(Del).
In addition, Section 146 of the India Patents Act, 1970, further exacerbates the uncertainty and scope of India’s CL provisions. Rules promulgated under that section require all patent holders to file an annual statement summarizing “the extent to which the patented invention has been worked on a commercial scale in India.”\textsuperscript{208} Notwithstanding the commercially sensitive nature of information required to satisfy Section 146, it also provides an impermissible basis for local companies to seek CLs, as occurred in 2012. Moreover, the rationale for requesting this information is unclear, and appears merely to be a disguise for facilitating questionable administrative challenges to existing patents. While Industry raised these shortcomings in its comments to the draft Patents (Amendment) Rules, 2019 (which was notified vide GSR 396(E) dated May 31, 2019, awaiting final Notification) they were not addressed.

We believe that resort to CLs is not a sustainable or effective way to address health care needs. Voluntary arrangements independently undertaken by our member companies can better ensure that current and future patients have access to innovative medicines. Statements from the Government incorrectly imply that CLs are widely used by other governments, both developed and developing.\textsuperscript{209} These are misunderstandings and do not justify widespread use of compulsory licensing.

At a minimum, India should ensure that CLs are exercised with extreme caution and as a measure of last resort. India should also clarify that importation satisfies the “working” requirement, pursuant to TRIPS Article 27.1. Further, India must eliminate burdensome working reporting requirements under Form 27 and maintain the confidentiality of the working statement disclosures.

Administrative Burdens

PhRMA welcomes the Indian Government’s ongoing work to address India’s patent examination backlog including the commitment to reduce examination periods from up to seven years to 18 months from initial submission. Backlogs undermine incentives to innovate and hinder timely patient access to valuable new treatments and cures. Because the term of a patent begins on the date an application is filed, unreasonable delays can directly reduce the value of granted patents and undermine investment in future research activity. For biopharmaceutical companies, patent examination backlogs can postpone clinical trial activity and ultimately the introduction of new medicines in India. Generic manufacturers are also affected by patent examination backlogs. So long as a patent application is unreasonably delayed, generic manufacturers cannot assess whether they will have freedom to operate. That lack of certainty could discourage the launch of generic medicines or expose generic companies to damages once the patent is granted. In addition to increasing the number of patent examiners, it is

\textsuperscript{208} India Patents Act, Section 146(2).

\textsuperscript{209} See, e.g., Nirupama Rao, The Hill (op-ed), “India honors – not dishonors – patent laws,” available at http://thehill.com/blogs/congress-blog/campaign/316883-india-honors--not-dishonors--patent-laws (last visited Feb. 6, 2020). These misstatements of wide-spread use of CLs in the U.S. and the premise that CLs can resolve access problems in India have been refuted by OPPI and PhRMA.
equally important to assess administrative procedures that unduly extend patent examination timelines.

Section 8 of the Patents Act sets forth requirements that have been interpreted in a manner that creates heightened and unduly burdensome procedures that mainly impact foreign patent applicants – those most likely to have patent applications pending in other jurisdictions. Section 8(1) requires patent applicants to notify the Controller and “keep the Controller informed in writing” of the “detailed particulars” of patent applications for the “same or substantially the same invention” filed outside of India. Section 8(2) requires a patent applicant in India to furnish details to the Indian Controller about the processing of those corresponding foreign patent applications if that information is requested. These additional patent application processing requirements have been interpreted in a manner that creates heightened and unduly burdensome patent application procedures that mainly impact foreign patent applicants – those most likely to have patent applications pending in other jurisdictions.

Section 8 was enacted in 1970 when the information was only available from the applicant; much of the information sought is now publicly available on patent office websites in most major jurisdictions. For example, through the Global Dossier Initiative of five major patent offices (the U.S. Patent and Trademark Office, the European Patent Office, the State Intellectual Property Office of China, the Japanese Patent Office, and the Korean Intellectual Property Office), the current file histories from each of these offices are accessible at one website. Thus, accurate information about counterpart foreign applications is readily available to the India Patent Office examiners. Recent court decisions provide greater clarity on the applicability and scope of Section 8. In particular, current jurisprudence limits Section 8 to information that is material to patentability and to deliberate failures to disclose this information.210

Additionally, requests pursuant to Section 8(2) for the translation of foreign search and/or examination reports are not only unduly burdensome but costly as well. In practice, attorneys routinely receive informal translations of foreign search and/or examination reports intermingled with local attorney advice and counsel (information subject to attorney-client privilege). Moreover, translations of the search and/or examination reports may not yet be available at the time of the Section 8(2) request.

Further, the remedy for failure to comply with Sections 8(1) and 8(2) is extreme compared to other countries with similar (but less onerous) administrative requirements. In India, the failure to disclose under Section 8 can be treated as a strict liability offense that by itself can invalidate a patent (although a recent court decision indicates some flexibility for mere clerical errors). This is in contrast to a requirement that the failure to

---

disclose be material and/or intentional as in the U.S. or Israel. Thus, India’s disclosure requirement and remedy are each more burdensome as compared to other jurisdictions, thereby creating a barrier to patentability that has an unfairly greater effect on foreign patent applicants, and, in some instances resulted in India revoking patents on the grounds of non-compliance with this particular provision.\footnote{See, e.g., Ajantha Pharma Ltd. v. Allergan, Intellectual Property Appellate Board (2013).}

We welcome the Guidelines provided for the examiners in the MPPP that was notified by CGPDTM on November 26, 2019. Of particular promise, Section 8 directs patent examiners to utilize resources available at WIPO DAS (Digital Access Service) and WIPO CASE (Centralised Access to Search and Examination) and to recognize the evolved jurisprudence by the Indian Courts. We also welcome that the initial proposal in the draft MPPP to expand the definition of “person interested” beyond the definition provided under the Patents Act, 1970 has been dropped in the final MPPP.

We also welcome the adoption of a Patent Prosecution Highway (PPH) programme between the Indian Patent Office (IPO) and the Japan Patent Office (JPO) and the release of the Procedure Guidelines for the PPH. However, the guidelines lay down procedures to file a PPH request in certain specified technical fields only, namely, Electrical, Electronics, Computer Science, Information Technology, Physics, Civil, Mechanical, Textiles, Automobiles and Metallurgy while JPO may receive applications in all fields of technology. We believe that PPH requests in India should be extended to all fields of technology, including biopharmaceuticals.

Regulatory Data Protection Failures

Contrary to its TRIPS Article 39.3 obligation, India fails to prevent unfair commercial use of the regulatory data submitted by a party in securing marketing approval in India or in a third country. Rather, when a pharmaceutical product has been previously approved by a Regulatory Authority in India or in another country, India requires only limited clinical data (in some cases involving as few as 16 Indian patients). This is \textit{in lieu} of requiring submission of the entire dossier for review by India’s regulatory authority. Moreover, in some instances when an applicant seeks approval for a generic or biosimilar product that has already been approved abroad, Indian authorities waive the requirement to submit even this data.\footnote{See Rules 75 and 80 of the MOHFW, “The New Drugs and Clinical Trials Rules, 2019,” available at http://www.egazette.nic.in/WriteReadData/2019/200759.pdf (last visited Feb. 6, 2020).} In those circumstances, any subsequent approval of the drug in India is based entirely on the prior approval in a third country.

By linking approval in other countries that require the submission of confidential test and other data to its own drug approval process, India, in effect, uses those countries as its agents. Approval by the Indian regulatory authorities based on third-country approvals amounts to indirect reliance on the clinical trial and other test data that underlie the third-country approvals. This indirect reliance results in unfair commercial use prohibited by TRIPS Article 39.3.
Market Access Barriers

High Tariffs and Taxes on Medicines

PhRMA member companies operating in India face high import duties for active ingredients and finished products. Though the basic import duties for pharmaceutical products average about 10 percent, due to the integrated GST imposed on imports, the effective import duty can exceed 20 percent. Moreover, excessive duties on the reagents and equipment imported for use in research and development and manufacture of biotech products make biotech operations difficult to sustain. Compared to other Asian countries in similar stages of development, import duties in India are very high. And while certain essential and life-saving medicines may be granted exemptions from some of the taxes, the eligibility criteria are vague and subject to constant revision and debate.213

GST was implemented in July 2017 and, while it is expected to significantly reduce layers and complexity in the indirect tax system, it levies an additional 5-12 percent tax on medicines.214 Proposals to exempt certain life-saving drugs from GST and customs duties should be expanded to all medicines.215

Insufficient Financing and Low Access to Care

PhRMA’s members are concerned about the general lack of access to health care in India. The Indian government released the National Health Policy in March 2017,216 which calls for greater access to health care for low-income patients, and the NHPS in February 2018.217 The National Health Policy denotes expanding comprehensive primary health care through “Health and Wellness Centres,” including care for major non-communicable diseases (NCDs), mental health, geriatric health care, palliative care and rehabilitative care services. The policy also calls for increasing public health expenditure to 2.5 percent of GDP by 2025.

India has insufficient numbers of qualified health care personnel, inadequate and poorly equipped health care facilities, and most importantly lacks a comprehensive system of health care financing that would pool financial risk through insurance and help to share the cost burdens. India has a shortage of doctors and as per current population

216 See supra n. 213.
estimate of 1.35 billion, the doctor-population ratio is 1:1456, which is lower than the WHO norm of 1:1000. This is further fueled by limited government investment and low allocation for health care in the national budget.\textsuperscript{218} Despite the encouraging and ambitious goals in the new National Health Policy, government spending on health care remains at about 1.5 percent of GDP, one of the lowest levels of expenditure in the world.\textsuperscript{219} Without increased resources (both in terms of government spending and through reducing barriers for commercial health insurance) and a full implementation of the reform, high out-of-pocket spending on health care and pressure on the cost of medicines will persist.

**Discriminatory and Non-Transparent Pharmaceutical Pricing Policies**

Despite decades of government price controls in India, ostensibly seeking to improve patient access to medicines, essential medicines are still not easily accessible. Still, India has thousands of manufacturers of pharmaceuticals who operate in a very competitive environment, and as a result, India has some of the lowest prices of medicines in the world.\textsuperscript{220} Instead, India should focus on the key barriers to access in India, including insufficient financing, infrastructure, and quality.

In 2014, an Inter-Ministerial Committee was constituted to suggest a methodology to be applied to pricing of patented medicines in India.\textsuperscript{221} Earlier, a DoP Committee on Price Negotiation for Patented Drugs report (February 2013) recommended an international reference pricing scheme with a purchasing power parity adjustment for government procured patented medicines, with those patented medicines to be provided through health insurance. A final decision on the 2014 Inter-Ministerial Committee recommendations is yet to be made. However, PhRMA members are highly concerned that the 2013 proposals could be adopted, which would significantly reduce the benefits of patent protection, \textit{de facto} discriminate against importers in order to pacify the domestic industry and create an unviable and unbalanced government pricing framework and business environment for innovative pharmaceutical companies.

The DoP is currently looking at amending the DPCO 2013 to include a provision for fixing retail prices of all drugs by way of a Trade Margin Rationalization formula. On February 27, 2019, NPPA implemented a pilot to cap the trade margins on 42 oncology drugs, including a few patented products.

While we commend the DoP for amending Paragraph 32 of the DPCO in January 2019 to provide exemptions from price controls for five years from the commencement of


\textsuperscript{219} \textit{Supra} note 195.

\textsuperscript{220} Analysis based on IMS MIDAS Data.

marketing in India for patented products and for life for orphan drugs, there remains significant concerns of an evolving pricing regime that is discriminatory, unpredictable and opaque. There remains the threat of including patented medicines in the NLEM and thereby a threat of direct price setting under the DPCO, significantly reducing the benefits of patent protection and creating an unviable business environment for the innovative industry. The broad authority granted to the NPPA and continued lack of transparency, predictability, and trust in the decision-making process hinders further investment in India.

Furthermore, expansion of price controls to a larger range of medicines will not substantially improve access to medicines in India; the real access barriers are insufficient health care financing, poor access to physicians, and inadequate health care facilities.\textsuperscript{222} For example, even medicines and vaccines that are offered free of charge often do not reach the patients who need these medicines.\textsuperscript{223} A 2015 study by IMS – “Analyzing the Impact of Price Controls on Access to Medicines” – found that price controls are neither an effective nor a sustainable strategy for improving patient access. The study found that the primary beneficiaries of price controls have been high-income patients, rather than the intended low-income population.\textsuperscript{224} A considerable body of evidence demonstrates that price controls contribute to lower investment in pharmaceutical research and development, ultimately harming patients who are in need of improved therapies.\textsuperscript{225}

PhRMA members believe that competitive market conditions are the most efficient way of allocating resources and rewarding innovation; however, the research-based pharmaceutical industry recognizes the unique circumstances in India and is committed to engaging with the Government to discuss pragmatic public policy approaches through industry and public consultations that will enable the development of simple and transparent government pricing and reimbursement mechanisms that provide access to medicines, reward R&D and innovation, encourage clinical trials, include the patient perspective, and encourage continued investment into unmet medical needs.


Unpredictable Environment for Clinical Research & Drug Approval

India has many of the components of an effective regulatory system, such as institutional capacity across central and state regulators and a robust technical framework. India also has several components to support a broader ecosystem for clinical research and drug development, such as the presence of a highly skilled workforce of qualified scientists, hundreds of medical colleges, and a large and diverse patient pool.

We welcome the fact that the MOHFW and CDSCO have undertaken regulatory reforms, including adoption of New Drugs and Clinical Trials Rules, 2019, with the goal of strengthening the regulatory regime and reinvigorating clinical research. Strong, transparent and predictable regulatory frameworks are essential to protecting patients as well as to promoting globally-competitive innovative and generic pharmaceutical industries. However, as noted above, the New Drugs and Clinical Trials Rules, 2019 include significant ambiguities and several discriminatory provisions, which create uncertainties in the regulatory process for clinical trials and threaten the overall clinical research environment in India. These issues must be addressed in order to increase the availability of new treatments and vaccines for Indian patients.

Further, certain challenges that existed in the Drugs and Cosmetics Rules, 1945 continue to exist in the New Drugs and Clinical Trials Rules, 2019. Rule 41 of the New Rules, which describes attributable causes of injury for clinical trials participants, is overly broad and lacks a legally or scientifically sound process for determining causality of injury. Definitions for “trial related injury” and “standard of care,” remain uncertain. Furthermore, many provisions in the New Rules are ambiguous and highly subjective. For example, the provisions on local clinical trial waiver lack clarity; the list of countries to be notified by the regulator under the New Rules for seeking waiver of local clinical trial is yet to be notified; the provision on deemed approval is discriminatory in nature as it is limited to drugs whose research and development was conducted in India; and the New Rules do not designate an appellate authority. Further, with no guidelines for the Subject Expert Committee reviewing the applications for clinical trials heightens the existing subjectivity.

As a result, adoption of the New Rules leaves great uncertainty relating to future costs and liabilities associated with conducting clinical trials in India, resulting in many sponsors not launching clinical trials in India until these uncertainties have been resolved. Research shows that if India were to address outstanding concerns, India could see an increase in the number of new clinical trials per year to above 800, adding over $600 million in economic gains.226 Greater clarity and predictability are needed for administrative procedures of drug registration applications, drug labelling standards and drug review standards and procedures in order to make the latest research products available in India.

---

INDONESIA

PhRMA member companies see tremendous opportunities to contribute further to Indonesia’s health care goals. However, significant and often discriminatory intellectual property (IP) and market access barriers in this large and growing market prevent possible partnerships from delivering on their full potential. The Indonesian Government appears sincere in its desire to address these barriers, but concrete action and meaningful results are needed before there can be any changes in Indonesia’s designation in the Special 301 Report.

Key Issues of Concern:

- **Restrictive patentability criteria**: 2017 amendments to the Patent Law preclude patents on new uses (indications) and establish an additional patentability criterion of “increased meaningful benefit” for certain forms of innovation, such as new salts or new dosage forms. These restrictions are overly broad and will undermine support for important innovations and appear to conflict with existing international obligations by imposing additional or heightened patentability criteria that discriminate against particular classes of technology. We are also concerned by amendments to the Patent Law that would impose new patent disclosure requirements regarding the source and origin of genetic resources. Such requirements introduce uncertainties into the patent system that inhibit innovation in relevant technologies and undermine the potential of benefit-sharing.

- **Compulsory licensing**: Indonesia has issued compulsory licenses (CLs) on nine patented pharmaceutical products (in 2004, 2007 and 2012), despite concerns raised by the affected PhRMA member companies. PhRMA is troubled by Indonesia’s decision to issue these licenses, which were granted without attempts to engage with the affected PhRMA member companies to find more sustainable and long-term solutions and in a manner that appears inconsistent with Indonesia’s international obligations. PhRMA is also concerned by 2017 amendments to the Patent Law and implementing regulations, which include provisions that discourage voluntary licensing between private parties and promote compulsory licensing on grounds that are vague or appear to be inconsistent with Indonesia’s international obligations. On December 28, 2018, Indonesia’s Ministry of Law and Human Rights (MLHR) issued Regulation 39 that dramatically increases the risk of CLs in Indonesia. The MLHR published the Regulation in final form without circulating a draft for public comment or otherwise engaging relevant stakeholders.

MLHR implemented a revised compulsory license regulation (No 30/2019) on December 9, 2019. While the revised regulation is an improvement, fundamental issues remain that can only be addressed by revising the Patent Law. To that point, MLHR has officially initiated a process to amend the existing Patent Law (2016), including early meetings with stakeholders in Jakarta, and we are hopeful that legislation will be passed in 2020. PhRMA member companies are prepared to
work collaboratively with Indonesian authorities to find solutions that benefit patients in Indonesia while maintaining adequate and effective IP protections.

**Registration delays:** Despite recent improvements, PhRMA member companies continue to face burdensome regulatory delays in the registration process of new products, in contravention of Indonesia’s own regulations. We understand that efforts to achieve stronger conformance with international best practices are being made with respect to regulatory timelines and processes as part of the ASEAN Pharmaceutical Regulatory Harmonization. We encourage the Indonesian Government to also make efforts to achieve stronger conformance with international best practices with respect to regulatory data protection and bioequivalence requirements.

**Forced localization requirements:** Government policies driving forced localization requirements have been increasing. The local manufacturing and technology transfer requirements of Decree 1010, and the apparent requirement in the Patent Law that patented products be made in Indonesia, are discriminatory, difficult to implement, or implemented inconsistently. Indonesia’s positions contravene its obligations under the World Trade Organization (WTO) rules, which prohibit members from discriminating based on whether products are imported or locally produced. Specifically, Article 27.1 of the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) states that “patents shall be available and patent rights enjoyable without discrimination as to the place of invention, the field of technology and whether products are imported or locally produced.” These requirements will have lasting implications for market access and patient health in Indonesia. To prevent import restrictions on innovative medicines, it is imperative that a solution is reached to allow all legitimate high-quality pharmaceuticals to be traded, sold and distributed in Indonesia, regardless of origin.

**Cost-focused formulary decisions:** While Indonesia is to be commended for developing guidelines and an online portal (eFORNAS) for listing new molecules on the Indonesian National Formulary, actual listing decisions appear to be primarily based on price and the overall Social Insurance Administration Organization (BPJS) budget. Consistent with the guidelines, listing decisions should better reflect all of the evidence submitted, including scientific data demonstrating the drug’s safety and efficacy. To this end, PhRMA’s member companies are encouraged by the fact that the government procurement agency is considering implementation of Multiple Criteria Decision Analysis (MCDA) for procuring pharmaceuticals.

**Mandatory halal certification:** On September 25, 2014, the Indonesian Parliament passed the Halal Products Law. The Law has broad application to all consumables, including pharmaceuticals, and requires that producers label their products as “halal” or as “non-halal,” based on whether the products are halal
certified. PhRMA’s member companies are strongly supportive of religious and cultural sensitivities, but are concerned that this mandatory labeling requirement could have unexpected negative implications on patient health.

For these reasons, PhRMA requests that Indonesia remain on the Priority Watch List in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

Intellectual Property Protection

Restrictive Patentability Criteria

The Patent Law precludes patents on new uses (indications) and establishes an additional patentability criterion of “increased meaningful benefit” for certain forms of innovation, such as new salts or new dosage forms. These restrictions undermine support for important innovations and are contrary to existing international obligations by imposing additional or heightened patentability criteria in a manner that discriminates against particular classes of technology.

Additional substantive requirements for patentability beyond that the invention be new, involve an inventive step and capable of industrial application, are inconsistent with the TRIPS Agreement. Article 27 of the TRIPS Agreement provides a non-extendable list of the types of subject matter that can be excluded from patent coverage, and this list does not include new uses of existing compounds. Therefore, the Patent Law appears to be inconsistent with the framework provided by the TRIPS Agreement. Moreover, the Patent Law imposes an additional hurdle for patents on inventions specifically relating to chemical compounds and, therefore, is in conflict with the non-discrimination principle provided by TRIPS Article 27.

To bring valuable new medicines to patients, biopharmaceutical innovators must be able to secure patents on all inventions that are new, involve an inventive step and are capable of industrial application. Restrictions that narrow patentability prevent innovators from building on prior knowledge to develop valuable new and improved treatments that can improve health outcomes and reduce costs by making it easier for patients to take medicines and improving patient adherence to prescribed therapies.

Burdensome and Vague Disclosure Obligations

The Patent Law also requires disclosure of the origin of genetic resources or traditional knowledge “related” to inventions. We support the objectives of the Convention on Biological Diversity (“CBD”) and recognize the national sovereignty of States over biological resources. However, such requirements introduce uncertainties into the patent system that inhibit innovation in relevant technologies and undermine the potential of benefit-sharing. We therefore recommend eliminating this vague requirement, which is likely to cause uncertainty for innovators and undermine the sustainable use of technology related to biological resources.
Compulsory Licensing

Between 2004 and 2012, Indonesia issued CLs on nine patented pharmaceutical products. PhRMA is troubled by Indonesia’s decision to issue government use permits without attempts to engage the affected PhRMA member companies in discussions to find more sustainable and long-term solutions. We are further concerned that a number of patents on different products were aggregated together and dealt with as a group rather than considering each on its merits as required by Article 31(a) of TRIPS. In addition, other than the stipulated remuneration, there is no ability to appeal the CL or otherwise obtain judicial or other independent body review, as required by TRIPS Article 31(i).

The Patent Law and implementing regulations create further uncertainty in this area by discouraging voluntary licensing agreements between private parties and by promoting compulsory licensing on grounds that are vague or appear to be inconsistent with Indonesia’s international obligations. In particular, the Patent Law unnecessarily requires disclosure of private licensing agreements and allows compulsory licensing if a patented product is not being manufactured in Indonesia within 36 months of receiving a patent grant. Requiring disclosure of private agreement terms would discourage entry into such agreements to the detriment of Indonesia. The local manufacturing requirement would also appear to contravene Indonesia’s national treatment obligations (including TRIPS Article 27.1), pursuant to which manufacturers should be able to meet the “local working” requirements through importation.

On December 28, 2018, the MLHR issued Regulation 39 that dramatically increases the risk of CLs in Indonesia. In addition, the regulation appears to go beyond what was required to implement relevant Patent Law provisions, e.g., providing the MLHR vague and unfettered discretion to issue a CL for any pharmaceutical product that would “remedy” a human disease; enabling anyone to petition the MLHR to issue a CL, and permitting the MOH to produce a list of medicines and medical devices for compulsory licensing. The MLHR published them in final form without circulating a draft for public comment of otherwise engaging relevant stakeholders. The MLHR implemented a revised compulsory license regulation (No 30/2019) on December 9, 2019. While the revised regulation includes improvements, fundamental issues – including the local working requirement – remain that can only be addressed by revising the Patent Law.

While meaningful engagement between the Indonesian Government and the private sector has resulted in improving the existing regulation, further engagement is essential to achieve durable solutions. PhRMA and its member companies welcome the process the MLHR has initiated to amend the existing Patent Law (2016). Indonesia should make clear in the revised law that any compulsory licensing action needs to be taken on a patent-by-patent basis with full consideration of particular circumstances in each case. CLs should only be used in extraordinary circumstances as a last resort rather than standard government practice. As a general matter, CLs are not a sustainable or effective way to address health care needs. Voluntary arrangements independently undertaken by member companies better ensure that current and future patients have access to innovative medicines.
Market Access Barriers

Registration Delays

Despite recent improvements, PhRMA member companies continue to face burdensome regulatory delays in the registration process of new products. There are a variety of causes for the unpredictable delays, which ultimately result in new products being temporarily or permanently blocked from entering the market. It is uncertain whether the lack of attention to new product applications is due to insufficient personnel capacity or other regulatory reasons. In addition to regulatory delays, PhRMA member companies would like to see Indonesia take steps to bring the National Agency for Food and Drug Control (BPOM) further in line with international best practices, namely in regard to regulatory data protection and bioequivalence requirements.

PhRMA members are encouraged to note that BPOM hired 20 additional registration staff again in 2019 making a total of 140 persons in the Drug Registration Directorate; however, that increase in staffing is not sufficient to meet BPOM's current need despite the newly introduced e-submission system. Both BPOM and the industry have agreed to improve the know-how and skills of their registration staff in order to improve the timeliness of the regulatory review process. PhRMA and its members recommend that BPOM evaluate the registration fees to ensure that it has sufficient resources and personnel to review marketing approval applications in a timely manner.

Forced Localization Requirements

Ministry of Health (MOH) Decree 1010/MENKES/PER/XI/2008 ("Decree 1010"), formally implemented in November 2010, prevents multinational research-based pharmaceutical companies from obtaining marketing authorization for their products. Under Decree 1010, only companies registered as "local pharmaceutical industry" are granted marketing approval. As several of PhRMA's member companies do not manufacture products in Indonesia, they are instead classified as distributors, or “PBF” enterprises. They are so classified despite following globally recognized good manufacturing practices in the same manner as other high quality pharmaceutical firms manufacturing in Indonesia. Product of multinational research-based pharmaceutical companies and other foreign companies are barred from the Indonesian market unless (1) a local manufacturing facility is established; or (2) sensitive IP is transferred to another pharmaceutical firm with local manufacturing facilities in Indonesia. The first condition is not possible for many PhRMA member companies, given the structure of their global pharmaceutical supply chains. The second condition poses a serious threat to IP protection and patient safety.

Another key concern of PhRMA member companies with Decree 1010 is the requirement to locally manufacture imported products within five years after the first importation with some exceptions, e.g., products under patent protection. Even for companies with local manufacturing facilities in Indonesia, this is not always possible for
several reasons, including the structure of their global pharmaceutical supply chains and lack of required technology within their local facilities to produce innovative products.

Rather than amend Decree 1010 to mitigate damaging provisions, the MOH created Decree 1799 on December 16, 2010, altering the definition of local manufacturing and introducing the concept of partial manufacture. PhRMA’s member companies have sought clarification on several vague and conflicting provisions of Decree 1799 since its release. The guidelines for Drug Registration (popularly known as the Brown Book), issued in July 2011 and revised in 2013 and 2016, were comprehensively renewed in November 2017; some of the provisions in this latest Brown Book provided leeway for PhRMA’s member companies to comply with the requirement to locally manufacture imported products within five years of patent expiration. However, under the 2017 revisions to the Patent Law, the requirements have been made more restrictive and appear to require a patent holder to manufacture or use the relevant patented product or process in Indonesia. (MLHR Regulation No. 15 of 2018 provides temporary relief in that it provides a mechanism for patent holders to seek an exception from fulfilling the local manufacturing requirement.) While PhRMA’s member companies acknowledge the initial steps taken by BPOM to engage in consultations, key concerns remain unresolved and several provisions of Decree 1010, 1799, and the Patent Law and its implementation regulations still require further clarification.

As a result of the Presidential Instruction No. 6/2016 to accelerate the development of the pharmaceutical and medical device industry in Indonesia, the Minister of Industry is planning to impose a local content requirement as one of the criteria for government procurement for biopharmaceutical and medical device products. The method to calculate the threshold lacks clarity such that it may be impossible to implement or to monitor, and might create another barrier to access to medicines and health care for patients.

In short, PhRMA’s member companies are concerned about the localization requirements as well as the lasting implications to market access, IP protection, and patient health if unresolved.

Cost-Focused Formulary Decisions

While Indonesia is to be commended for developing guidelines and an online portal (eFORNAS) for listing new molecules on the Indonesian National Formulary, actual listing decisions appear to be primarily based on price and the overall BPJS budget. Consistent with the guidelines, listing decisions should better reflect all of the evidence submitted, including scientific data demonstrating the drug’s safety and efficacy. PhRMA’s member companies are encouraged by the fact that the government procurement agency is considering implementation of MCDA in their procurement system.

Mandatory Halal Certification

Indonesia’s Mandatory Halal Certification Bill, enacted in September 2014, mandates Halal certification and labeling for food and beverages, medicines, cosmetics,
chemical products, biological products, and genetically-engineered products. The legislation establishes a new Halal certification authority called BPJPH, and requires pharmaceutical firms to hire a Halal specialist and disclose sensitive product formulas to the new Halal authority.

Despite public opposition to the Law, including the objection of the MOH, Regulation No 31/2019 on the implementation of the Halal Law was signed by the President on April 29, 2019, stipulating a phased implementation of the law (subject to a further Presidential Regulation, which is currently being drafted by the MOH). According to the Decree of Minister of Religious Affairs no. 26/2019, dd. October 15, 2019, biopharmaceutical products must be halal certified by 2034. PhRMA’s member companies recognize and support the religious and cultural sensitivities of all Indonesians, but are concerned that these measures may have negative implications for patient health. In particular, significant questions remain regarding the process for securing halal certification and how the government will ensure that the new requirements do not impact patient access to the medicines they need.

**Counterfeit Medicines**

Although PhRMA’s member companies welcome Indonesia’s ongoing efforts to promote the use of safe medicines, there is an urgent need to expand national enforcement efforts. Although new leadership at BPOM have focused their efforts on combatting counterfeit food and medicine products, the budget and resources for this effort remain inadequate. Increasing and enforcing the penalties for criminals caught manufacturing, supplying, or selling counterfeit pharmaceuticals as well as unsafe medicines will greatly assist Indonesia’s efforts to reduce the harmful impact of counterfeit medicines.

Research conducted by Masyarakat Indonesia Anti-Pemalsuan (MIAP), Indonesia’s anti-counterfeiting society, suggests that losses incurred by the state as a result of counterfeiting continue to rise each year. Greater collaboration and government initiatives, such as a nationwide campaign and devoted budget to combat counterfeit products, should be intensified to ensure the health and safety of Indonesian patients.
THAILAND

PhRMA’s member companies face significant market access and intellectual property (IP) concerns in Thailand. Thailand does not provide equitable and reasonable market access to new medicines developed and manufactured in the United States. Furthermore, many of the reforms proposed by the Government of Thailand are out of step with international or regional best practices.

**Key Issues of Concern:**

- **Inequitable access to the Thai market due to deficient IP protections and enforcement:** The Government of Thailand’s failure to provide appropriate and predictable IP protections and enforcement hinders the ability of U.S. innovators – in particular, biopharmaceutical innovators – to equitably and reasonably access the Thai market. Key IP concerns in Thailand include significant patent backlogs, failure to provide meaningful regulatory data protection (RDP) and broad, vague, and non-transparent standards for compulsory licenses (CLs).

- **Discriminatory and non-transparent government procurement policies:** The Thai Government continues to implement policies that favor the domestic Thai industry at the expense of medicines imported from the United States. These policies have created discriminatory and unpredictable procurement practices that harm the ability of U.S. companies to compete in Thailand.

For these reasons, PhRMA requests that Thailand be placed on the **Priority Watch List** in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

**Intellectual Property Protection**

**Significant Patent Backlogs**

Although the Department of Intellectual Property (DIP) has taken some important initial steps to help clear the patent backlog – including hiring more patent examiners – the waiting-period for a patent review and grant in Thailand remains unpredictable and averages ten years after application submission. Further, these long patent grant delays create uncertainty regarding investment protection and increase the risk that a third party will use a patentable invention that is the subject of a pending patent application during the pending/review periods. Indeed, at least one PhRMA member has experienced a third-party launch of a product that was the subject of a pending patent application. In that instance it took over 18 years for the patent to be granted, and even then the member was unable to obtain meaningful enforcement of the patent. Patent term adjustments are not available in Thailand to compensate for unreasonable patent office delays, thereby reducing the effective patent term and further exacerbating the uncertainty caused by its patent grant delays.
Additionally, though some of the recent draft amendments to the Patent Act seek to streamline some procedures during the patent application process, other draft provisions could undermine efforts to support innovation and further exacerbate Thailand’s backlog. For example, one draft amendment seeks to introduce a pre-grant opposition mechanism allowing third-parties to oppose a patent application up to the date of patent grant.

**Regulatory Data Protection Failures**

Ministerial regulations issued by the TFDA regarding the Trade Secrets Act of 2002 do not provide RDP that would prevent generic or biosimilar drug applicants, for a fixed period of time, from relying on the innovator’s regulatory data to gain approval for generic versions of the innovator’s product. The Act aims only to protect against the “physical disclosure” of confidential information.

PhRMA’s member companies strongly encourage the Royal Thai Government to institute meaningful RDP. Specifically, Thailand should: (1) implement new regulations that do not permit generic or biosimilars producers to rely directly or indirectly on the originators’ data, unless consent has been provided by the originator, for the approval of generic or biosimilar pharmaceutical products during the designated period of protection; (2) bring the country’s regulations in line with international standards by making clear that data protection is provided to test or other data submitted by an innovator to obtain marketing approval; (3) provide protection to new indications; and (4) require TFDA officials to protect information provided by the originator by ensuring it is not improperly made public or relied upon by a subsequent producer of a generic or biosimilar pharmaceutical product.

**Compulsory Licensing**

Despite assurances that Thailand would be judicious in its use of CLs and consult with affected parties as required by the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), Thailand continues to threaten the use of CLs. Further, royalty payments have not been made on products for which CLs have been issued. Thailand’s compulsory licensing regime lacks sufficient due process and dialogue with affected companies, and suffers from a lack of transparency in the reasoning behind CL decisions. PhRMA believes governments should grant CLs in accordance with international rules and only in exceptional circumstances and as a last resort. Decisions should be made on public health grounds through fair and transparent processes that involve participation by all stakeholders and consider all relevant facts and options.
Market Access Barriers

Inconsistent and Unpredictable Median Procurement Price

The Thai Ministry of Public Health (MoPH) and the National Drug System Development Committee are authorized to establish a “median procurement price” for pharmaceuticals. In practice, this price is not calculated as a median, but rather used as a “maximum procurement price” (MPP) for each medicine. The price calculation process lacks clarity and transparency.

The MPP process, combined with Thailand’s recent preference for domestic companies (see below), harms U.S. innovators and could delay or prevent the introduction of new medicines. Promisingly, the recent Public Procurement Act introduced in August 2017, mandates the creation of a Reference Price Subcommittee for Pharmaceutical and Medical Supplies, which would be responsible for handling the reference price issues and standardizing the procedure. The innovative biopharmaceutical industry seeks the expedited formation of this subcommittee as well as the inclusion of members from the private sector so that a balance of stakeholders may collaborate on fair and equitable policies that address the fiscal concerns of the Thai government in the procurement of pharmaceuticals in a fair and equitable manner.

Discriminatory Thai “Innovation” List

In 2016, the Thai Government established the Thai Innovation List, an initiative to develop domestic industrial capacity in several innovation sectors, including pharmaceuticals. Only Thai majority owned companies qualify to be listed. Once listed, Thai companies receive special government procurement privileges including an earmark for at least 30 percent of orders by Thai government agencies. It appears that as long as the Thai company has demonstrated that their generic copy is bioequivalent, it is eligible to be included on the List. As such, the so-called Innovation List exists solely to favor local companies to the exclusion of U.S. and other foreign owned research-based biopharmaceutical companies.

Inconsistent and Non-Transparent Oncology Pre-authorization System (OCPA)

The OCPA was established in 2006 as a direct reimbursement system to hospitals for “high-cost cancer drugs” administered to patients under the Civil Servants Medical Benefit Scheme (CSMBS). The system was intended to reduce out-of-pocket disbursements for its beneficiaries, by identifying those products for which hospitals would be directly reimbursed through prior authorization and approval based upon a pre-defined protocol of individual cancer drugs in the list.

Unfortunately, the process and criteria involved in the OCPA lack predictability and are applied inconsistently between different companies and different products. Further,
recent revisions to the OCPA will result in “non-direct reimbursement” for certain innovator products, based on unclear selection criteria.

Specifically, while many innovative medicines, including cancer drugs, had been directly reimbursable by the CSMBS immediately upon being granted marketing authorization, revisions to OCPA procedures in February 2018 structured reimbursements on a tiering or “Group” system: drugs in Group 1 or Group 2 will continue to be directly reimbursable, while those in Groups 3 will require patients to provide advance payment for their medicines and then apply to OCPA for reimbursement, and the cost of drugs in Group 4 will be fully paid by the patient. These revisions, which were due to government budget constraints, will create a barrier to access for patients who cannot afford to pay for their drugs out-of-pocket, even if reimbursed later. The criteria for how drugs will be placed into each of these Groups is unclear, and potentially revolve around which drugs have the lowest net procurement price. Only one product per indication will be allowed in Group 1, meaning that patients on other drugs will be forced to pay for their drugs or switch to the product placed in Group 1.

**Discriminatory Privileges for the Government Pharmaceutical Organization (GPO)**

The GPO – a Thai State enterprise that manufactures pharmaceutical products in Thailand – benefits from discriminatory privileges. Per Ministerial Regulation B.E.2560 (2017), MoPH must procure at least 80 percent of medicines on the National List of Essential Medicines from the GPO or the Thai Red Cross and other central government and regional government offices must procure no less than 60 percent from these entities. In addition to these procurement preferences, under the Drug Act B.E. 2510 (1967), the GPO is not required to obtain FDA approval prior to launching medicines on the Thai market. There is no such exemption for private sector manufacturers or sellers, all of whom must obtain market authorization from the Thai FDA prior to selling their products in the Thai market.
EUROPE
RUSSIA

PhRMA and its member companies operating in Russia are concerned with a number of market access barriers, especially those linked to intellectual property protection and import substitution efforts, all of which decrease the value awarded to innovation in Russia and the benefits it brings to Russian patients.

Key Issues of Concern:

- **Compulsory licensing and restrictive patentability criteria**: The Russian Government is pursuing draft legislation and other measures that appear to improperly limit certain types of patents for innovative medicines and create vague and arbitrary criteria enabling Russia to seek compulsory licensing actions of patented medicines. In addition, Russian courts in two cases have granted compulsory licenses (CLs) to generic companies for innovative foreign medicines based on an extremely low evidence test and standard of proof.

- **Weak patent enforcement**: There is no effective mechanism in place in Russia to provide patent holders with the opportunity to resolve patent disputes prior to the launch of a follow-on product. This has led to the approval and marketing of follow-on products during the period of patent protection. Because Russian courts rarely grant preliminary injunctions in patent infringement cases related to pharmaceuticals, pharmaceutical innovators face significant legal challenges in seeking to effectively protect their innovative products against infringement, resulting in significant damages that are rarely compensable.

In light of these problems, PhRMA and its member companies are encouraged by recent legislative proposals to implement a Unified Register of Pharmacologically Active Substances Protected by Patent at the level of the Russian Federation and EAEU (which may serve as a basis for patent status check during the registration of generic medicines).

- **Localization and restrictions for state procurement**: Despite being in the process of acceding to the World Trade Organization (WTO) Agreement on Government Procurement (GPA), Russia continues to impose pressure to locally produced finished dosage forms through its government procurement system (e.g., restrictions on public procurement of imported drugs where there are at least two pharmaceuticals with locally produced finished dosage forms, so-called “three’s a crowd”), and a 15 percent price preference if “three’s a crowd” is not applicable. In addition, in 2018 the “three’s a crowd” regulation was amended and a 25 percent price preference for local full cycle products (products made from domestically manufactured active pharmaceutical ingredients) was introduced and implemented in 2019. Moreover, the Ministry of Industry and Trade (MoIT) suggests further restrictive measures to boost “import substitution”.
• **Pricing environment:** On October 18, 2018, a new pricing methodology for products included on the Essential Drug List (EDL) came into force. In addition, in December 2019, the Russian Government approved Resolution No. 1683 that requires the re-registration of all maximum selling prices for EDL medicines in 2019-2020. These regulations may discourage local investment and hinder the launch of new medicines, promoting a downward spiral for pharmaceutical prices in Russia. On December 19, 2019, the Ministry of Health (MoH) annulled its Order No. 871n (Oct. 26, 2017) and adopted new Order No. 1064n, which sets forth the procedure for determining the initial auction prices for medicines. Motivated by significant disruptions to state tenders and drug shortages caused by Order No. 871n, MoH Order No. 1064n seeks to improve the regulatory framework for calculating a medicine’s initial auction price. Implementation of the new order will need to be closely monitored to ensure it improves patient access to the medicines they need.

For these reasons, PhRMA requests that Russia remain on the **Priority Watch List** in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

**Intellectual Property Protection**

**Compulsory Licensing**

PhRMA and its member companies are deeply concerned by recent compulsory licensing in Russia and by proposed plans to expand the use of this drastic measure in the future.

As an initial matter, there has been a rising trend in court cases seeking CLs for dependent patents. In its decision dated June 8, 2018, the Moscow Arbitration Court (1st Instance) granted a CL for an innovative cancer medicine developed in the United States to a local generic drug company. This decision was based on an extremely low evidence test and standard of proof. The dependent patent was later annulled by the Russian Federal Service for Intellectual Property (Rospatent) on November 26, 2018, and the court case was dismissed, following an amicable agreement between the parties. In early 2019, the Moscow Arbitration Court (1st Instance) issued a CL against another innovative manufacturer based on a counterclaim by the same local generic drug company; the decision was upheld by the appellate court and Russian IP courts. Although the patent holder intends to seek further judicial review by the Civil Chamber of the Supreme Court of the Russian Federation, the lower court decisions constitute very dangerous precedent based on low or incorrect standards of proof and which misinterpret the situations in which compulsory licenses have been granted internationally.

---

227 Available at http://kad.arbitr.ru/Card/322413fa-38a7-4085-9cc7-3c8ff9fd7d92 (last visited Feb. 6, 2020).
Furthermore, on December 21, 2017, the Russian President signed Order No. 618 “On Key Areas for the Development of Competition Policy,” which approved the National Plan for the Development of Competition in the Russian Federation in 2018-2020. The Order allows compulsory licensing on the vague and unduly broad grounds of whenever it is determined to be in the interests of national security and health protection under Article 1360 of the Russian Civil Code.228 Building on the Competition Development Plan, on January 12, 2018, the Russian Government issued Decree No. 9-r, which approves the Roadmap for Development of Competition in Healthcare (the “Roadmap”). Further from March 25 until April 19, 2019, public consultations were held on a draft Resolution229 aimed at establishing a procedure for the government use of an invention under Article 1360 of the Russian Civil Code (the Draft Resolution). Inter alia, the relevant draft described the circumstances under which government use of an invention is possible, the tender procedure for election of a licensee, and rudimentary provisions on determining the appropriate royalty for that use. The relevant draft contained unreasonably broad interpretation of the provisions of Article 1360 of the Russian Civil Code, lacked transparency, and contained a number of gaps in its legal reasoning.

On November 22, 2019, the Russian Government submitted to the State Duma the Draft Federal Law “On Amendments to Article 1360 of the Civil Code of the RF” considering the use of an invention, utility model, or industrial design in the interests of national security.230 According to the Draft Law, the Government has the right, in case of extreme urgency related to ensuring the defense and security of the state or protecting the life and health of citizens, to issue a government use license. Among the main industry concerns are risks of broad interpretation of “purpose of protection of the life and health of citizens” and “extreme urgency” and that the scope and duration of such use may not be limited to the purpose for which it was authorized, as required by the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).

Meanwhile, the Russian Government appears to be using the pretext of implementing a limited amendment to TRIPS to force hasty legislation that could dramatically expand the use of compulsory licensing on grounds that do not appear to be consistent with TRIPS rules. On July 26, 2017, the Russian President signed the Federal Law No. 184-FZ “On Approval of the Protocol Amending the TRIPS.” Since then there have been proposed bills to incorporate the “TRIPS Protocols on CL for Export Purposes” into the Russian Civil Code.231 The most recent draft reflects consultations held by the Ministry of Education and Science from June 19 until July 2, 2019. While the draft law reflects a number of the comments that the pharmaceutical industry provided on previous versions of the draft law, the revised text remains unclear, and this lack of clarity could result in arbitrary interpretations.

Restrictive Patentability Criteria

On May 27, 2016, the Federal Antimonopoly Service (FAS) published on its official website the draft Roadmap for Development of Competition in the Healthcare Sector. As noted above, the Roadmap was approved by the Russian Government on January 12, 2018, via Decree No. 9-r. The Roadmap, *inter alia*, proposes amendments to patentability criteria, for any new property or new application of a known active ingredient of a medicinal product (including new indications, new treatment methods, new combinations, and new pharmaceutical forms and manufacturing methods).

On December 15, 2018, the Order of Ministry of Economic Development (MoED) No. 527 entered into force. This Order seeks to eliminate the possibility of “double patenting” of already known pharmaceutical compositions and their use. Although patent experts believe that these amendments should not adversely influence innovative manufacturers, PhRMA and its member companies are closely monitoring the implementation of the relevant amendments.

Weak Patent Enforcement

Russia does not maintain an effective mechanism for early resolution of patent disputes before potentially infringing products enter the market. Follow-on drug manufacturers can apply for and receive marketing approval for a generic product – and in turn participate in state tenders – even though a patent for the original drug is still in force. The Law on the Circulation of Medicines does not include provisions for patent status review when a company applies for marketing authorization or for price registration on the EDL. Moreover, Russian courts rarely grant injunctive relief. As a result, pharmaceutical innovators face significant legal challenges in seeking to effectively protect their innovative products against infringement, resulting in significant damages that are rarely compensable.

These practices are contrary to Russia’s obligations under TRIPS and the assurances Russia made to the WTO Working Party on the Accession of the Russian Federation to the WTO. In particular, they appear to violate TRIPS Article 41, which requires Members to provide “expeditious remedies to prevent infringements” (emphasis added) and provisions of Article 50 with respect to provisional measures. Russia assured the WTO Working Party that it would “counteract ... infringements of intellectual property through improvements in enforcement.”

However, in 2019 the Russian Government assigned Rospatent and the MoH to elaborate amendments to the Federal Law on the Circulation of Medicines in order to introduce some patent linkage elements (*e.g.*, creation of the Unified Register of Pharmacologically Active Substances Protected by Patent, the usage of which by the MoH during drug registration may prevent generic launch on the market while the original patent is in force). Consultations on the relevant draft law were held from September 6
until September 19, 2019. Predictable and effective patent enforcement procedures are especially important for the development of an innovative pharmaceutical industry. Therefore, PhRMA and its member companies encourage prompt passage and implementation of the proposed amendments.

Moreover, during the October 25, 2019 meeting of the Eurasian Economic Commission (EEC) working group on medicines’ regulation, it was decided to establish a separate EEC working group on the implementation of the EAEU Unified Register of Pharmacologically Active Substances Protected by Patent. The industry welcomes the proposals of the MoED and stands ready to work with the EEC on the creation of effective and transparent instruments for protection of intellectual property across the EAEU.

In a further positive development, in 2019 the Russian Supreme Court confirmed the findings of the lower courts that registration of a generic as well as registration of its price may be considered as a threat of violation of original patent protecting the active ingredient of an original product. As a result, the generic manufacturer was ordered to apply to the MoH in order to annul its registration certificate. Although the industry welcomes the Supreme Court decision, there are still very few mechanisms to help enforce court decisions. Further, some lower courts do not appear to be following the Supreme Court’s decision. For example, on November 12, 2019, the Arbitration court of Moscow Region again rejected the claim on patent violation filed by an innovative manufacturer against a local manufacturer of a generic product. The innovative manufacturer plans to appeal this decision.

Recognizing the current efforts of the Government to improve the existing investment environment, industry stands ready to contribute to the formation of effective IP protections in Russia.

---

233 Available at http://kad.arbitr.ru/Card/414811f6-22f6-4719-a406-23e3c00a82eb (last visited Feb. 6, 2020).
Regulatory Data Protection Failures

As part of its accession to the WTO, Russia agreed to provide six years of regulatory data protection (RDP). While the Law on the Circulation of Medicines provides for this protection, Russia’s weak judicial system is particularly concerning to PhRMA members in light of amendments to Russia’s Law on the Circulation of Medicines passed in 2014. Specifically, beginning in 2016, the amendments allowed competitors to apply for marketing approval of follow-on medicines as early as four years after marketing authorization for a reference small molecule drug and three years after marketing authorization of a reference biologic medicine. While, on paper, marketing is restricted until after the six-year RDP term has expired, the lack of injunctive relief in Russia (discussed above) could lead to the launch of infringing follow-on products during the RDP term.

This issue is especially important in light of formation of the common EAEU market of medicines. Currently, RDP is not regulated at the EAEU. Industry is ready to work with the EEC and to share the best international experience on harmonization of RDP regulations in a process of international economic integration.

Parallel Imports

Currently, parallel imports are prohibited from countries outside the EAEU, based on the regional principle of exhaustion of trademark rights. However, the EAEU has discretion to allow parallel imports and recent Russian court decisions are already eroding trademark rights. In April 2017, the Board of the EEC approved the draft Protocol on Amendments to the Treaty on the Eurasian Economic Union of May 29, 2014. If approved by all EAEU member states, the Protocol would grant the Eurasian Intergovernmental Council the authority to use the international principle of exhaustion of trademark rights in respect to certain products (pharmaceuticals are one of the product groups under discussion). PhRMA and its member companies remain concerned that such exemptions could cause medicine shortages in exporting countries and compromise the security of medicine supply chains. Despite concern voiced by some member states, the EEC in March 2019 reaffirmed its recommendation to amend the EAEU Treaty to allow temporary application of the parallel importation regime for certain types of goods in the EAEU.


In the meantime, the ability of trademark owners to protect their rights against parallel imports is already being limited by the courts. On February 13, 2018, the Russian Constitutional Court published its position on parallel imports. The Court ruled that it is not allowed to apply similar sanctions against the parallel importer of an original product and the parallel importer of a counterfeit product, except in cases when the original product may cause harm similar to a counterfeit product. This Constitutional Court interpretation may affect existing court practice on parallel imports and increase the number of cases when the trademark owner is not able to prevent parallel imports or obtain compensation from parallel importer.

Moreover, at the end of October 2018, the FAS at the direction of the Prime Minister drafted a law (without consultation and outside of the established legislative process) to amend Part IV of the Russian Civil Code to enable the Russian Government to authorize parallel imports of certain products which are: in deficit on the Russian market, or sold for “excessive prices”, or if their quality significantly differs from the quality of analogue products available in foreign countries. This initiative directly contradicted the EAEU Treaty and the Constitutional Court decision mentioned above, which was also confirmed by the EEC. PhRMA and its member companies are concerned that the FAS announced this initiative despite its conflict with these international regulations. Moreover, during a September 2019 meeting between the EEC Minister of Competition and heads of the antimonopoly bodies of the EAEU member states, the FAS stated that it is necessary to finish the EAEU discussions on parallel imports and at the initial stage enable the Eurasian Intergovernmental Council to authorise the usage of the international principle of exhaustion of trademark rights in respect to certain product groups.239

Market Access Barriers

Localization Barriers

Russia is in the process of acceding to the GPA, has provisions regarding accession to the GPA in its protocol of accession to the WTO, and participates in the GPA Committee as an observer.240 Notwithstanding the GPA accession process, Russia continues discriminatory practices in its government procurement system.

On November 30, 2015, the Russian Government adopted Resolution No. 1289 “On Restrictions and Conditions of Access of Foreign Essential Medicines to State and Municipal Tenders,” which codifies the so-called “three’s a crowd” approach in relation to medicines included on the EDL. According to Resolution No. 1289, if two or more pharmaceutical manufacturers in the Eurasian Economic Union (EAEU) bid on a tender for an EDL product, then any foreign bid for that same tender must be rejected. Medicines not covered by Resolution No. 1289’s “three’s a crowd” approach remain subject to the

---


tender preferences established by the MoED, where local companies receive a 15 percent price preference.

On May 12, 2018, the Russian Government adopted Resolution No. 572 “On Amendments to the Resolution of the Russian Government No. 1289,” amending the so called “three's a crowd” regulation and introducing the regulatory framework for additional preferences in state procurement of essential medicines for products made using locally manufactured active pharmaceutical substances applicable from January 1, 2019.

Further, per Order No. 126n, dated June 4, 2018, an additional 25 percent price preference is granted for locally-produced (EAEU) medicines.

Moreover, in November 2019, the MoIT announced a proposal to introduce quotas for locally manufactured goods of not less than 50 percent. The MoIT states that the Russian Government must approve the list of product groups for which such quotas must be applicable, and has recommended that certain medicines should be included on this list (e.g., antibiotics, drugs for the treatment of cardiovascular diseases). PhRMA’s members are concerned that these proposals may hinder patient access to necessary medical treatments.

The Russian Government has also taken a number of steps to reserve certain segments of the pharmaceutical market for sole-supply contracts given to Russian companies. For example, in March 2018, the Russian Government signed Decree No. 520-r appointing the National Immunobiological Company (NIB) as the sole supplier of certain blood products subject to procurement in 2018-2019 by a number of state purchasers. Furthermore, in April 2018, the Russian Government signed Decree No. 744-r appointing NIB as the sole supplier of certain local full-cycle immunobiological products in 2018-2019 purchased by the MoH under the National Immunization Schedule. The draft resolution appointing NIB in 2020-2021 as a sole supplier of certain immunobiological products under the National Immunization Schedule was introduced to the Russian Government.

A number of other measures aimed at supporting local manufacturers are under development and implementation in Russia. For instance, on November 16, 2019, the Russian Government signed Resolution No. 1464 and approved the Rules for granting subsidies from the federal budget to Russian organizations for the partial reimbursement of expenses to implement industrial projects related to “modern technologies”, including the launch and sale of medicines. And on December 27, 2019, the Russian Government

---

242 Available at https://vademec.ru/news/2020/01/15/natsimbio-predlozhit-ostavit-edinstvennym-postavshchikom-vaktsin-na-2020-2021-gody/?fbclid=IwAR1A_vQyABCIunc0gTaFvImJGPfvAKaTs23aWREAU1PYSFg0LzIUNv0zk (last visited Feb. 6, 2020).
issued Resolution No. 1908, which approved rules for the provision of federal subsidies to stimulate demand and increase the competitiveness of Russian industrial products.

The Russian Government is also drafting a “Pharma 2030” strategy, which *inter alia* is expected to make innovative development as one of the key priorities for the pharmaceutical industry. In 2018, the industry actively participated in consultations regarding the “Pharma 2030” strategy, and a revised draft is expected to be released. PhRMA’s members are concerned that in November 2019 the MoIT suggested that the “Pharma 2030” strategy should include provisions tying the level of drug reimbursement to the level of local production. PhRMA members believe that this may adversely affect patient access to needed therapies.

Deteriorating Pricing Environment

On October 18, 2018, new Pricing Registration Rules and Pricing Methodology came into force. These measures change the methodology for calculating maximum ceiling prices for EDL medicines and skew the reference basket used to set prices towards the lowest-price in the following countries: Belgium, the Czech Republic, France, Greece, Hungary, The Netherlands, Poland, Romania, Slovakia, Spain, Turkey and the country of origin. In addition, Federal Law 134-FL “On Amending the Law on the Circulation of Medicines” in Terms of Regulation of Prices for the Medicines Included in the List of Vital and Essential Drugs” came into force on June 7, 2019. It could result in a downward price spiral.

In accordance with Federal Law No. 134-FZ, all prices for EDL medicines are subject to obligatory re-registration in 2019-2020. On December 16, 2019, the Russian Government approved Resolution No. 1683 “On Amendments to Certain Acts of the Russian Government in Relation to Registration and Re-registration of Maximum Selling Prices for Essential Medicines” (Resolution No. 1683). As part of that resolution’s re-registration process, all 2019-2020 prices for EDL medicines are set based on a step-down coefficient of the price of the innovator drug. Products that are not re-registered by January 1, 2021, can no longer be sold. The holder of the registration certificate must file an application to the MoH to lower the price for any EDL medicine sold in Russia where the price decreases in a reference country. Prices for generic and/or biosimilar medicines are re-registered by the MoH on the basis of calculations made by the Federal Antimonopoly Service (FAS) without respective applications from the market participants.

On December 19, 2019, MoH annulled its Order No. 871n (Oct. 26, 2017) and adopted new Order No. 1064n, which sets forth the procedure for determining the initial auction prices for medicines. Motivated by significant disruptions to state tenders and

---

244 Available at https://pharmvestnik.ru/content/news/Vseobshee-lekobespechenie-grajdan-stanet-vozmojnym-prf-forsirovannom-scenarii-Farma-2030.html?fbclid=IwAR3v31U7L2sbCkxh_bgPUI7srXd7yCzOObBlyIn66poNXXOgcZQ9L2z0oQtFA (last visited Feb. 6, 2020).
drug shortage caused by Order No. 871n, MoH Order No. 1064n seeks to improve the regulatory framework for calculating a medicine’s initial auction price. Implementation of the new order will need to be closely monitored to ensure it improves patent access to the medicines they need.

**Interchangeability of Medicines**

Federal Law No. 475-FZ, amending the Law On the Circulation of Medicines, reduces the existing list of non-interchangeable medicines and sets out a number of options for considering the interchangeability of medicines under one international non-proprietary name (INN). According to that law, the initial list of interchangeable medicines must be published by MoH by July 1, 2020. The interchangeability of all other medicines must be determined by January 1, 2021 (though it is unclear at this time whether this includes biologics and biosimilars). Further, Law No. 475-FZ contains a number of provisions that may adversely affect patients, including establishing a pathway for “non-medical switches.” PhRMA members are closely monitoring these developments, regulatory practice and the decisions of the medical experts responsible for the interchangeability determinations.

**Eurasian Economic Union**

The EAEU, comprised of Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan, entered into force on January 1, 2015. The treaties establishing the Eurasian Customs Union and the Single Economic Space were terminated by the agreement establishing the EAEU, which incorporated both into its legal framework. The EAEU envisages the gradual integration of the economies of its member states, establishing a free trade area, unbarred financial interaction and unhindered labor migration. One of the first sectors to be integrated is the pharmaceutical sector through the creation of a single pharmaceutical market. To this end, the EAEU Agreement on Common Principles and Rules of Drug Circulation in the EAEU was executed on December 23, 2014, and the EAEU Intergovernmental Council approved the necessary regulations to establish a common pharmaceutical market in the EAEU entered into force on May 6, 2017. From January 1, 2021, all new pharmaceutical registrations will need to be registered under the EAEU regulations, and all medicines on the market must meet these registration requirements by January 1, 2026 (or they will be withdrawn from the market).

Although the first EAEU market authorization was approved in 2018 in Kazakhstan245 and the first market authorization under EAEU rules was issued by the MoH in November 2019,246 a number of technical issues with electronic dossier format

---


remain unresolved, which creates additional barriers for the formation of the common EAEU market.

The EAEU unified system should ensure integrity and continuous communication with national information systems so that applicants in all territories of the EAEU can follow the mutually recognized procedures. The innovative pharmaceutical industry stands ready to work with the Government and EEC to ensure that there is a robust regulatory review system and continued patient access throughout the EAEU.

Track and Trace System

Under Federal Law 462-FZ (Dec. 2019), Russia has will introduce a new, compulsory system for tracking pharmaceuticals from manufacturer to end user on July 1, 2020. Government Resolution No. 1954 (Dec. 2019) requires all relevant market participants to register (by Feb. 29, 2020) in the labelling system ahead of staged implementation of the new labelling requirements. Medicines placed into circulation before July 1, 2020, are exempt from the track and trace system until those drugs' shelf life expires.

Moreover, the EAEU Agreement on Labelling of Products with Identification Marking signed by the heads of governments of the EAEU countries in Almaty on February 2, 2018, entered into force on March 29, 2019. The essential aim of the Agreement is the harmonization of processes of labelling of different products with machine-readable and mutually-readable symbols across the EAEU area. However, if the countries fail to strike a compromise on an appropriate labelling system, each country will have its own system, defeating the purpose of the EAEU common market. Moreover, the EEC already stated that the proposed labelling system in Russia may be considered as a trade barrier within the EAEU borders.247

The industry is ready to work with the Russian Government and EEC to ensure that the new track and trace requirements are not implemented in a manner that imposes unnecessary obstacles to trade and medicine shortages for Russian patients.

Good Manufacturing Practice

Since January 2016, Russia has required local Good Manufacturing Practice (GMP) certificates for foreign producers as part of the drug registration application or for any further regulatory product changes. Industry has reported increased denials of GMP certificates, highlighting the lack of a process for paper review of corrective actions submitted by inspected sites. As such, every site that received a negative decision has to be re-inspected. Each re-inspection is treated as a brand-new inspection, managed by a new inspectors’ team, includes a full scope of GMP topics and lasts multiple days. Each

inspection of a foreign site costs upwards of $50K, while it is free for a local manufacturing site.

PhRMA’s members are concerned with the existing non-unified approaches exercised by the MoIT related to GMP inspections of foreign sites. However, PhRMA’s members hope that these constraints (and any unnecessary trade obstacles that they create) may be addressed through constructive dialogue between the inspectorate, MoIT and industry.

Orphan Drugs Legislation

The Law on the Circulation of Medicines includes a definition and an accelerated registration procedure for orphan drugs that eliminates the need for otherwise obligatory local trials. To date, however, MoH has only listed approximately 250 orphan diseases, while the European Organization of Rare Diseases list identifies more than 5,000 orphan diseases.

Although the industry, as a general matter, supports accelerated pathways for orphan drugs, the procedure lacks sufficient detail to fully evaluate its effectiveness. PhRMA’s members are hopeful that these issues may be resolved under the EAEU regulatory framework.

Biologic and Biosimilar products in Russia

The Law on the Circulation of Medicines sets forth the basic regulations for biologics and biosimilars. Although PhRMA’s members welcome Russia’s actions to better regulate biologics and biosimilars, there remain some concerns regarding implementation of the relevant regulations (including assessment guidelines for biosimilar drugs, determining the interchangeability of biologic drugs, mutual recognition of inspections and import testing, etc.). PhRMA’s members are hopeful that these issues may be resolved under the EAEU regulatory framework.

---

TURKEY

PhRMA and its member companies face market access barriers in Turkey due to forced localization policies, unpredictable registration timelines and reimbursement processes, strict and unpredictable government pricing and deficiencies in Turkey's intellectual property (IP) framework. Ongoing currency issues related to the application of an artificially low Euro/Turkish Lira exchange rate and inflation are causing severe pressure on prices of pharmaceuticals and threatening both supply continuity and the sustainability of the industry.

During the last decade, Turkey has undertaken reforms to modernize its economy and expand its health care system in many positive ways for Turkish patients. However, a general lack of transparency and inconsistency in decision-making has contributed to unclear policies that undermine Turkey's investment climate and damage market access for PhRMA member companies.

While PhRMA and its member companies appreciate the increased dialogue that exists between the Turkish Government and the innovative pharmaceutical industry in Turkey, and welcomes the recently passed Industrial Property Law that better aligned Turkey with the European Patent Convention, still more attention needs to be paid to the impact of Turkish government policies on the innovative pharmaceutical industries' research and development process, including the potential of PhRMA member companies to invest in Turkey.

Key Issues of Concern:

- **Weak patent enforcement and regulatory data protection failures**: While patents and regulatory test data have received IP protection in Turkey since 1995 and 2005, respectively, significant improvements are still needed. For instance, while Turkey's new Industrial Property Law, which was passed by the Turkish Parliament in 2016, better aligns Turkey with the European Patent Convention, certain provisions in the new law inappropriately expand the possibility of granting compulsory licenses (CLs) in Turkey. In addition, Turkey does not provide an effective mechanism for resolving patent disputes before the marketing of follow-on products. Further, Turkey inappropriately ties the regulatory data protection period (RDP) to the patent term and the lack of RDP for combination products is still an unresolved issue. Critically, the RDP term begins with first marketing authorization in the European Union (EU) and thus, as a result of significant regulatory approval delays in Turkey, the effective RDP term is reduced significantly. Consistent with Turkey's international obligations, the RDP term should begin when a product receives marketing authorization in Turkey.

- **Fixed exchange rate**: The Turkish Government continues to set sub-optimal levels for the overall pharmaceutical budget that disregard exchange rate fluctuations. The practice Turkey uses of an international reference pricing system
that employs a fixed FX rate instead of market value to convert the value of the Euro into local currency is problematic. Though Turkish regulations specified that the exchange rate be updated at the beginning of the year to reflect 70 percent of the average exchange rate the preceding year, the Turkish Government changed the regulation (only a day before the execution) to lower this to 60 percent of the average exchange rate starting from 2019. Such actions create uncertainty in the Turkish marketplace. This practice coupled with the current currency issues and inflation (11.8 percent in 2019) is causing severe pressure on pharmaceutical prices and is threatening both supply continuity and the sustainability of the industry. Industry is asking for immediate resolution of the issue.

- **Localization policies:** Following the implementation of the 10th Development Program and provisions in Article 46 of the 64th Government Action Plan (released on December 10, 2015), the Turkish government has initiated a localization program which calls for the delisting of imported products from the reimbursement list if they are not produced locally, and provides preferential reimbursement arrangements for health care products produced domestically. PhRMA member companies began receiving notices in February 2017 that their products would be delisted within 12 months unless localization plans were in place. Subsequently, new waves of product delistments were announced in May and November 2018.

On April 2, 2019, the European Union (EU) formally launched a case at the World Trade Organization (WTO) against these forced localization measures. Because parties to the dispute have failed to reach a settlement during the consultation process, the WTO Dispute Settlement Body (DSB) agreed on September 30 to establish a panel. These forced localization policies could have significant long-term consequences for the industry’s operating environment and for patient access to certain medicines in the country.

- **Local inspection requirements:** PhRMA and its member companies welcome efforts by the Turkish Drug and Medical Device Agency (TITCK) to improve the regulatory approval procedures of highly innovative and/or life-saving products with no or limited therapeutic alternatives in Turkey. Specifically, prioritizing the Good Manufacturing Practices (GMP) audit procedures and allowing a parallel marketing application process for those products has decreased the delays in approving those products. However, while products deemed highly innovative are receiving preferential reviews, products without this designation face increased delays due to the lack of resources and the absence of efficient procedures for conducting GMP inspections. PhRMA and its member companies commend Turkey for becoming a PIC/S (Pharmaceutical Inspection Convention and Co-operation Scheme) member to better align its GMP inspections practices with the other members of the scheme. However, GMP inspection delays continue to add to registration delays, hindering patient access to innovative medicines and negating the benefits of the patent and data protection periods for many products.
In addition, the Ministry of Health (MOH) has recently begun requiring companies to submit a two-year budget analysis as part of the GMP and registration prioritization submission, inappropriately linking pricing and reimbursement to the separate science-based determination of whether a potential new medicine (and the facility in which that medicine is manufactured) is safe and effective.

For these reasons, PhRMA requests that Turkey remain on the Priority Watch List in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

Intellectual Property Protection

Weak Patent Enforcement

In January 2017, Turkey enacted a new Industrial Property Law (No. 6769) to support and strengthen IP rights, including patent rights. However, the IP Court judges lack relevant training and capacity to effectively resolve disputes. Consequently, the quality of IP trials has substantively decreased, and the IP Court judges refer and defer cases to court-appointed expert panels, which often consist of a single patent attorney and lecturers from universities. Despite the new law on court appointed experts, the expert examination system also lacks appropriate procedural safeguards. While relevant case law provides that the IP Court judge can deviate from the expert panel’s opinion where he or she provides a reasoned opinion to the contrary, in practice, decisions in the majority of cases mirror the opinions of the panel.

Compulsory Licensing

In addition, PhRMA and our member companies are concerned about the compulsory license (CL) provisions of Industrial Property Law No. 6769. That law inappropriately expands the discretion to consider CLs in cases of non-use of the patent and in cases where a third-party claims that domestic demands are not being met. The vagueness of that provision creates tremendous uncertainty for patent holders, and may be abused by competitor third parties. PhRMA believes governments should grant CLs in accordance with international rules and only in exceptional circumstances and as a last resort. Decisions should be made on public health grounds through fair and transparent processes that involve participation by all stakeholders and consider all relevant facts and options.

Furthermore, compulsory licensing is included as a provision in the draft registration regulation. According to the draft regulation, a guideline will be published for execution. The scope and content of this guideline is not yet known.

Regulatory Data Protection Failures

In 2005, the Turkish Government took positive steps toward establishing protection for the commercially valuable regulatory data generated by innovative pharmaceutical
companies, and now provides RDP for a period of six years for products starting from the 
first MA registration in any of the EU-Turkey Customs Union member states. Several 
aspects of this regime are however of significant concern for the innovative 
pharmaceutical industry.

First, the period of RDP currently begins on the earliest marketing authorization in 
any country of the EU-Turkey Customs Union. Considering the extended regulatory 
approval times and delays stemming from the GMP certification approval period, current 
estimates are that it could take one to three years to register a new medicine in Turkey 
and result in approval in Turkey long after approval in the EU. Under these adverse 
circumstances, new products receive, in practice, no more than one to two years of RDP 
in Turkey, undermining incentives needed for innovators to undertake risky and expensive 
research and testing.

In addition, if a product is patented in Turkey, RDP ends when that patent expires, 
even if this is prior to the end of the six-year RDP term. RDP is a form of protection that 
serves a different purpose than patent protection and is thus independent and separate 
from patent protection. Therefore, it should not be limited to the period of patent 
protection.

RDP in Turkey was further undermined by the Regulation to Amend the 
Registration Regulation of Medicinal Products for Human Use.249 This Regulation, 
contrary to EU standards, does not provide RDP for combination products, unless the 
combination product introduces a new indication. Innovative companies invest 
considerable amounts of time and effort to develop products that provide increased 
efficacy and safety, as well as new indications, from new combinations of separate 
molecules.

Finally, Turkey does not provide RDP for biologics. RDP is essential for all 
medicines, and particularly critical for biologic therapies. Made using living organisms, 
biologics are complex and challenging to manufacture and may not be protected 
adequately by patents alone. Unlike generic versions of traditional chemical compounds, 
biosimilars are not identical to the original innovative medicine and there is greater 
uncertainty about whether an innovator’s patent right will cover a biosimilar version. 
Without the certainty of RDP, innovators will not have the incentive needed to conduct 
the expensive, risky and time-consuming work to discover and launch new biologics.

Market Access Barriers

Localization Policies

PhRMA and its members have serious concerns about the Turkish government’s 
implementation of its forced localization efforts for medicines. In 2018, the Turkish
Government began to implement policies announced in December 2015, calling for the delisting of certain products manufactured outside of Turkey from the reimbursement list. Initial announcements indicated that there would be five waves of delisting, and so far the first two phases have been implemented. However, additional products, including from the third wave, continue to be included in the list as they meet the defined criteria.

As part of the first wave of delisting notices, which impacted 71 products in total with the addition of new products in 2018, PhRMA members began receiving notices in February 2017 that their products would be delisted within 12 months unless they submitted plans to “localize” these products in Turkey. Critically, “localize” has never been defined. The second phase of product delisting notifications, impacting 176 products, was announced in May 2017, of which 119 products were delisted as of July 31, 2018. Another delisting under the scope of Phase II was carried out in November 2018. Further action under the third and subsequent waves has halted as of this submission, and no formal announcements have been made regarding subsequent phases.

PhRMA and its members believe that these measures are inconsistent with Turkey’s national treatment obligations under several WTO Agreements and constitute a significant restriction on trade. An administrative lawsuit challenging the validity of this measure has been filed by the Association of Research-Based Pharmaceutical Companies (AIFD). The hearing was held on October 3, 2019, and a decision is pending. In addition, on April 2, 2019, the EU initiated a WTO dispute raising the inconsistency of this measure with Turkey’s national treatment obligations, among other commitments. Following the end of the consultation period, the DSB agreed to establish a panel on September 30, 2019.

The vast majority of medicines sold in Turkey are distributed through the Social Security Institution (SSI) reimbursement list, and exclusion from this list effectively bars market access for these products. This forced localization in Turkey could have significant long-term consequences for the ability of U.S. biopharmaceutical companies to operate in Turkey and for patient access to certain medicines in the country.

Pricing and Non-Transparent Reimbursement

In Turkey, pharmaceutical pricing is regulated by TITCK. Pharmaceutical companies are still burdened with a substantial price discount from the lowest price in a

---

250 See, e.g., Article 46 of the 64th Government Immediate Action Plan.

251 See, e.g., the General Agreement on Tariffs and Trade (GATT), Art. III:4 (requiring that imported products “shall be accorded treatment no less favourable than that accorded to like products of national origin in respect of all laws, regulations and requirements”), as incorporated into Article 2.1 of the WTO Agreement on Trade-Related Investment Measures. Compelling manufacturers of patented pharmaceuticals to produce locally in order to remain or be added to the reimbursement list as part of the fifth phase of implementation of this policy would also be inconsistent with Article 27.1 of the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) (requiring that “patents shall be available and patent rights enjoyable without discrimination as to the place of invention, the field of technology and whether products are imported or locally produced” (emphasis added)).
basket of five European countries (France, Portugal, Spain, Italy and Greece) and the
country of origin. Over the last couple of years, TITCK has begun to annually adjust the
fixed Euro/Turkish Lira exchange rate used to set prices under the Pricing Decree.
However, per that decree, the annual exchange rate is set at 60 percent of the preceding
year’s average real exchange rate, automatically building in further discounts for the
Government. Setting aside the inappropriateness of fixing the exchange rate in this
manner, each year the goal posts have moved with either the fixed percentage not being
met, as in 2018, or the percentage rate being changed (from 70 to 60 percent), as in
2019. Overriding the regulation for two consecutive years exacerbates the business
environment and hinders sustainability and predictability for pharmaceutical companies.

By definition, Turkey’s fixed exchange rate discriminates not only against
pharmaceuticals – the only sector subject to this fixed exchange rate – but also against
imported pharmaceuticals contrary to Turkey’s national treatment obligations. Whereas
prices for imported products are determined based on the fixed exchange rate, domestic
manufacturers of innovative products that are only available in Turkey may negotiate
prices directly with the MOH based on cost and pharmaco-economic data. It also appears
to be inconsistent with Article II:3 of the Bilateral Investment Treaty (BIT) between U.S.
and Turkey, which requires that investments “shall at all times be accorded fair and
equitable treatment and shall enjoy full protection and security in a manner consistent
with international law.” Failure to update the exchange rate to reflect the actual exchange
rate has undermined the U.S. pharmaceutical industry’s “legitimate expectations” as to
the manner in which prices would be calculated. It is also “tantamount to expropriation,”
in that it substantially deprives the U.S. pharmaceutical industry of the reasonably-to-be-
expected economic benefits of its investments in Turkey to the obvious benefit of the
Turkish Government, contrary to Article III:1 of the U.S.-Turkey BIT.

The reimbursement system is based on a positive list and reimbursement
decisions are made by the inter-ministerial Reimbursement Commissions, led by the SSI
under the Ministry of Family, Labor and Social Services (MoFLLSS). The reimbursement
decision process lacks transparency and is not subject to clearly defined decision criteria.
Further, contrary to global health technology assessment best practices, the process is
not based on pre-defined medical evaluation criteria, does not require the publication of
an official medical evaluation decision/report to support the assessment and does not
consider the perspectives of patients, physician associations and other relevant
stakeholders. On the economic evaluation front, companies are required to submit cost-
effectiveness analyses during reimbursement submission; however, the evaluation of
these submissions is opaque. Further, on the rare occasion that a company receives a
formal written decision, it is a simple one-page document stating acceptance or rejection,
without any explanation of the grounds on which the decision was made.

Financial Impact Projection Request in GMP Prioritization Process

TITCK recently began to request a “two-year financial impact projection” in their
assessment process for “prioritization of good manufacturing practices (GMP)” and
“prioritization of registration” applications for innovative products. Prioritization of GMP
and registration inspections should be based on a clinical and technical evaluation based on scientific data, not the proposed price of the drug or its price in other markets (particularly when prices in other countries may not yet be available or indicative of the actual price/appropriate price in Turkey).

Pharmaceutical Product Registration

Marketing of new drugs in Turkey is governed by the regulatory procedures prescribed by the TITCK affiliate of the MOH for the approval of medicinal products. The data and documents required to register medicinal products are listed in the MOH’s Registration Regulation of Medicinal Products for Human Use (Registration Regulation). Although this regulation requires TITCK to assess and authorize the registration of medicinal products within 210 days of the product's dossier being submitted, and efforts have been taken to improve the regulatory process, a 2018 survey by AIFD indicates that the median regulatory approval period is 261 days for high priority products, 272 days for prioritized products and 659 days for products in the normal prioritization category. Furthermore, without additional resources to complete product registrations, expediting certain applications over others only further delays the review time for those applications not receiving prioritized attention.

In May 2016, TITCK published a “Guideline for the Operating Procedures and Principles of the Priority Evaluation Committee of Medicinal Products for Human Use” and PhRMA’s member companies appreciate TITCK’s efforts to create an expedited pathway for product registration. While not included in the May 2016 TITCK document, the agency is inappropriately requiring companies to commit to a specific retail and public sale price and to estimate the number of SKUs that will be sold at the time the company submits its prioritization application.

TITCK is also in the process of updating the Registration Regulation to achieve harmonization with the relevant legislation of the EU. While the initial draft was promising, subsequent amendments raise a number of concerns:

- No provisions to bring Turkey’s RDP mechanism into line with EU practices;
- Vague definition of manufacturing sites;
- Inadequate clinical trial data requirements for combination products;
- Redefines “generics” as “equivalent,” blurring the lines between these two distinct terms; and
- Deviates from global best practices to reduce the standards for biosimilars.

TITCK became an observer in the International Council for Harmonisation (ICH) in 2017, and aims to become a full ICH member by 2021. The ICH provides valuable work toward harmonizing international drug development and regulatory standards. In light of

---

252 Official Gazette No. 25705 (Jan. 19, 2005) (Registration Regulation).
253 Based on AIFD Survey 2018.
TITCK’s intent to gain full ICH membership, it is important that this Regulation meets international standards.

Local Inspection Requirements

The MOH’s revisions to the Registration Regulation have compounded the country’s registration delays. Effective March 1, 2010, a GMP certificate that is issued by the Turkish MOH must be submitted with each application to register a medicinal product for each of the facilities at which the product is manufactured. The GMP certificate can only be issued by the MOH following an on-site inspection by Ministry staff, or by the competent authority of a country that recognizes the GMP certificates issued by the Turkish MOH. However, for the reasons explained further below, neither option can be completed in a timely manner.

Despite increasing the number of inspectors at the end of 2013, the MOH still does not have adequate resources to complete these GMP inspections in a timely manner, with a median inspection period of 381 days for highly prioritized products (GMP 1). The inspection period for GMP 2 (prioritized) and GMP 3 (normal) products without priority is 739 days, although when they are added to an existing inspection the period is 307 days for GMP 2 products.

PhRMA views it as a positive development that the TITCK’s 2018-2022 Strategic Plan stipulates that the Agency is responsible for accelerating the GMP inspection and certification processes of priority medicines which are needed on the market within 1 year. However, the absence of strategic performance indicators for products prioritized by TITCK may give rise to uncertainty in the GMP inspection processes of these products.

Furthermore, although the Amended Registration Regulation permits applicants to submit GMP certificates issued by competent authorities in other countries, it does so only to the extent that the pertinent country recognizes the GMP certificates issued by Turkey. While PhRMA commends Turkey for joining PIC/S, this is but the first of many steps that will be required before Turkey could enter into mutual recognition agreements with the United States and other trading partners.

Orphan Drug Guidelines

Since 2009, the MOH has been developing a pathway for orphan medicines in Turkey. Although there have been some successful workshops to progress the issue, there still remains no published pathway.

254 Regulation to Amend the Registration Regulation of Medicinal Products for Human Use, Official Gazette No. 27208 (Apr. 22, 2009) (Amended Registration Regulation); MOH, Important Announcement Regarding GMP Certificates, (Dec. 31, 2009) (establishing an implementation date for the GMP certification requirement).

255 Based on AIFD Survey 2017.
In August 2015, the Ministry of Science, Industry and Technology (MoSIT) published an in-depth analysis of the impact of rare diseases on Turkey’s population in its “Pharmaceutical Sector Strategy and Action Plan of 2015.” This study called for the creation of a national orphan drug policy. The innovative pharmaceutical industry looks forward to working with key stakeholders, including the MOH, SSI, MoSIT, Ministry of Economy, Ministry of Development, Ministry of Treasury & Finance and civil society organizations, to establish a market access pathway and appropriate incentives to facilitate the development and commercialization of medicines to treat rare diseases. As part of this process, it will be critical for Turkey to define orphan drugs based on international best practices, including EU prevalence standards, and thereby better ensure that Turkish citizens have access to the medicines they need.
UKRAINE

PhRMA and its members are highly troubled by the reintroduction of proposed intellectual property legislation that would impose impermissible exclusions on patent-eligible subject matter as well as restrictive patentability criteria. As the government of Ukraine begins to roll-out national health care insurance and drug reimbursement to its population, PhRMA’s member companies believe that expanding limited reimbursement lists, bolstering poorly funded medicines budgets, and reforming its discriminatory, and non-transparent procurement practices are essential.

Key Issues of Concern:

- **Proposed intellectual property law**: Intellectual property policies and laws in Ukraine are not certain or predictable. While the Verkhovna Rada rejected Draft Laws 7538, 1199, and 2089, a new bill, Draft Law 2259 was recently introduced promoting similar provisions as previously considered draft laws – including impermissible patentable subject matter exclusions, restrictive patentability criteria, and vague compulsory licensing provisions.

- **Limited reimbursement list and inadequately funded medicines budget**: Patients in Ukraine largely pay out-of-pocket for most medicines due to inadequate hospital funding and an extremely limited out-patient reimbursement list that is not set to expand beyond basic conditions until at least 2020.

- **Defunct procurement system**: Public procurement of medicines has long been a major challenge in Ukraine as State procurements are riddled with duplication, corruption, inefficiency, and conflicts of interests due to multiple, non-harmonized lists that favor local producers and are non-transparent in nature. Recent reform efforts promise to restructure and modernize the system, though considerable work lies ahead.

For these reasons, PhRMA requests that Ukraine remain on the Priority Watch List in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

**Intellectual Property Protection**

**Proposed Intellectual Property Law**

PhRMA members are concerned with the unpredictability and uncertainty created by recently proposed amendments to Ukraine’s intellectual property law. The Ukrainian Parliament has published for legislative consideration new Draft Law 2259 “On Amendments to Certain Legislative Acts of Ukraine on implementation of certain provisions of European Union legislation in the sphere of intellectual property”. Three previous draft laws were rejected throughout 2017-19.
Draft Law 2259 contains problematic provisions regarding the patentability of certain inventions, i.e., the exclusion from patentability of certain classes of follow-on medicinal products, which build upon earlier inventions, including, inter alia “new forms of a medicinal product known from the state of the art, including salts, compound esters, simple ethers, compositions, combinations and other derivatives, polymorphs, metabolites, pure forms, particle sizes, isomers, new dosages or any new property or new use of a known medicinal product”.

Such restrictions would not be consistent with Ukraine’s obligations under Article 27.1 of the TRIPS Agreement to ensure that “patents shall be available for any inventions, whether products or processes, in all fields of technology, provided that they are new, involve an inventive step and are capable of industrial application.

Market Access Barriers

Limited Reimbursement List and Inadequately Funded Medicines Budget

PhRMA Members are enthusiastic about Ukraine’s pivotal new national health care reform bill signed in January 2018, 2018-VIII, “On state financial guarantees of medical care of the population,” which established the National Health Service of Ukraine (NSZU) to provide mandatory national health care insurance and reimbursable medicines for its population.

Although the law requires the State to pay for drugs used during in-patient care, due to the State’s failure to provide appropriate funding for public-sector hospitals, many patients are nevertheless forced to pay for these treatments out-of-pocket. Moreover, the vast majority of citizens with national health care currently pay out-of-pocket for outpatient medicines, though a pilot reimbursement scheme was rolled out in April 2017 for essential medicines for cardiovascular conditions, type 2 diabetes, and asthma. Though it was initially anticipated that this pilot would soon be expanded to other therapeutic areas, it was announced in June 2018 that such expansions would not take place until at least 2020.256

Ukraine is the only European country where patients largely pay out-of-pocket for most medicines, particularly as out-patients. While PhRMA members understand the budgetary pressures Ukraine faces as it rolls out national health care insurance, we encourage the government to both expand its reimbursement list and make appropriate allocations to support the modernized health system it seeks to create.

Procurement System Reform

Public procurement of medicines has long been a major challenge in Ukraine as State procurements are riddled with duplication, corruption, inefficiency, and conflicts of

---

256 IHS (June 2018). Ukrainian MoH publishes updated Affordable Medicines price list, postpones expansion to 2020.
interests due to multiple, non-harmonized lists that favor local producers and are non-transparent in nature.

The Ministry of Health (MoH) of Ukraine started work on reforming this sphere back in 2015, creating a working group on reforming the system of procurement of medicines and medical products and in late August of 2018, the Cabinet of Ministers approved establishment of the Central Procurement Organization (CPO), which will procure medicines and medical products at national, local and international levels using long-term framework agreements and e-procurement tools.

PhRMA is encouraged by this work, as well as recently released Draft Laws seeking to improve the procurement process in Ukraine, and urges the MoH to continuously monitor the roll-out and performance to ensure that the country’s renewed approach to procurement sufficiently eliminates corruption risks, minimizes inefficiency, facilitates transparent criteria and decision-making, reflects patient needs, and encourages a level playing field among local and foreign producers.
LATIN AMERICA
ARGENTINA

PhRMA and its member companies operating in Argentina recognize the important economic reforms the Government of Argentina has implemented since 2016. We welcomed the resumption of bilateral dialogue through the Trade and Investment Framework Agreement concluded in March 2016. Recent reforms have the potential to drive future economic growth in Argentina, and constructive dialogue that delivers real results could transform an important bilateral trade and investment relationship. Regulatory reforms by the sanitary authority that brought Argentina closer to international standards and reduced clinical trials approval times are already attracting investment in early phase trials. Although general registration and evaluation regulations for biopharmaceutical products exist, some complementary regulations are missing and the established evaluation deadlines are not being met, thus generating legal and business uncertainty for companies.

Biopharmaceutical innovators in the United States continue to face longstanding market access barriers and serious intellectual property (IP) issues put in place by the previous Argentine Government. While the previous administration had signaled willingness to address significant IP concerns related to patentability and regulatory data protection (RDP), it is unlikely that the Fernandez administration will advance these proposals. Despite positive engagement by our local sister association La Cámara Argentina de Especialidades Medicinales (CAEMe) and the American Chamber of Commerce in Argentina (AmCham) at various levels of the Argentine Government over the last several years, these IP issues remain.

Key Issues of Concern:

- **Restrictive patentability criteria**: The Argentine Government amended its criteria for granting pharmaceutical patents in 2012. A joint regulation issued by the Ministries of Health and Industry and the Argentina Patent Office (Instituto Nacional de la Propiedad Industrial or INPI) established guidelines that significantly limit the type of pharmaceutical inventions that can be patented. These guidelines are contrary to Argentina’s obligations under the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and have led to the rejection of many pharmaceutical patent applications. In addition, there have been reported instances of courts invalidating patents granted under the previous rules by applying the new guidelines retroactively.257

- **Regulatory data protection failures**: Argentina does not provide protection for regulatory test data, as required under TRIPS. Specifically, Law 24,766 permits Argentine officials to rely on data submitted by originators to approve requests by competitors to market similar products.

---

**Compulsory licensing:** On December 21, 2019, the Argentine Congress passed economic emergency legislation that, among other things, raises the risk of compulsory licenses of patents in Argentina. Article 70 of the new law empowers the Ministry of Health to establish a mechanism to monitor the prices of medicines and to utilize measures such as compulsory licensing against “problems of availability or unjustified or irrational price increases.”

**Discriminatory reimbursement policies:** On October 1, 2015, the Ministry of Health and the Secretary of Commerce issued a Joint Resolution establishing a “preferential” reimbursement system for national generics and biosimilar products, to the potential detriment of manufacturers producing medicines outside Argentina.

For these reasons, PhRMA requests that Argentina remain on the **Priority Watch List** in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

### Intellectual Property Protection

**Restrictive Patentability Criteria**

In 2012, the Argentine Government published a regulation that significantly narrowed the scope of chemical compounds and compositions that can be patented, leading to the rejection of many pharmaceutical patent applications. The regulation contemplates that similar limitations could be added in the future for “pharmaceutical biological inventions.”

The regulation (Nos 118/2012, 546/2012 and 107/2012), issued jointly by the Ministries of Health, Industry and INPI sets out Guidelines for Patentability Examination of Patent Applications on Chemical and Pharmaceutical Inventions. It expressly states that pharmaceutical patents are not available for compositions, dosages, salts, esters and ethers, polymorphs, analogous processes, active metabolites and pro-drugs, enantiomers, and selection patents. Also, the ability to describe and claim an invention using Markush-type claims is severely limited.

The imposition of additional patentability criteria for pharmaceutical patents beyond those of demonstrating novelty, inventive step and industrial application is inconsistent with Articles 1 and 27.1 of TRIPS, as well as Argentina’s obligations under its bilateral investment treaty with the United States. While the Argentine Government recognizes that the guidelines and resolution are problematic, it has yet to reform its approach.\(^{258}\)

\(^{258}\) On June 6, 2012, CAEMe, joined by over 40 innovative biopharmaceutical companies, filed an administrative petition seeking to invalidate the Joint Resolution. That administrative review petition was dismissed on April 5, 2013. On August 30, 2013, CAEMe filed a civil complaint in federal court challenging the Joint Resolution, the administrative review dismissal, and application of the Guidelines to pharmaceutical patent applications. That complaint is still pending.
In 2015, the INPI passed Resolution 283/2015 which narrows the patentability of certain biotechnological inventions, including inventions based on nucleotide or amino acid sequences. The resolution also expands the scope of subject matter that is not patentable to include genetically modified organelles. These and other restrictions in Resolution 283/2015 potentially create an unprecedented class of inventions that are excluded from patentability.

**Regulatory Data Protection Failures**

Biopharmaceutical innovators work with hospitals, universities and other partners to rigorously test potential new medicines and demonstrate they are safe and effective for patients who need them. Less than 12 percent of medicines that enter clinical trials ever result in approved treatments.259

To support the significant investment of time and resources needed to develop test data showing a potential new medicine is safe and effective, governments around the world protect that data submitted for regulatory approval from unfair commercial use for a period of time. WTO members considered such protection so important to incentivize biopharmaceutical innovation that they established a TRIPS provision (Article 39.3) requiring each country to safeguard regulatory test data for a period of time after the approval of a new medicine in that country.

Argentina was among the countries that crafted that provision, but has so far failed to provide protection of test and other data in a manner consistent with its international obligations. Indeed, Law No. 24,766 allows Argentine officials to rely on data submitted by innovators in other markets to approve requests by competitors to market similar products in Argentina. The Law provides no period of protection against reliance and does not define key terms including “dishonest” use.

**Weak Patent Enforcement**

A critical tool to protect against irreparable harm from the loss of IP is the ability to seek a preliminary injunction to prevent the sale of an infringing product during litigation. Preliminary injunctions become all the more important when there are no other effective mechanisms to facilitate early resolution of patent disputes.

Articles 83 and 87 of Law No. 24,481 on Patents and Utility Models provide for the grant of preliminary injunctions. These Articles were amended in 2003 by Law 25,859 to fulfill the terms in the agreement to settle a dispute between the United States and Argentina (WT/DS171/13). The agreed-upon terms were intended to provide, under

---

certain conditions, effective and expeditious means for patent owners in Argentina to obtain relief from infringement before the conclusion of an infringement trial. Unfortunately, these terms, as implemented in the Argentine legal system, have not had the intended effect. Member companies have reported that the process of obtaining injunctive relief has become very lengthy and burdensome, thereby denying the relief that they were intended to provide.

**Patent Backlogs**

The ability to secure a patent in a reasonable period of time is critical to attracting investment in the research and development needed to create new medicines and bring them to patients who need them. Patent backlogs hinder innovation by creating uncertainty and significantly raising investment risk.

Patent application delays can be lengthy in Argentina, where life science innovators wait an average of 6.6 years for patents to be granted.260 According to some estimates, the overall patent backlog is approximately 21,000 applications. Argentina’s patent law does not provide for patent term adjustments to compensate for unwarranted delays in the examination of patent applications.

To address this challenge, Argentina should hire additional qualified examiners and consider participating in work sharing arrangements, such as Patent Prosecution Highway programs, with other major patent offices. Argentina should also accede to the Patent Cooperation Treaty (PCT), a step that would facilitate the filing and examination of patent applications in Argentina as it does now in more than 152 Contracting Parties. Accession to the PCT could allow Argentina to reduce its current patent application backlog and use the PCT system to reduce the review period for future patent applications.

The Argentine Senate approved accession to the PCT in 1998. However, it was never discussed in the Lower House. In 2011, the Lower House resumed consideration at committee level, but with no results. Promisingly, Argentina signed a Memorandum of Understanding with the World Intellectual Property Office on May 6, 2016, related to establishing a Patent Prosecution Highway, offering hope that Argentina will move forward with acceding to the PCT.

**Compulsory Licensing**

Among other things, the economic emergency law passed by the Argentine Congress in December 2019 (Law 27541, “Social Solidarity and Productive Reactivation”) empowers the Ministry of Health to establish a compulsory or mandatory licensing mechanism, or to directly import certain medicines, to address potential problems caused

---

by unjustified or unreasonable price increases that affect the population's access to medicines in a way that could put their health at risk.

Empowering the Ministry of Health to establish new mechanisms of compulsory licensing will undermine the incentives for innovators to develop and bring new therapies to Argentine patients, and will lead to greater uncertainty and potential legal challenges. Moreover, such a mechanism appears to encourage additional use of compulsory licensing in a manner that will not only undermine patient access to new medicines but also appears inconsistent with Argentina's international obligations.

**Market Access Barriers**

**Discriminatory Reimbursement Policies**

On October 1, 2015, the Ministry of Health and the Secretary of Commerce issued Joint Resolutions 1710 and 406, which establish a preferential reimbursement system for national generics and biosimilar products. These resolutions provide that Health Insurance Agents must give preference to Argentine products available in the market that have the same active ingredient or that are biosimilar to those originating abroad. This resolution is subject to the condition that the final selling price of the Argentine products must be significantly lower than the average price of similar products of foreign origin.

Key terms are undefined, but on its face the new reimbursement system appears to be inconsistent with international biosimilar guidelines (providing that biosimilars cannot be automatically substituted for the original biologic) and Argentina’s national treatment obligations under the WTO General Agreement on Tariffs and Trade.

In addition, provisions of the “Buy Argentine and Development of Suppliers (27.437)” policy further condition market participation in Argentina for foreign innovators. Foreign companies are required to enter “Productive Cooperation Agreement Proposals” (ACPs) with local firms in order to participate in public tenders – including subcontracting companies, mandatory levels of direct investment, technology transfer or other capacity building programs.
BRAZIL

PhRMA and its member companies operating in Brazil recognize the efforts of the new Brazilian Government to liberalize economic opportunities by attracting foreign trade and investment. The current government has a tremendous opportunity to address long standing issues facing PhRMA members in Brazil, including, restrictive patentability criteria and procedures, the lack of regulatory data protection (RDP) and government pricing policies.

Key Issues of Concern:

- **Restrictive patentability criteria and procedures**: Since 1999, Article 229-C of Brazil’s Patent Law has been interpreted to permit the health regulatory agency, the Brazilian National Health Surveillance Agency (ANVISA), to review all patent applications for pharmaceutical compound and/or process inventions. That article created a dual patent examination process for pharmaceutical inventions, resulting in both: contradictory and/or additive patentability requirements to those established by Brazilian Patent Law and adopted by the Brazilian Patent Authority (INPI); and duplicative, prolonged patent reviews that contribute to the existing patent backlog. Under the terms of regulatory changes adopted in 2017, ANVISA’s opinion on the patentability of new biopharmaceutical inventions are no longer binding on INPI. This is a welcome step, but does not end Brazil’s “dual examination” system. In addition, the Federal Prosecutor’s Office has challenged the 2017 ANVISA regulatory changes and that challenge is pending review.

- **Patent backlogs**: With around 135,000 patent applications pending at INPI, Brazil’s patent backlog still exceeds 11 years (and is even longer for pharmaceuticals), hindering innovation and significantly raising investment risk. We welcome INPI’s recent efforts to tackle this examination backlog and look forward to its successful implementation. In June 2019, INPI published a resolution to standardize and increase the efficiency of patent prosecution in Brazil. In July 2019, INPI announced a new “Plan to Tackle Patent Backlog,” which aims to reduce the current backlog by 80 percent within the next two years. The Plan also commits INPI to examine new patent applications within two years from the applicant’s examination request. We applaud INPI’s recently announced technology-neutral Patent Prosecution Highway (PPH) pilot program and hope to see that work expanded in the future.

- **Regulatory data protection failures**: Although Brazil applies RDP for veterinary, fertilizer, and agrochemical products, the same protection is not given to biopharmaceutical products.

- **Regressive taxes on medicines**: Combined federal and state taxes add up to 34 percent to the cost of medicines in Brazil – one of the highest tax burdens on
medicines in the world. While there had been promising proposals to eliminate taxes on certain products including medicines, those proposals have lapsed.

- **Product Development Partnerships (PDPs) and government purchasing:** Brazil has developed a regulatory framework for the establishment of PDPs. While this framework provides improved transparency around PDPs, Brazil still lacks clear rules regarding the purchasing preferences offered to PDPs. In addition, while the Ministry of Health (MoH) is tasked with reviewing and approving PDPs, it does not take into account the patent status of products that are the object of a PDP proposal submitted by third parties.

For these reasons, PhRMA requests that Brazil be placed on the **Priority Watch List** in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

### Intellectual Property Protection

#### Restrictive Patentability Criteria and Procedures

A significant problem facing the pharmaceutical industry in Brazil was created by Article 229-C, the 1999 amendment to the Brazilian Patent Law that authorizes ANVISA to conduct reviews of patent applications claiming pharmaceutical products and/or processes that may present a “health risk.” This review has been an additional procedure to, and been given equal weight as, the patent examination conducted by INPI.

This “dual examination” is incompatible with Brazil’s obligations under the “anti-discrimination” provisions of Article 27.1 of the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Until recently, ANVISA did not limit its role to the review of the potential sanitary risk aspects of the subject matter of the patent application but also reviewed the patentability requirements. ANVISA lacks sufficient technical expertise on patentability and its role in reviewing patentability has generated uncertainty for patent applicants and undermined incentives for innovation.

Under the terms of a Joint Ordinance signed in April 2017, and new rules published by INPI in May 2017 and by ANVISA in August 2017, ANVISA may issue opinions on the patentability criteria of new biopharmaceutical inventions, although those opinions are no longer binding on INPI. However, ANVISA opinions are binding for patent applications for biopharmaceutical products and processes which are deemed as presenting a “health risk” (i.e., substances whose use has been prohibited in Brazil). While communications between INPI and ANVISA have improved and biopharmaceutical patent applications are

---

being granted, PhRMA continues to believe that Brazil must end its “dual examination” system and bring its patent system in line with global rules and norms.

In addition, the Brazilian Federal Prosecutor’s Office has challenged the 2017 ANVISA amendments and that challenge is pending review.

**Patent Backlogs**

While PhRMA recognizes efforts underway at INPI to reduce the patent backlog, delays in patent grants reduce the incentive companies to bring innovative products to Brazil.

With around 135,000 patent applications pending at INPI, Brazil’s patent backlog still exceeds 11 years (potentially longer for pharmaceuticals), hindering innovation and significantly raising investment risk. In June 2019, INPI published a new “fast track” resolution to standardize and increase efficiency within patent processing. In July 2019 INPI announced a new “Plan to Tackle Patent Backlog,” aiming to reduce the current patent backlog by 80 percent within the next two years, and to complete the examination process for new patent applications within two years from the applicant’s examination request.

PhRMA fully supports INPI’s plan to tackle its patent backlog and suggests that the U.S. Government should support the Brazilian Government in fully implementing this plan. Brazil’s recently announced technology-neutral PPH pilot program between INPI and major IP offices, including the United States, is highly encouraging. We look forward to working together with the Government of Brazil to expand fully that pilot program.

**Regulatory Data Protection Failures**

Brazilian law (Law 10.603/02) provides data protection for veterinary, fertilizer, and agrochemical products, but still does not provide similar protection for pharmaceutical products for human use, resulting in discriminatory treatment. Contrary to TRIPS Article 39, Brazil continues to allow Government officials to grant marketing approval for pharmaceuticals to competitors relying on test and other data submitted by innovators to prove the safety and efficacy of their products. Additional efforts are needed to provide certainty that test and other data will be fully protected against unauthorized use to secure marketing approval for a fixed period of time.

PhRMA members continue to seek protection for their data through the judicial system. Although there have been lawsuits seeking to secure a period of data protection for specific products, so far the cases are still pending in the Brazilian courts, leaving innovators without reliable RDP.
Market Access Barriers

Regressive Taxes on Medicines

In Brazil, federal and state taxes on medicines can add nearly 34 percent to the retail price of medicines – among the highest tax burdens on medicines in the world. Recognizing the significant burden that this imposes on Brazilian patients, the innovative pharmaceutical industry supports the proposals to eliminate taxes on certain products including medicines, such as PEC 491/11, under consideration by the Special Committee in the House.

High tariffs and taxes can prevent access to new treatments for patients that need them. Under the WTO Pharmaceutical Agreement, 34 countries agreed to eliminate import duties on a wide range of medicines and other health products. However, the majority of Latin American economies, including Brazil, are not parties to the WTO Pharmaceutical Agreement. Between 2006 and 2013, the value of worldwide biopharmaceutical trade in countries that are not parties to that Agreement increased at a compound annual growth rate of more than 20 percent. This means that a larger proportion of medicines distributed around the world are potentially subject to tariffs. To help remedy this trend, Brazil should accede to the WTO Pharmaceutical Agreement.

Government Purchasing and PDPs

The Brazilian Government issued Federal Law 12.349/10 granting preferences for locally manufactured products and services in public tenders. Locally produced medicines automatically have on average a 25 percent price preference in government tenders. More recently, an amendment to Portaria MDIC 279/11 provided a list of pharmaceutical products eligible for preference margins and defined the parameters for its application in public purchases. While the issuance of Portaria MDIC 279/11 brought more transparency to the purchase process, it still does not adequately define the compensation to be offered by those companies that benefit from this mechanism.

More recently, in July 2017, Brazil’s MoH announced it was investigating the introduction of new price criteria for public purchases of certain types of drugs in order to further cut spending. The MoH plans to begin with drugs for the treatment of rheumatoid arthritis, and has already contacted the industry to discuss the new measure. According to the MoH, six of the eight drugs currently included in the treatment protocol for the disease would be dropped as a consequence of the new price criteria (although industry

---

262 Id.
was able to convince MoH that patients already using drugs under the former treatment protocol should not be required to change their treatments). No official statements about a new cost-cutting mechanism have been published by the MoH as of yet, and it is unknown which and how many other therapeutic areas are being considered for cost-cutting.

Meanwhile, a new PDP regulation (Portaria 2531/14) was issued in 2014 with participation of the private sector, which on its face appears to provide greater transparency and predictability. Recently, the Brazilian Government announced several PDPs under the new regulation. Even still, it remains unclear what criteria were evaluated in assessing and approving these PDPs and the purchasing preferences that will be extended to an approved PDP. In addition, the MoH does not take into account or assess relevant intellectual property rights of products that are the object of a PDP application. As a result, the MoH has approved several third-party PDP applications for innovative and patent protected products. Recognizing these shortcomings, Brazil is currently revisiting the PDPs contracts and conducting a public consultation that intends to improve the transparency and predictability of the PDP process.
CHILE

PhRMA members are very concerned about recent actions by the National Congress that are pressuring Chile’s government to issue compulsory licenses (CLs) for certain innovative medicines. These developments add to longstanding intellectual property (IP) problems, including Chile’s failure to fully implement its patent enforcement and regulatory data protection (RDP) obligations under the U.S.-Chile Free Trade Agreement.

Since October 2019 Chile has faced significant social unrest. This has forced the government to radically review its policy and legislative agenda, including a planned plebiscite on April 26, 2020, to determine whether Chile will amend its Constitution.

**Key Issues of Concern:**

- **Compulsory licensing:** Action is needed to protect American innovation in Chile. There has been a series of politically-driven Congressional resolutions calling for the compulsory licensing of innovative medicines that provide a cure for many patients suffering from hepatitis C. Bills currently being considered by the Congress also seek to make it easier to obtain compulsory licenses (CLs).

- **Weak patent enforcement:** PhRMA member companies believe that the Chilean Government’s draft legislative and regulatory proposals would, if approved by the Chilean National Congress and implemented, represent a step toward compliance with Chile’s treaty obligations. Unfortunately, this legislation, introduced in 2012, continues to be unlikely to move forward in the near term.

- **Regulatory data protection:** The Chilean Government’s enactment in December 2010 of Supreme Decree 107 corrected several deficiencies in Chile’s existing system for protecting proprietary pharmaceutical test data against unfair commercial use and disclosure. The correction of remaining weaknesses, however, will depend upon whether the government makes certain necessary changes to Chile’s Industrial Property Law.

- **Proposed trademark limitations:** Chile’s Congress is currently considering a bill to significantly limit the use of trademarks in all pharmaceutical products packaging through proposed amendments to the Medicines II Law. That bill also requires health care providers to prescribe medicines using trademarked names, establishing that products with fewer than three active pharmaceutical ingredients (APIs) must be prescribed by International Non-Proprietary Name (INN) only.

- **Unjustified delays during patent prosecution:** Patent applicants are not being adequately compensated for INAPI delays, due to arbitrary interpretations by the TDPI (Industrial Property Court) of what constitutes an unjustified delay during the patent prosecution process.
For these reasons, PhRMA requests that Chile remain on the Priority Watch List in the 2020 Special 301 Report. Further, we urge USTR to provide an opportunity for an assessment of Chile’s IP regime through an Out-of-Cycle Review, so that the U.S. Government can evaluate progress on these important issues and dedicate the required bilateral attention necessary to make progress on the barriers confronted by U.S. businesses in Chile.

**Intellectual Property Protection**

**Compulsory Licensing**

The “Medicines II Bill” is now pending consideration in a conference committee of the Chilean Congress. That bill seeks to amend Article 99 of the Sanitary Code to establish that access to medicines is not adequate “when there are economic, financial, geographic or opportunity barriers that prevent access to a medication.” A finding of inaccessibility or lack of supply, based on the vague grounds established by the bill, would permit the Chilean government to grant CLs. The Bill also proposes a new definition of the legal nature of medicines, opening the door for future legislation making it easier to restrict related patent rights.265

Moreover, there have been a series of politically-driven Congressional resolutions calling for the compulsory licensing of innovative medicines that provide a cure for many patients suffering from hepatitis C, among other therapeutic areas:

- On January 11, 2017, the Chilean Chamber of Deputies of the National Congress passed Resolution No. 798.266 That resolution calls on the Minister of Health “to incorporate and use the compulsory licensing mechanism provided for in Article 51(2) of the Industrial Property Law N° 19.039 to facilitate [medicines] acquisition at competitive prices.”267 It also calls for the prioritization of certain classes of medicines to be considered for compulsory licensing and highlights the alleged price reductions realized by certain countries after issuing CLs on biopharmaceutical products.

- In addition, the Chamber of Deputies approved Resolution No. 1014 in January 2018, seeking to establish that access to certain hepatitis C medicines is not consistent with the constitutional right to health, thus warranting, they assert, a CL.

265 The “Medicines II” Bill also proposes to significantly restrict pharmaceutical medical representatives from visiting doctors. These interactions provide an important forum for manufacturers and health care professionals to exchange valuable educational information about medicines to ensure medicines are used correctly.


267 Id. (emphasis added) (unofficial translation).
Further, on March 9, 2018, the former Minister of Health issued Resolution 399 declaring that the compulsory licensing of hepatitis C treatments would be justified on public health grounds. In June 2018, the Chamber of Deputies approved Resolution No. 68 requesting the Minister of Health to request directly a CL for hepatitis C medicines. On August 28, 2018, the new Minister of Health issued Resolution 1165 rejecting the patentee’s challenge to Resolution 399/2018. As a result of this latest resolution, there remains a heightened risk of a CL being issued in Chile.

The research-based pharmaceutical industry is very concerned that these actions inappropriately expand the scope of the government’s compulsory licensing authority to pursue objectives that are not clearly related to legitimate health emergencies.

Weak Patent Enforcement

Notwithstanding the requirement contained in Article 17.10.2 of the U.S.-Chile FTA, Chile has thus far failed to establish a satisfactory mechanism to enable effective patent enforcement before marketing approval decisions are made and implemented. Article 17.10.2 requires Chile to “make available to the patent owner the identity of any third party requesting marketing approval effective during the term of the patent” and “not grant marketing approval to any third party prior to the expiration of the patent term, unless by consent or acquiescence of the patent owner.”

During 2011, the Chilean Government indicated to USTR and the innovative pharmaceutical industry its recognition of the need to enact new legislation aimed at establishing an effective patent enforcement mechanism that would bring Chile closer to compliance with its FTA obligations. PhRMA would support a final proposal that:

- Provides sufficient time prior to the grant of sanitary registration of a follow-on product to obtain a final decision regarding the validity or non-infringement of the relevant patents;
- Ensures that the patent holder will have access to the courts to assert its patent rights prior to the grant of sanitary registration for a potentially patent-infringing medicine; and
- Excludes the imposition of additional requirements or conditions that might prove unreasonable or unduly burdensome, and that might discourage reasonable patent enforcement efforts (e.g., excessive bond requirements and disproportionately high fines for declarations subsequently judged to be inaccurate).

PhRMA welcomed the government’s work to introduce relevant draft legislation in January 2012. Unfortunately, that legislation has not received any attention since its introduction, and the impact of a lack of effective patent enforcement continues to worsen.
Delays in Granting Pharmaceutical Patents

For many years, applicants for pharmaceutical patents in Chile have had to wait a significant amount of time to obtain final action on their applications by the Chilean patent office. In 2008, the Chilean Government, through the Under Secretariat of Economy and specifically the DPI, issued a special resolution “Circular N° 9,” in part to remedy these unacceptably long delays. One of the Circular’s stated objectives is to streamline the patent application review process by limiting the number of substantive office actions and facilitating rapid communication between applicants and examiners, thereby enabling it to rule more expeditiously on patent applications.

The administrative and procedural reforms implemented by INAPI to date have decreased waiting times, with most patent applications filed after 2007 receiving a definitive decision within 4 to 5 years. Therefore, while PhRMA supports the Chilean Government’s work to improve patent application processing times, it believes that some further work must be done to expedite a bit more patent application reviews in Chile.

Furthermore, despite a right granted to applicants in the Chilean Patent Law to request an extension to the patent term to offset unjustified delays during the patent prosecution process, applicants are being denied adequate patent term compensation due to arbitrary interpretations by the TDPI of what constitutes “unjustified delay.” Without any legal basis for doing so, the TDPI has determined that many types of delays that are outside of the applicants’ control are in fact justified, resulting in inadequate patent term restoration in Chile.

Trademarks

In January 2018, Chile’s Senate approved the “Medicines II Bill,” which is now pending final consideration by a Senate conference committee, after lengthy analysis by the Chamber of Deputies. That Bill, if enacted, would significantly limit the use of trademarks or other “fanciful” designations for any prescribed medicine. This measure appears to deny another important IP protection that is critical to ensure that innovator companies can distinguish their products from others. A trademark for a medicine designates its source and helps doctors and patients identify the quality, safety, and intrinsic effectiveness of a given product – reputational capital that manufacturers strive to build over time.

The Bill proposes a considerable departure from the current trademark protection guaranteed in Article 19 of Chile’s Constitution and its international (e.g., WTO TRIPS) and bilateral (e.g., U.S.-Chile FTA) obligations.

The Bill also severely limits the prescription of medicines based on their trademarked names, requiring that a medicine’s INN be used “exclusively” instead of its brand or proprietary name.
Regulatory Data Protection

Final enactment in December 2010 of Supreme Decree 107 resolved several longstanding concerns of the U.S. Government and PhRMA regarding deficiencies in Chile’s RDP system. Nevertheless, Chile’s RDP system still contains the following weaknesses, correction of which will likely require amendment of the Industrial Property Law. Specifically:

- RDP is unavailable for certain pharmaceutical innovations (e.g., new uses, formulations, compositions, dosage forms, etc.) that require the presentation of additional clinical test data as a condition of sanitary registration, but that do not involve a new chemical entity not previously registered in Chile;
- Prior voluntary disclosures by the data owner made in the interest of transparency can still justify incomplete recognition or denial of RDP;
- An applicant for sanitary registration must explicitly request RDP and provide a copy of the data for which protection is sought (Art. 4);
- RDP applicants are required to submit sworn statements and other formalities that could conceivably justify denial of RDP if judged to contain technical or procedural errors (Art. 4);
- RDP is only provided to data specifically identified (by title or name) in the sanitary registration application (Art. 6);
- It is not clearly stated that Instituto de Salud Pública de Chile’s obligation to not disclose protected data does not expire after 5 years; and
- S.D. 107 (Art. 10) repeats the IP Law’s enumeration of various grounds for revocation or denial of the right to exclusive use that are not stated in TRIPS or Chile’s bilateral trade agreements with the United States and the EU; these conditions significantly weaken the applicability and usefulness of the available data protection.

Although PhRMA recognizes that enactment of Supreme Decree 107 constituted an advance toward implementation of Chile’s obligations regarding data protection under the U.S.-Chile FTA, TRIPS, and other multilateral agreements, it believes that full compliance with these obligations will require additional action by Chile to correct the aforementioned deficiencies.
COLOMBIA

PhRMA member companies face urgent market access challenges and intellectual property (IP) issues in Colombia. Significant market access barriers have arisen from the Government’s adoption of cost containment measures, which aim to address the sustainability of the Health System by disproportionately imposing price reductions on prescription drugs. Other barriers include Decree 1782 of 2014, which establishes an unprecedented “third pathway” for approval of non-comparable biologics contrary to World Health Organization (WHO) guidelines and accepted standards of the United States and other countries. These standards are essential for ensuring the safety and efficacy of biosimilar products. Moreover, the Council of State may, in the near future, implement Article 72 of Law 1753 of 2015, which, as part of Colombia’s National Development Plan (NDP), would apply price and health technology assessment (HTA) measures for all new drugs before they could be granted marketing approval.

PhRMA’s member companies also face a challenge concerning a new interpretation of the data protection Decree 2085 of 2002 by the Colombian food and drug regulatory authority (INVIMA). INVIMA has recently begun denying regulatory data protection upon approval of some new chemical entities, simply because they share a minor portion of their chemical structure with previously approved products. Finally, a number of concerning bills are being discussed in the Colombian Congress related to price framework agreements on health technologies and IP. If enacted, the policies proposed in these bills would be inconsistent with international best practices and Colombia’s international commitments.

Key Issues of Concern:

- **Compulsory licensing**: Compulsory licensing in Colombia is a continued and looming risk to manufacturers of innovative medicines in the United States. In December 2017, Colombia’s Ministry of Health and Social Protection (MOH) accepted a Declaration of Public Interest (DPI) petition for review that could lead to the compulsory licensing of the entire class of innovative treatments for hepatitis C. The petition was accepted contrary to Colombia’s own procedures and appears to provide no justification for such an extreme and drastic action. Recently, a DPI request was made relating to a medication for acute myeloid leukemia. However, that DPI request was abandoned once a price reduction was reached between the Colombian government and the drug’s manufacturer. Although no compulsory licenses have been granted at this time, it remains an issue of deep concern for the industry.

- **Regulatory data protection failures**: Colombia fails to respect existing legislation that would otherwise provide regulatory data protection upon approval of novel pharmaceutical products.
- **Restrictive patentability criteria:** Contrary to its obligations under the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), Colombia does not grant patents for second uses.

- **Weak patent enforcement:** There is no mechanism in place to provide patent holders with the opportunity to resolve patent disputes prior to the launch of a follow-on product. This has led to the approval and marketing of follow-on products, despite the fact that a patent for the original drug is still in force.

- **Substandard biologics regulation:** On September 18, 2014, Colombia issued Decree 1782, which establishes marketing approval evaluation requirements for all biologic medicines. As part of the Decree, Colombia has established an unprecedented “abbreviated” pathway for the registration of non-comparable products, which is inconsistent with sanitary and WHO standards and practices in the United States and other countries and which could result in the approval of medicines that are not safe and/or effective. Industry urged the Colombian Government to remove this third pathway from the Decree, to no avail.

- **Cost containment measures focused exclusively on the pharmaceutical industry:** Government measures to improve the sustainability of the Colombian health system have focused solely on the pharmaceutical industry, and have not addressed issues within the pharmaceutical supply chain or other health sectors. Moreover, measures have been developed in an arbitrary, hasty, and non-transparent way that leaves industry unable to transition or plan.

  Further, Colombia’s international reference pricing methodology and other cost containment measures are being used to set the same price for both the public and private segments of the market. Such a practice does not account for different supply chain costs in the reference countries, and does not reflect the realities of the Colombian market vis-à-vis other jurisdictions.

- **Increased regulatory barriers under the NDP:** Colombia’s NDP, which was enacted as part of Law 1753 on May 7, 2015, undermines recent gains Colombia has made to encourage innovation, delays access for Colombians to cutting edge technologies, and is inconsistent with Colombia’s international commitments on IP and trade. Particular concerns include Article 72, which inserts price and health technology assessment (HTA) criteria into the regulatory approval process.

  For these reasons, PhRMA requests that Colombia be placed on the **Priority Watch List** in the 2020 Special 301 Report. Further, we urge USTR to provide an opportunity for an assessment of Colombia’s IP and market access environment through an **Out-of-Cycle Review**, so that the U.S. Government can evaluate progress on these important issues and dedicate the required bilateral attention necessary to make progress on the barriers confronted by U.S. businesses in Colombia.
Intellectual Property Protection

Compulsory Licensing

On December 20, 2017, the MOH issued Resolution 5246 accepting for review a DPI petition filed by Fundación IFARMA. The petition calls for the compulsory licensing of the entire class of innovative medicines for the treatment of hepatitis C, following a similar petition granted against an innovative cancer medicine in 2016. That earlier petition did not result in the awarding of any compulsory licenses but was resolved through a price reduction for the medicine in question.

Resolution 5246 is both legally and procedurally deficient. It appears to be inconsistent with Colombia’s international obligations and aspirations. First, Resolution 5246 is based on a petition that failed to identify the patents for which the DPI is being requested, clearly falling short of the standard set forth in Decree 1074 of 2015 (“Decree”). There is no provision in the Decree that allows for the MOH to unilaterally correct omissions in the petition. On the contrary, Article 2.2.2.24.4 of the Decree expressly places the burden of proof on the petitioner to identify the patented technologies that are supposedly affecting the public interest.

Second, a DPI on a broad category of medicines, namely “antivirals for treatment of hepatitis C” would be baseless for a number of reasons, including that: a) the petition itself identifies an entire class of medicines, a class within which significant competition already exists; b) hepatitis C drugs were just recently the subject of significant price reductions in Colombia, and the Ministry itself has publicly asserted over the course of months that this price reduction was between 80 and 90 percent; and c) there is no indication that a health-related emergency regarding hepatitis C exists in Colombia. To the contrary, the incidence of hepatitis C is quite low in Colombia.

The MOH could act on this deeply flawed petition at any time, potentially destroying an entire market for a class of innovative medicines developed in the United States. PhRMA urges USTR and other federal agencies to address this serious threat to American innovation through ongoing discussions under the U.S.-Colombia Trade Promotion Agreement.

Regulatory Data Protection Failures

Existing Colombian legislation, Decree 2085 of 2002 (and its subsequent interpretation through a March 2003 joint act signed by the Ministers of Trade and Health), requires that new chemical entities receive a five-year period of regulatory data protection upon approval. Nevertheless, the Colombian regulatory authority INVIMA recently has begun denying regulatory data protection upon approval of some new chemical entities, simply because they share a minor portion of their chemical structure with previously approved products.
This sudden and drastic change in procedure is inconsistent with the requirements of Decree 2085 of 2002 and contrary to the practice in other countries that provide regulatory data protection for such products. Such disregard of existing legislation undermines incentives to conduct clinical trials and develop new biopharmaceutical products in Colombia.

Restrictive Patentability Criteria

The Andean Court of Justice (ACJ) has issued several legal opinions (89-AI-2000, 01-AI-2001 and 34-AI-2001) holding that Andean Community members should not recognize patents for second uses. These decisions are contrary to long-standing precedents and inconsistent with TRIPS Article 27.1. Andean member countries, including Colombia, have chosen to honor their Andean Community obligations, while ignoring their TRIPS obligations.

The failure to provide patents for second uses harms patients by undermining incentives for biopharmaceutical innovators to invest in evaluating additional therapeutic benefits of known molecules (second uses) and provide more effective solutions for unsatisfied medical needs. The ACJ position is dispositive on the issue and no further domestic appeals or remedies are possible.

In addition, Colombia’s Congress is currently considering a bill that would force biopharmaceutical innovators to disclose International Non-proprietory Names (INN) in all patent applications and to report INNs for previously granted patents. If it becomes law, this requirement would be inconsistent with Andean Community law.

Weak Patent Enforcement

There is no mechanism in place to provide patent holders with the opportunity to resolve patent disputes prior to the launch of a follow-on product. This has led to the approval and marketing of follow-on products, despite the fact that a patent for the original drug is still in force.

Market Access Barriers

Substandard Biologics Regulation

On September 18, 2014, Colombia issued Decree 1782, which establishes marketing approval evaluation requirements for all biologic medicines. As part of the Decree, Colombia has established an unprecedented “abbreviated” pathway for the registration of non-comparable products, which is inconsistent with sanitary and WHO standards and practices in the United States and other countries, and which could result in the approval of medicines that are not safe and/or not effective. Since issuing the Decree, the MOH has issued implementing guidelines, but these guidelines have not served to resolve the fundamental deficiencies of the abbreviated pathway.
PhRMA members participated actively in the public consultations and engaged extensively with MOH and their technical experts, specifically highlighting that the abbreviated “third pathway” created by the Decree is not in line with the WHO guidelines for approval of biologics. In contrast to the Full Dossier Route (for originators) and the Comparability pathway (pathway for Biosimilars) found in WHO guidelines, the “Abbreviated Comparability Pathway” as described in the Decree allows for summary approval of non-comparable products and does not provide adequate controls or any clarity regarding how the safety or efficacy of a product approved via this pathway will be evaluated and assured.

Furthermore, per the Decree, a product approved via the “Abbreviated Comparability Pathway” will use the same non-proprietary name as the innovator, despite the fact that any similar biologic product would be a distinct biologic product from that of the originator or other biosimilar products. Assigning identical non-proprietary names to products that are not the same could result in inadvertent substitution of the products and would make it difficult to quickly trace and attribute adverse events to the correct product.

Arbitrary and Non-Transparent Market Access Policies

Colombia sets a maximum price for both the private and institutional markets by setting the price at the level of the distributor. These markets are dissimilar in most characteristics, in that they service different patient populations via different business models.

Moreover, the pricing system is highly subjective. For example, it provides that certain price control exceptions may be made for products providing a significant technical benefit over medicines containing the same active ingredient (i.e., regular versus modified release tablets), yet it does not clearly establish the criteria required to grant such exceptions. On September 24, 2019, the MOH issued its most recent circular through which the National Commission for the Regulation of Prices of Medicines and Medical Devices (CNRPMDM) is limiting the maximum sale price of more than 1,800 medications and chemical compounds, including products such as contraceptives, anti-hypertensives and psychiatric drugs. These products are facing an average price reduction of 50 percent since January 2019.

Cost containment measures focused exclusively on the pharmaceutical industry

Facing sustainability issues within its Health System, the Government of Colombia has focused on measures targeting the pharmaceutical industry for cost containment, and has not proposed any measures that would target other actors within the supply chain for medicines. PhRMA’s member companies request that any new cost containment measures should be developed and implemented transparently, through a process that includes transition periods, in order to allow the industry to participate in the policymaking process and respond meaningfully to new cost containment measures.
The Government has also disclosed that it is considering a new initiative to cap the expenditure of drugs not included in the publicly funded Health Benefit Plan (HBP). The majority of such drugs are innovative drugs developed by the branded pharmaceutical industry, including drugs manufactured by PhRMA members. This measure would establish a budget ceiling for drugs currently approved for marketing in Colombia but not included in the HBP; non-covered innovative drugs that are subsequently approved for marketing in Colombia would be included under the same budget cap. As the proposed budget cap would remain set at its 2018 level, this policy would effectively block new innovative drugs from entering the country.

Price framework agreements on health technologies

Industry is also closely monitoring a bill being promoted in Congress that would undermine IP protections. If it becomes law, drugs prioritized for acquisition by the Ministry of Health via centralized purchase, Price Framework Agreements or Demand Aggregation Instruments will be procured exclusively through the national purchasing portal – Colombia Compra Eficiente – thereby disallowing direct purchase through the General Social Security Health System Resource Administrator (ADRES), and even purchases through the Pan American Health Organization (PAHO), which the country already used for the purchase of hepatitis C drugs. The problems posed by these exclusive pricing frameworks are further exacerbated by their failure to guarantee purchase volumes or payment methods.

Increased regulatory barriers under the NDP

Colombia’s NDP, which was enacted on May 7, 2015 as part of Law 1753, undermines recent gains Colombia has made to encourage innovation, delays access for Colombians to cutting edge technologies, and is inconsistent with Colombia’s international commitments on IP and trade. Particular concerns include Article 72, which inserts price and HTA criteria into the regulatory approval process. Significantly, it states that for certain identified drugs, including innovative medicines, a health technology assessment by the Instituto de Evaluación Tecnológica en Salud (IETS) and the setting of a price by the Ministry on the basis of that evaluation should both be prerequisites for registration and renewal.

The MOH, following a warning from the Colombian Constitutional Court, implemented regulations for Article 72 that would separate INVIMA’s market approval processes from HTA and price measures. However, the Council of State responded by issuing Decree 710 of 2018, which partially and provisionally suspended these regulations and again required assessments for new drugs by the IETS: “The IETS must carry out the assessment … simultaneously with the Sanitary Register process before INVIMA. The assessment carried out by the IETS cannot be a condition for the granting of the Sanitary Register by that entity, which may issue it once its own assessment procedure is completed.”
At this time, the Council of State is reviewing an appeal filed against its provisional suspension, and a decision on this appeal will most like be provided within the first quarter of 2020. If a full suspension is declared, the assessment carried out by the IETS would be a requirement for the issuance of a marketing approval by INVIMA, as set forth in Article 72 of Law 1753 of 2015. It is additionally concerning for the industry that no maximum term is provided for IETS to carry out its assessments, as the 180-day term initially contemplated was removed by Decree 710. Without a fixed term for IETS to carry out its price and HTA assessments, these requirements could have the additional impact of severely delaying the market entry for innovative medicines in Colombia.
ALGERIA

Algeria’s policies and actions pose significant intellectual property and market access challenges for PhRMA members. PhRMA and its member companies believe, however, that Algeria has the potential to foster investment in pharmaceutical innovation and address the unmet medical needs of the country.

PhRMA noted some success in collaborating with the prior government in place until mid-2012, with that government stating publicly its support for a new strategy that better integrates the innovative pharmaceutical sector into Algeria’s economy and health care system. Subsequent Ministers have reaffirmed their commitment to boosting Algeria’s competitiveness in the innovative biopharmaceutical sector, but dozens of proposed reforms have not been implemented. Despite deterioration in the overall business and investment environment, PhRMA’s member companies are hopeful for a cooperative dialogue with the government to address the key challenges they face in Algeria.

Key Issues of Concern:

- **Weak patent enforcement and regulatory data protection failures**: Algeria has inadequate patent protection, ineffective mechanisms to enforce patents, and does not grant regulatory data protection (RDP). Trademark infringement is a growing problem.

- **Import restrictions and forced localization**: Algeria prohibits imports of most pharmaceutical products that compete with similar products that are manufactured domestically. Pharmaceutical products and active pharmaceutical ingredients (APIs) that are not locally manufactured are subject to annual import quotas.

- **Pricing procedures**: Algeria’s pricing and reimbursement mechanisms are cumbersome and delayed. Historically, some patented medicines with no generic equivalent on the market have been referenced against generic products deemed to be in the same therapeutic class. In addition, the new drug pricing procedure issued in August 2015 has key weaknesses related to its reference pricing system and the frequency of updates. As a result, prices in Algeria do not recognize the value of innovative products, nor do they reward the significant investment involved in developing new medicines or encourage the development of tomorrow’s cures.

- **Cumbersome and slow regulatory system**: Despite significant improvements in the Ministry of Health’s (MOH’s) registration process in 2013, the registration process remains slow and burdensome. As a result, patient access to innovative medicines in Algeria lags significantly behind peer countries. While the industry welcomes the creation of a new National Agency of Pharmaceutical Products (ANPP) to resolve the registration backlog, it is unclear how it will operate and its mandate as compared to the Ministries of Health and Labor.
• Failure to renew representative office licenses: Many pharmaceutical companies operating in Algeria have established representative offices. Licenses for such offices must be renewed every two years, and yet in 2018 the Ministry of Commerce suspended renewing these licenses until September 2019. (Renewals have been granted for companies in other sectors, but not for the pharmaceutical industry.) In addition to creating significant uncertainty as to the ability of these companies to continue operating in Algeria, it has resulted in local banks blocking access to member accounts and MoH suspending promotional activities as per an October 28, 2019 notice, until their office licenses are renewed.

For these reasons, PhRMA requests that Algeria remain on the Priority Watch List in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

Intellectual Property Protection

Weak Patent Enforcement

Marketing approval authorities in Algeria improperly interpret current laws and regulations by granting marketing approval to patent infringing follow-on products while relevant patent(s) are still in effect. Despite patent owners’ repeated attempts to alert Algerian authorities, Algeria’s marketing approval agency has approved infringing follow-on products many years in advance of the original product patent expiration.

Compounding these actions, effective judicial remedies are not available to prevent infringement of patent rights. Algerian courts do not provide injunctive relief that could prevent irreparable harm prior to the resolution of the patent dispute, thus placing originators in an untenable position with no possibility to defend their rights. Violations of Algerian patents that have occurred in recent years have still not been corrected.

Regulatory Data Protection Failures

Algeria does not protect pharmaceutical test and other data from unfair commercial use and disclosure. Algeria should correct this deficiency through implementation of meaningful RDP.

Market Access Barriers

Import Restrictions

On October 21, 2008, the Algerian Government issued a decision268 stipulating that, effective January 2009, the importation of pharmaceutical products that compete

268 The decision was published in November 2008 under the name “Arrêté du 30 novembre 2008 relatif à l’interdiction des produits pharmaceutiques et dispositifs médicaux destinés à la médecine humaine fabriqué en Algérie.”
with similar products that are being manufactured locally is prohibited. This decision was essentially a reinstatement of a previous ministerial decree that was suspended as part of the WTO accession process. Subsequently, the MOH published lists of such products comprising hundreds of branded medicines, and this import policy continues to be implemented in a non-transparent and arbitrary manner. Repealing this decision should be a prerequisite before Algeria can join the WTO.

In August 2015, the MOH issued a procedure for the inclusion of products on a list of pharmaceutical products prohibited for import. The innovative pharmaceutical industry is highly concerned about the proposed procedures to ban imports of certain products to promote local manufacturing. This proposal contradicts the government’s aspirations to attract more investment by the innovative biopharmaceutical industry and for Algeria to accede to the WTO. As the procedures themselves recognize, such restrictions could have major consequences on patient access to innovative products as well as on the operations and sustainability of our member companies in Algeria.

In 2017, the Algerian Government arbitrarily imposed volume restrictions on imports of pharmaceutical products that compete with similar products produced domestically and/or imported generic products.

Algeria’s restrictions on the importation of pharmaceuticals severely restrict patient access to innovative medicines, discriminate unfairly against PhRMA members, and are a significant barrier to trade. They have resulted in shortages of some drugs, further harming Algerian patients. During numerous discussions over the last few years between the Algerian government and industry, officials signaled their intent to reform the system to improve access and minimize stock disruptions. As of today, however, the system remains unchanged.

Investments and Commercial Laws

In December 2008, the Algerian Government declared that any company engaged in foreign trade should have a minimum of 51 percent of local Algerian shareholders. Promisingly, the 2020 Finance Bill has removed this restriction for “non-strategic sectors”. As yet, however, the government has not defined which sectors will be exempt from the rule.

Since 2009, importers have been required to secure letters of credit and set aside a percentage of the import value as a deposit on their purchase.

In May 2010, the MOH issued a circular that prohibits local manufacturers from selling products to wholesalers, and requires them to sell such products directly to pharmacies. Therefore, PhRMA members who invested in local manufacturing will now also have to invest in distribution infrastructure. While this circular has never been applied, the uncertainty of the regulation continues to concern PhRMA members.

269 Instruction #5 for the Generalization of Generics (Sept. 2003).
Volume Control

Algeria continues to impose an annual import quota for medicines and active pharmaceutical ingredients with the “requirement that each shipment receives prior clearance from the MOH.”

The Government routinely blocks imports as a temporary cost-containment tool. The unintended consequence, however, is that it leads to shortages in the market, to the detriment of Algerian patients. The narrow focus on cost means that it cannot capture the underlying value of promising new medicines for patients or reduce other costs in the health care system, such as avoiding expensive hospitalizations, surgery, rehabilitative or long-term care.

Pricing Procedures

The Algerian Government utilizes international reference pricing (IRP) to determine the government price level of medicines. As a general matter, IRP is a sub-optimal tool for setting drug prices because it doesn’t take into consideration the local health and economic interests. Instead of recognizing the value that innovative medicines can provide for patients in a specific country, IRP imports prices from other countries that typically have different disease burdens, indications, willingness (preferences) and ability (income) to pay, industrial goals or market structures. In short, IRP as a policy is not consistent with Algeria’s goal of promoting a local innovative biopharmaceutical industry.

In August 2015, the Algerian Government issued a new procedure for determining drug prices. Key weaknesses in Algeria’s new pricing procedure and the IRP model include:

- The new pricing procedure references a list of countries including Greece and Turkey. Neither Greece nor Turkey are appropriate reference countries. Prices in Turkey are based on deflated prices in Europe as a result of a discriminatory fixed Euro-Turkish Lira exchange rate and prices in Greece have been set based on the ongoing economic crisis in that country. In short, the artificially low prices in both of these countries do not reflect the true value of innovative medicines and certainly are not consistent with a country seeking to encourage local R&D. This measure ignores the damage that such policies have had on the innovative biopharmaceutical industry in those countries, where investment has stagnated and the industry is in a state of contraction. As such, Turkey and Greece should be removed from Algeria’s basket of reference countries.

- To ensure predictability and fairness, the IRP calculation should be based on the average or median price in the basket of countries, not the lowest price in the basket (or even worse, the lowest European price less 10 percent).

- Re-referencing should be predictable, objective (i.e., follow the same procedures for both price increases and decreases in the reference countries) and limited to
reasonable intervals, such as every five years during the marketing approval (MA) renewal process. While the industry commends Algeria for providing a process for allowing manufacturers to seek adjustments during the MA renewal process to account for changes in the reference countries, it is not reasonable to require manufacturers to continually monitor prices in all of the reference countries (a significant administrative burden) and report on relevant alterations.

- Greater clarity is needed in the procedures around the exchange rates to be used to determine prices in the reference countries and how Algeria defines “the country of origin.”

- While the innovative pharmaceutical industry commends the Algerian Government for providing an appeal mechanism, ten days is an insufficient period for a company to prepare the appropriate supporting documents for the appeal, particularly given that this will likely require coordination with regional offices and headquarters in other countries. Instead, we would propose that the appeal deadline should be extended to 30 days after the date of the notification of the price established by the Economic Committee.

Cumbersome and Slow Regulatory System

Despite some improvements in the MOH’s registration process since 2013 and recent structural changes to MOH’s engagement with the pharmaceutical industry, the registration process remains slow and is now falling further behind regulatory reform trends observed in the region, namely in the largest pharmaceutical markets Egypt and Saudi Arabia. In those countries, new review procedures are expected to significantly reduce the time it takes to register new medicines by 90 percent. This will accelerate marketing authorizations and enable patients to access promising new treatments in as little as 30-60 days after those new medicines are approved for use in Europe or the United States. Algeria should adopt similar review procedures to achieve the same results.

Additional burdensome requirements for obtaining registration to market pharmaceutical products, especially innovative products, have been implemented. As a result, patient access to innovative medicines in Algeria lags significantly behind peer countries.

The ANPP has been recently instituted with the stated goal of streamlining drug registration processes in Algeria. However, clear processes and a division of responsibilities between the new agency and the Ministries of Health and Labor has not yet been adopted. While the Agency will report to the MOH and will take responsibility for drug registration and pricing (which was previously managed by the pharmacy and drug department at MOH), it is unclear which entity will make decisions regarding drug importation licenses. The Agency is also facing a lack of resources and staffing which will prevent it from handling the current backlog in drug registration, price approval and testing on importation (TOI). For new drug applications, no assessment of pre-submissions has
taken place since September 2018. Additionally, 700 new applications have been submitted to the Agency which are pending registration due to the Agency’s lack of quality testing capabilities

In addition, the innovative industry continues to face significant and growing access challenges within the Reimbursement Committee (CRM) process led by the Ministry of Labor (MOL):

- The MOH via the Price Committee (MOL is a member of this committee) approves a price for the new medicine as part of the marketing approval process. However, this price is rarely accepted during the separate reimbursement process, even though MOH is a member of CRM. As a result, manufacturers are required to enter into separate reimbursement negotiations with the CRM, and the new lower price must then be re-approved by the MOH. These combined procedures are inefficient, redundant, and unfair to innovative pharmaceutical manufacturers.

- There is no clarity or fixed timeline between the first submission to the CRM of the dossier for reimbursement and the application at the pharmacy level. While the intent of the MOL is to reduce the maximum number of products on the list of reimbursable products, this particularly affects imported products so that a new (innovative) product has a very low chance of being reimbursed. And recently even locally produced medicines are affected. Further, even when MOH lists the products, hospitals have not been supplied with those products creating significant uncertainty and operational challenges for PhRMA member companies and lack of access for Algerian patients.

Finally, since June 2010, pharmaceutical companies have noticed lengthy delays of many months in approving variations for imported products already available on the market. The previous government had begun to recognize the negative impact that unnecessary delays have on patients and the business climate, but the backlog continues.

Failure to Renew Representative Office Licenses

Many pharmaceutical companies operating in Algeria have established representative offices. Licenses for such offices must be renewed annually, and yet in 2018 the Ministry of Commerce suspended renewing these licenses. In addition to creating significant uncertainty as to the ability of these companies to continue operating in Algeria, it has resulted in local banks blocking access to member accounts and MoH suspending promotional activities as per an October 28, 2019 notice, until their office licenses are renewed.
SAUDI ARABIA

Over the last several years, PhRMA and its member companies operating in the Kingdom of Saudi Arabia have observed many improvements in the policy environment. These reforms are consistent with Saudi Arabia’s effort to encourage biopharmaceutical innovation, employment, and investment. However, recent actions by the Saudi Food and Drug Administration (SFDA) are undermining these positive developments and the investment climate in Saudi Arabia. We look forward to a constructive dialogue with the relevant Saudi authorities to resolve these concerns.

Key Issues of Concern:

- **Ineffective patent enforcement and regulatory data protection (RDP):** In mid-2017, the SFDA granted marketing approval to a generic version of an innovative medicine during the patent term of that product. SFDA’s approval and related price listing of a generic product corresponding to a patented innovator medicine undermines the integrity of Saudi Arabia’s patent linkage system. PhRMA member companies are also concerned by Saudi Arabia’s failure to provide a sufficient period of RDP from the date of marketing authorization of innovator products in Saudi Arabia, contradicting the country’s own regulations and World Trade Organization (WTO) commitments. Current draft Regulations proposed for RDP include significant exceptions that would render the proposed regulation essentially useless.

For these reasons, PhRMA requests that Saudi Arabia remain on the **Priority Watch List** in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

Intellectual Property Protection

Ineffective Patent Enforcement and Regulatory Data Protection

Despite creating a mechanism to provide for effective patent enforcement in 2013, in mid-2017 the SFDA granted marketing authorization to a domestic company to produce a generic version of a U.S. innovative product prior to the expiration of the patent term on that product. Furthermore, the Ministry of Health (MOH) proceeded to procure the infringing product despite multiple appeals from the relevant innovator company. The local company is now distributing these copies to the MOH and selected hospitals.

This action appears to be part of a broader pattern of abuse of American innovation, following SFDA's earlier decision to grant marketing approval to copies of another innovative medicine during the period of RDP provided by Saudi law. Indeed, while Saudi Arabian law provides for RDP, in practice it is not applied effectively.
Specifically, Article 5 of a Council of Ministers’ Trade Secrets Protection Regulation (decision No. 3218, dated 25/03/1426 H, May 4, 2005), as amended by Ministerial Decision No. 431 of 1.5.1426H (June 8, 2005) states that the submission of confidential tests or other data, obtained as a result of substantial efforts, for the approval of the marketing of drugs or agricultural products which utilize a new chemical entity, shall be protected by the competent authority against unfair commercial use for at least five years from the approval date. Unfortunately, the Kingdom of Saudi Arabia has not complied with its own regulation and WTO commitments which gave rise to the regulations. Specifically, Saudi Arabia confirmed during its accession to the WTO that:

[Its] Regulations provided for protection of undisclosed tests and other data submitted to obtain approval of a pharmaceutical or agricultural chemical against unfair commercial use for a minimum period of five years from the date of obtaining the approval including the establishment of the base price. No person other than the person who submitted such data could, without the explicit consent of the person who submitted the data, rely on such data in support of an application for product approval. Any subsequent application for marketing approval would not be granted a market authorization unless the applicant submitted its own data, meeting the same requirements applied to the initial applicant, or had the permission of the person initially submitting the data to rely on such data.270

Member companies have approached Saudi authorities concerning the need to enforce their RDP regulations, yet authorities continue to insist they are not sharing the content of the drug registration file of the innovator product. The draft new amendment to the Trade Secrets Protection Regulation (Article 4(4)(a)) provides that the 5-year period shall start from the first approval anywhere in the world and includes a number of limitations (including publication of the confidential data of the innovator) which would, if adopted, significantly undermine RDP protection in Saudi Arabia.

The WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), however, imposes more than a non-disclosure obligation. Rather, TRIPS Article 39.3 additionally requires WTO member states to implement an effective system of pharmaceutical drug registration, which prevents “unfair commercial use” of data generated by others. This is fulfilled by preventing reliance on regulatory test data and approvals based on such data for a fixed period of time. In other words, protected data may not be used to support marketing approval for follow-on products for a set amount of time unless authorized by the original submitter of the data.

Additionally, PhRMA’s members are concerned that SFDA – in an apparent effort to encourage local production and investment – appears to be actively soliciting on its

website for manufacturers to seek approval for generic products even where the innovative product is still subject to intellectual property protections.

In short, these actions appear designed to benefit Saudi Arabia’s local industry at the expense of U.S. innovators, as evidenced by the tenders awarded by the National Unified Procurement Company, which is overseen by the MOH. These actions harm U.S. manufacturing workers, infringe proprietary technology and damage U.S. exports. Contrary to the country’s aspirations to promote local investment, intellectual property (IP) infringement, and the lack of effective enforcement sends a hostile message to U.S. inventors and investors that their valuable IP rights are not secure in Saudi Arabia.

To establish meaningful regulatory data protection in Saudi Arabia, authorities must establish a mechanism to ensure both that proprietary information submitted to obtain a license for product approval are confidentially maintained and, as the Saudi government has previously agreed, that no person other than the person who submitted such data could, without the explicit consent of the person who submitted the data, rely on such data in support of an application for product approval. This protection must apply to all biopharmaceutical innovation including both chemically-synthesized and biological pharmaceuticals.

Further, the Kingdom of Saudi Arabia should ensure recognition and enforcement of patent rights obtained according to the GCC Patent Regulation and uphold its obligation to allow inventors to secure legal protection in all GCC Member States.

We stand ready to work with the Saudi and U.S. governments to ensure that U.S. innovators can rightfully protect and enforce their IP rights in Saudi Arabia, consistent with Saudi Arabia’s international obligations.
WATCH LIST
ASIA – PACIFIC
AUSTRALIA

PhRMA and its member companies support the U.S.-Australia Free Trade Agreement (AUSFTA) ratified by both countries in 2004. The Agreement has contributed to expanded patient access to new medicines in Australia, a key priority for PhRMA. However, we believe there is much more to do to further protect and strengthen Australia’s intellectual property (IP) regime for new and innovative medicines, as well as improve market access which will also serve to foster innovation in Australia’s pharmaceutical and biotechnology sectors domestically and abroad – a key priority of the Australian Government.

In the Pharmaceuticals Annex to the AUSFTA, Australia and the United States agreed to provisions for increased transparency and accountability, and enhanced consultation between the United States Government, industry and the Australian Government to improve the operation of Australia’s Pharmaceutical Benefits Scheme (PBS). Annex 2-C of the AUSFTA at [1] commits the Parties to four principles to facilitate high quality health care and continued improvements in public health. These principles are: “(a) the important role played by innovative pharmaceutical products in delivering high quality health care; (b) the importance of research and development in the pharmaceutical industry ...; (c) the need to promote timely and affordable access to innovative pharmaceuticals through transparent, expeditious and accountable procedures ...; and (d) the need to recognize the value of innovative pharmaceuticals through the operation of competitive markets or by adopting or maintaining procedures that appropriately value the objectively demonstrated therapeutic significance of a pharmaceutical.” Annex 2-C of the AUSFTA at [3] also establishes a Medicines Working Group (MWG) to promote discussion and mutual understanding of the importance of pharmaceutical research and development to continued improvement of health care outcomes.

While progress has been made in implementing these agreed principles, on-going collaboration is required to ensure that the full potential of the pharmaceutical industry can be realized. We look forward to constructive outcomes from the locally-established, bilateral (Government-Industry) Access to Medicines Working Group (AMWG), first established in 2006 as part of reforms to the PBS. Industry has also welcomed the implementation of a tranche of reforms to the regulations for the registration and market approval of medicines and medical devices in Australia. These reforms are starting to streamline processes and regulations and make some life-saving medicines and medical devices available to Australian patients in a more timely manner.

PhRMA recommends that, as set out in the AUSFTA, regular meetings under the MWG (which is distinct from AWMG) resume as a matter of urgency; it has been approximately ten years since this MWG last met. While intervening negotiations and meetings may have provided opportunity for our officials to remain in contact, those contacts have been insufficient to address industry issues.
Key Issues of Concern:

- **Uncompetitive IP environment:** There are several weaknesses in Australia’s IP regime that harm both domestic and multinational companies:
  
  o **Weak Patent Law Enforcement:** Contrary to its obligations under Art. 17.10(4) of the AUSFTA, Australia has not implemented a system by which patent holders, as a matter of practice, receive advance notice of third party applications for marketing approval of potentially patent-infringing pharmaceutical products. The lack of adequate patent holder notification makes it difficult to resolve patent challenges prior to competitor market entry, creating significant uncertainty for patent right holders. In the rare circumstances where any such advance notice is actually provided, the amount of notice is inadequate to enable the final resolution of any patent infringement claims before the relevant third-party product obtains regulatory approval for market entry during the term of the relevant patent/s.

  PhRMA welcomes the recent Therapeutic Goods Administration (TGA) consultation on “Whether the TGA should publish that a prescription medicine is under evaluation.” While this consultation is ostensibly about transparency, one option proposed is that the TGA would provide public notice when generic and biosimilar medicines apply for evaluation prior to acceptance on the Australian Register of Therapeutic Goods (ARTG).

  While this consultation was not designed to deliver the outcome expected under Art. 17.10(4) of the AUSFTA, if the Minister for Health accepts this as a recommendation from the TGA, the effect will be to afford approximately 12 months’ notice of a generic/biosimilars intent to enter the market.

  o **Market-size Damages:** In cases of patent invalidation by the courts, the Australian Government has sued innovators for damages attributed to a delay in the PBS price reduction while the patent dispute is being resolved. These so-called “market-sized damages” create significant uncertainty for pharmaceutical patent owners, who need to be able to rely on the rights conferred by granted patents (unless and until they are finally invalidated) to support the large investments needed to develop new medicines. It also undermines the rights of patent holders in Australia by introducing a strong disincentive to exercise their core right to enforce their IP protections and is inconsistent with Australia’s international commitments under the AUSFTA and the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).

  o **Compulsory Licensing:** In 2016, the Australian Government launched a Productivity Commission (Commission) inquiry into Australia’s “Intellectual
Property Arrangements.\textsuperscript{271} The Commission’s report was publicly released on December 20, 2016, and contained a number of concerning findings. In its August 2017 and November 2018 responses to the report, the Australian Government indicated that some of the more concerning recommendations would not be accepted. However, in August 2019 the Government introduced amendments to the intellectual property legislation which appear inconsistent with AUSFTA and which would unnecessarily broaden the scope of compulsory licensing. These amendments would permit compulsory licensing on grounds that are not related to a judicially or administratively determined remedy for anticompetitive behavior, a national emergency, or other circumstance of extreme urgency.

- Regulatory Data Protection (RDP) Failures: Australia should strengthen its regulatory data protection (RDP) to align with international best practice, to improve the country’s attractiveness as a destination for foreign investment by global pharmaceutical companies, and to encourage companies to bring new medicines to Australia sooner.

### Market access

- Difficulties in listing new medicines on the PBS: Companies continue to face challenges and uncertainty in the listing of new medicines on the PBS. As one of the only health programs required to demonstrate cost effectiveness, an ongoing risk is the growing inadequate investment in the PBS compared to other parts of the health system. For new medicines, navigating the regulatory framework of market authorization and reimbursement remains complex and, particularly for reimbursement, iterative. This is compounded by an “offset” policy that requires every new dollar spent on new medicines to be counterbalanced by an equivalent offset, determined in advance, from within the existing health budget, as well as the lowest cost comparator pricing policy. These policies are not sustainable alongside a policy of investment in innovation and delays access to innovative and important medicines for Australian patients.

- Biosimilars: There have been significant developments regarding the introduction of biosimilar medicines into the Australian market. We welcome the commitment and ongoing efforts of the Australian Government, through the Strategic Agreement with Medicines Australia, to ensure appropriate and broad consultation with the sector to help deliver a coordinated and balanced policy. This policy should strike the right balance between broader access to biological medicines, the freedom of physicians to prescribe the right treatment for the right patients and continued access to innovation.

Government-initiated post-market reviews of PBS listed medicines: While important steps have been taken by the Australian industry and Government to implement an improved process for post-market reviews, the focus of post-market reviews on cost containment continues to be a concern for industry.

Beyond the relative inadequacy of the RDP term that Australia provides for therapeutic goods containing active components which have not previously obtained market approval, it is highly unsatisfactory that Australia does not provide any RDP relating to the registration of new formulations, combinations, indications, populations or dosage forms of currently registered therapeutic goods. Indeed, the absence of any such protection is in direct contravention of Australia’s obligations under Article 17.10(2) of the AUSFTA, which mandates that the Parties provide at least three years of RDP protection from the date of marketing approval in circumstances where new clinical information must be submitted to obtain regulatory approval of the relevant new therapeutic good (other than information relating to bioequivalence).

For these reasons, PhRMA requests that Australia be placed on the **Watch List** in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

**Intellectual Property Protection**

**Weak Patent Law Enforcement**

Mechanisms that provide for the early resolution of patent disputes before a potentially infringing product is allowed to enter the market are critical to ensuring adequate and effective protection of IP rights for the research-based pharmaceutical sector. Such mechanisms prevent marketing of a product potentially covered by a patent until expiration of the patent or until any dispute relating to infringement or validity of such a patent is resolved. An effective early resolution mechanism provides a procedural gate or safeguard. It ensures drug regulatory entities do not enable marketing authorization, PBS listing or the launch of a product which has been asserted to infringe patent rights. In this regard, the Australian Government’s approach is highly concerning to PhRMA members because it encourages unnecessary, costly, and lengthy litigation processes. The Australian Government has indicated that it will grant an application to list a competing generic product on the PBS, even when it has received a certificate submitted by the patent holder that:

- patent infringement proceedings in respect of that product have been commenced in good faith;
- the proceedings have reasonable prospects of success;
- the proceedings will be conducted without unreasonable delay; and
• even when a court has granted a preliminary injunction preventing the generic company supplying that generic product.

As indicated above, the AUSFTA provides that when marketing approval is sought by an applicant for a generic product or “product for an approved use,” where the product or approved use is claimed by a patent, the Party (here, Australia) should “provide measures in its marketing approval process to prevent” marketing of the generic product or use during the patent term without consent or acquiescence of the patent owner. Further, if Australia permits a third party to request marketing approval for a product or approved use claimed by a patent identified as claiming that product or approved use, it “shall provide for the patent owner to be notified of such request and the identity of any such other person.” 272 This should include a database or other mechanism by which a third party may determine whether there are patents that may be infringed by the product or use for which the third party is seeking approval.

However, originator pharmaceutical companies in Australia generally do not receive any notice of a third party’s intention to enter the market with a product that may infringe a valid and enforceable patent prior to its listing on the ARTG. Originator companies usually only become aware of such third-party intention once the generic has already been registered on the ARTG, and even then, the originator company itself has to actively seek that information on the ARTG website – originators are generally not notified of the ARTG listing by the generic company or the TGA. While in recent years the Australian Government has been quicker to identify and publish newly approved generics on the ARTG website, this is not what was envisaged in the AUSFTA. Publishing information on the ARTG that a generic has already been granted marketing approval for its product is not sufficient notification of the request by a third party for marketing approval under the AUSFTA.

Originator companies are significantly impacted when generic medicines enter the market prior to the expiry of the originator patent, in part through mandatory and irreversible price cuts for innovator products listed on the PBS, and through market share erosion. The only legal option available to the innovator patentee to prevent the generic company from launching is to obtain preliminary injunctive relief (or equivalent relief), which in the case of PBS listing must be obtained in the few months between the time marketing approval of the generic product is published on the ARTG and the next possible PBS listing date, in order to prevent the irreversible price reduction. The preliminary injunction process also comes with risk of market-sized damages as discussed below.

This lack of effective mandatory notification, the absence of an effective mechanism for the early resolution of patent disputes before an infringing product is launched in Australia, and the unduly prejudicial penalties being sought by the Australian Government from patent holders for seeking to defend their IP (including liability for market-sized damages as discussed in detail above) significantly weakens the level of IP protection for pharmaceutical innovation in Australia, serving to deprive patent holders of

272 See Article 17.10(4) of AUSFTA.
expected benefits under international agreements including the AUSFTA. The Australian Government should implement an effective patentee notification system. This system would allow for mandatory notification by a generic company seeking marketing approval, providing notice to the patentee at the time of filing that the generic company has applied for approval to market a generic product during the life of an identified patent. Additionally, such a system would allow patentees the opportunity to assert their IP rights prior to generic launch.

PhRMA and its member companies welcome the recent TGA consultation on “Whether the TGA should publish that a prescription medicine is under evaluation.”273 While this consultation is ostensibly about transparency, one option proposed is that the TGA would provide public notice when generic and biosimilar medicines apply for evaluation prior to acceptance on the ARTG. While this consultation was not designed to deliver the outcome expected under Art. 17.10(4) of the AUSFTA, if the Minister for Health accepts this as a recommendation from the TGA, the effect will be to afford approximately 12 months’ notice of a generic/biosimilars intent to enter the market.

Market-Size Damages

Biopharmaceutical innovators must be able to rely on and enforce patents issued by competent government authorities. Laws or policies that allow governments or other non-parties to a patent dispute to collect “market-size damages” from innovators that pursue unsuccessful patent claims after being granted a preliminary injunction unfairly penalize and discourage the use of provisional enforcement measures as part of well-functioning early resolution mechanisms. These policies undermine legal certainty, predictability and the incentive provided by patents to invest in new treatments and cures.

Australia’s Therapeutic Goods Act, as amended by the legislation implementing the AUSFTA, provides for the award of damages in limited specific circumstances, where a court determines that the patent holder has engaged in improper conduct specifically identified in that legislation in commencing proceedings or seeking a preliminary injunction.274 Damages under this scheme have not been sought since its introduction. However, outside of that scheme, and pursuant to the usual undertaking as to damages provided by patent holders as a requirement for obtaining a preliminary injunction, since around 2012 the Australian Government has stated its intent to seek – and has sought – market-size damages from biopharmaceutical innovators that have legitimately but ultimately unsuccessfully pursued patent claims. It has done so even where the preliminary injunction was granted several years before the Australian Government first stated its intention to seek such damages. Those claims are purported to compensate the PBS for the effect of any delays in price reductions for patented medicine during the period of a preliminary injunction. The PBS imposes automatic price cuts on medicines

---


as soon as competing versions are listed on the PBS, but the policy does not include any corresponding mechanism to automatically compensate innovators for losses if an infringing product is launched prematurely.

By pursuing market-size damages, the Australian Government is unfairly tipping the scales in pharmaceutical patent disputes – and discouraging innovators from enforcing their granted patents. This policy permits the same court that granted a provisional enforcement measure in a patent dispute to allow that measure to be used as the basis for a claim for compensation by the government or another non-party to the dispute. It exposes innovators to significant additional compensation claims that may be difficult to quantify and were not agreed to or contemplated at the time the preliminary injunction was granted. The punitive size of these additional claims effectively equates legitimate patent enforcement, in circumstances where the market effects of infringing generic entry are difficult to quantify, with patent abuse. Allowing governments or other non-parties to a patent dispute to collect market-size damages undermines legal certainty, predictability and the incentives that patents provide for investment in new treatments and cures. Australia’s practice appears to be inconsistent with the AUSFTA and with WTO intellectual property rules, including with respect to provisional measures.

Indeed, in the course of claiming market-size damages, representatives of the Australian Government have stated that the Australian Government will grant an application to list a competing generic product on the PBS (the effect of which is an automatic price cut), even when:

- the patentee has lodged a certificate, required as a result of the amendments to the Therapeutic Goods Act as a result of the legislation implementing the AUSFTA as a precondition for commencing patent infringement proceedings, stating that infringement proceedings in respect of that product have been commenced in good faith, have reasonable prospects of success, and will be conducted without unreasonable delay; and/or

- a preliminary injunction has been granted by a court which prohibits the supply of that product by the generic company.

Such comments typify the Australian Government’s conflict of interest, as well as the disregard paid by the Australian Government to the legitimate interests of innovators in enforcing their granted patent rights.

PhRMA members urge USTR and other federal agencies to prioritize actions to address Australia’s pursuit of market-size damages. The Australian Government should immediately and publicly abandon its policy of seeking market size damages, or any damages, when a patent holder has legitimately sought to enforce its patent rights.
Compulsory Licensing

In 2016, the Australian Government launched a Productivity Commission (Commission) inquiry into Australia’s “Intellectual Property Arrangements.” The Commission’s report was publicly released on December 20, 2016, and contained a number of findings that biopharmaceutical innovators did not consider appropriate or reasonable, such as calls to restrict patent term restoration in Australia, to allow manufacture for export during the restored patent term, and to raise the threshold for a patentable inventive step.

In its August 2017 and November 2018 responses to the report, the Australian Government indicated that some of the report’s most damaging recommendations would not be accepted. However, recent (October 2019) amendments to Australia’s intellectual property legislation on compulsory licensing, including Crown use, are unnecessary, weaken patent protection, discourage investment and limit the potential benefits of innovation for Australians. These changes may encourage or make it easier for third parties to acquire innovative technologies without authorisation, which could have significant unintended consequences. The amendments could also permit compulsory licensing on grounds that are potentially broader than the circumstances outlined in AUSFTA Article 17.9.7.

Regulatory Data Protection (RDP) Failures

Biopharmaceutical innovators work with hospitals, universities and other partners to rigorously test potential new medicines and demonstrate that they are safe and effective for patients who need them. Less than 12 percent of medicines that enter clinical trials ever result in approved treatments.

To support the significant investment of time and resources needed to develop test data showing that a potential new medicine is safe and effective, governments around the world protect such data submitted for regulatory approval from unfair commercial use for a period of time. Indeed, TRIPS Article 39.3 requires each WTO member to protect undisclosed test and other data submitted for marketing approval in that country against disclosure and unfair commercial use.

---

RDP is essential for all medicines, and particularly critical for biologic therapies. Made from living organisms, biologics are complex and challenging to manufacture and may not be protected adequately by patents alone. Unlike generic versions of traditional chemical compounds, biosimilars are not identical to the original innovative medicine and there is greater uncertainty about whether an innovator’s patent right will cover a biosimilar version. Without the certainty of some substantial period of market exclusivity, innovators may not have the incentives needed to conduct the expensive, risky and time-consuming work to discover and bring new biologics to market.

Strengthening RDP in Australia so it is aligned with global best practice would further enhance Australia’s ability to compete for foreign investments in the knowledge- and innovation-intensive biomedical sector that can drive future economic growth. Australia should extend the term of RDP for new formulations, new combinations, new indications, new populations (e.g., pediatrics) and new dosage forms. Indeed, the absence of such protection is in direct contravention of Australia’s obligations under Art. 17.10(2) of the AUSFTA, which mandates that Parties provide at least three years of RDP from the date of marketing approval in circumstances where new clinical information must be submitted to obtain regulatory approval of the relevant new therapeutic good (other than information relating to bioequivalence).

Market Access

Beginning with legislative changes implemented in June 2017, significant progress has been made with the implementation of the Medicines and Medical Devices Review; this progress highlights the benefits of regulatory review involving industry consultation. Measures such as the “Priority Review” and “Provisional Approval” pathways that deliver expedited access for some medicines in areas of high unmet need are welcome. However, unlike other jurisdictions, there is currently no corresponding change in the health technology assessment system to accommodate these fast-track approvals, especially in the case of the Provisional Approval pathway. Industry looks forward to working with the Australian Government to implement a fit for purpose reimbursement system to ensure that Australians have timely access to life-saving immuno-oncology medicines.

Difficulties in Listing New Medicines on the PBS

Prescription medicines accessed via the PBS constitute the vast majority of prescription medicines dispensed in Australia.\textsuperscript{278} Accordingly, the reimbursement process to obtain PBS-listing, as well as PBAC guidelines and decision making, effectively dictate access to the Australian pharmaceutical market. Predictable and equitable outcomes and processes in PBS listings are therefore critical to securing market

access to ensure Australian patients have access to innovative medicines. The purpose of the PBS is to provide timely, reliable and affordable access to medicines for all Australians.

In 2017, Medicines Australia signed a Strategic Agreement with the Australian Government to secure predictability and stability in the PBS and policy environment and to support business planning. This Agreement was not without significant cost to the industry by cementing the application of structured, predictable price reductions for on-patent medicines during their term in the single brand (F1) formulary at 5, 10 and 15 years post listing. Additionally, the Agreement aims to resolve issues with the interpretation of section 99ACB of the National Health Act and commits to no new determination of any Therapeutic Groups during the term of the Agreement.

It is now particularly important that the PBS remains fit for purpose as new and more advanced health technologies become available. To this end, we look forward to the delivery of the Australian Government’s commitment in the Agreement to improve and streamline PBS processes to achieve faster access to new medicines.

The PBAC’s approach of comparing new products to the “lowest cost” comparator creates an increasingly difficult barrier to patient access, due to these comparisons being made to cheaper, off-patent medicines that have undergone several rounds of competitive price reductions through price disclosure. As the price-disclosure measure has expanded and matured, creating downward pressure on prices in the multi-brand, competitive market for older medicines, comparators are increasingly being drawn from very low-cost drugs. Additionally, in therapy areas where has been less recent innovation, the clinical comparator may be off-patent. These medicines are commonly in the F2 formulary, having reached the end of patent life and subject to generic or biosimilar competition. Today's innovative medicines are increasingly targeted and personalized and can provide great value in some of the hardest-to-treat diseases and may offer a more targeted treatment, meaning they may be more effective than other available options. Comparing these medicines to older existing medicines that are less complex and developed decades earlier does not represent a fair value for the innovation involved.

Comparator price erosion undermines the intent of Australia’s split formulary system – which was designed to recognize the value of innovation by excluding patented products from statutory and administrative price reductions applied to off-patent products subject to market competition – and is an additional disincentive to bringing innovative medicines to Australia. Recent activities to provide clarity on this issue have not led to widespread selection of the most appropriate comparator. There is ongoing work to be done in this area and we welcome the Australian Government’s commitment to consider the issue of comparator selection as part of the AMWG discussions.

Biosimilars

The continued inclusion of Medicines Australia as a key stakeholder in the development and monitoring of the implementation of biosimilars policy through the
Agreement remains a positive element. The application of stakeholder-agreed biosimilar uptake drivers is in its early stages, but offers the potential to encourage competition. It remains critical that measures be taken to improve prescriber and patient understanding in order to build confidence in the appropriate use of biologics and biosimilars medicines. The impact of the Australian Government’s policy of allowing decisions regarding substitution (i.e., enabling a patient’s medicine to be switched) between biologic and biosimilar products at the pharmacy level, particularly in a system that does not support unique naming conventions for biological medicines, has not yet been assessed. It will be important to ensure that policies seeking to increase the use of biosimilars do not inadvertently disincentivize or hamper competition and discourage innovative manufacturers of original biologics to enter and remain in the Australian market.

Contrary to Australia’s goal of fostering a biotechnology industry, the Government elected in early 2018 not to implement a unique naming convention for biologic medicines. It is regrettable that the Government did not recognize the benefit to clinical confidence that such a system would provide, as its absence has the potential to weaken pharmacovigilance, post market monitoring, and confidence in the introduction of biosimilar medicines.

We would strongly encourage the Australian Government to consult with Medicines Australia as it seeks to develop evidence-based, consistent and comprehensive biosimilars policies that support safe introduction and balanced uptake of biosimilars.

Government-Initiated Post-Market Reviews of PBS Listed Medicines

Recently completed and ongoing post-market reviews include Chronic Obstructive Pulmonary Disease (COPD) Medicines and Ezetimibe in 2015; Post-Market Review of Pulmonary Arterial Hypertension (PAH) Medicine in 2016; and Post-Market Review of Biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) to treat Severe Chronic Plaque Psoriasis in 2016.279

PhRMA has previously expressed strong concerns about the cost-focus of post-market reviews of medicines listed on the PBS. While the stated objective of the reviews has been to improve Quality Use of Medicine (QUM), in reality, most reviews have narrowly focused on cost. Industry hopes that considering the statutory price reductions included in the Agreement, the focus of future post-market reviews will be to improve QUM.

SINGAPORE

PhRMA’s member companies face several market access barriers in Singapore. Singapore serves as a strong model for protecting and creating innovation in the research-based pharmaceutical sector. With continued collaboration between PhRMA member companies and the Government of Singapore, and with U.S. Government support, we are confident we can resolve outstanding issues and strengthen the country’s global leadership position.

**Key Issues of Concern:**

- **Intellectual property protection:** Singapore generally maintains a strong intellectual property protection and enforcement system. However, Singapore artificially limits patent term restoration (PTR) for biopharmaceutical inventions to the product registration period in Singapore, even when that registration relies on clinical trials conducted outside of Singapore. Improvements to the manner in which Singapore provides PTR, as well as its data protection regime would support the country’s goal of becoming a global hub for biomedical innovation.

- **Drug formulary listing practices in public sector:** Public healthcare institutions exercise their own autonomy in maintaining independent formulary and subsidy lists with undisclosed evaluation criteria and varied timelines across different hospitals and polyclinics, resulting in fewer treatment options for some patients.

- **Government drug subsidies:** The Agency for Care Effectiveness (ACE), is the national health technology assessment agency in Singapore. Established by the Ministry of Health (MOH), it conducts drug evaluations to inform government subsidy decisions on treatments, and produces guidance on the appropriate use of treatments for public hospitals and institutions in Singapore. There is an opportunity for greater industry and general public involvement in the initiation and subsidy decision-making input process. There is also the opportunity for the subsidy decision-making progress to be accelerated and government subsidies provided for a greater number of medicines. Limited annual windows for public health care institutions to submit dossiers and a protracted review process including infrequent Drug Advisory Council meetings for final decisions slows patient access to innovation.

The government through its Healthy SG task force has recently announced plans to subsidize all vaccines included in the National Adult and Childhood Immunization schedules. This is a positive move that should enhance coverage rates and the industry calls for greater public-private collaboration in the design and implementation of this policy. However, by announcing that patients can access these subsidized vaccines through private GP clinics that subscribe to the Community Health Assist Scheme (CHAS), ostensibly to prevent patients
accessing public services, this announcement risks eroding the delineation between Singapore’s public and private systems.

- **Review of Medishield Life (MSL):** MSL is a national healthcare insurance that provides hospitalization and limited out-patient benefits to patients. ACE recently held an industry briefing announcing potential changes to oncology coverage under this insurance program. As ACE considers these changes, it is imperative that it consults will all stakeholders to ensure that the revised program does not delay or restrict patient access to innovative oncology therapies.

- **Challenges in conducting clinical trials:** Singapore is consistently recognized as a leading location to conduct clinical trials as a result of its high-quality sites and globally-renowned researchers. However, the high cost and slow speed of setup of clinical trials in Singapore are observed as key barriers. Besides high administrative and resource costs, patients enrolled in clinical studies are charged at private patient rates. Lack of coordinated setup and infrastructure compounded with already inherent challenges of low patient enrolment and retention are significant obstacles for establishing effective clinical trial research and development.

For these reasons, PhRMA requests that Singapore be placed on the Watch List in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

**Intellectual Property Protection**

Singapore generally maintains a strong intellectual property protection and enforcement system. PhRMA members fully support the country’s objective of and progress toward becoming a global hub for biomedical science and innovation hub. To fully realize this goal, and in keeping with the U.S.-Singapore Free Trade Agreement, Singapore should adjust its PTR mechanism to compensate the patent holder for the time invested in conducting clinical trials either in Singapore or in any other market when such data is a condition of obtaining marketing approval in Singapore.

In addition, PhRMA continues to urge Singapore to improve its regulatory data protection regime. In particular, Singapore should extend regulatory data protection to new formulations, combinations, indications and dosage regimens.

**Market Access Barriers**

**Drug formulary listing practices in public sector**

While PhRMA's member companies are encouraged by the formation of three new public institution clusters, gaps between market access and timeline variances could be improved through a standardized evaluation process across the health care institutions within each cluster. Moreover, industry engagement in the formulary evaluation process
and policy decision-making processes should be improved. PhRMA’s member companies believe that such measures will enhance consistency and transparency of the listing process in public formularies and a broader range of medicinal choices will create more effective treatment options for patients and physicians in public institutions.

**Government drug subsidies**

PhRMA’s member companies encourage ACE to allow greater involvement of both the industry and general public during the listing initiation and subsidy decision-making input processes. This could enhance the quality of submissions and speed of decision making, thereby expediting access to innovative new medicines in the public sector.

The government through its Healthy SG task force has recently announced plans to subsidize all vaccines included in the National Adult and Childhood Immunization schedules. This is a positive move that should enhance coverage rates and the industry calls for greater public-private collaboration in the design and implementation of this policy. However, by announcing that patients can access these subsidized vaccines through private GP clinics that subscribe to the Community Health Assist Scheme (CHAS), ostensibly to prevent patients accessing public services, this announcement risks eroding the delineation between Singapore’s public and private systems.

**Review of Medishield Life**

The Ministry of Health needs to carefully consider the impact of any potential changes to national health insurance in Singapore. While containment of health care expenditures is a key concern of the government, this needs to be carefully balanced with timely availability and broad accessibility of innovative oncology therapies to cancer patients in Singapore. PhRMA’s member companies would encourage ACE to continue engaging in a dialog on the upcoming Medishield Life changes, and potentially involve all impacted stakeholders such as health care professionals, public health care institutions, and patient groups in guiding its decision moving forward.

**Challenges in conducting clinical trials**

Clinical trials in Singapore can be better promoted by managing the high cost of clinical trials and accelerating the speed of setup and recruitment through standardizing clinical trial agreement/contract across all public institutions. PhRMA member companies urge the MOH to continue work with industry to find collaborative solutions to encourage conducting more clinical trials in Singapore.
EUROPE
EUROPEAN UNION

PhRMA member companies face a variety of government restrictions across Europe that jeopardize patient access to innovative medicines. As a result of Europe’s on-going economic challenges, several European Union (EU) Member States continue to seek additional cost savings at the expense of the innovative biopharmaceutical sector, thereby imposing a disproportionate burden on the United States to support R&D for new medicines.

In addition, while the EU generally maintains intellectual property (IP) protections that enable the research and development of innovative biopharmaceuticals, PhRMA and its member companies are concerned by the potential future direction of an ongoing European Commission (EC) review of IP incentives for innovative biopharmaceuticals that could result in weakening of IP rights in one of the world’s largest markets.

Key Issues of Concern:

- **Intellectual property incentives review:** The EU is conducting an analysis of the current EU legislative instruments and related incentives that aim to facilitate and support the investment in the development of medicinal products. PhRMA and its member companies are concerned that this review can result in the weakening of existing incentive mechanisms for biopharmaceutical innovation and create an unlevel playing field for transatlantic medicines trade and investment. Recently, the EU introduced changes to its legislation amending Regulation EC 469/2009 concerning the supplementary protection certificate (SPC) for medicinal products, to introduce an SPC export and stockpiling waiver (in force as of July 1, 2019). The waiver allows companies to manufacture generic and biosimilar products in Europe during the effective SPC period for export purposes to third (non-EU) countries and stockpiling during the last six months of the validity of the SPC for the domestic market. The SPC manufacturing waiver weakens the scope of the exclusive rights conferred by an SPC and sends a negative signal to the world that the EU is weakening its commitment to IP incentives and innovation. In addition to the SPC manufacturing waiver, PhRMA is also concerned with the ongoing review of pharmaceutical incentives in Europe where proposals are being considered to weaken existing incentives, including the evaluation of the Regulations concerning orphan and pediatric medicinal products, expected to culminate in Q1 2020.

- **Government price controls and patient access to innovative medicines:** Among numerous other government price controls in effect, many EU/EFTA Member States set prices of patent-protected innovative medicines based on prices in less wealthy countries that are not representative of efficient markets for the normal exploitation of innovations and/or based on older products deemed to be within the same therapeutic class, including generics. Moreover, several countries in Europe are pursuing initiatives to jointly procure innovative medicines, or jointly negotiate their prices to gain stronger bargaining power against innovative
biopharmaceutical companies and lower prices. Such government practices – coupled with rigid health technology assessment (HTA) interpretations of value – are putting at risk biopharmaceutical innovation and will seriously harm patient access to needed medicines. As such policies continue to ratchet European prices lower, there are increased calls for cross-border sharing of confidential price information. Furthermore, although EU legislation\textsuperscript{280} requires transparent and timely processes (e.g., within 180 days) for national pricing and reimbursement decisions, delays for launched medicines average 426 days,\textsuperscript{281} and therefore these requirements need to be enforced more rigorously and with broader oversight of national practices.

For these reasons, PhRMA requests that the European Union be placed on the \textbf{Watch List} in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

**Intellectual Property Protection**

\textbf{EU Incentives Review}

In June 2016, under the Dutch Presidency of the Council of the EU, the European Member State Health Ministers asked the European Commission, with assistance from Member States, to undertake a review of existing intellectual property-related incentives for the biopharmaceutical industry to gauge their effectiveness and impact on innovation and the availability, accessibility and affordability of medicines. The Commission undertook a review process which concerns the following pieces of legislation: SPCs (Regulation EC 469/2009), Medicinal products for human use (Directive 2001/83/EC and Regulation EC 726/2004), Orphan medicinal products (Regulation EC 141/2000) and Paediatrics (Regulation EC 1901/2006). The review involves a number of studies, many of which have been completed.

While the review is still ongoing, PhRMA and its member companies are very concerned that it could weaken existing incentive mechanisms that support biopharmaceutical innovation. Failure to effectively safeguard these incentives in one of the world’s largest markets for innovative medicines would harm American exports and jobs and reduce investment in new treatments and cures for patients in Europe and around the world. For example, the Commission is reportedly running an analysis of orphan and pediatric incentives critical for the development of medicines for underserved populations. While this analysis is ongoing, we understand that proposals to reduce the existing incentives are being considered that would further undermine the ability of innovative companies to bring new medicines to European patients.


\textsuperscript{281} EFPIA Patient W.A.I.T. Indicator Survey, 2018. Note that the Patient W.A.I.T. indicator also reflects delays which are not requirements under European Council Directive 89/105/EEC.
Supplementary Protection Certificates

As part of the broader incentives review, PhRMA is very concerned about the recently introduced SPC manufacturing waiver which weakens the scope of the exclusive rights conferred under an SPC and may encourage other countries to reduce or eliminate intellectual property protections.

On May 28, 2019, the EC published legislation amending the SPC Regulation (469/2009) to introduce an SPC manufacturing waiver. The waiver allows companies to manufacture generic and biosimilar products in Europe during the effective SPC period for export purposes to third (non-EU) countries and stockpile during the last six months of the validity of the SPC for the EU market. This legislation reduces IP rights and sends a signal to the world that Europe is weakening its commitment to IP incentives and innovation.

SPCs are a critical part of the European IP system. They partially restore the effective patent term and thereby help to compensate for a portion of the time incurred during the testing and regulatory review period that may “make the period of effective protection under the patent insufficient to cover the investment put into that research.”

The SPC Regulation itself declares that: “[p]harmaceutical research plays a decisive role in the continuing improvement in public health.” It states that “[m]edicinal products, especially those that are the result of long, costly research will not continue to be developed in the Community and in Europe unless they are covered by favourable rules that provide for sufficient protection to encourage such research.”

Preventing potential abuses of the SPC waiver will be very difficult. Such abuses could consist of illegal diversion of medicines produced pursuant to the exception within Europe, or in foreign markets where the relevant patent term has not expired. In the end, it may well be impossible to ensure that the exemption is used only to achieve its intended purpose. This could further reduce the effective protections SPCs are intended to provide.

In addition, the SPC waiver may be copied by other economies and may also encourage other countries to maintain or even weaken their already-low patent protection standards – possibly in an exaggerated form that is even more damaging to biopharmaceutical innovators in the United States, Europe and elsewhere around the world. Already, lawmakers in one Asian country have proposed to permit “manufacturing for export” during the 20-year patent term, which would be inconsistent with World Trade

---


284 Regulation No. 469/2009.
Organization rules.\textsuperscript{285} If a leading developed economy like the European Union bends the rules, others are sure to break them.

**Market Access**

**Government Price Controls and Patient Access to Innovative Medicines**

As detailed further below, many EU Member States engage in practices that restrict availability, limit patient access, and fail to reward the value of state-of-the-art medicines. Moreover, since the U.S. research-based industry is the world leader in the development of new medicines, PhRMA members and their innovative products disproportionately bear the brunt of these measures as they undermine the financial incentive for privately sponsored research and development. Furthermore, even though EU legislation requires transparent and timely processes (\textit{e.g.}, within 180 days) in making such national pricing and reimbursement decisions, these requirements need to be enforced more rigorously and broader oversight of national practices should be in place.

**Austria**

Though Austria is one of the wealthiest countries in Europe,\textsuperscript{286} it has adopted a spate of cost-containment measures that have held the retail pharmaceutical share of health spending stable at 12.3 percent over the past decade despite increases in consumption.\textsuperscript{287} For example, Austria sets and adjusts the prices of innovative medicines using a broad basket of 26 European countries and, as of 2017, the government extended this methodology to non-reimbursed products. Industry has grown increasingly concerned about the unilateral nature of such policies which are being made with little opportunity for engagement and despite considerable discounts offered as part of a framework agreement that was in effect at that time.

Moreover, not covered in expenditures are clawbacks, pricing models for reimbursed products as well as price contracts in the hospital sector. Since 2008, pharmaceutical industry and social health insurance have been working together on a contractual basis to support the efficiency of the state social security (Pharma Master Agreement). Between 2016 and 2018 the contribution of the industry will be about €225 million. The last Pharma Master Agreement expired in 2018, without any renewals thus far. According to this contract there are still payments to be made by 2020.


\textsuperscript{286} IMF WEO, 2018.

\textsuperscript{287} OECD Health Statistics (last accessed Sept. 2019).
Belgium

The Belgian government has instituted a variety of price controls that target medicines. For example, manufacturers are subject to a number of taxes including turnover (6.73 percent), crisis (1 percent), clawback if the pharmaceutical budget is exceeded (2.5 percent in both 2017 and 2018), orphan drug (5 percent for turnover greater than Euro 3 million), marketing (0.13 percent), and per pack fees, as well as a variable clawback based on health care spending and other government-imposed pricing measures. Domestically manufactured new medicines are also permitted to request a 5 percent price premium, to the detriment of their imported competitors. Patients in Belgium are also subject to co-pays for certain types of medicine (e.g., contraceptives, antihistamines, influenza vaccine) that range from 60 percent to over 140 percent of MSP, with no maximum limit.288

Czech Republic

While the Czech government is making positive strides to increase health care expenditures and provide increased access to innovative medicines, the country’s pharmaceutical share of total health spending has nevertheless declined from 21.5 percent in 2012 to 17.4 percent in 2016 due to rigid cost-containment policies such as its “double referencing” system.289 Under this system, the price of a new medicine cannot exceed the average of the lowest three priced countries among 19 European countries including Greece. In addition, in most cases, the reimbursed price will then be set at the lowest European price of a therapeutic cluster of interchangeable medicines, which can combine both patented and generic medicines.290

In addition to facing some of the lowest prices in Europe, innovative medicines in the Czech Republic are additionally subject to lengthy delays and non-transparent processes. The target decision-making timeline for individual pricing decisions is 75 days from receipt of an application, and for joint pricing and reimbursement applications the target timeline is 165 days. In reality, decisions take more than a year on average.291

One additional provision of the Czech health care legislation which could be a significant threat to pharmaceutical companies is mandatory delivery of medicinal products to wholesalers based on their market share, which imposes inappropriate limits on a manufacturer’s freedom to select and contract with specific wholesalers and imposes obstacles to entering the market.

290 Id.
291 Id.
Denmark

Although Danish law does not directly regulate prices, the government decides which medicines are reimbursed and in effect sets the prices of those products through an agreement with the local industry association that requires international reference pricing, price caps, tendering and other cost-containment measures. These practices have caused the country’s pharmaceutical share of health care spending to decline from a high of 8.9 percent in 2007 to 6.3 percent in 2017 which is well below the OECD average of 16.3 percent.\textsuperscript{292} At $318 per capita, Denmark also spends comparably less on medicines than the OECD average of $588.

These practices have also created uncertainty for biopharmaceutical innovators. For example, of 21 reimbursement applications in 2017, only ten were granted automatic reimbursement, while eight were granted conditional reimbursement. Moreover, from 2013 to 2016, the government rejected reimbursement applications for ten medicines over concerns that the medicines might be used outside of the target patient population, creating unforeseen expenditure.\textsuperscript{293} Additionally, although a price cap system is in place for hospital medicines, actual prices paid tend to be even lower due to largely varying discounts in tendering processes, with an average 2017 discount of 27.1 percent.\textsuperscript{294}

Finland

The Finnish pricing and reimbursement environment is restrictive and lacks support for innovative medicines. Initially, almost all new products are awarded basic reimbursement status (including innovative therapies for serious conditions, such as new cancer therapies and orphan drugs), leaving patients to cover 60 percent of costs. Manufacturers seeking more substantial coverage of a medicine must then apply for special reimbursement status through a lengthy, complex, non-transparent process where there is little dialogue with manufacturers. Although international and therapeutic reference pricing is not formally part of the Finnish system, resulting prices often resemble those of lower-priced countries and lower-priced products in a therapeutic cluster.\textsuperscript{295} Finland also engages in ad hoc price cuts to all reimbursed medicines such as the 5 percent cuts taken in 2006 and 2013.\textsuperscript{296} These and other measures have led to an overall decrease in the pharmaceutical share of total health spending from 14.6 percent in 2008 to 12.3 percent in 2017, despite a 1.1 percent gain in overall health spending as a percent of GDP during the same period.\textsuperscript{297}

\textsuperscript{292} OECD Health Statistics (last accessed Sept. 2019).
\textsuperscript{294} Id.
\textsuperscript{296} Id.
France

Until recently, France had adopted increasingly punitive policies toward innovators through layered mechanisms such as taxes, price-volume clauses that trigger price cuts or clawbacks, and an industry-wide clawback when national spending growth on reimbursed medicines exceeded 0 percent for retail medicines and 3 percent for hospital medicines. Clawbacks were up to 70 percent of net sales revenue. Additionally, there are serious challenges with France’s HTA system, which rates the clinical added value of a product as major (ASMR I), important, (ASMR II), moderate (ASMR III), minor (ASMR IV) or no clinical improvement (ASMR V), with corresponding impacts on both pricing and speed of patient access. In practice, only one-third of new medicines were assigned ASMR ratings of I, II or III. Such products were guaranteed prices no lower than the lowest price applied in Germany, Italy, Spain and the United Kingdom for five years, after which prices were commonly cut.\textsuperscript{298}

However, in July 2018, France announced several positive reforms to improve market access and boost the life sciences sector. 2019 was marked by an improvement in the 2019 social security finance law to ensure minimum market growth of 1 percent, from 2019-2022, corresponding to 1.0 percent growth for reimbursed medicines and 3.0 percent growth for innovative medicines. Nevertheless, the upcoming 2020 bill foreseen for the biopharmaceutical sector remains a challenge, and growth in the French market still lags its competitors. Progress has also been made through an agreement between LEEM (the French Pharmaceutical Association) and the French government to speed up lengthy reimbursement processes. The government has committed to reduce the reimbursement process to 180 days by 2022.

Germany

Germany’s Pharmaceutical Market Restructuring Act (AMNOG) of 2011 restructured its pharmaceutical market away from market-based pricing toward a government-controlled system of clinical evaluation and price-setting. AMNOG reimburses new medicines at manufacturer prices for one year, while the government oversees a rigid early clinical benefit assessment by the Federal Joint Committee (G-BA) and price negotiations with the umbrella organization of the German payers that are tied to the outcome of the G-BA assessment. The prices of products deemed not to provide additional clinical benefits are generally limited to the price of the comparator selected by the G-BA or to the lower price of a therapeutic cluster. Lowest-cost comparators and generics are often considered appropriate comparators.\textsuperscript{299}

One of the chief complaints with AMNOG concerns the serious restrictions on demonstrating proof of additional clinical benefit. By 2019, this rigid process resulted in 40 percent of innovative medicines (and 60 percent of assessments for patient

\textsuperscript{298} IHS Global Insights (2019).
subpopulations) being found to demonstrate no additional clinical benefit. In contrast, many of these treatments have been widely recognized as important and even breakthrough therapies in the United States. An analysis by the VFA (the German Association of Research-based Pharmaceutical Companies) determined that the system is so unfavorable that 14 percent (31 of 221) of innovative medicines subject to with reimbursement amounts set under AMNOG have been withdrawn from the market during or after the price negotiations.

In July 2019, a new law (GSAV) enabled the G-BA to also recognize registry data in the assessment of certain medicines (e.g., medicines for orphan conditions or with conditional approval). It remains to be seen whether this new law will facilitate greater recognition of real-world data and a less rigid assessment system, or if the G-BA will create additional pricing hurdles for certain medicines. The GSAV also calls for the introduction, after three years, of mandatory automatic substitution in pharmacies for biosimilars (the products have yet to be selected).

Greece

Greece’s pharmaceutical environment remains among the most challenging in Europe given onerous price controls and other market access barriers that undermine innovation, including mandatory clawbacks and rebates. Because of these practices, the government’s expenditure on outpatient medicines declined by 62 percent between 2009 to 2017. The 2019 clawback is expected to reach €1.3 billion, which is a 26 percent increase over 2018 and more than 50 percent of the total public pharmaceutical reimbursement budget (€2.5 billion). While declining, government arrears to the industry as of the end of 2018 were still valued at approximately €583 million.

Hungary

Government pricing and reimbursement of medicines in Hungary has been under substantial pressure since the Pharma Economic Act of 2007 and the two Széll Kálmán austerity plans. With the amount spent on pharmaceutical reimbursement frozen since 2010, Hungary additionally cuts the prices of innovative medicines by capping the prices for new products in Hungary to the lowest price at launch in any EU country. Hungary also engages in a “blind bidding system” for therapeutic reference pricing groups which can be comprised of both patented medicines that have been marketed for at least one year and off-patent medicines. The system requires manufactures to submit “blind” price reductions to the National Health Insurance Fund of Hungary (NEAK) every six months.

300 Id.
301 VFA analysis of AMNOG procedure database, 2019.
Ireland

To constrain health care spending, Ireland employs highly restrictive and layered cost-containment measures. With harsh cost-effectiveness requirements, a price freeze on all reimbursed medicines since 2016, annual price cuts, and monthly clawback payments of 5.5 percent, Ireland’s operating environment is extremely challenging for innovative manufacturers.\(^{303}\) The planned 2020 renegotiation of the agreement between the Irish government and the Irish Pharmaceutical Healthcare Association (IPHA) represents an opportunity to correct these imbalances.

Italy

Government pricing and reimbursement policies in Italy have historically resulted in an uncertain and challenging business environment for innovative biopharmaceutical companies and in restricted patient access to innovative medicines, though two funds created in 2017 for innovative medicines have recently improved the situation. For many years, a clawback system was in place that required biopharmaceutical companies to repay revenues when spending exceeded a budget cap. This system heavily penalized U.S. innovators, which paid 51 percent of the total clawback while accounting for only 30 percent of the spending. In 2019, a simpler clawback system was announced that allocates repayments based on market share.

Even if the environment is now more predictable, the pharmaceutical system is still underfunded with large mandatory clawbacks and structural imbalances that remain challenging for innovative biopharmaceutical companies, including challenges associated with data collection and calculation methodology. For example, there is an increasing surplus in retail medicines spending (more than Euro 800 million in 2018) which is used to support non-pharmaceutical spending, and a large and increasing deficit in hospital medicines spending (more than Euro 2.9 billion in 2019) that requires a 50 percent clawback.\(^{304}\) In January 2019, an agreement was reached between the industry and the Regions to rebalance this allocation of funds, but the 2020 Budget Law did not introduce any positive change on this matter. Moreover, the new system set by law since 2019 rescinded exemptions from the clawback system for orphan drugs not listed in the EU Register.

The Italian Drug Agency (AIFA) also fails to adequately recognize the value of innovative medicines through use of therapeutic groups that force patented medicines to compete against other patented medicines and generic medicines with different active ingredients, where price is the only selection criteria. Finally, expected changes to pricing and reimbursement regulations may allow AIFA to reimburse a medicine only if the government determines that it has a clear added therapeutic value over existing treatment options; otherwise, the price would be significantly lower than other marketed alternatives.

---


The impact of these recent harmful measures are likely to be amplified by the underfunding of the pharmaceutical system.

Netherlands

PhRMA member companies are concerned about the rising interest by the Netherlands government to consider using compulsory licensing as a way to address the cost of medicines. Earlier this year the government commissioned an academia-led compulsory licensing committee to examine the legal and economic issues as it relates to the use of compulsory licensing. Another area of concern is the use of “compounding” as a means of controlling prices of pharmaceuticals. With the national elections coming up in early 2021, there is a heightened risk of some candidates promoting this approach as a means to abrogate U.S. innovator's intellectual property rights.

Regarding market access, in 2015, the Netherlands began placing new high-value medicines into a reimbursement “lock” system that denies patient access until completion of an HTA and subsequent negotiations to force discounts. The Netherlands initially implemented this system on a case-by-case basis but announced in May 2018 that it would apply to all new medicines with an annual cost of €50,000 per patient (when combined costs exceed €10 million) or a combined cost of €40 million. The Netherlands also imposes pressure on the prices of retail medicines deemed by the Ministry of Health, Welfare and Sport to be therapeutically-interchangeable based on the average price of the therapeutic group, which can include patented medicines, off-patent medicines and generics. Additionally, as of January 2020, all medicines will be subject to an updated international reference pricing system (previously included Belgium, France, Germany, and the United Kingdom), that will replace Germany with Norway specifically because Norway’s prices are an average of 9-13 percent lower than those in the Netherlands. The government estimates this change will reduce annual spending on medicines by around €300 million.

Poland

Total health care spending in Poland was 6.3 percent of GDP in 2018 (72 percent of which was from public sources, which is equivalent to 4.5 percent of GDP) and well below the OECD average of 8.8 percent, with Poland ranking 32nd of 36 OECD countries. In this context, the share of public spending on pharmaceuticals has remained relatively stable and under the 17 percent ceiling at which point industry clawbacks are mandated. Despite the introduction of several new medicines in recent years, the government has constricted this share growth through a combination of therapeutic reference pricing that can tie the price of patented medicines to the lowest

305 IHS Global Insights (May 2018). Netherlands expands criteria for inclusion of high-cost drugs in “reimbursement lock,” renegotiates price of Tecentriq and Soliris.
price generics, price cuts, fixed margins, high co-pays and other measures.\textsuperscript{308} Poland’s government pricing and reimbursement system is discriminatory, non-transparent, and significantly backlogged, taking more than 630 days on average from regulatory approval to patient access.\textsuperscript{309} As a result, Poland lags far behind most other EU countries in availability of innovative medicines.\textsuperscript{310} More recently, the government announced in February 2018 that public health care spending would continue to be increased to reach 6.0 percent of GDP by 2023; however, the 2019 budget was finalized with a $1 billion increase to the overall health care budget but no increase to the medicines budget.\textsuperscript{311}

**Romania**

The Romanian health care system is one of the most underfunded in Europe, comprising an estimated 4.3 percent of GDP in 2019, and budget challenges remain due to the many contribution exemptions introduced over the years. There are also significant government price controls and other market access barriers for pharmaceuticals – including government price controls, other cost-containment measures and administrative hurdles that significantly delay patient access (e.g., on average it takes 850 days between marketing authorization and government reimbursement). For example, the government sets prices based on the lowest price in the EU and does not consider reimbursement applications until a new innovative medicine has been granted reimbursement in at least 14 EU countries.

The government’s clawback requires manufacturers to cover the entire reimbursed medicines budget deficit (including wholesale and retail margins). In 2019, this deficit was 26 percent due to a flat pharmaceutical budget since 2009 that ignores the growing health care needs of the Romanian population.\textsuperscript{312} The lack of funding needs to be maintained high on the political agenda and is currently part of an Inter-Ministerial Working Group with the industry.

**Spain**

During the financial crisis of 2010-2012, Spain imposed a number of aggressive cost-containment measures that remain in place despite the country’s economic rebound since 2014. The effect of these measures is still noticeable, with public pharmaceutical expenditure in the retail sector in Spain 15 percent lower in 2018 than its historical maximum in 2010. Specific measures include the reimbursement delisting of more than 400 medicines, frequent direct and indirect price cuts, the imposition of mandatory discounts on reimbursed patented medicines, restricted access to certain patient

\textsuperscript{310} PhRMA analysis of IQVIA and regulatory data, updated Sept. 2018.
\textsuperscript{311} IHS Global Insights (May 2019). Polish patient groups oppose MoH’s decision to increase healthcare funding without raising drug reimbursement.
\textsuperscript{312} Romanian National Health Insurance House (CNAS 2018 official data).
subpopulations, and a change in pharmaceutical co-payment policy (e.g., pensioners began contributing a 10 percent co-payment, subject to caps and other limits).

Like in other European markets, Spain struggles with how to make innovative medicines available to patients given its aging population, increased demand for higher cost specialty care and underfunded health care system. The gap in needs versus available resources remains a significant challenge. For example, despite its gradual economic recovery, Spain continues to spend a decreasing proportion of GDP on health care, with 6.4 percent in 2016, 6.3 percent in 2017 and 6.2 percent in 2018. This continues a downward trend and is also the lowest level since 2009. In an effort to provide greater predictability and avoid further ad hoc cost-containment measures, the local industry association (Farmaindustria) and the current administration recently agreed to tie growth of public spending on original branded medicines to GDP growth. However, in practice historical market access barriers persist, including those listed above.

National reimbursement of most innovative medicines are being restricted to certain patient populations considering additional clinical benefit and facing additional market restrictions at regional level. Innovative price and reimbursement practices are being introduced progressively: outcomes-based agreements (payment for performance), spending ceilings, discount and volume based price negotiations and installment payments. Until now, these practices have only been applied to innovative products and in the hospital market.

Hospital pharmaceutical spending has grown steadily triggered by the reimbursement of innovative medicines. In 2018, total retail and hospital pharmaceutical recovered to 2010 levels, exceeding €17 billion. Despite its gradual economic recovery, Spain continues to spend a decreasing proportion of GDP on health care, with 6.4 percent in 2016, 6.3 percent in 2017 and 6.2 percent in 2018. This continues a downward trend and is also the lowest level since 2009.

Additional market access challenges have emerged with the new administration. These include therapeutic reference pricing, which sets prices of innovative medicines based on a group of products that includes generics and biosimilars, mandatory prescribing by active ingredients for small molecules and biologics, and other initiatives aimed at mandatory automatic substitution with biosimilars. In 2019, there was an unprecedented level of rejections and delays by the Ministry of Health that has negatively impacted patient access to new medicines.

Switzerland

Switzerland has compulsory private health insurance, but the government regulates which medicines are reimbursed and sets the prices of those products based on the prices in other European countries (all with lower GDP per capita) as well as based on the prices of alternative therapies which may represent a lower standard of care.
Moreover, the pricing and reimbursement system lacks predictability and transparency, and fails to appropriately account for currency appreciations as well as the local cost structure. For example, in 2015 Switzerland expanded the basket of countries used in its international reference pricing system for setting and adjusting prices of patented medicines to nine European countries. However, given the strength of the Swiss franc relative to other currencies in the basket (Euro, UK pound, Swedish and Danish crowns), the practice has become highly damaging as many of these currencies continue to lose value.

Compounding this issue, in 2017 the Swiss Government began setting prices based on giving equal weight to the average international reference price and the average therapeutic reference price. Every year, one-third of the reimbursement list is subject to price adjustments based on this approach. For the group of original brands evaluated in 2018, 53 percent of 543 medicines had their price cut by an average of 18.9 percent. Moreover, manufacturers may be required to pay back revenue after a drug’s first triennial price review if the drug’s price is reduced by more than 3 percent; and its previous, higher MSP generated over CHF 20,000 in (excess) revenue. Over the last two years, the pricing authorities began using additional tools such as capitation, budget impact tests and rebating for drugs using in combination or by indication.

As a result of these combined policies, Switzerland has experienced more pronounced market access delays for certain innovative medicines in recent years.
UNITED KINGDOM

PhRMA and its member companies operating in the United Kingdom (UK) continue to work with the UK Government, the National Institute for Health and Care Excellence (NICE), NHS England and National Health Service (NHS) partners to support implementation of policies to strengthen the innovative pharmaceutical industry and address long-standing market access and pricing issues. Of particular concern are the continued lack of patient access to innovative medicines, intellectual property (IP) threats from Brexit and the need for continued support for the government’s life sciences strategy.

Key Issues of Concern:

- **Intellectual property threats from Brexit:** With the UK’s exit from the European Union (EU), it is important that the UK maintain strong IP protections, including effective periods of regulatory data protection and supplementary protection to restore a portion of the time lost during the marketing approval process. Future U.S.-UK trade negotiations provide an opportunity to cement these protections and pursue higher IP standards.

- **Government restrictions on reimbursement and patient access to innovative medicines:** Because of long-standing market access barriers such as rigid health technology assessment (HTA), mandated discounts to meet unreasonable cost-effectiveness thresholds and insufficient health care budgets, the ability of UK patients to access the latest, innovative medicines remains problematic. In comparison to peer countries, adoption of the newest medicines remains low and slow.

- **Need for UK government life sciences industrial strategy:** Sir John Bell published a Life Sciences Industrial Strategy (LSIS) report in 2017, outlining policy changes the industry believes will strengthen the life sciences sector in the UK. PhRMA members welcome the proposed changes and are working to ensure adoption and successful implementation of LSIS policies in the NHS and elsewhere that would foster adoption of new life sciences technologies in the UK.

For these reasons, PhRMA requests that United Kingdom be placed on the Watch List in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

**Intellectual Property Protection**

Effective intellectual property protection and enforcement is essential to develop new medicines for patients who need them. As the UK exits the EU, it is important that the UK maintain robust IP protections and that the UK and EU systems remain sufficiently aligned to ensure business continuity and certainty for PhRMA member companies.
Brexit does not change the UK’s membership under the European Patent Convention (EPC), and any patent granted under the EPC can still be validated and enforced in UK after Brexit. However, other IP rights already obtained or available in the UK under EU law or applications thereof, should continue to be in force as a matter of UK law. In addition, such rights should be available to be granted immediately upon Brexit for new products. Furthermore, the life sciences industry would strongly advocate for finding possible ways for the UK to remain in the scope of the Unitary Patent Agreement to provide the life sciences industry predictability and stability when faced with the uncertainty of Brexit and scope for the UK government to align other aspects of the IP framework in partner countries, such as the U.S., with global gold standards.

As the UK Government considers future free trade agreements post-Brexit, as well as the UK’s opportunities to build its life-sciences sector, it should seek to strengthen IP protections. In particular, it should repeal the manufacturing waiver to SPCs recently adopted by the EU, enshrine the provision of stable RDP, orphan and pediatric exclusivities that meet the highest international standards (at a time when some in the EU are seeking to undermine those incentives), and recognize that it is never appropriate to threaten compulsory licenses in order to secure price cuts. Further, as the UK works with the EU to determine their post-Brexit relationship, it will be critical that the UK measure the provision of RDP, SPCs and orphan and pediatric protections from the date of UK marketing authorization (rather than the earliest date of authorization in the EU or UK, as proposed in the event of a no-deal Brexit).

**Market Access Barriers**

**Government Restrictions on Reimbursement and Patient Access to Innovative Medicines**

New products in the UK can be launched upon regulatory approval, potentially making it one of the world’s fastest countries for market access. However, UK patients experience materially longer delays in accessing new medicines than patients elsewhere due to a range of policies aimed at containing costs to meet unreasonable budgets. For every 100 patients in comparable countries who get access to a new medicine in its first year of launch, just 21 patients in the UK receive the same. Even five years after the launch of a new medicine, UK patients are significantly less likely to have access than are patients living in other countries.

Another key reason why UK patients experience reduced access to new medicines is the high rate of rejections by NICE. When making coverage recommendations, NICE assesses medicines using a baseline cost-effectiveness threshold of between £20,000 and £30,000 per quality-adjusted life year (QALY). This baseline threshold has not been revised – even in line with inflation – since NICE’s inception in 1999, which means that the threshold has declined in real terms by over 30 percent over the past two decades. Innovative medicines exceeding a cost per QALY threshold of £30,000 (or £50,000 for

---

end-of-life interventions) are generally viewed as not cost-effective, leaving patients without access to clinically superior products. In addition, as companies develop new therapeutic advances, often in areas where there are many older off-patent medicines that are much lower in cost, demonstration of cost-effectiveness becomes exceedingly difficult by design. Moreover, NICE’s inflexibility surrounding new medicines for which there is greater uncertainty about data (e.g., due to the immaturity of data or single-arm trials) disproportionately impacts patient access to treatments for small patient populations (e.g., rare conditions) or for subsets of populations (e.g., targeted therapies).

Using only cost per QALY to measure cost-effectiveness in this way fails to appropriately recognize the value of innovative medicines. In this context, between March 2000 and May 2019, just 55 percent of all technology appraisals were recommended by NICE in line with marketing authorization; while 24 percent were recommended in a restricted subset of patients, 3 percent under the Cancer Drug Fund (CDF), and 3 percent in research only – and 15 percent were rejected altogether. Recommendations for cancer medicines were even more restrictive with just 52 percent of cancer appraisals recommended in-line with marketing authorization; while 12 percent were recommended in a restricted subset of patients, 9 percent under the CDF, 2 percent in research only – and 24 percent rejected altogether.\(^\text{315}\) Industry welcomes the ongoing review into NICE methodologies and looks forward to its meaningful reform.

PhRMA members recognize the UK government’s interest in controlling NHS spending, but spending on medicines is not currently a driver of growing health care costs. On the contrary, over the course of the last five years, NHS spending on the majority of branded medicines was capped to 1.1 percent growth per year, a decline of 0.4 percent after inflation while overall NHS spending has risen at 3.3 percent over the same period. Innovations in prevention and treatment will be vital to delivering further enhanced efficiencies in the UK health system, as well as improving health outcomes and providing high-quality care. Indeed, with the new Voluntary Scheme, the government has certainty that spending on branded medicines will not rise more than 2 percent per year, so there is no reason not to bring requirements for new products in line with other leading nations. Currently, uptake of new medicines approved by NICE remains low and slow due to system fragmentation and insufficient health care budgets.

UK Government Life Sciences Industrial Strategy

During 2017, the Association of the British Pharmaceutical Industry (ABPI) and its industry partners collaborated with the LSIS Board led by Professor Sir John Bell to produce the LSIS. This publication followed the UK Government’s industrial strategy green paper from January 2017. The LSIS is a roadmap to building a thriving life sciences sector in the UK. The UK Government has published its response in the form of two Life Sciences Sector Deals, which marks the first phase of implementing the

recommendations of the LSIS. As such, ABPI continues to call for implementation of all the recommendations in the LSIS.

An industrial strategy approach is particularly well suited to biopharmaceuticals since the sector is highly impacted by UK Government policy at every stage of the product lifecycle. A holistic approach and comprehensive delivery across the Government, in partnership with the NHS, is a powerful way to support the sector’s economic contribution to the UK, but will only be meaningful if coupled with other reforms to ensure that UK patients have access the latest innovative medicines. To realize the ambition of the LSIS, the UK Government should amplify its efforts:

- Continue to invest in the UK’s strong science base;

- Build foundations and infrastructure for the research, development and production of innovative therapies in the UK;

- Transform the NHS into an early adopter of new cost-effective medicines and technologies which are adopted at pace and scale;

- Enable the NHS to make best use of data and digital tools to support research and improve patient care; and

- Recognize the potential challenges and opportunities for the industry as a result of Brexit and prioritize regulatory cooperation on medicines and the ability to trade medicines in the second phase of Brexit negotiations.
LATIN AMERICA
MEXICO

PhRMA and its member companies operating in Mexico are growing increasingly concerned with recent changes to Mexico’s pharmaceutical policies, particularly with respect to market access delays due to challenges in accessing public formularies and new public procurement processes, weak patent enforcement and other significant intellectual property (IP) issues, and, more broadly, with growing legal uncertainty and a lack of transparency around government decision-making processes.

Key Issues of Concern:

- **Weak patent enforcement and regulatory data protection failures:** The Federal Committee for Protection from Sanitary Risks (COFEPRIS) and the Mexican Patent Office (IMPI) have committed to improve the application of Mexico’s 2003 Linkage Decree and to provide protection for data generated to obtain marketing approval for pharmaceutical products. Despite these commitments, PhRMA member companies are unable to obtain accurate and timely information from COFEPRIS prior to marketing authorization being granted on a generic or biosimilar drug where the innovator product is used as a reference. As a result, PhRMA members have little to no notice that a potentially patent infringing product is entering the market. Further, obtaining effective preliminary injunctions or final decisions on cases regarding IP infringement within a reasonable time (as well as collecting adequate damages when appropriate) remains the exception rather than the norm. Further, consolidation of substantive regulatory data protection (RDP) at a federal law, including a specific provision of RDP for biologics, is still pending.

- **Market access delays:** COFEPRIS has put on hold the marketing authorization process for pharmaceutical products since the beginning of the administration. In addition, significant market access barriers remain due to lengthy, non-transparent and unpredictable reimbursement processes. The lack of transparency around the development of a National Medicines Compendium and disease-specific treatment guidelines, as well as challenges and uncertainty in accessing the formularies of public health institutions is further delaying patient access to innovative medicines.

- **Challenges with new public procurement practices:** In 2019, Mexico further consolidated and transferred authority for the public procurement of medicines from the individual public health institutions to the Ministry of Finance. Several tenders were conducted based on new rules that lack transparency in process and requirements, and that are inconsistent with Mexican law and Mexico’s international commitments. In addition, the many significant changes and unreasonable implementation timelines could result in product shortages for Mexican patients.
For these reasons, PhRMA requests that Mexico remain on the Watch List in the 2020 Special 301 Report. Further, we urge USTR to provide an opportunity for an assessment of Mexico’s IP and market access environment through an Out-of-Cycle Review, so that the U.S. Government can evaluate progress on these important issues and dedicate the required bilateral attention necessary to make progress on the barriers confronted by U.S. businesses in Mexico.

Intellectual Property Protection

Legislative Challenges

Legislation has been proposed in Mexico which aims to reform the General Health Law and the Industrial Property Law by weakening the ability of IMPI to limit the importation of patent-infringing medicines. In particular, the draft bill would potentially allow for patented medicines to be imported without the patent holder’s authorization on bases which appear to be inconsistent with Article 31 bis of the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). This legislation is being promoted in Congress (notably in the Senate) by prominent legislators belonging to the ruling party’s parliamentary group.

More recently, legislation was proposed in November 2019 in Mexico’s Senate that would require the national health system to identify three chronic non-transmissible diseases of highest incidence in the country. The Ministry of Health would then be required to initiate steps that would enable the grant of a public utility license, effectively equivalent to issuing a compulsory license for any applicable patents on medicines treating the listed diseases.

Weak Patent Enforcement

To ensure adequate and effective protection of IP rights for the research-based biopharmaceutical sector, mechanisms that provide for the early resolution of patent disputes before an infringing product is allowed to enter the market are critical. Mexico has taken some positive steps to improve patent enforcement, including adopting the Linkage Decree of 2003. However, the continued lack of regulatory guidance requires innovators to redirect significant resources to seek judicial orders compelling Mexico’s relevant agencies to follow their own rules and regulations.

Mexico’s Linkage Decree (2003) constituted important progress toward an early resolution mechanism and the full recognition of pharmaceutical patent rights in Mexico. However, the decree has not been implemented in a comprehensive and consistent manner. For example, the publication in the Official Gazette of medicine-related patents is a positive step toward the goal of eliminating unnecessary, costly and time-consuming court actions to obtain appropriate legal protection for biopharmaceutical patents. However, COFEPRIS appears to apply linkage inconsistently and possibly in a discriminatory manner. In some cases, marketing authorizations have been issued despite patents listed in the Official Gazette. As a result, there have been concerning
instances (at least three in April 2017) where COFEPRIS granted marketing authorization for entry of products for which a valid patent exists. This undermines company confidence in the IP system in Mexico and impedes companies’ ability to do business in Mexico.

Furthermore, current legislative proposals and a proposed pilot program would further undermine the Linkage Decree by restricting the mechanism to only small molecule medicines and limiting notification to patents related to active substances/ingredients. Implementation of these legislative proposals or the COFEPRIS pilot program diminish the standard of protection for pharmaceutical patents in Mexico and are inconsistent with Mexico’s international commitments.

Both of Mexico’s NAFTA partners provide patent enforcement systems for product, formulation and method of use patents. It is therefore inappropriate for Mexico to not provide effective patent enforcement for method of use patents. Furthermore, effective patent enforcement mechanisms are necessary to protect innovator products from patent infringement by premature commercialization of follow-on products.

A critical tool to protect against irreparable harm from the loss of IP rights is the availability of preliminary injunctions to prevent the sale of an infringing product during litigation. Preliminary injunctions become all the more important when there are no other effective mechanisms to facilitate early resolution of patent disputes.

In Mexico, PhRMA member companies are unable to obtain accurate and timely information from COFEPRIS prior to marketing authorization being granted on a generic or biosimilar drug where the innovator product is used as a reference. As a result, innovators have little to no notice that a potentially patent infringing product is entering the market. Further, obtaining effective preliminary injunctions or final decisions on cases regarding IP infringement within a reasonable time (as well as collecting adequate damages when appropriate) remains the exception rather than the norm. Although injunctions may be initially granted subject to the payment of a bond, counter-bonds, or in some proceedings mere applications, may be submitted by the alleged infringer to lift the injunction.

In the event that an innovator successfully enforces its intellectual property rights in Mexico, seeking monetary damages is extremely burdensome. In order to claim damages from patent infringers in Mexico, litigants are required to first obtain a final administrative action and then seek damages through a civil action. It is not uncommon for this process to last longer than ten years because these actions must be adjudicated in two separate legal venues. While aspects of the proposed new IPR Law would improve the efficiency of legal actions to secure damages, the lack of procedural clarity raises concerns that these improvements may be illusory.

Mexico has repeatedly committed to provide effective patent enforcement mechanisms in the North American Free Trade Agreement, the recently concluded U.S.-Mexico-Canada Agreement (USMCA), and the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). As such, PhRMA’s members encourage
Mexican authorities to establish uniform criteria consistent with court precedents ordering the listing of use patents in the Official Gazette. In addition, PhRMA and its member companies encourage the Mexican Government to hasten patent infringement proceedings; use all available legal mechanisms to enforce Mexican Supreme Court decisions and implement procedures necessary to provide timely and effective preliminary injunctions.

Regulatory Data Protection Failures

Biopharmaceutical innovators work with hospitals, universities and other partners to rigorously test potential new medicines and demonstrate they are safe and effective for patients who need them. Less than 12 percent of medicines that enter clinical trials ever result in approved treatments.316

To support the significant investment of time and resources needed to develop test data to prove that a new medicine is safe and effective, the international community has developed a mechanism recognized as essential to biopharmaceutical innovation whereby the data submitted for regulatory approval is protected from unfair commercial use for a period of time. The mechanism is ensconced in TRIPS Article 39.3 which requires WTO members to protect undisclosed test and other data submitted for marketing approval in that country against disclosure and unfair commercial use.

RDP is essential for all medicines, and particularly critical for biologic therapies. Produced using living organisms, biologics are complex and challenging to manufacture and may not be protected adequately by patents alone. Unlike generic versions of traditional chemical compounds, biosimilars are not identical to the original innovative medicine and there is greater uncertainty about whether an innovator’s patent right will cover a biosimilar version. Without the certainty of some substantial period of market exclusivity, innovators will not have the incentives needed to conduct the expensive, risky and time-consuming work to discover and bring new biologics to market.

The leaders of COFEPRIS and the IMPI have committed to provide protection for data generated to obtain marketing approval for all pharmaceutical products, including biologics. However, PhRMA and its members remain concerned with the apparent distinction made by the regulatory authorities between the provision of RDP to chemically synthesized (small molecule) and biologic drugs. Consistent with TRIPS and Mexico’s other international commitments, RDP should be provided regardless of the manner in which the medicine is synthesized. Implementation of substantive RDP reform is still pending.

---

In June 2012, COFEPRIS issued guidelines to implement RDP for a maximum period of five years – an important step toward fulfilling Mexico’s international obligations. PhRMA members initially welcomed this decision as an important confirmation of Mexico’s obligations and its intention to fully implement the NAFTA and TRIPS provisions. As guidelines, however, their validity may be questioned when applied to a concrete case. Further, they could be hard to enforce and may be revoked at any time. Therefore, PhRMA members strongly urge the passage of binding federal regulations on RDP to provide certainty regarding the extent and durability of Mexico’s commitment to strong IP protection, consistent with Mexico’s international commitments.

Potential Abuse of the “Bolar” Exemption

Mexico allows generic manufacturers to import active pharmaceutical ingredients and other raw materials contained in a patented pharmaceutical for “experimental use” during the last three years of the patent term, per the Bolar exemption. Mexico fails, however, to impose any limits on the amount of raw materials that can be imported under this exception.

Given some of the import volumes reported, PhRMA’s members are very concerned that some importers may be abusing the Bolar exemption by stockpiling and/or selling patent-infringing and potentially substandard medicines in Mexico or elsewhere. PhRMA members encourage Mexican authorities to establish clear criteria for the issuance of import permits that respect patent rights and appropriately limit imports to quantities required for testing bioequivalence.

Market Access Barriers

Market Access Delays

PhRMA’s local sister association (Asociación Mexicana de Industrias de Investigación Farmacéutica (AMIIF)) has estimated that on average it takes 1,500 days for Mexican patients to access innovative medicines, and this delay is growing given the changes made by the current administration. Key reasons are the excessive times required for public formulary inclusion and five-year marketing authorization renewals, both of which significantly exceed stated timelines. COFEPRIS had made improvements in the marketing authorization process despite limited resources; however, since the beginning of the current administration, further progress has stalled as the agency ceased communication with the pharmaceutical industry and put on hold the work and processes of its New Molecules Committee.

Once COFEPRIS grants marketing authorization, there remain significant barriers for patients, primarily those covered by public institutions, in accessing important medicines. This additional delay is caused by the lengthy, non-transparent, and uncertain reimbursement system used in Mexico, which adds, on average, two years to patient access timelines in the public sector (if a medicine is made available at all). In addition,
inclusion into the basic formulary of a public health institution does not automatically result in the purchase and availability of medicines to patients.

More specifically, after COFEPRIS grants marketing authorization, the National Health Council (NHC) decides which medicines should be included on the national formulary. Until 2018, recommended prices of patented and unique medicines (or those with exclusive distributors) for all public health institutions were formerly negotiated with the Coordinating Commission for the Negotiation of Prices of Medicines and Other Medical Supplies under the supervision of the Ministry of Public Function (SFP) and the Mexican Antitrust Authority (COFECE). Following this recommendation, the public health institutions at federal and local levels, such as the Mexican Institute for Social Security (IMSS) and Institute of Security and Social Services for State Workers (ISSSTE), procured the medicines at the negotiated prices. While this process had significant flaws, it has been largely supplanted since the beginning of the current administration.

Challenges with New Public Procurement Practices

In 2019, the Mexican government further consolidated and transferred authority for the public procurement of medicines from the individual public health institutions (e.g., IMSS, ISSSTE, Seguro Popular, etc.) to the Ministry of Finance. Several tenders were conducted based on new rules that lack transparency in process and requirements, and that are inconsistent with Mexican public procurement and antitrust laws, as well as Mexico’s obligations under several free trade agreements including USMCA. The NHC is supporting this centralized process by developing disease-specific treatment guidelines aimed at reducing the number of medicines on the National Medicines Compendium, but without clear criteria and transparency in the decision-making process. PhRMA member companies are deeply concerned that these many significant changes and unreasonable implementation timelines could result in product shortages for Mexican patients.

Recent actions by the Mexican government are being made without meaningful consultation and are further contributing to an uncertain business environment. In January 2020, the Mexican government published modifications to laws that would allow procurement and importation of medicines that have not been approved by COFEPRIS as long as the products are approved by one of several foreign regulators or the WHO Prequalification Program. We urge the Mexican government to limit the procurement process to products approved by COFEPRIS and that meet all relevant regulatory standards.

Based on industry’s experience with the new procurement practices, we urge the Mexican government to provide greater clarity in process and requirements, ensure consistency with Mexican law and international commitments, and allow for appropriate lead times so that companies can make any necessary operational adjustments to ensure continued supply for Mexican patients.
Differentiated Packaging

The Executive Branch sponsored an amendment to the General Law of Health which, among other things, will require different packaging for pharmaceutical products supplied to the Public Health Services. That amendment has been approved by the Congress and was enacted in late November. The measure of different packaging (originally raised and rejected in 2002) will effectively require pharmaceutical manufacturers to develop a separate line of production for drugs intended for Government purchasers. Further regulations on how the measure will be implemented are yet to be released (due within 180 days of the enabling legislation). However, at this stage it is unclear why, as a technical matter, different packaging is required, and as such it would appear to be a technical barrier to trade that imposes unnecessary obstacles to trade contrary to Mexico’s commitments in the WTO Technical Barriers to Trade Agreement.
MIDDLE EAST / AFRICA
EGYPT

PhRMA and its member companies remain concerned about the intellectual property (IP) environment and market access issues in Egypt.

Egypt is one of the most populous countries in the Middle East-Africa region. There is tremendous unmet medical need in the country. While market access and IP challenges remain and PhRMA member companies still struggle with stabilizing and growing their operations, the Egyptian health care system is undergoing a major reform to support universal health coverage. Consequently, in August 2019 the Egyptian president approved a law establishing the Egyptian Drug Authority, the Egyptian Authority for Purchasing Medical Supplies, and the Department of Medical Technology. The creation of these three authorities aims to support the reforming health system and medical industries, provide medication on a regular basis, counter monopolies in the health sector and combat counterfeit medicines in Egypt.

During the past several very challenging years, PhRMA and its member companies have tried to work in good faith with Egyptian officials to address health and industrial issues. Specifically, in 2017, PhRMA and its member companies faced major challenges in meeting the Health Minister to address the government pricing challenges facing the industry. These challenges were a consequence of the Egyptian Government’s decision in November 2016 to liberate the foreign exchange rate. That decision triggered a precipitous decline in the value of the Egyptian Pound, jeopardizing the largest, most established pharmaceutical sector in the Middle East region.

Despite the Ministry of Health’s (MOH’s) pledge to implement the second phase of price adjustments in August 2017, to date the Egyptian Government did not implement this pledge resulting in significant financial losses for member companies and widely-reported shortages of medicines. To avoid previous pitfalls and a public outcry as a result of a wave of repricing, MOH has adopted an open and flexible approach to support individual companies in alleviating some of the losses due to the devaluation of the Egyptian pound via repricing proposals.

PhRMA notes that the Minister of Investment and International Cooperation and the Minister of Health, have shown a willingness to meet and discuss issues of concern and potential comprehensive solutions. Those officials recognize the threat to the industry and have expressed interest in supporting the innovative biopharmaceutical industry and encouraging investment in the country. They understand that the industry faces stagnation and contraction if immediate steps are not taken to redress the combined impact of fixed prices and a devaluing Egyptian Pound. Accordingly, in addition to the short term interventions, they have been actively engaging the industry in their current reform as an opportunity for the introduction of pro-innovation policies including a new pricing policy.
Key Issues of Concern:

- **Weak patent enforcement**: Egypt lacks effective patent enforcement, enabling manufacturers to obtain marketing licenses for follow-on products prior to the expiration of the patent on the original product.

- **Market access policies**: Despite the support of the MOH in alleviating some of the losses on an individual company basis, our member companies remain concerned that Egypt has yet to develop a transparent and equitable pricing system that would systematically address current drawbacks of the current pricing systems such as a methodology for absorbing currency fluctuations.

For these reasons, PhRMA requests that Egypt remain on the Watch List in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the challenges described herein are quickly and effectively resolved.

Intellectual Property Protection

Weak Patent Enforcement

Egypt does not provide an effective mechanism to ensure that marketing licenses are not granted to companies making products that infringe on an originator’s patent. Some Egyptian officials have opposed putting in place an effective patent enforcement system similar to the process used by the United States or in other neighboring countries.

In those neighboring countries, regulators who receive a marketing application from a generics company are required to check for any existing patents applying to the reference drug. If an existing patent applies, the patent holder should be notified and the MOH should have a procedure in place whereby it can either: (i) defer review of the generics company’s application for examination closer to the date of the patent’s expiration, (ii) defer grant of the application until after a sufficient period to resolve the patent dispute, or (iii) grant a marketing license that is valid only after the expiration of the innovator’s patent.

As Egypt is a World Trade Organization (WTO) member, has enacted patent laws, and issues patents through the Egyptian Patent Office, it follows that the Egyptian MOH should have in place an effective mechanism whereby it can defer marketing approval of newly licensed medicines until after the expiration of any applicable patents, or at least until after a sufficient period to allow for resolution of any underlying patent disputes.
Market Access Barriers

Market Access Policies

Despite the support of the MOH in alleviating some of the losses on an individual company basis, our member companies remain concerned that Egyptian authorities are yet to develop a new transparent and equitable pricing system that would systematically address the current drawbacks of the current pricing systems such as a methodology for absorbing currency devaluations. On a positive note, industry is engaged in constructive discussions with the new Minister of Health on the gaps in the current pricing decree 499 regarding pricing of new innovative products.

As part of the ongoing health care reform and roll out of universal health coverage, the Egyptian president approved a law in August 2019 establishing the Egyptian Drug Authority, the Egyptian Authority for Purchasing Medical Supplies, and the Department of Medical Technology. The creation of these three authorities aims to develop the health system and medical industries, provide medication on a regular basis, counter monopolies in the health sector, and combat counterfeit medicines in Egypt.

While the Egyptian government has been open to seeking input from the industry on the law during the drafting process, we strongly urge that the constructive dialogue continues as this law and the subsequent executive regulations will set forth critical policies that will impact access to innovative products and hence the future of the innovative biopharmaceutical industry in Egypt.
UNITED ARAB EMIRATES

The United Arab Emirates (UAE) has made great progress in recent years to provide an increasingly competitive environment for investment in the pharmaceutical sector and life sciences. This effort has resulted in attracting the regional headquarters for many international companies, increased investment in clinical research, and expanding manufacturing operations. Transparency of policies, predictability of the business environment and intellectual property protection have served as mainstay policies for attracting growth. Nevertheless, an issue of growing concern has emerged in this otherwise promising country related to the protection of patents of innovative pharmaceutical products based on the country of origin.

Key Issues of Concern:

- **IP Protection based on Ministerial Decree No. 404 of April 30, 2000**: Contrary to Decree 404, in 2017 the Ministry of Health and Prevention (MOHAP) registered generic pharmaceutical products for sale in the UAE that appeared to infringe the patents on innovative medicines produced by our member companies. At that time, the patents in the countries of origin remained in force and thus should have been honored in the UAE as required by Decree 404. In addition, the UAE lacks an adequate regulatory data protection (RDP) framework to ensure that generic and biosimilar manufacturers cannot prematurely rely on the confidential information that innovators must submit to regulatory authorities to demonstrate the safety and efficacy of a medicine for marketing approval.

The innovative biopharmaceutical industry has been in regular consultations with the UAE Government, and there are signals that MOHAP and the Ministry of Economy (MOE) are open to solutions that would meet the UAE’s obligations. In 2019, the industry submitted a series of proposals to address the concerns of innovator companies. As of this writing, we have not received a formal response to those proposals.

For these reasons, PhRMA requests that United Arab Emirates remain on the Watch List in the 2020 Special 301 Report, and that the U.S. Government continue to seek assurances that the problems described herein are quickly and effectively resolved.

Intellectual Property Protection

**IP Protection based on Ministerial Decree No. 404 of April 30, 2000**

The UAE’s commitment to protect IP started in earnest with the issuance of Ministerial Decree No. 404 on April 30, 2000, which prohibits the registration of any pharmaceutical product until the expiry of the patent term of the original product. Furthermore, the UAE clarified its commitments in Decree 404 via a letter to the U.S. Ambassador (Memorandum of Understanding or MOU) which specifically clarifies that for any drug registration application filed after January 1, 2000, the “protection period shall
be extended and remain valid during the validity period of protection related to patent in the Country of Origin of the original drug."

Contrary to Decree 404, in 2017, MOHAP registered generic pharmaceutical products for sale in the UAE that appeared to infringe the patents on innovative medicines produced by our member companies. At that time, the patents in the countries of origin remained in force and thus should have been honored in the UAE as required by Decree 404.

PhRMA and its member companies have engaged with MOHAP and MOE to address the pharmaceutical industry’s concerns that MOHAP may register generic or biosimilar pharmaceutical products for sale in the UAE without regard to our member companies’ intellectual property. We are encouraged by recent activities in the UAE to evaluate the pharmaceutical IP regime. PhRMA member companies urge the UAE to effectively enforce patents on innovative medicines and to develop a RDP framework that reflects the highest international standards.